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The Stoltz group, and moreover the synthetic community at large, has long been 
interested in the development of methods for the synthesis of enantioenriched all-carbon 
quaternary stereocenters. This thesis present three projects all unified by the development 
and use of the palladium-catalyzed decarboxylative allylic alkylation to synthesize 
enantioenriched all-carbon quaternary stereocenter containing cyclopentanones as well as 
the natural product total synthesis. 
An enantioselective total synthesis of the norditerpenoid alkaloid nigelladine A 
utilizing the asymmetric allylic alkylation to set the central all-carbon quaternary center is 
described. Strategically, the synthesis relies on a late-stage C–H oxidation of an advanced 
intermediate. While traditional chemical methods failed to deliver the desired outcome, an 
engineered cytochrome P450 enzyme was employed to effect a chemo- and regioselective 
allylic C–H oxidation in the presence of at least four oxidizable positions. The enzyme 
variant was readily identified from a focused library of three enzymes, allowing for 
completion of the synthesis without the need for extensive screening. 
Lastly, we describe a unified synthetic approach toward scabrolide A. The first 
generation route to scabrolide A hinged upon the asymmetric allylic alkylation reaction to 
synthesis the key hydroxymethyl-cis-1,3-cyclopentenediol fragment. Ultimately, assembly 
of the tetracyclic scaffold is accomplished in a convergent manner from (–)-carvone and 
(–)-linalool. A key intramolecular Diels–Alder reaction and a photocatalytic [2+2]-ring 
expansion construct the [5,5,6,7] carbocyclic core of scabrolide A. Various other synthetic 
strategies, including transannular Diels–Alder and oxidative enolate coupling, are also 
discussed. 
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Asymmetric Synthesis of  
Quaternary Stereocenters via Metal Enolates† 
 
1.1  INTRODUCTION 
 By definition, a quaternary center is a carbon atom bonded to four other carbon 
atoms by single bonds.1,2 Due to the multitude of names for quaternary centers—all-carbon 
quaternary centers, all-carbon quaternary carbon, quaternary compound, and quaternary 
carbon—some functional groups have been falsely labeled as quaternary centers in the 
literature. Common moieties that are misrepresented as quaternary centers include tertiary 
alcohols (1) and tertiary centers bonded to other heteroatoms (2,3). Quaternary centers as 
used in this chapter must have the general structure of compound 4, where R1–R4 are any 
carbon substituted group (Figure 1.1.1).  
                                               
† This research was performed in collaboration with Katerina Korch, an alumni of the Stoltz group.  
Additionally, this research has been published and adapted with permission Korch, K. M., Loskot, S. A. and 
Stoltz, B. M. (2017). Asymmetric Synthesis of Quaternary Stereocenters via Metal Enolates. In PATAI'S 
Chemistry of Functional Groups, Z. Rappoport (Ed.). doi:10.1002/9780470682531.pat0858 
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Figure 1.1.1. Commonly Mislabeled Tetrasubstituted C-Centers 
 
 The ubiquitous nature of quaternary centers in pharmaceuticals and biologically 
active natural products (5–7) creates the need for their efficient and stereoselective 
synthesis.3 Because of their significance, the synthesis of chiral quaternary centers has 
garnered much attention in chemical research (Figure 1.1.2). Although great advances have 
been made, quaternary center synthesis remains an active research topic due to the 
difficulty of synthesizing and functionalizing these centers.4 
Figure 1.1.2. Natural Products Containing Quaternary Centers Possessing Potent 
Biological Activities 
 
 Since all the substituents on a quaternary center are carbon-linked, there is a large 
steric encumbrance during the C–C bond-forming event compared to less substituted 
centers. Elevated steric congestion creates high-energy transition states that must be 
overcome with the use of harsh forcing conditions or catalytic methods. To accomplish this 
stereospecificity, an endogenous (e.g., chiral auxiliary) or exogenous (e.g., chiral catalyst) 
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 In most cases, metal enolates are sufficiently strong nucleophiles to overcome the 
energy barrier required to form sterically hindered quaternary centers. Because of this, 
metal enolates are commonly employed in the asymmetric formation of quaternary centers 
at the a-position of a ketone, aldehyde, ester, or amide (a-quaternary centers). Moreover, 
enolates strongly coordinate with Lewis acids, thereby facilitating stereoinduction through 
the use of chiral Lewis acids. This chapter will review common methods to prepare metal 
enolates and, more importantly, the stereoselective synthesis of a-quaternary centers that 
they facilitate. 
1.2   ENOLATE TYPES AND THEIR FORMATION 
 The most common method used to form enolates is through the a-deprotonation of 
a carbonyl compound. With an asymmetric ketone in hand, a regioselective deprotonation 
can occur depending on the conditions used.5 If the reaction is performed at low, typically 
below 0 °C, in aprotic ethereal solvents, and over short reaction times, deprotonation will 
occur at the most accessible position (i.e., lowest transition state energy) to obtain the so-
called ‘kinetic’ enolate. On the other hand, if the deprotonation is performed at warmer 
temperatures, in protic solvents, and over increased reaction times, the deprotonation is 
allowed to reach equilibrium and will form the thermodynamically stable enolate. Other 
factors must be taken into account when considering the stereoselectivity in enolate 
formation. 
 Metal enolates can exist in either the (Z)- or (E)- configuration (8 and 9 
respectively, Scheme 1.2.1). Each stereoisomer has its own unique steric and electronic 
characteristics that dictate reactivity. Over the past several decades, the conditions needed 
to dictate enolate geometry have been extensively studied, particularly for the 
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diastereoselective aldol reaction.6 Both enolates form different Zimmerman–Traxler 
transition states, in order to minimize 1,3-diaxial interactions (10 and 11), ultimately 
resulting in the production of syn- (12) and anti- (13) diastereomers. Thermodynamic 
enolates predominantly exist in the Z conformation excluding the small- and mid-sized 
rings, in order to minimize A1,3-strain.7 Kinetic enolates, on the other hand, depend on an 
array of variables, including base, solvent, counterion, co-solvents, and various additives. 
Scheme 1.2.1. Zimmerman-Traxler Transition States for Aldol Reactions of (Z)- and 
(E)-Enolates 
 
1.2.1  ALKALI AND ALKALINE EARTH METAL ENOLATES 
 Alkali metal bases are one of the most common reagents used to form kinetic 
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strong amide bases or metal hydrides. Common alkali bases include lithium 
diisopropylamide (LDA), lithium hexamethyldisilazide (LiHMDS), lithium 2,2,6,6-
tetramethylpiperidide (LiTMP), lithium t-butyl-t-octyl amide (LOBA), lithium 
bis(dimethylphenylsilyl)amide, and N-t-butyl-N-tritylamide, as well as their sodium and 
potassium analogs. The first model used to describe the inherent selectivity of enolate 
formation was postulated by Ireland in 1975,8 and stated that the deprotonation occurred 
through a closed, chair-like transition state (Scheme 1.2.1.1). Ireland demonstrated that 
treating ketones 14 with strong bases LiNR22 can result in two potential closed transition 
states. When R1 is small and R2 is large, the steric interaction between R2 and the methyl 
(Me) is greater than the interaction between R1 and Me (transition state 15). Consequently, 
the (E)-enolate 16, is favored. On the other hand if R2 is small and R1 is large, the steric 
interaction between R1 and Me is greater than the interaction between R2 and Me (transition 
state 17), and the (Z)-enolate 18 is favored. 
Scheme 1.2.1.1. Ireland’s Model for Selective Enolate Geometry Formation 
 
 While the Ireland model is predictive for most systems, it is important to realize 
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usually di-, tetra-, or hexameric structures.9 Treatment of esters (e.g. 19) and amides, with 
a strong alkali base, tends to result in the E- (20) and Z-enolates (21), respectively. It is 
possible, however, to reverse the selectivity of esters by adding a strong solvating co-
solvent (i.e., HMPA), which can reverse this trend by disturbing the aggregates (Scheme 
1.2.1.2), albeit with diminished selectivity.10 
Scheme 1.2.1.2. Selective Ester Enolate Isomer Formation. 
 
 While alkali metal (Group 1) enolates are commonly used, their counterparts, alkali 
earth metal (Group 2) enolates, are far less common, largely due to their attenuated 
reactivity. These enolates can be formed by the same methods as the alkali enolates, using 
strong basic amides like bromomagnesium diisopropylamide.11 Other methods of alkaline 
earth metal enolate formation include the transmetalation of lithium enolate by addition of 
a magnesium(II) salt,12 the Cu-catalyzed conjugate addition of a Grignard reagent to an 
a,b-unsaturated ketone,13 or the insertion into an a-bromoketone.14 
1.2.2   SILYL ENOL ETHERS 
 Silyl enol ethers are considered masked enolate equivalents. The increased stability 
allows these trapped or protected enolates to be carried through multiple steps in a 
synthesis.15 Another advantage is that silyl enol ether can be purified by distillation or 
column chromatography over neutralized silica. Because of the versatility of silyl enol 
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conditions, using a wide range of silyl sources (Scheme 1.2.2.1). These methods include 
silylation of enolates,16 silylation of enols,17 hydrosilylation of a,b unsaturated ketones,17 
trapping the intermediate enolate formed during a 1,4-conjugate addition to an a,b-
unsaturated ketone,18 isomerization of allyl silyl ethers,19 reaction of vinyllithiums with 
silyl peroxides,20 simultaneous carbonylation  and silylation of alkyl acetates,21 and Brook-
like rearrangements.22 Common silylating reagents include silyl chlorides, silyl iodides 
(often formed in situ), and silyl triflates. 
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1.2.3   BORON ENOLATES 
 While the versatility of boron enolates is significantly decreased compared to silyl 
vinyl ethers, boron enolates are heavily relied on in aldol, and aldol-like reactions.23 The 
breadth of boron enolates has been extensively explored by Evans, Masamune, 
Mukaiyama, and Brown with their use in aldol chemistry, which shows excellent diastereo- 
and enantioselectivity. A considerable amount of research, performed by Evans, 
Masamune, Mukaiyama, and Brown, has enabled stereoselective boron enolate formation. 
Numerous factors play a role in forming boron enolates stereoselectively, including 
substituents on the ketone and boron precursor, the leaving group X on the latter, and the 
amine base (Table 1.2.3.1).24 
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Table 1.2.3.1. Enolate Selectivity Due to Leaving Group, Alkyl Substituents, and 
Amine Base 
 
 a Aldol product with benzaldehyde, syn:anti = 5:95. b Aldol 



















X R1 Base Yield (%) Z (%) E (%)
22
OTf t-Bu NEt3 90 10 90
Ms t-Bu NEt3 87 <3 >97
I t-Bu NEt3 95 >97 <3
Br t-Bu NEt3 94 <3 >97
Cl t-Bu NEt3 94 <3 >97
OTf Ph NEt3 97 >97 <3
Ms Ph NEt3 96 >97 <3
I Ph NEt3 98 >97 <3
Br Ph NEt3 96 83 17
Cl Ph NEt3 97 52 48
23
OTf t-Bu NEt3 85 <3 >97
Ms t-Bu NEt3 66 <3 >97
I t-Bu NEt3 96 >97 <3
Br t-Bu NEt3 82 10 90
Cl t-Bu NEt3 60 <3 >97
OTf Ph NEt3 96 67 33
Ms Ph NEt3 95 62 38
I Ph NEt3 97 >97 <3
Br Ph NEt3 97 5 95
Cl Phb Hunigs 51 49
Cl Ph NEt3 97 <3 >97
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1.2.4  TRANSITION METAL ENOLATES 
 Research on transition metal enolates has gained much attention over the past 
several years. At least 23 different transition metal enolates have been prepared25 and used 
in organic synthesis, especially those of palladium, zinc, copper, titanium, and nickel. 
Transition metal enolates are synthesized using a wide variety of methods26 including ion 
exchange, oxidative addition, carbene insertion, conjugate addition, and metal alkylation 
(Scheme 1.2.4.1).  
Scheme 1.2.4.1. Common Methods to Form Transition Metal Enolates 
 
The three main types of binding modes that transition metal enolates can adopt are 
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configurations are capable of interconversion, but each complex has a preferred one, 
depending on multiple factors, including the hardness or softness of the metal, the steric 
and electronic environments of the ligands, and the solvent. Although there are exceptions, 
the general trend for preferred enolate configurations is that early transition metals tend to 
primarily adopt the h1-O-bound configuration (24), while late transition metals primarily 
adopt the h1-C-bound (26).27 Since transition metals generally have higher coordination 
numbers, chiral ligands can be used to control the stereochemical outcome. 
Scheme 1.2.4.2. Equilibrium Between Transition Metal Enolate Coordination Sites 
 
1.3   ALDOL REACTION 
1.3.1  INTRODUCTION 
 First discovered in 1872 by Wurtz,28 the aldol reaction has long served as an 
important method of carbon–carbon bond formation. Due to the highly organized cyclic 
transition state, diastereoselective aldol methodologies including those utilizing chiral 
auxiliaries29 have long been employed in organic synthesis.30 More recently catalytic 
asymmetric aldol reactions relying on organic catalysts31 or metal complex catalysts have 
been explored. Although many examples of metal-catalyzed asymmetric aldol reactions 
exist in the literature, few methods tolerate the construction of quaternary centers. 
1.3.2   RHODIUM-CATALYZED REACTIONS 
 First reported in 1998 by Kuwano and Ito, the asymmetric aldol reaction of 
aldehydes (27) with 2-cyanopropionates (28) catalyzed by trans-chelating chiral 
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cyanocarboxylate products (30 and 31) bearing two vicinal stereocenters, one of which is 
quaternary (Table 1.3.2.1).32 Good anti to syn ratios were achieved only for a few substrates 
although with poor to good enantioselectivities.  
Table 1.3.2.1. Substrate Scope of Rhodium-Catalyzed Aldol Reaction 
 
In order to explain the anti-selectivity of their system, Kuwano and Ito propose 
several possible transition state structures of the zwitterionic (enolato)rhodium 
intermediate and suggest that an antiperiplanar transition state (32) in which the steric 
interaction between the aldehyde substituent (R1) and the alkyl group (R2) of the ester is 
minimized is most likely (Figure 1.3.2.1). 
Figure 1.3.2.1. Transition State of Zwitterionic (Enolato)Rhodium Intermediate 
 
1.3.3  PALLADIUM- PLATINUM- AND NICKEL-CATALYZED REACTIONS 
Sodeoka and coworkers have reported an asymmetric hydroxymethylation of 
substituted b-ketoesters with formaldehyde produced in situ, using chiral palladium or 














27 28 30 31
Rh(acac)(CO)2
(R,R)-29 (1 mol %)
Bu2O, 0 °C







Me Et 24 63 45/55 31 23
Me i-Pr 24 61 47/53 55 50
Me CH(i-Pr)2 24 67 81/19 86 33
Et CH(i-Pr)2 48 76 75/25 57 10
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bisphosphine catalysts were able to affect the same reactivity. Their proposed mechanism 
for the reaction proceeds through the enolization of the substituted b-ketoester (35 and 36) 
to form a chiral palladium enolate that reacts with the highly electrophilic aldehyde in a 
selective fashion to produce the chiral quaternary center containing products (37 and 38) 
in good yield (up to 92% yield) and enantioselectivity (up to 80% ee, Scheme 1.3.3.1). The 
reaction was also found to work for less acidic ketones such as β-tetralone (39), with more 
electrophilic aldehydes such as ethyl glyoxalate, albeit only to form tertiary centers (40). 
Figure 1.3.3.1. Scope of Palladium- and Platinum-Catalyzed Hydroxymethylation of 
Substituted b-Ketoesters 
 
 In 2009, Matsunaga and Shibasaki reported the synthesis of asymmetric 
hydroxymethylated derivatives (43) of substituted b-ketoesters with formaldehyde, but 
their catalyst was a homodinuclear Ni2-Schiff base complex (42).34 With relatively low 
catalyst loading (0.1–1.0 mol %) they were able to obtain a variety of hydroxymethylated, 
PPh2
PPh2









33 or 34 (5 mol %)
(CH2O)n, THF





for 33: 84% yield, 60% ee




33 or 34 (5 mol %)
(CH2O)n, THF
for 33: 23 °C, 110 h
for 34: 0 °C, 56 h





for 33: 65% yield, 67% ee





33 (10 mol %)







50%, dr= 1:1, 43% ee
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quaternary carbon containing products in modest to good yields, featuring 
enantioselectivities of 66% ee or better (Table 1.3.3.1). 
Table 1.3.3.1 Scope of Nickel-Catalyzed Hydroxymethylation Reaction of 
Substituted b-Ketoesters 
 
1.3.4  SCANDIUM- AND NEODYMIUM-CATALYZED REACTIONS 
 Feng and coworkers, in 2010, disclosed an asymmetric aldol reaction where a 
Sc(OTf)3 complex, formed from chiral ligand 46, catalyzes the reaction of 3-substituted-2-
oxindoles (44) and glyoxal derivatives (45) to form enantioenriched 3-(a-hydroxy-b-
carbonyl)oxindoles (47).35 The reaction’s mild conditions tolerate a variety of substituents 
on both the glyoxal electrophile as well as on the oxindole substrate with yields ranging 
from 62% to 92%, enantioselectivities ranging from 82% to 99%, and diastereoselectivities 
as high as 99:1 (Table 1.3.4.1). They also found that the reaction was scalable with no 
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Table 1.3.4.1. Substrate Scope of Scandium-Catalyzed Asymmetric Aldol Reaction 
 
 The mechanism proposed feature a scandium enolate (48) which serves to 
coordinate the glyoxal electrophile in a bidentate fashion (49), thereby allowing the aldol 
reaction to form the enantioenriched products (47) with vicinal stereocenters (Figure 
1.3.4.1).  
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In another report, Feng and coworkers disclosed the use of chiral neodymium 
catalysts in the asymmetric aldol reaction of 3-substituted-2-oxindoles and formalin.36 
Again, N,N’-dioxide ligands were utilized, and the optimal ligand for this transformation 
was found to be 50. Good yields ranging from 60% to 93% and excellent 
enantioselectivities all above 87% were obtained, producing enantioenriched 1,3-
bis(hydroxymethyl)-2-oxindoles (51, Table 1.3.4.2). 
Table 1.3.4.2. Scope of Neodymium-Catalyzed Asymmetric Aldol Reaction 
 
1.3.5  REACTIONS PROCEEDING THROUGH BORON ENOLATES 
 The aldol reaction of aldehydes and stereochemically defined tetrasubstituted enol 
borinates generated by the 1,4-hydroboration of a,b-unsaturated morpholine carboxamides 
with diisopinocampheylborane, (L-Ipc)2BH, has been reported by Roush and coworkers in 
2013.37 Based on the stereochemistry of product (55), they propose that the reaction 
proceeds through an organized six-membered transition state (54) of a Z(O)-enolborinate 




R1 50-Nd(OTf)3 (2 mol %)
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syn and anti products could both be predictably obtained. Moderate to good yields (40 to 
90%) were obtained for almost all of the quaternary carbon containing products with 
diastereoselectivities greater than 20:1 and enantioselectivities above 92%. 
Scheme 1.3.5.1. Transition State and Substrate Scope of Aldol Reaction of Aldehydes 
and Stereochemically Defined Tetrasubstituted Enol Borinates 
 
1.4  MANNICH REACTION 
1.4.1  INTRODUCTION 
 A C–C bond forming reaction that has been used by chemists since the nineteenth 
century is the aminoalkylation reaction known as the Mannich reaction, named after 
German chemist Carl Mannich, who played a pivotal role in developing this reaction for 
broad synthetic use. The Mannich reaction produces b-amino carbonyl compounds by 
nucleophilic attack if an enol or enolate on a n electrophilic iminium salt.38 This reaction 
has been employed in the synthesis of several bioactive compounds39 and a number of 
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catalysts.41 To date, direct asymmetric Mannich reactions employing transition metal 
catalysts are limited to stabilized enolates (1,3-dicarbonyl, b-keto nitriles, or oxindoles). 
1.4.2  COPPER-CATALYZED REACTIONS 
 Jørgensen and coworkers first reported the direct catalytic asymmetric Mannich 
reaction of malonates and b-ketoesters in 2003.42 They found that by using Cu(OTf)2 and 
the (S)-t-Bu-BOX ligand (57) in the reaction between substituted b-ketoesters (41) and N-
tosyl-a-imino ester (56), they could obtain the quaternary carbon-containing products (58) 
in modest to good yields, diastereoselectivities as high as 99:1, and enantioselectivities 
ranging from 86% to 95% (Table 1.4.2.1). Although the best enantioselectivities were 
observed at –20 °C, these reactions were also plagued with low yields. The yields could be 
greatly improved upon warming to room temperature with only a slight decrease in ee. 
Table 1.4.2.1. Substrate Scope of Copper-Catalyzed Asymmetric Mannich Reaction 
 
1.4.3   PALLADIUM-CATALYZED REACTIONS 
 Chiral palladium enolates have also found use in the asymmetric Mannich reaction, 
such as one reported by Jørgensen, Sodeoka and coworkers for b-ketoesters.43 However, 





















T (°C) dr ee (%)yield (%)
41 56 58
–(CH2)4–
Me Me –20 55 97:3 95
Et Me –20 17 98:2 93
i-Pr Me –20 15 84:16 92
Me Me 23 87 93:7 88
Et Me 23 80 98:2 92
i-Pr Me 23 55 84:16 91
23 89 99:1 86
Bn Me 23 83 96:4 93
i-Pr All 23 69 92:8 87
R2R1
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electrophiles. Two palladium catalysts one with BINAP ligand (61) and the other with 
SEGPHOS ligand (62), were used to optimize their substrate scope that features a variety 
of b-ketoesters and imines (Table 1.4.3.1). Good to excellent yields of the vicinal 
quaternary and secondary stereocenter-containing products (60) could be obtained with 
good diastereoselectivity for most b-ketoester/imine combinations. The enantioselectivity 
of the reaction is also excellent, with enantioselectivities as high 99%. After assigning the 
absolute stereochemistry of their products by comparison to previously published results, 
they propose that the excellent enantioselectivity comes from the face selection of the chiral 
palladium-enolate. 
Table 1.4.3.1. Scope of Palladium-Catalyzed Asymmetric Mannich Reaction 
Reported by Sodeoka, and Coworkers 
 
 Another Pd-BINAP catalyst system utilized in an asymmetric Mannich reaction 
was reported by Kim and coworkers in 2009.44 This time the targeted substrates were a-
cyanoketones (65) and N-Boc protected aldimines (66). The reaction was tolerant of a 
































62 X = H, Ar = Ph, SEGPHOS
63 X = F, Ar = Ph, DIFLUORPHOS
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with yields ranging from 71–95% (Table 1.4.3.2). The enantioselectivity of the reaction 
was also good with enantioselectivities as high as 91%. Several products could be obtained 
with complete diastereoselectivity, selective for the syn product. 
Table 1.4.3.2. Scope of Palladium-Catalyzed Mannich Reaction Reported by Kim and 
Coworkers 
 
 N-heterocyclic carbene Pd2+ diaqua complex (70) has been utilized as a catalyst by 
Shi and coworkers, who found that under mild conditions cyclic b-ketoesters (68) and N-
Boc imines (66) could ne reacted with these complexes to form Mannich adducts (69) in 
good yield (80–95%) and good enantioselectivity (70–96%, Table 1.4.3.3).45 The reaction, 
however, was not very diastereoselective for many of the substrate combinations; the 
diastereoselectivities ranged from 2:1 to 1:20. They propose a mechanism almost identical 
to that of Sodeoka43 with the reaction proceeding through a chelated palladium enolate, 
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Table 1.4.3.3. Palladium-Catalyzed Mannich Reaction Reported by Shi and 
Coworkers 
 
1.4.4  SCANDIUM-CATALYZED REACTIONS 
 Prior to Kim and coworkers’ report44 on the asymmetric Mannich reaction of a-
cyanoketones and N-Boc protected aldimines, a similar reaction was reported by Shibasaki 
and coworkers.46 Unlike Kim and coworkers, Shibasaki’s conditions were able to 
preferentially form the anti-product. By using scandium complex with amide ligand (73), 
the quaternary carbon-containing products (72) could be obtained in good to excellent 
yields (80–99% and good to excellent enantioselectivities for most substrate combinations 
(77–96%) at a broad range of temperatures (Table 1.4.4.1). The anti-selectivity of the 
reaction was excellent, with diastereoselectivities as high as 97:3. Mechanistic 
investigations were not conclusive and suggested that the catalyst exists in solution as a 
conglomerate without order or regularity that must dissociate in order to form the highly 
ordered transition state necessary for the high enantioselectivity and diastereoselectivity 
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Table 1.4.4.1. Scandium-Catalyzed Asymmetric Mannich Reaction 
 
1.4.5  NICKEL-CATALYZED REACTIONS 
 Shibasaki and Matsunaga reported a second asymmetric Mannich reaction of N-
Boc protected aldimines in 2008.47 However this reaction utilized a homodinuclear nickel 
Schiff base complex catalyst instead of a scandium complex. The targeted nucleophilic 
partner in this reaction was substituted nitroacetates resulting in tertiary stereocenter-
containing products, but they also showed two examples of a b-ketoester 74 with aldimine 
(66) resulting in quaternary stereocenter-containing products. These two products (75) 
were obtained in good yields (82% and 92%) and with great enantioselectivities (91% and 
99%, Scheme 1.4.5.1). 
Scheme 1.4.5.1. Nickel-Catalyzed Asymmetric Reaction 
 
1.4.6  LITHIUM-CATALYZED REACTIONS 
An asymmetric Mannich reaction of cyclic and acyclic 1,3-dicarbonyl compounds 
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reported by Ishihara and coworkers.48 All products (78) were obtained in good yield (above 
90%), good diastereoselectivity (most greater than 9:1), and good to excellent 
enantioselectivities (82%–97%, Table 1.4.6.1). Interestingly they found that the syn/anti 
selectivity of the reaction and the absolute stereochemistry at the newly formed amino-
carbon stereocenter switched depending on whether the 1,3-dicarbonyl substrate was cyclic 
or acyclic. Cyclic substrates resulted in high syn selectivities whereas acyclic substrates 
exhibited high anti selectivity with the exception of the ketolactone. Two mechanistic 
pathways were purposed for the reaction. In pathway A, the aldimine is activated by the 
Lewis acidic lithium center, allowing for the conformational flexibility preferred by acyclic 
substrates, and in pathway B the pronucleophile is activated as a lithium enolate, forming 
a more rigid structure promoting chelation by the 1,3-dicarbonyl. Pathway A would most 
likely result in attack of the pronucleophile, coordinated by a naphtholate oxygen, on the 
re face of the lithium-coordinated aldimine resulting in anti-products, whereas in the 
pathway B the aldimine is activated by the naphthol proton and the lithium enolate attacks 
the aldimine on the si face resulting in syn products. 
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1.4.7  CALCIUM-CATALYZED REACTIONS 
 Kobayashi and coworkers reported an asymmetric Mannich reaction of 3-
substituted oxindoles (80) and N-Boc-imines (59) in 2015.49 Their optimized conditions 
utilized catalytic triethylamine, CaI2, and a PyBOX ligand (83) to generate 3-
tetrasubstituted oxindoles (81, 82) with vicinal quaternary and secondary stereocenters. 
Yields as high as 99% and enantioselectivities greater than 99% could be obtained for some 
substrate combinations (Table 1.4.7.1). The diastereoselectivity of the reaction was 
excellent, ranging from 93:7 to 98:2 with preferential formation of diastereomer 81. 
Table 1.4.7.1. Scope of Calcium-Catalyzed Asymmetric Mannich Reactiona 
 
                                      a R3 = Boc. 
1.5.   CONJUGATE ADDITION AND MICHAEL REACTION 
1.5.1   MICHAEL ADDITIONS INVOLVING POTASSIUM ENOLATES 
The earliest example of an asymmetric Michael reaction50 resulting in the formation 
of a quaternary center was published in 1973 by Långström and Bergson,51 relying on the 
use of 2-(hydroxymethyl)-quinuclidine enantiomer as the chiral organic catalyst to obtain 
optically active products. Their substrate scope was very limited and no conclusions could 

































Me Ph 87 95:5 98
Me 2-tol 93 97:3 97
Me i-Bu 99 94:6 84
Bn 2-thi 84 96:4 98
n-Pr Et 43 97:3 72
i-Pr Ph 80 95:5 >99
R2R1
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of an asymmetric Michael reaction proceeding through a metal enolate was reported by 
Cram and Sogah,52 using potassium enolates in conjunction with chiral crown ethers to 
effect this transformation. Although the enantioselectivity of the products was fair (low 
60’s) for most reactant combinations, one exceptional case resulted in an enantioselectivity 
of 99%. The chiral crown ether hosts could be recovered and reused many times. 
1.5.2  MICHAEL ADDITIONS INVOLVING COBALT ENOLATES 
The use of cobalt catalysts in the asymmetric Michael reaction first appears in the 
literature in 1984, where Brunner and Hammer, investigated the Michael reaction of cyclic-
b-ketoesters and methyl vinyl ketone with Co(acac)2 in the presence of enantiomeric 
diamines (e.g. 87, Scheme 1.5.2.1).53 Subzero temperatures were required to obtain modest 
enantioselectivities (up to 66%). However, lowered temperatures also resulted in 
diminished yields. The highest enantioselectivity obtained corresponded to only a 50% 
yield at –50 °C. In a subsequent publication the substrate scope of this reaction was of this 
reaction was explored and it was found that substrate architecture played an enormous role 
in the selectivity of the reaction.54 The highest enantioselectivity obtained in the substrate 
scope study was only 39%, which was the result for the reaction of cyclohexanone derived 
b-ketoester with acrolein at 20 °C. 
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Scheme 1.5.2.1. Cobalt-Catalyzed Asymmetric Michael Reaction Reported by 
Brunner and Hammer 
 
 In 1991, Botteghi, Boga, and coworkers reported the asymmetric Michael reaction 
using cobalt catalysts derived from a number of ligand architectures (Scheme 1.5.2.2).55 
For the formation of the quaternary carbon-containing product the optimal ligand was 
found to be a tetradentate diaminodiol ligand 91. Under optimized conditions the reaction 
only proceeded with 38% enantioselectivity accompanied by a low 46% yield. Higher 
yields could be achieved but only at the cost of lowered enantioselectivity. Brunner 
revisited the asymmetric Michael reaction again in 1999. In this report a number of chiral 
transition metal complexes are utilized as the catalyst.56 Although cobalt was only one of 
several metals tested, its complex with 1,2-diphenylethylenediamine gave the highest 
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Scheme 1.5.2.2. Cobalt-Catalyzed Asymmetric Michael Reaction Reported by 
Botteghi and Boga 
 
1.5.3  MICHAEL ADDITIONS INVOLVING NICKEL ENOLATES 
Chiral nickel complexes of various ligand architectures have found use in 
asymmetric Michael reactions since the early 1990s. Botteghi and coworkers first reported 
the use of nickel chiral Schiff base complexes in a Michael addition of methyl vinyl ketone 
and ethyl 2-methylacetoacetate with slight asymmetric induction topping out at 6% for the 
quaternary carbon-containing product.57 Their intention was not to optimize the reaction 
conditions but rather to study the mechanism of the reaction which they propose proceeds 
through a chelated nickel enolate intermediate. The use of tridentate ligands in coordination 
with nickel centers in the asymmetric Michael reaction has been explored by Christoffers 
and coworkers. A series of tridentate diamino thioethers (94), diimino thioethers, and 
oxazolines (95)58 were screened with a variety of metal salts in reaction of 1,3-dicarbonyl 
(e.g. 92) with methyl vinyl ketone (Scheme 1.5.3.1).59 They concluded that the nickel 
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oxazoline ligand 95 produced the best results in terms of both conversion and 
enantioselectivity. However  enantioselectivities of the product 93 did not exceed 19% for 
any of the tested combinations and optimized reaction conditions with these ligands. 
Scheme 1.5.3.1. Nickel-Catalyzed Asymmetric Michael Reaction 
 
 Instead Christoffers and coworkers have reported mild conditions utilizing nickel 
diamine complexes for the asymmetric Michael reaction of cyclic b-ketoesters and methyl 
vinyl ketone.60 The enantioselectivity of the reaction was hugely dependent on the ring size 
of the cyclic b-ketoester; the cyclohexanone derived product could be obtained in 91% ee 
but the cycloheptanone derived product was nearly racemic with an ee of only 2% (Table 
1.5.3.1). The other disadvantage of this reaction is that the chiral diamine is not catalytic, 
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Table 1.5.3.1. Scope of Nickel-Diamine Catalyzed Asymmetric Michael Reaction 
 
 More recently chiral diamine complexes have also been utilized in the conjugate 
addition of 3-substituted oxindoles (99) and nitroolefins (100).61 These mild conditions 
employ Ni(OAc)2 with ligand 102 and deliver the products (101) in good yield, 
diastereoselectivity, and enantioselectivity for a range of substrates (Table 1.5.3.2). 
Aliphatic nitroolefins were note tolerated and the oxindole nitrogen needed to be 
substituted as a carbamate; free N–H oxindole as well as N-benzyl substituted oxindole 
produced no reaction. This suggests that the 1,3-dicarbonyl motif is critical for reactivity 
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Table 1.5.3.2. Scope of Nickel-Diamine Catalyzed Conjugate Addition of 3-
Substituted Oxindoles and Nitroolefins 
 
1.5.4  MICHAEL ADDITIONS INVOLVING COPPER ENOLATES 
 Chiral copper(II) complexes (103–107) were used by Desimoni and coworkers62 in 
the reaction of methyl 1-indanone-2-carboxylate (84) and methyl vinyl ketone 85 to yield 
the chiral Michael adduct 86 (Table 1.5.4.1). Initially tridentate Schiff base ligands bearing 
ethyl or phenyl substituents were investigated along with carious solvents and it was found 
that the ethyl-substituted ligand (103) gave the highest ee when carbon tetrachloride was 
used as the solvent. Based on these results, they reasoned that catalysts with increased 
rigidity would result in higher ee’s and thus tetradentate ligands should be investigated. 
Two tetradentate ligands, one derived from (S)-2-amino-1,5-pentandiol (104) and the other 
derived from (S,S)-2-amino-1,3-propandiol, were screened with a variety of solvents; 
although there was no clear difference between the two ligands and that the highest ee’s 
were obtained from reactions carried out in carbon tetrachloride. The highest ee obtained 
was 70% which corresponded to a stoichiometric use of the copper catalyst; although the 
catalyst loading could be dropped to 10 mol % with only a minor loss of enantioselectivity. 
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efficiency of the copper catalyzed asymmetric Michael reaction.63 Eight new Schiff base 
ligands were investigated and the ligand 105 derived from (S)-aspartic acid gave the highest 
ee value of 75% which outperformed the ligands investigated in their previous publication. 
Unlike 104 and 105, the methionine derived methyl thiol (106) and its gem-dimethyl analog 
(107) result in enantioselectivities equal to or worse than the original ligand 103, 
suggesting the pendant alcohol acts as an axial coordinating ligand. It was concluded that 
minor modifications in the ligand structure will not be enough to significantly improve the 
enantioselectivity of the reaction and alternative avenues will need to be investigated to 
obtain better results. 
Table 1.5.4.1. Copper(II)-Catalyzed Reaction of Methyl Vinyl Ketone and Methyl 1-
Oxo-2-Indanecarboxylate 
 
1.5.5  MICHAEL ADDITIONS INVOLVING EUROPIUM ENOLATES 
 Scettri and coworkers reported in 199364 an early example of the Michael reaction 
of a 1,3-dicarbonyl compound and methyl vinyl ketone to produce various quaternary 
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(trifluoromethylhydroxymethylene-d-camphorate)) as the catalyst under very mild 
conditions. The yields were modest to good but only with modest enantioselectivities up 
to 36%. 
1.5.6  MICHAEL ADDITIONS INVOLVING RHODIUM ENOLATES 
 Ito and coworkers reported in 199265 the first asymmetric Michael reaction of vinyl 
ketones (108) using chiral rhodium–TRAP (29) catalysts. The products (109) were in 
quantitative yields and enantioselectivities as high as 89% (Table 1.5.6.1). The nucleophilic 
partner in this reaction was an a-cyanocarboxylate (28) which they propose is key to the 
selectivity of the reaction because of coordination of the cyano group to the rhodium center 
forming a cationic rhodium species, which serves as the counterion for the enolate. The 
trans-chelating TRAP ligand66 (29) was also essential to the selectivity of the reaction as 
cis-chelating chiral diphosphines such as BINAP produced very little asymmetric 
induction. 

















R1 R2 Time (h) Yield (%) ee (%)
Me Me 10 99 72
Me i-Pr 10 99 84
p-An i-Pr 1.5 99 89
4-ClC6H4 i-Pr 4 98 85
Ph i-Pr 1.5 95 83
H i-Pr 2.5 88 87
Me t-Bu 10 95 81
Me CH(i-Pr)2 23 99 93
H CH(i-Pr)2 3.5 88 92
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 In a followup publication, addition substrates were investigated and 
enantioselectivities up to 93% were obtained.67 Considering the potential synthetic use of 
the quaternary carbon containing Michael adducts, subsequent product elaborations were 
also conducted. The use of a-cyano Weinreb amides (110) as the nucleophilic partner was 
also investigated and enantioselectivities up to 94% could be obtained (Table 1.5.6.2).68 
These highly useful enantioenriched products (111) could also be further elaborated. 
Table1.5.6.2. Rhodium-Catalyzed Asymmetric Michael Reaction of a-Cyano 
Weinreb Amides 
 
 Takaya and coworkers69 reported about the rhodium catalyzed asymmetric Michael 
addition of a-cyanocarboxylates (112). They used a bisphosphine ligand (114) with large 
bite angles capable of forming trans-chelating metal complexes to obtain good yields of 
the quaternary carbon-containing products (113, Table 1.5.6.3). Temperature played a large 
role in the enantioselectivity of the reaction, with the best enantioselectivities (up to 73% 
ee) were obtained at 0 °C. Interestingly, lower temperatures resulted in sluggish reactions 
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Table 1.5.6.3. Scope of Rhodium-Catalyzed Asymmetric Michael Reaction of a-
Cyanocarboxylates 
 
 Suzuki and Torii70 in early 2000’s reported another rhodium-catalyzed asymmetric 
Michael reaction yielding products bearing quaternary centers that likely proceeded 
through a metal enolate. This was the first example of a Michael reaction with a b-ketoester 
(115) rather than an a-cyanocarboxylate serving as the nucleophilic partner in conjunction 
with a rhodium catalyst (Table 1.5.6.4). Using a chiral rhodium complex, prepared in situ 
from [Cp*RhCl2]2 and partially sulfonated diamine 117, enantioenriched products (116) 
were obtained from cyclic b-ketoesters and methyl vinyl ketone in quantitative yield with 
enantioselectivities as high as 67%. Acyclic b-ketoesters also exhibited good reactivity but 
very poor selectivity. Iridium and osmium catalysts were also investigated in this report, 




















R1 R2 R3 Solvent Temp (°C) Time (h) Yield (%)  ee (%)
Me Et Me PhH 30 4 90 55
Me Et Me PhMe 0 13 86 73
Me Et Me PhMe –30 20 88 11
Et Et Me PhH 30 13 89 14
Me Et OMe PhH 30 212 0 ND
Me i-Pr Me PhH 0 6 93 72
Me t-Bu Me PhMe 0 11 95 66
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Table 1.5.6.4. First Example of Rhodium-Catalyzed Asymmetric Michael Reaction 
with b-Ketoesters 
 
1.5.7  MICHAEL ADDITIONS USING LANTHANUM–BINOL COMPLEXES 
 Lanthanum–BINOL complexes,71 initially developed by Shibasaki and coworkers 
for the asymmetric nitroaldol reaction,72 have found use in the asymmetric Michael 
reaction of malonates and β-ketoesters.73 First reported in 1994, the asymmetric Michael 
reaction of several symmetrical malonates with cyclic enones using lithium-free lanthanum 
BINOL catalysts proceeds in up to quantitative yield and up to 95% ee.74 In this initial 
report, one example of a quaternary carbon-containing product (119) is shown; the reaction 
of methyl vinyl ketone with benzyl 2-methyl-3-oxobutanoate (118) proceeds in good yield 
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Scheme 1.5.7.1. Lanthanum-BINOL Complex-Catalyzed Asymmetric Michael 
Reaction 
 
 The proposed mechanism for this reaction features a chelated lanthanum enolate 
(120) that undergoes the conjugate addition to yield lanthanum enolate product (121) that 
is then turned over by deprotonating 1,3-dicarbonyl (118, Figure 1.5.7.1) 
Figure 1.5.7.1 Proposed Mechanism of the Lanthanum-BINOL Complex-Catalyzed 
Asymmetric Michael Reaction 
 
 The asymmetric Michael addition of β-ketoesters (115) with vinyl ketones (108) 
producing quaternary carbon-containing products (122) was the focus of a later report from 
the Shibasaki group.75 Of their three lanthanum-BINOL catalysts developed at the time 











 86% yield 
62% ee
La(Oi-Pr)3, (S)-BINOL
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and the Al–Li–BINOL complex (125, ALB)), the highest enantioselectivities were 
observed when using the LSB catalyst. The catalyst loading could be decreased from 10 to 
5 mol % and an increased enantioselectivity of 91% could be observed when using 
dichloromethane as the solvent, without the slow substrate addition necessary for high 
enantioselectivities when using toluene as the solvent (Table 1.5.7.1). The reaction was not 
very sensitive to the choice of rare earth metal and praseodymium, samarium, gadolinium, 
and dysprosium could all be substituted for the lanthanum with only minor drops in yield 
and enantioselectivity. Cyclic and acyclic β-ketoesters were both tolerated in this reaction 
and methyl vinyl ketone as well as acrylates were competent Michael electrophiles, all 
proceeding in good yield and enantioselectivity. The proposed mechanism of this reaction 
proceeds through a chelated sodium enolate rather than a lanthanum enolate, as was 
suggested for the reaction using alkali metal-free lanthanum–BINOL catalyst (123). 
Table 1.5.7.1. LSB-Catalyzed Asymmetric Michael Reaction 
 
 In efforts to improve the stability and reusability of the lanthanum–BINOL 
catalysts, Shibasaki and coworkers prepared in 200076 a lanthanum complex from La(i-
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be stored under air with no decrease in enantioselectivity after four weeks of storage. At 
10 mol % catalyst loading, 97% yield and 75% ee can be obtained from the reaction of 
methyl vinyl ketone and ethyl 2-oxocyclohexane-1-carboxylate. Thanks to solubility 
differences between the catalyst and the Michael adducts the catalyst can easily be 
recovered and reused. Very minor decreases in enantioselectivity were observed upon 
using recycled catalyst. 
 In 2005, Shibasaki and coworkers reported an enantioselective diastereoselective 
Michael reaction of substituted b-ketoesters (126) and cyclic enones (127) yielding 
products (128) containing vicinal tertiary and quaternary stereocenters (Table 1.5.7.2).77 
After optimization of the amino-linked BINOL ligand (129), modest to excellent yields 
(37–100%) were obtained for a diverse array of substrates. The diastereoselectivity also 
was somewhat substrate dependent with dr’s ranging from 68:32 up to 86:14. The 
enantioselectivity of the reaction was good for a few substrates with ee’s as high as 86% 
for the major isomer but many substrate combinations result in enantioselectivities around 
60% with some as low as 39% for the major isomer. 
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Table 1.5.7.2. Lanthanum NR-Linked-BINOL-Catalyzed Asymmetric Michael 
Reaction 
 
 The use of chiral alkali metal base catalysts in the asymmetric Michael reaction to 
form quaternary centers extends beyond the work of Shibasaki. Tamai and Miyano reported 
the asymmetric Michael addition of cyclic-b-ketoesters (115) and methyl vinyl ketone 
using podand-type alkali metal 2’-substituted 1,1’-binapthalene-2-oxides (Table 1.5.7.3).78 
A number of alkali metals were investigated but sodium provided the products (116) in the 
highest yields and enantioselectivities in combination with the optimized oligoether 
bearing ligand 130. Cooling the reaction to –78 °C provided an additional boost in 
























n R1 R2 Yield (%) dr ee major (%) ee minor (%)
0 Me Me 100 76:24 79 73
0 Me All 86 77:23 56 63
0 i-Pr Me 71 86:14 63 16
1 Me Me 92 86:14 86 80
1 Me (CH2)3Ph 37 68:32 56 86
1 i-Pr Me 42 84:16 80 35
2 Me Me 89 86:14 82 82
2 Me All 69 74:26 42 72
2 Me (CH2)3Ph 45 81:19 39 67
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Table 1.5.7.3. Scope of Michael Reaction of Cyclic b-Ketoesters and Methyl Vinyl 
Ketone Using Podand-Type Alkali Metal 2’-Substituted 1,1’-Binaphthalene-2-Oxides 
 
1.5.8  MICHAEL ADDITIONS INVOLVING PLATINUM AND IRON 
ENOLATES 
 Williams and coworkers have reported the use of platinum catalysts in the 
asymmetric Michael reaction. Although the major focus of their report was the synthesis 
and characterization of novel platinum phosphino-oxazoline complexes, they did 
demonstrate the use of two cationic platinum complexes in the asymmetric Michael 
addition of ethyl cyanopropionate and methyl vinyl ketone.79 Although good yields were 
obtained, the reaction proceeded with low enantioselectivity (up to 25%). Iron has also 
found use in the asymmetric Michael reaction of β-ketoesters and methyl vinyl ketone with 
the use of a dipeptide ligand.80 Although several metals work to catalyze this reaction, the 
highest enantioselectivity, 18%, was observed using iron(III). This was a surprising result 








98%, 28% ee at 20 °C



























4 Å MS, CH2Cl2
 –78 °C
Asymmetric Synthesis of Quaternary Stereocenters via Metal Enolates 
 
42 
1.5.9  MICHAEL ADDITIONS INVOLVING PALLADIUM ENOLATES 
 One metal that has found widespread use in a symmetric addition reactions is 
palladium.82 The first palladium catalyzed asymmetric Michael reaction forming 
quaternary stereocenters was reported in 2000 by Richards and coworkers.83 A number of 
cationic palladium pincer complexes were screened in the reaction of a-cyanocarboxylates 
and methyl vinyl ketone. Modest to good yields of 132 were obtained in most reactions 
however the enantioselectivities were generally low. The best ee obtained was 34% for the 
reaction of ethyl 2-cyanopropanoate 131 and methyl vinyl ketone, in the presence of 
DIPEA, catalyzed by 133 (Scheme 1.5.9.1). 
Scheme 1.5.9.1. The First Palladium Catalyzed Asymmetric Michael Reaction 
Forming Quaternary Centers 
 
 The use of palladium pincer complexes in the asymmetric Michael reaction was 
further explored by Uozumi and coworkers in 2004.84 They also investigated the 


















86% yield, 34% ee
133, DIPEA
toluene, –78 °C
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their palladium pincer complexes had pyrroloimidazolone coordinating groups. With low 
loading of their optimal catalyst 134 (0.5 mol %), they were able to obtain enantioenriched 
products (ent•109) in up to 91% yield and 83% ee (Table 1.5.9.1). The use of palladium 
pincer complexes was revisited again in 2007 by Fossey and coworkers.85 They used chiral 
palladium bis-aldimine NCN–pincer complexes in the reaction of vinyl ketones and a-
cyanocarboxylates. Although the reaction proceeded in nearly quantitative yield the 
product was completely racemic due to the conformational flexibility of the halide-
abstracted catalyst. 
 Table 1.5.9.1. Palladium Pincer Complex-Catalyzed Asymmetric Michael Reaction 
 
 The first highly enantioselective palladium catalyzed Michael reaction was 
reported in 2002 by Sodeoka and coworkers.86 They targeted β-diketones as their 
nucleophilic partner in the reaction because no work prior had attempted to utilize this type 
of dicarbonyl compound. The reaction of ketone 76 and 135, which proceeds through a 
chelated chiral palladium enolate,87 as evidenced by NMR and ESI-MS, is promoted by 
triflic acid and capable of generating product 136 in good yield and enantioselectivity at 























R1 R2 Yield (%) Time (h) ee (%)
Et Me 89 4 81
i-Pr Me 90 4 80
CH(i-Pr)2 Me 93 24 80
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β-ketoesters and their substrate scope features both cyclic and acyclic b-ketoesters bearing 
bulky t-butyl or phenyl groups on the ester. Yields ranging from 69% to 93% and ee’s 
narrowly ranging from 86% to 93% were obtained for several substrate combinations. 
Revealed in a subsequent full paper, the reaction is somewhat sensitive to substitution on 
the β-ketoester with some substrates proceeding in yields as low as 8% and ee’s as low as 
30%.88 β-substituted trans-enones were also competent substrates in combination with t-
butyl-2-oxocyclopentane-1-carboxylate, yielding vicinal stereocenter-containing products 
in good yield and excellent enantioselectivity as high as 99% for the major isomer with 
diastereoselectivities of 3.6:1 for (E)-4-phenylbut-3-en-2-one and 8:1 for (E)-pent-3-en-2-
one. Good enantioselectivities but poor diastereoselectivities were observed for β-
substituted cis-enones. 
Table 1.5.9.2. Palladium-Catalyzed Michael Reaction Reported by Sodeoka and 
Coworkers 
 
 In a follow-up paper, Sodeoka and coworkers report the use of their palladium 

















R1 R2 R3 R4 R5 Yield (%) dr ee, major (%)
CH2t-Bu H Me 89 ND 90
Me Me Ot-Bu H Me 88 ND 90
Ot-Bu H Me 92 ND 92
Ot-Bu H Me 92 ND 90
Ot-Bu H Et 84 ND 88
Ot-Bu Ph Me 83 3.6:1 97
Et Me Ot-Bu H Me 8 ND 35






Me Me OPh H Me 69 ND 93
Ot-Bu Me Me 89 8:1 99–(CH2)3–
33, THF
–20 °C
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catalyst recycling.89 The optimal ionic liquid for single use was 1-hexyl-3-
methylimidazolium tetrafluoroborate ([hmim][BF4]), generating products with yields as 
high as 97% and ee’s as high as 88%, which is comparable to the results obtained in usual 
organic solvents. The optimal ionic liquid for recycling was found to be 1-butyl-3-
methylimidazolium trifluoromethanesulfonate ([bmim][OTf]); unfortunately, the catalyst 
could be recycled only once before a significant drop in reaction rate took place. They 
could preserve the reactivity by using a palladium catalyst recycled previously in an 
asymmetric fluorination reaction, but only five cycles could be completed with this 
pretreated catalyst before a significant drop in reaction rate was observed. 
 Shi and coworkers demonstrated the use of palladium(II)-N-heterocyclic carbene–
diaqua complexes in the asymmetric Michael reaction of b-ketoesters (137) and methyl 
vinyl ketone.45 Using complex 70 they were able to obtain enantioenriched products (138) 
in up 98% yield and 71% ee (Scheme 1.5.9.2) They did not broadly explore the substrate 
scope of the asymmetric Michael reaction but instead investigated the use of complex 70 
in the asymmetric Mannich reaction. (See Section 1.4). 
Scheme 1.5.9.2. Palladium N-Heterocyclic Carbene Diaqua Complexes in 
Asymmetric Michael Reaction of b-Ketoesters and Methyl Vinyl Ketone 
 
 More recently in 2018, Schneider and coworkers were able to utilize a palladium-
aqua–BINAP complex 33 in order to perform an asymmetric Michael reaction with ortho 














70 (5 mol %)
4Å MS, CH2Cl2
85
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ketoesters 140 is believed to proceed through a chelated chiral palladium enolate which is 
then capable of undergoing a conjugate addition to ortho quinone methide, generated in 
situ with trifluoromethyl sulfonic acid, to form tricyclic chroman cores bearing vicinal 
tertiary and quaternary stereocenters (Table 1.5.9.3). The enantioenriched chroman 
products 141 were obtained in excellent yield (up to 99%), enantioselectivity (as high as 
99%), and diastereoselectivity (as great as 95:5). Mechanistically, the reaction is believed 
to progress through a stepwise process. Palladium coordinated complex 33 first undergoes 
a conjugate addition to the Re-face of ortho-quinone methide through an open transition 
state. The initial addition product can then rearomatize through the hemi-ketalization to 
form the desired chroman core 141. 























R1 R2 X n Yield (%) dr ee (%)
H p-OMe O 1 95 90:10 98
H p-Me O 1 99 89:11 98
p-OMe H O 1 96 90:10 >99
p-t-Bu Thi CH2 2 94 88:12 99
H p-OMe S 1 83 88:12 99
p-t-Bu p-OMe S 1 92 >95:5 >99
p-OMe p-OMe NMoc 1 78 87:13 >99
H p-OMe CH2 1 99 84:16 99
p-t-Bu H CH2 1 93 86:14 99
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1.5.10  MICHAEL ADDITIONS INVOLVING SCANDIUM AND YTTRIUM 
ENOLATES 
 Chiral N,N’-dioxides have been used in a number of asymmetric transformations as 
organic catalysts or as tetradentate ligands for metal-catalyzed reactions.91 Nakajima and 
coworkers in 200192 first utilized chiral N,N’-dioxides in the scandium-catalyzed 
asymmetric Michael reaction of indanone-2-carboxylates (142) and methyl vinyl ketone. 
By using a 1:1 mixture of ligand 144 and Sc(OTf)3 in dichloromethane the enantioenriched 
products 143 could be obtained in good yield but with variable enantioselectivities. The 
highest ee observed was for the reaction of 142 and methyl acrylate, which proceeded with 
89% yield and 84% ee although ee’s as low as 38% were observed for some indan-2-
carboxylate substrate combinations (Table 1.5.10.1).93 The indanone-2-carboxylate 
skeleton appears to be important in the enantiocontrol of the reaction, as using substrate 
145–147 instead of 142 afforded good yields of totally racemic products. 
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Table 1.5.10.1. Chiral Scandium-N,N’-Dioxide-Catalyzed Asymmetric Michael 
Reaction 
 
 Feng and coworkers utilized scandium N,N’-dioxide complexes in the asymmetric 
Michael reaction and their targeted substrates were 4-substititued-5-pyrazolones (148) and 
4-aryl-4-oxo-butenoic esters (149, Table 1.5.10.2).94 Interestingly, they were able to use 
one enantiomer of their optimized (S)-pipecolic acid-derived ligand 151 to obtain either 
enantiomer of the Michael adduct by switching the metal from scandium to yttrium. With 
scandium yields ranging from 83–97% and enantioselectivities from 86–95%. The 
diastereoselectivity of the reaction was also good with dr’s as high as 19:1, with yttrium 
the yields ranged from 75–95% and enantioselectivities from –83 to –98% with 
significantly improved diastereoselectivity, usually greater than 49:1. This reaction was 
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Table 1.5.10.2. Asymmetric Michael Reaction of 4-Substituted-5-Pyrazolones and 
1,4-Dicarbonyl But-2-enes  
 
1.5.11  MICHAEL ADDITIONS INVOLVING CALCIUM ENOLATES 
 An example of a calcium catalyzed Michael addition that generates products 
bearing quaternary stereocenters comes from Kumaraswamy and coworkers.95 Their 
calcium–octahydro-BINOL complex 154 catalyzed the addition of a variety of cyclic b-
ketoesters 152 to methyl vinyl ketone 85 in good yield and moderate to good 



























M(OTf)3 (M = Sc, Y)
151
solvent, temp
R1 R1 R1 yield (%) dr ee (%)
Bn Ph Et 95 4.6:1 86
Et Ph i-Pr 97 19:1 93
Bn 3-ClC6H4 i-Pr 83 13.3:1 92
Bn p-An i-Pr 85 5.7:1 92
Bn Ph Et 95 >49:1 –96
Bn p-An i-Pr 75 >49:1 –91
Et Ph Et 93 >49:1 –83
Ph 4-BrC6H4 i-Pr 95 >49:1 –98
With Y(OTf)3 in CH2Cl2 at 0 °C
With Sc(OTf)3 in EtOH at 30 °C
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Scheme 1.5.11.1. Calcium-Octahydro-BINOL Complex-Catalyzed Asymmetric 
Michael Reaction 
 
1.5.12  CONJUGATE ADDITION REACTIONS INVOLVING MANGANESE 
ENOLATES 
 An Asymmetric conjugate addition reaction of 3-substittuted oxindoles 155 and 
nitroolefins 100, similar to that in Table 1.5.3.2 was reported by Shibasaki and coworkers 
in 2009.96 A homodinuclear manganese–Schiff base complex (157) catalyzed the conjugate 
addition of a variety of substrate combinations in high yields and excellent 
enantioselectivities ranging from 87–96% (Table 1.5.12.1). The diastereoselectivity of the 
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Table 1.5.12.1. Homodinuclear Manganese-Schiff Base Complex-Catalyzed 
Conjugate Addition Reaction 
 
1.6  ALLYLIC ALKYLATION 
1.6.1  INTRODUCTION 
 Asymmetric transition metal-catalyzed allylic alkylation has been an area of 
interest to many organic chemists.97 Specifically, the use of palladium catalyzed allylic 
alkylation to asymmetrically generate stereocenters has received much attention over the 
last 30 years, but the generation of quaternary stereocenters using this strategy has only 
been utilized in the last 20 years.98 In 1992, Ito and coworkers published a palladium-
catalyzed asymmetric allylation of b-diketones using chiral phosphine ligands modified by 
crown ethers. Enantioselectivities up to 75% were obtained for a limited number of 
substrates.99 Similarly in 2000, Tenaglia, Buono, and coworkers published a palladium-
catalyzed asymmetric allylic alkylation reaction that generated a quaternary stereocenter 
using a chiral QUIPHOS ligand and a stabilized prochiral nucleophile derived from b-
ketoesters.100 Good yields and enantioselectivities were obtained for some select substrate 
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and coworkers were able to get consistently good enantioselectivities for the palladium-
catalyzed allylic alkylation of their b-ketoester substrates using P-chirogenic 
diaminophosphine oxide ligands.101 
1.6.2  PALLADIUM-CATALYZED ASYMMETRIC ALLYLIC 
ALKYLATION OF NON-STABILIZED ENOLATES 
 The first example of palladium-catalyzed asymmetric allylic alkylation of non-
stabilized enolates bearing other enolizable positions was reported by Behenna and Stoltz 
in 2004.102 In this initial report, both cyclic enol carbonates (159) and cyclic silyl enol 
ethers (160), in the presence of TBAT, a diallyl carbonate, a palladium(0) complex, and t-
butyl-PHOX ligand 158 to give the enantioenriched product 161 in good yields and 
enantioselectivities (Scheme 1.6.2.1). This work was later extended to include b-ketoesters 
substrates 162 as well.103 
 Scheme 1.6.2.1. Palladium Catalyzed Asymmetric Allylic Alkylation of Non-
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 The proposed mechanism for the enantioselective decarboxylative allylic alkylation 
of a racemic allyl b-ketoester (162) to a chiral a-allyl ketone (161) catalyzed by Pd-
phosphine complex 158, proceeds through a number of intermediate steps (Scheme 
1.6.2.2). Initial p-coordination of the allyl moiety to Pd generates complex (163), which 
then allows for oxidative insertion of the ester bond to for Pd(II) complex (164). Complex 
164 is then able to undergo decarboxylation to form chiral Pd-enolate (165) followed by 
an inner-sphere sigmatropic reductive elimination to generate the desired product.104 
Scheme 1.6.2.2. Proposed Mechanism of the Palladium-Catalyzed Asymmetric 
Allylic Alkylation Reaction. 
 
 Stoltz and coworkers also found that the use of the more electron deficient (CF3)3-
t-Bu-PHOX (168) was found to give excellent yields and enantioselectivities with benzoyl-
protected lactam substrates (e.g. 169) as well as strained cyclobutanones (e.g. 166) 
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Scheme 1.6.2.3. Asymmetric Allylic Alkylation of Cyclobutanones and Protected 
Lactams 
 
 Utilize the PHOX ligand scaffold the Stoltz group has been able to perform the 
asymmetric decarboxylative allylic alkylation on a wide variety of substrates exhibiting  
great functional group tolerance (Figure 1.6.2.1). Recently the Stoltz group has been able 
to expand the scope of the asymmetric allylic alkylation chemistry to encompass Mannich 
adduct products,107 as well as create chiral acyclic quaternary centers for the first time from 
stabilized palladium enolates utilizing the PHOX ligand scaffold.108 Moreover, the catalyst 
loading could be dropped as low as 0.125 mol % Pd(OAc)2 without greatly diminishing 
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Figure 1.6.2.1. Representative Products of the Palladium-Catalyzed Asymmetric 
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 Work by Trost and coworkers in the area of palladium catalyzed allylic alkylation 
to form quaternary stereocenters was first published in 1997.110 Their initial work was on 
the asymmetric allylic alkylation through stabilized enolates of tetralone-derived β-
ketoesters using palladium and the Trost ligand 173. In 1999, they pursued ketone 
substrates that would give non-stabilized enolate intermediates.111 LDA was used to 
generate the lithium enolate in situ in the presence of the Lewis acid trimethyltin chloride,  
allyl acetate, a palladium source, and the Trost ligand 173. An a-blocking group was 
required but thioacetals, benzylidene, furanylidene, and tetralones were all tolerated and 
generated their corresponding quaternary centered products (Table 1.6.2.1).  
Table 1.6.2.1. Asymmetric Allylic Alkylation of b-Ketoesters Using LDA, Palladium, 
and the Trost Ligand 
 
 In 2002, Trost showed that aryl substituted cyclic ketones (174) could be subjected 
to a base like NaHMDS in the presence of allylpalladium(II) chloride dimer, a Trost ligand 
176, and allyl acetate to give good yields and enantioselectivities of the allyl-substituted 
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Table 1.6.2.2. Formation of Aryl Substituted Cyclic Ketones Using NaHMDS, 
Allylpalladium(II) Chloride Dimer, a Trost Ligand, and Allyl Acetate 
 
In 2005, Trost demonstrated that lithium enolates could be generated in situ in the 
presence of a tin Lewis acid, palladium source, and a Trost Ligand 173 to effect the 
asymmetric allylic alkylation of a variety of substituted tetralones.113 Good yields and 
enantioselectivities were obtained for a variety of allyl sources and for a variety of 
substituted tetralones 177 (Table 1.6.2.3).114 Other substrates with blocking groups were 
also tolerated including the dithioacetal. This method was featured in the synthesis of 
hamigeran B 179. 
Table 1.6.2.3. Asymmetric Allylic Alkylation of Lithium Enolates in the Presence of a 
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 Trost investigated the use of 3-aryloxindoles (180) as substrates for asymmetric 
allylic alkylation.115 The anthracenyl-Trost ligand 182 was found to be optimal, with no 
need to form the lithium enolate in order to obtain good yield and enantioselectivity of the 
corresponding products (181, Table 1.6.2.4).  
Table 1.6.2.4. 3-Aryloxindoles In the Asymmetric Allylic Alkylation Reaction 
 
This work has also been extended to b-ketoesters and allyl enol carbonates (183).116 
For the latter, Trost Ligand 182 was found to be optimal although a-blocking groups were 
necessary to obtain good yields of the quaternary stereocenter-containing product, for 
example, as in the 2,3-benzo cyclic ketones (Scheme 1.6.2.5), or in 2-
benzylidenecyclohexanone undergoing the same process (yields 99%, 95% ee). Allylated 
products bearing tertiary stereocenters could also be generated using these reaction 
conditions from unsubstituted all enol carbonates. Vinylogous esters were also found to be 
































 –78 to 4 °C NH HN
O O
PPh2 Ph2P
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Table 1.6.2.5. Allyl Enol Carbonates In the Asymmetric Allylic Alkylation Reaction 
Using Trost Ligand 182 
 
 Hayashi and coworkers found that sodium enolates could be subjected to chiral 
ferrocenylphosphine-palladium complexes and allyl acetate to form quaternary 
stereocenters bearing allyl substituents in good yields and modest enantioselectivities.118 
Unfortunately, no ee’s exceeding 82% were observed for any of the substrates tested and 
some of them yielded nearly racemic products (185–189, Figure 1.6.2.2). 
Figure 1.6.2.2. Scope of Chiral Ferrocenylphosphine-Palladium Complex-Catalyzed 
Allylic Alkylation 
 
1.6.3 MOLYBDENUM-CATALYZED ASYMMETRIC ALLYLIC ALKYLATIONS 
 In 2006, the first example of molybdenum-catalyzed asymmetric allylation of 
oxindoles (190) to create quaternary stereocenters was reported by Trost.119 A variety of 
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enantioselectivities when using catalyst [Mo(C7H8)(CO)3] and ligand 192 (Table 1.6.3.1). 
This method was also applied in the formal synthesis of (–)-physostigmine. 
 Table 1.6.3.1. Molybdenum-Catalyzed Asymmetric Allylic Alkylation 
 
1.6.4  IRIDIUM-CATALYZED ALLYLIC ALKYLATIONS 
 You and coworkers have reported in 2010120 on the iridium-catalyzed 
intramolecular allylic alkylation reaction generating vicinal quaternary and tertiary 
stereocenters. Using [Ir(cod)Cl]2, phosphoramidite ligand 195 and cesium carbonate in 
dichloromethane they were able to transform indoles (193) into spirocyclic quaternary 
stereocenter-containing products (194) with good yields, diastereoselectivities, and 
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Table 1.6.4.1. Iridium-Catalyzed Intramolecular Allylic Alkylation Generating Six-
Membered Rings 
 
 You and coworkers also targeted Spirocyclic products (197) bearing five-
membered rings in 2012. These products originated from indoles (196), this time using a 
BINOL-phosphoramidite derived ligand (198, Table 1.6.4.2).121 
Table 1.6.4.2. Iridium-Catalyzed Intramolecular Allylic Alkylation Generating Five-
Membered Rings 
 
Initial work in the area of intermolecular iridium-catalyzed allylic alkylation by 
Takemoto and coworkers was focused on the generation of products bearing a tertiary 
stereocenter vicinal to a quaternary one.122 Stoltz and coworkers used iridium catalysis in 
































































    Cs2Co3, dioxane
2. NaBH3CN, MeOH
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3-phenynylallyl acetate compounds bearing vicinal quaternary and tertiary stereocenters 
(201, 202, Table 1.6.4.3).123 [Ir(cod)Cl]2 and phosphoramidite ligand 195 in the presence 
of the TBD base were used to preferentially generate these branched products by 
electrophilic attack of position 3 of the allyl group with good regio-, diastereo-, and 
enantioselectivity. Linear allylation products 202 were also obtained but as minor 
byproducts. Branched to linear ratios as high as 95:5, diastereoselectivities greater than 
20:1 and enantioselectivities exceeding 99% ee were obtained. Acyclic substrates were 
targeted in a later publication with some products being obtained in >99% ee and 20:1 
diastereoselectivity.124 
Table 1.6.4.3 Intermolecular Iridium-Catalyzed Allylic Alkylation to Generate 
Compounds Bearing Vicinal Quaternary and Tertiary Stereocenters 
 
Hartwig and coworkers have reported on an intermolecular iridium-catalyzed 
allylic alkylation reaction of tetralones and cyclohexanones and allylcarbonates using 
Ba(Ot-Bu)2 in tetrahydrofuran. The vicinal quaternary and tertiary stereocenter-containing 
products were obtained in diastereoselectivities up to >20:1 and enantioselectivities up to 
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Finally Stoltz and coworkers reported the enantioselective synthesis of acyclic a-
quaternary-containing carboxylic acid derivatives through iridium-catalysis (equation 
1).125 Masked acyl cyanides were used as the stabilized nucleophile to add into the Ir p-
allyl complex formed from allylic carbonates and a phosphoramidite ligand. After an acidic 
workup, a-quaternary-center containing carboxylic acids were obtained in high yields and 
enantioselectivities. 
 
1.6.5  RHODIUM-CATALYZED ALLYLIC ALKYLATIONS 
 In 2016, Evans and coworkers reported the first example of a rhodium-catalyzed 
allylic alkylation of acyclic a-alkyl-benzaldehydes to form a quaternary center.126 Utilizing 
a BINOL-derived phosphite ligand (205), DMPU additive, and LiHMDS, Evans and 
coworkers successfully generated a,a’-disubstituted benzaldehydes in excellent yields and 
enantioselectivities (Table 1.6.5.1). While the substrate scope is fairly limited, reaction 
conditions tolerate a variety of steric bulk a- to the aldehyde as well as electron rich and 






1. BEt3 (200 mol %)
    [Ir(COD)Cl]2 (2 mol %)
    Ligand (4.2 mol %)
    TBD (10 mol%) THF, 60 °C







32 – 90% yield
85 – 95% ee
Ar
(1)
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Table 1.6.5.1. Scope of the Rhodium-Catalyzed Asymmetric Allylic Alkylation of 
Acyclic Aldehydes 
 
1.6.6  NICKEL-CATALYZED ALLYIC ALKYLATION 
 In 2018, the Stotlz group reported the first example of a nickel-catalyzed 
intermolecular allylic alkylation of b-ketoesters with allyl alcohols (equation 2).127 
Utilizing P-PHOS and Ni(COD)2 in Et2O at 10 °C Stoltz and coworkers successfully 
generated a-quaternary-center containing d-valerolactone in moderate yield and excellent 
yields. This method was further explored with benzoyl protected d-valerolactams to afford 
excellent yields and enantioselectivities. 
 
1.7  MISCELLANEOUS ALKYLATIONS 
1.7.1  ASYMMETRIC ALKYLATIONS OF CHROMIUM ENOLATES 
 The first asymmetric alkylation of cyclic tin enolates using chromium. Complexes 





CHOR2i.  RhCl(PPh3)3 (10 mol %)
    (R)-BINOL-MeOP (205)
    DMPU, AllOBz, THF, 23 °C
ii. LiHMDS
203 204





H Et 74 92
H i-Pr 64 92
H Cy 62 91
OMe Et 79 91
Me Et 75 92
F Et 72 86






Ni(COD)2 (10 mol %)







60 – 90% yield
64 – 90% ee
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enolates (206) were exposed to an alkyl halide (bromide or iodide) electrophile and a chiral 
salen-chromium complex catalyst (208) in benzene at 0 °C to give the enantioenriched 
alkylated cyclic ketone product (207) in good yield and enantioselectivity (Table 1.7.1.1). 
Table 1.7.1.1. Scope of Asymmetric Alkylation of Cyclic Tin Enolates Using 
Chromium Complexes 
 
 This work was extended to acyclic tin enolates (209) in 2007.129 Using a modified 
chiral (salen)–chromium complex catalyst (211), to generate a variety of linear quaternary 
stereocenter-containing products (210) in good yield and enantioselectivity, although the 
latter were not as high as those observed in the cyclic case (Table 1.7.1.2). 
















































R2X (X = Br, I)
211
o-xylene, –27 °C
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1.7.2  ASYMMETRIC ALKYLATION OF LITHIUM ENOLATES 
 Asymmetric alkylation to construct quaternary stereocenters has also been achieved 
from achiral lithium enolates using chiral tetradentate ligands. Reported in 1999 by Koga 
and coworkers, Lithium enolates were generated from the silyl enol ethers (212) and were 
subjected to a chiral tetradentate amine ligand (214) and a bromide electrophile to achieve 
the asymmetric alkylation product (213) in good yield and enantioselectivity for some of 
the ligands tested (Scheme 1.7.2.1).130 The scope of the reaction was not investigated in 
detail and although catalytic conditions were investigated, the best yields and 
enantioselectivities were observed when using the chiral ligand in stoichiometric ratio. 
Scheme 1.7.2.1. Asymmetric Alkylation of Cyclic Lithium Enolates Utilizing 
Tetradentate Amine Ligands 
 
 In 2017, Zakarian and coworkers utilized similar conditions to perform the 
asymmetric alkylation of carboxylic acid 215 with various electrophiles to generate all-
carbon quaternary center containing products 216.131 Double deprotonation of the acid 215 
by n-BuLi in the presence of stoichiometric chiral amine 214 followed by addition of the 
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Scheme 1.7.2.2. Asymmetric Alkylation of Acyclic Acids Using Tetradentate Amines 
 
1.8   a-ARYLATION AND a-ALKENYLATION 
1.8.1   INTRODUCTION 
 The first metal-catalyzed a-arylation reaction132 of a carbonyl compound was 
reported in 1973 by Semmelhack and coworkers,133 using [Ni(cod)2] to effect the ring-
closure of 217 to obtain cephalotaxinone (218) in 25–30% yield (Scheme 1.8.1.1). In 1992 
Musco, Santi, and coworkers reported the first asymmetric α-arylation reaction,134 using 
palladium–(R)-BINAP complex generated in situ to obtain in 68% yield and 54% ee from 
a silyl ketene acetal and bromobenzene. Other chiral phosphine ligands provided reduced 
enantioselectivities. In 1997 Muratake and Natsume135, Buchwald,136 Hartwig,137 and 
Miura138 independently reported palladium-catalyzed catalyzed a-arylation reactions that 
produced racemic or achiral products from readily available ketones; these methods served 
as a foundation for the development of an asymmetric a-arylation reaction that forms 
asymmetric quaternary stereocenters. 





i.  214, n-BuLi
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1.8.2  PALLADIUM-CATALYZED REACTIONS 
 In 1998, the first asymmetric a-arylation reaction of ketone enolates yielding 
quaternary stereocenter-containing products was reported by Buchwald and coworkers.139 
Using 10–20 mol % of a palladium(0)–(R)-BINAP complex catalyst in toluene at elevated 
temperatures, 2-methyl- a-tetralone (220) could be a-arylated with a variety of aryl 
bromides giving modest to good yields (40–74%) and enantioselectivities (61–88% ee) of 
the quaternary stereocenter-containing products 224 (Table 1.8.2.1). 2-Methyl-1-indanone 
and 2-methylcyclopentanone derivative could also be obtained in high yields and 
enantioselectivities. Interestingly, a-arylated 2-methylcyclohexanone derivative could 
only be obtained with low enantioselectivity and no clear explanation was provided for this 
phenomenon. An intramolecular variation of this method was applied in Zhang’s synthesis 
of physovenine albeit proceeding in extremely low enantioselectivity and only moderate 
yield.140 
Table 1.8.2.1. Scope of Palladium BINAP-Catalyzed a-Arylation Reaction 
 
 Buchwald and coworkers extended this methodology to the asymmetric α-
vinylation of ketone enolates.141 Considering that the palladium–BINAP catalyst led to the 
desired product in low yield and enantioselectivity, additional ligands were investigated. 
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and simpler desamino ligands 223 and 224 as efficient ligands for a-arylation (Figure 
1.8.2.1).  
Figure 1.8.2.1. Aminophosphine and Desamino Ligands for a-Vinylation 
 
Therefore, enantiomerically pure analogs of these ligands were synthesized and 
screened in the asymmetric a-vinylation reaction. Aminophosphine ligand 225 was found 
to provide the best yields and enantioselectivities in the synthesis of asymmetric vinylated 
ketones 228, in combination with [Pd2(dba)3] for the reaction of cyclic ketones 226 
(R1 = Me) and trans-1-bromopropene (227, R2 = H, R3 = Me, Table 1.8.2.2). Lower 
temperatures provided increased enantioselectivities, but room temperature was found to 
provide the best balance of reactivity and selectivity. The scope of the reaction was quite 
broad with, a-vinylated derivates of 2-alkylcyclopentanones, 2-methylcyclohexanone, 2-
methyl-a-tetralone (229), and 2-methyl-1-indanone (230) all being obtained in good to 













R = t-Bu, Cy
R' = H, Me, i-Pr
JohnPhos
R = t-Bu, Cy
R' = H, Me, i-Pr
DavePhos KenPhos
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Table 1.8.2.2. Scope of Palladium-Catalyzed a-Vinylation Reaction 
 
 Following the success of enantiomerically pure aminophosphine and desamino 
phosphine ligands in the asymmetric a-vinylation reaction, they were also utilized in the 
asymmetric a-arylation reaction.143 Aminophosphine ligand 233, the  optimal ligand found 
for the asymmetric a-vinylation reaction, was found to give the highest combined yield 
and enantioselectivity in the a-arylation reaction. The reaction with aminophosphine 
ligand 225 could be conducted at room temperature rather than the elevated temperatures 
required in the initial system, and a lower catalyst loading was also possible. Some ligands 
that were not previously screened in the asymmetric a-vinylation reaction, namely MOP-
derived ligands, were also tested in the a-arylation reaction. Ligand 233 outperformed 
aminophosphine ligand 225 in the a-arylation reaction of cyclopentanone 231 with 3-
bromotoluene, consistently giving higher yields and better enantioselectivities (up to 94% 



























n R1 R2 R3 yield (%) ee (%)
1 Me H Me 95 90
1 Me H Ph 92 89
1 Me H H 94 92
1 Me Me Me 95 71
1 n-Pr H H 86 90
1 n-Pen H H 84 92
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Table 1.8.2.3. Scope of Palladium MOP-Derived Ligand-Catalyzed a-Arylation 
 
 Further work by Buchwald and coworkers investigated P-chirogenic binaphthyl 
substituted monophosphine ligands in palladium-catalyzed asymmetric a-arylation and a-
vinylation reactions.144 Diastereomeric ligand 236 was found to give similar results as 225 
for the a-vinylation reaction of 234 but reactions with 236 or its diastereomer 237 tested 
in the a-arylation of 234 were unable to exceed 10% ee of ketone 235 (Table 1.8.2.4) 
Table 1.8.2.4. Scope of Palladium P-Chirogenic Binaphthyl Monophosphine Ligand-
Catalyzed a-Arylation and a-Vinylation Reactions 
 
These ligands were studied again in the context of palladium-catalyzed a-arylation 
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arylation reaction of oxindoles (e.g. 238) using 237 as the chiral ligand, good yields and ee 
values greater than 99% could be obtained of 239 (Table 1.8.2.5). 
Table 1.8.2.5. Scope of Palladium-Catalyzed a-Arylation and a-Vinylation of 
3-Substituted Oxindoles 
 
Enantioenriched 3-alkyl-3-aryloxindoles (240) were also the targeted products of 
Aoyama and coworkers. however, they were interested in an asymmetric intramolecular a-
arylation reaction to close the oxindole ring in N-arylamides (241) rather than 
intermolecular arylation on an existing oxindole skeleton.146 Using palladium and the (S)-
H8-BINAP ligand (242), they were able to effect this ring closing reaction (Table 1.8.2.6) 
in good yields (up to 97%) but only moderate enantioselectivities (51–67%) for a small 
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Table 1.8.2.6. Scope of Palladium-Catalyzed Intramolecular a-Arylation Reaction to 
Form Oxindoles 
 
In addition to the success of phosphine and aminophosphine ligands, carbene 
ligands have also found widespread use in the palladium catalyzed asymmetric a-arylation 
reaction (Table 1.8.2.7). The first report of carbene ligands in a palladium-catalyzed 
asymmetric a-arylation reaction generating quaternary stereocenter-containing products is 
by Lee and Hartwig in 2001,147 who investigated N-heterocyclic carbene (NHC) ligands  
245–247 in the intramolecular a-arylation reaction of N-(2-bromophenyl)-a-
arylpropionamides (243) to form enantioenriched 3,3-disubstituted oxindoles 244 (Table 
1.8.2.7). Ligand 245, derived from trans-1,2 diaminocyclohexane, performed as well as 
the phosphine ligands that were also investigated, although the enantioselectivities for both 
did not exceed 61%. Ligands  246 and 247, derived from (–)isopinocamphenylamine and 
(+)-bornylamine respectively, gave slightly higher enantioselectivities. Additionally, 
reactions with ligand 247 proceeded quite rapidly at room temperature allowing for even 
greater selectivities. After optimization of the base and solvent, the substrate scope was 
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33% to 69% were obtained when using ligand 246 at room temperature or above. Ligand 
247 performed slightly better, with enantioselectivities ranging from 40% to 76% at room 
temperature or below, but yields were highly variable, ranging from 5% to 95%. 
Table 1.8.2.7. Scope of Palladium Carbene Ligand-Catalyzed Intramolecular a-
Arylation Reaction to Form Oxindoles 
 
 Further studies suggest the mechanism consists of oxidative addition of the catalyst 
to form palladacycle 249, base-mediated formation of a C-bound palladium enolate (250), 
and reductive elimination to form the achiral product (251, Figure 1.8.2.2). 
Figure 1.8.2.2. Proposed Mechanism of Palladium-Catalyzed Intramolecular a-






















R1 Ar X Ligand Yield (%) ee (%)
Bn 1-Naph Br 88 67
Bn 1-Naph Br 75 76
Me 1-Naph Cl 91 69
Me 1-Naph Cl 5 58
Me 1-Naph I 75 0
Me 1-Naph I 30 40
Me Ph Br 94 34
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The use of chiral carbene ligands in the palladium-catalyzed intramolecular a-
arylation reaction to form enantioenriched 3,3-disubstituted oxindoles has also been 
investigated by Glorius and coworkers.148 Although the major focus of this report was the 
synthesis and characterization of enantioenriched oxazoline-derived imidazolium salts, 
their subsequent deprotonation, and coordination to palladium, they also demonstrate the 
use of their novel NHC-palladium complex in the enantioselective synthesis of oxindole 
253 (Scheme 1.8.2.1). Compound 253 has been previously synthesized by Lee and 
Hartwig, also via a palladium-catalyzed intramolecular a-arylation reaction, using 5 mol 
% of their palladium/NHC (247) catalyst to obtain a 74% yield of 253 with 57% ee at room 
temperature. Glorius and coworker’s oxazoline-derived imidazolinium triflate 254 in 
combination with Pd2(dba)3 and sodium tert-butoxide was able to catalyze the formation 
of 253 in an improved 95% yield but with slightly diminished 43% ee at room temperature. 
Scheme 1.8.2.1. NHC-Palladium Complex-Catalyzed Intramolecular a-Arylation 
 
 An asymmetric palladium-catalyzed intramolecular a-arylation reaction to form 
enantioenriched 3,3-disubstituted oxindoles using carbene ligands was also reported by 
Kondo, Aoyama, and coworkers.149 They screened a number of NHC ligands 255 and 256 
in the synthesis of 253, a product targeted by Hartwig and Glorius. Using 255 as the NHC 
ligand precursor and sodium t-butoxide as the base, they were able to obtain the product in 
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base to lithium t-butoxide but the enantioselectivity was slightly diminished to 61% ee 
(Figure 1.8.2.3). 
Figure 1.8.2.3. NHC Ligands Screened in Intramolecular a-Arylation Reaction 
Reported by Kond, Aoyama, and Coworkers 
 
 In 2007, Kündig and coworkers150 synthesized five novel imidazolium salts 260–
264 and screened them in the palladium-catalyzed ring-closing reaction of 252 to form 253 
(Table 1.8.2.8). Previously the highest enantioselectivity seen in this reaction was 67% by 
using Kondo and Aoyama’s 255 as the NHC ligand precursor. Kündig and coworker’s 
NHC ligand precursor 264 in combination with Pd(dba)2 and sodium tert-butoxide was 
able to catalyze the formation of 253 in 94% ee and quantitative yield. The scope of this 
reaction was also investigated and found to be quite broad, with only ortho- or electron-
withdrawing substituents on the aniline ring resulting in low reactivity. 
Table 1.8.2.8. Ligand Screen for Palladium-Catalyzed Intramolecular a-Arylation 
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 The asymmetric a-arylation of aldehydes was first reported in 2008 by Buchwald 
and coworkers.151 Initial optimization of reaction conditions concluded that the use of t-
Bu-PHOX ligand 158 in t-BuOH with Pd(OAc)2 and excess Cs2CO3 provided the highest 
yield (92%) and best enantioselectivity (81% ee) for the cyclization product (266) of 265 
(Scheme 1.8.2.2). 
Scheme 1.8.2.2. Palladium-Catalyzed Intramolecular a-Arylation of Aldehydes 
Reported by Buchwald and Coworkers 
 
 Additional PHOX ligands with varied steric and electronic properties were 
screened. No clear trend in ligand electronics could be seen but steric factors did play a 
major role in selectivity; bulky substituents on the phosphine leading to reduced 
enantioselectivities. Using t-Bu-PHOX ligand 269 a number of enantioenriched indane 
derivatives 268 bearing alkyl or aryl substituents were obtained in moderate to good yields 
and good to excellent enantioselectivities from aryl bromide 267 (Table 1.8.2.9). 
Tetrahydronaphthalene derivatives proved to be more challenging products to obtain in 









92% yield, 81% ee
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Table 1.8.2.9. Scope of Asymmetric Intramolecular a-arylation of Aldehydes Forming 
Indanes 
 
 Hartwig and coworkers were the first to report on the a-arylation of ketones using 
aryl triflates rather than aryl halides.152 Using DIFLUOROPHOS ligand and Pd(dba)2 
catalyst in the presence of two equivalents of sodium tert-butoxide, the arylation of 
tetralone 220 using bromobenzene or phenyl trifluoromethanesulfonate was investigated 
(Scheme 1.8.2.3). Although both reactions yielded product in 85% ee at 80 °C, the reaction 
of the aryl triflate proceeded faster allowing this reaction to be carried out at a lower 
temperature. At 60 °C, arylation of tetralone 220 with phenyl triflate provided the product 
in 90% ee. These optimized conditions were then applied in a substrate scope study. A 
variety of cyclic ketones were a-arylated with electron-rich and electron-neutral aryl 
triflates yielding quaternary stereocenter-containing products in good yields and 
enantioselectivities. a-Arylation using electron-poor aryl triflates required switching the 
palladium(0) catalyst to Ni(cod). Tetralone 220 and the analogous indanone were a-
arylated under these nickel-catalyzed conditions to yield products in moderate to good 
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Scheme 1.8.2.3. Palladium-Catalyzed Asymmetric a-Arylation of Ketones Using Aryl 
Triflates 
 
Finally in 2019, Stoltz and coworkers reported the first enantioselective a-arylation g-
lactams (equation 3).153 Using dialkylferrocelane type ligands with Pd2(pmdba)3 and a 
strong base in dioxane, a-quaternary containing g-lactams were obtained in moderate to 
good yield and great enantioselectivities. Interestingly depending on the choice of base 
both aryl chlorides and aryl bromides could successfully undergo the desired 
transformation. 
 
1.8.3  NICKEL-CATALYZED REACTIONS 
 In addition to the nickel-catalyzed a-arylation using electron-poor aryl triflates 
discussed in relation to Scheme 1.8.5.3, Hartwig and coworkers have utilized nickel also 
in the catalytic asymmetric intermolecular a-arylation and heteroarylation of ketones using 




220 X = Br, OTf
*
O
X= OTf at 80 °C: 85% ee
X= Br at 80 °C: 85% ee









X = Cl, Br
Pd2(pmdba)2 (2.5 mol %)
Ligand (7.5 mol %)
LiHMDS or NaHMDS













R = Et or Me
44 – 88% yield
78 – 95% ee
(3)
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arylation of indanone 271 to form 272 using a variety of bidentate phosphine ligands 
(Scheme 1.8.3.1). For all ligands tested the yields and enantioselectivities of the reactions 
using phenyl chloride (X = Cl) exceeded the results obtained for the other electrophiles (X 
= Br, I, OTf). BINAP (61), SEGPHOS (62), DIFLUORPHOS (63), and P-PHOS (273) 
complexes of nickel were all able to catalyze the formation of 272 with yields ranging from 
67% to 80% and enantioselectivities from 93% to 96%. Because of its availability and low 
cost, BINAP was selected as the ligand in further substrate scope studies.  
Scheme 1.8.3.1. Nickel-Catalyzed Asymmetric a-Arylation of Indanones 
 
Electron-neutral, electron-rich, and electron-poor aryl chlorides were all competent 
substrates for the a-arylation of alkyl-substituted indanones and tetralones 274 with yields 
ranging from 58% to 89% and enantioselectivities from 90% to 99%. When heteroaryl 
bromides were investigated, no product was observed with BINAP (61) as the ligand; 
however, switching to DIFLUORPHOS (63) recovered the reactivity, albeit only in 
moderate yield and enantioselectivity (Table 1.8.3.2). Switching from heteroaryl bromides 
to heteroaryl chlorides boosted the yield and enantioselectivity dramatically. Several 
chloropyridine derivatives bearing electron-donating and electron-withdrawing groups, as 
well as 3-chlorothiophene, were successfully coupled with methyl-substituted indanone 




X = Cl, Br, I, OTf
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enantioselectivities (81–99%). Reactions of 2-chloro-6-methoxypyridine proceeded in low 
enantioselectivity presumably due to chelation to the nickel center and two of the electron-
deficient 2-chloropyridines proceeded in low enantioselectivity due to competing 
uncatalyzed nucleophilic aromatic substitution.154  
Table 1.8.3.1. Nickel-Catalyzed Intermolecular a-Heteroarylation of Cyclic Ketones 
 
Prior to Hartwig’s work on the asymmetric α-arylation of ketones using nickel–
BINAP complex catalysts and aryl chlorides, Buchwald and coworkers reported the 
asymmetric a-arylation of g-lactones (276) using nickel–BINAP complex catalysts and 
both aryl bromides and aryl chlorides.155 The optimized conditions included the use of 
catalytic [Ni(cod)2], BINAP, and ZnBr2 along with 2.3 equiv of NaHMDS and an excess 
of the lactone in toluene–THF (3:1) solution at elevated temperatures. It is postulated that 
the ZnBr2 acts as a Lewis acid facilitating halide abstraction generating a cationic nickel 
complex that undergoes transmetalation more rapidly resulting in the observed rate 
increase as well as the improved yield. The scope of this reaction was studied and it was 
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electron-poor aryl halides can be coupled with yields of g-lactones (277) ranging from 57% 
to 95% and enantioselectivities ranging from 90% to 99% (Table 1.8.3.2). Various alkyl 
substitution on the lactone were tolerated with yields as high as 91% and 
enantioselectivities up to 98%. 
Table 1.8.3.2. Asymmetric a-Arylation of Lactones Using Nickel BINAP Catalysts 
 
 The asymmetric nickel-catalyzed a-arylation reaction leading to quaternary 
stereocenters (Table 1.8.3.3) was reported by Kwong, Chan, and coworkers in 2006.156 The 
P-PHOS (273)–nickel complex in combination with sodium t-butoxide in toluene was able 
to effect the a-arylation of tetralone 274 with bromobenzene in 85% yield and 92% ee at 
elevated temperatures. Bromobenzene, chlorobenzene, and iodobenzene were all 
competent aryl coupling partners although yields were diminished when using 
chlorobenzene. A variety of meta- and para-substituted aryl bromides could be coupled in 
moderate to good yield and good to excellent enantioselectivities. Indanone 274 and 
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Table 1.8.3.3. Asymmetric Nickel Catalyzed a-Arylation Reaction Using P-Phos 
Ligand 
 
1.8.4  COPPER-CATALYZED REACTIONS 
 One example of an asymmetric copper-catalyzed a-arylation was reported by Ma 
and coworkers in 2006.157 This Ullman-type reaction involves the use of CuI and trans-4-
hydroxy-l-proline, the chiral ligand, with sodium hydroxide as the base and aqueous DMF 
as the optimal solvent (Scheme 1.8.4.1). Notably these reactions are performed at low 
temperatures which is rare for Ullman-type reactions. Substituted b-ketoester 279 could be 
a-arylated with aryl iodides 278 under optimized conditions to generate 280 in yields 
ranging from 70% to 82% and enantioselectivities ranging from 60% to 93%. The 
NHCOCF3 group on the aryl iodide is necessary as it promotes the Ullman-type reaction. 
Additional substitution on the aryl ring is tolerated although aryl iodides bearing electron-
withdrawing groups require increased temperatures to ensure complete conversion and 
suffer from reduced yields due to competing reductive homo-coupling. Ethyl, isopropyl, 
and t-butyl ester substituents were also well tolerated, although the scope of the reaction in 
regards to the a-substituent on the b-ketoester was not examined. 
+
274 n = 1, 2, 3
ArX
275 n = 1, 2, 3
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Scheme 1.8.4.1. Copper-Catalyzed Asymmetric a-Arylation Reported by Ma and 
Coworkers 
 
1.9   PERICYCLIC REACTIONS 
1.9.1  CLAISEN-TYPE REACTIONS 
 Pericyclic reactions have long served as important carbon-carbon bond forming 
reactions especially fir the generation of quaternary centers. The Claisen rearrangement, 
discovered in 1912,158 has seen over 100 years of use and many variations have been 
developed, including asymmetric methods.159 Three asymmetric Claisen-type reactions 
yielding quaternary stereocenter-containing products that proceed through a metal enolate 
intermediate have been reported. The first one was reported by Corey and coworkers in 
1995.160 Their enantioselective Ireland-Claisen rearrangement relies on the use of chiral 
boron reagent 283, which provides good control over the geometry of the intermediate 
boron enolate. Previous work with this reagent found that use of triethylamine as the base 
in toluene resulted in the formation of the (Z)-boron enolate.161 Corey applied this method 
to the synthesis of (+)-b-elemene (283). Compound 284 was treated with chiral boron 
reagent 283 and triethylamine in toluene to yield 282 as a mixture of two diastereomers 
(Scheme 1.9.1.1). After reduction of the carboxylic acid to a primary alcohol and 


















NaOH, DMF/H2O, –45 °C
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Scheme 1.9.1.1. Corey’s Synthesis of (+)-b-Elemene 
 
Corey also applied this method in the synthesis of dolabellatrienone in which 286 
was reacted with chiral boron reagent 283 and Hünig’s base affording 287 in >97:3 dr and 
>99% ee but only a 31% yield (Scheme 1.9.1.2).162 The yield could be increased to 86% 
with no major loss in enantioselectivity or diastereoselectivity by switching to the more 
hindered base penta-isopropylguanidine. 
Scheme 1.9.1.2. Enantioselective Ireland-Claisen Rearrangement in Corey’s 
Synthesis of Dolabellatrienone 
 
The second example of an asymmetric Claisen-type reaction yielding quaternary 
stereocenter-containing products that proceeds through a metal enolate was reported by 
Krebs and Kazmaier in 1996.163 Addition of LHMDS and excess Al(Oi-Pr)3 to 
trifluoroacetyl-protected disubstituted allylic glycine ester 288 in the presence of quinine 




















–70 °C to 4 °C
85% yield of two diastereomers
LiAlH4, Et2O, 23 °C

















31% yield, >97:3 dr
>99% ee
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which, upon warming to room temperature undergoes an ester enolate Claisen 
rearrangement forming enantioenriched amino acid 290 (Scheme 1.9.1.3), containing a b-
quaternary carbon stereocenter in high diastereoselectivity and good enantioselectivity. A 
variety of alkyl and aryl substituents were tolerated at the R1 position with 
diastereoselectivities ranging from 9:1 to 49:1 dr and enantioselectivities from 81% to 93%, 
although the yields were quite low with none exceeding 51% and some as low as 12%. The 
only substituent investigated at the R2 position was methyl because Z-configured esters 
failed to give the desired rearranged product, indicating that large cis-oriented substituents 
sterically crowd the quinine ligand in the coordination sphere. 
Scheme 1.9.1.3. Asymmetric Claisen-Type Reaction Using Aluminum Reported by 
Krebs and Kazmaier 
 
The third example is an asymmetric ketene-Claisen rearrangement, also known as 
a Belluš–Claisen rearrangement, reported by MacMillan and coworkers in 2001. The 
Belluš-Claisen rearrangement, discovered in 1978,164 is the reaction of an allylic ether, 
thioether, or amine (292) with a ketene (293), producing a zwitterionic intermediate (294) 
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thioester, or amide (295) (Scheme 1.9.1.4).165 Prior work by MacMillan and coworkers 
found that Lewis acids could serve to coordinate and activate the in situ formed ketene 
resulting in high yields and excellent diastereoselectivities of racemic rearranged 
products.166 They envisioned that chiral Lewis acids may be able to effect enantioinduction 
in this rearrangement and in a subsequent publication they reported an asymmetric ketene-
Claisen rearrangement.167  
Scheme 1.9.1.4.  Generic Asymmetric Ketene-Claisen Rearrangement 
 
Optimized reaction conditions of the acyl-Claisen rearrangement using N-
allylmorpholines (e.g. 296) included the use of an excess of chiral Lewis acid [Mg-
ARBOX](I)2 complex 300 in CH2Cl2 with Hünig’s base and acid chloride 297 serving as 
the ketene surrogate (Scheme 1.9.1.5).167 The -OBn group of 297 was crucial to obtaining 
good yields and enantioselectivities of the rearranged products as it serves to chelate the 
magnesium center in the intermediate magnesium enolate 298. Although the reaction 
optimization was conducted on substrates yielding enantioenriched products bearing 
tertiary stereocenters, these conditions were also readily applied to 3,3-disubstituted allyl 
morpholine 271 which undergoes the acyl-Claisen rearrangement with acid chloride 297 



















R1, R2 = H, alkyl, Cl, CN
X = O, S, NR
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Scheme. 1.9.1.5. Asymmetric Ketene-Claisen Rearrangement 
 
1.9.2  CONIA-ENE REACTION 
 The Conia-ene reaction was first reported in 1968 by Conia and coworkers as the 
thermal intramolecular cyclization of a ketone or aldehyde with a tethered terminal alkene 
or alkyne.168 Mechanistically, the reaction proceeds by two distinct steps (Scheme 1.9.2.1): 
first the ketone or aldehyde (301) is tautomerized at elevated temperatures to form the enol 
(302), which then undergoes a hydrogen shift from the enol group to the terminal double 
or triple bond with simultaneous formation of the new carbon–carbon bond (303).169 A 
number of metals have been utilized in the asymmetric Conia-ene reaction including 
palladium, copper, lanthanum, and iron. 




































R = H, Alk
301 302 303
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Toste and coworkers reported the first palladium-catalyzed Conia-ene reaction in 
2005.170 Stemming from their interest in the gold(I)-catalyzed intramolecular addition of 
b-ketoesters to alkynes,171 they envisioned that a chiral gold complex may be able to 
catalyze an asymmetric Conia-ene reaction. Although good yields were observed for this 
gold-catalyzed transformation the product was racemic. A screen of other metals identified 
the palladium complex with DTBM-SEGPHOS (64) as a competent catalyst for this 
reaction with moderate enantioselectivity, although the yield was low and the reaction 
proceeded slowly. Further optimization identified Yb(OTf)3 as a co-catalyst which boosted 
the rate of the reaction and excess acetic acid as an additive which improved the 
asymmetric Conia-ene reactivity with good yields of 305 ranging from 70% to 97% and 
enantioselectivities ranging from 70% to 94%, with the exception of the aliphatic b-
ketoester 305 (R1 = Cy, R2 = OEt), which proceeded in only 44% ee (Table 1.9.2.1). 
Mechanistically they propose the reaction proceeds through a palladium enolate that 
undergoes Lewis acid-promoted addition to the alkyne. 
































AcOH, Et2O, 23 °C
Asymmetric Synthesis of Quaternary Stereocenters via Metal Enolates 
 
90 
Dixon and coworkers reported a copper-catalyzed asymmetric Conia-ene reaction 
in 2009.172 Their cooperative catalysis approach aimed to utilize a cinchona-derived 
bifunctional catalyst (306) as well as a “soft” transition-metal ion. After optimization 
copper(I) triflate in combination with 306 was found transform 305 to b-ketoester 305 
yielding up to a 92% ee and 98% conversion (Table 1.9.2.2). A number of pentynyl b-
ketoesters with varying substituents on the ester and ketone groups were subjected to this 
reaction. Aliphatic, electron-rich, and electron-poor aromatic substrates were all competent 
participants in the cyclization reaction, with yields ranging from 67% to 98% and 
enantioselectivities ranging from 79% to 93%. b-Ketoamides were also found to be good 
substrates. Homologation of the carbon chain leading to the terminal alkyne was not 
tolerated in the reaction and products bearing six- or seven-membered rings could not be 
generated. Detailed kinetic and computational studies were completed in order to elucidate 
the mechanism of this transformation.173 
Table 1.9.2.2.  Scope of Copper-Catalyzed Asymmetric Conia-Ene Reaction 
 
The proposed mechanism (Scheme 1.9.2.2) begins with rate-determining 
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cinchona-derived pre-catalyst to the copper center is followed by the stereo-determining 
syn-carbocupration generating 309, which undergoes protonation–demetallation to form 
the product 310 and regenerate the catalyst. 
Scheme 1.9.2.2. Proposed Mechanism of Copper-Catalyzed Asymmetric Conia-Ene 
Reaction 
 
Another example of the use of cooperative catalysis in the asymmetric Conia-ene 
reaction of malonic ester amide 311 comes from Kumagai, Shibasaki, and coworkers.174 
Their initial catalyst system used the combination of La(NO3)3, an amide-based chiral 
ligand 313, and the protonated amino acid ester H-l-Val-Ot-Bu, in 1:1:3 ratio, in the 
presence of a soft Lewis acid. Screening of soft Lewis acids found that AgOAc in the 
presence of phosphine ligand 314 gave the desired product 312 in 55% yield, albeit with 
only slight enantioinduction (Scheme 1.9.2.3). The selectivity of the reaction was improved 
by modifying the metal to ligand ratios, switching from 314 to triphenylphosphine, and 
cooling the reaction down to 0 °C. With optimized conditions in hand a variety of 
substrates were subjected to the asymmetric Conia-ene reaction. Yields ranging from 63% 
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of substrates, with the exception of one bearing an electron-donating methoxy substituent 
which gave only 26% yield despite extended reaction time. 
Scheme 1.9.2.3. Use of Cooperative Catalysis in the Asymmetric Conia-Ene Reaction 
 
Shaw and White recently reported an iron-catalyzed asymmetric Conia-ene 
reaction with a broader substrate scope than that of the previous reports.175 Their initial 
screen of metal–salen complexes identified iron salen complex 317 as able to catalyze the 
transformation of 315 to 316 in moderate yield and selectivity. Addition of silver 
trifluoroacetate or silver triflate boosted the yields of these reactions; however, the 
enantioselectivity of the reaction remained unsatisfactory (Scheme 1.9.2.4). New salen 
ligands were synthesized and investigated in this reaction and the optimal reaction 
conditions were found to be 7.5 mol% 317 in chloroform. A variety of b-ketoesters, 
thioesters, and ketones bearing the pentynyl group were found to be good substrates for 
this reaction, forming the products in good yields and excellent enantioselectivities. Unlike 
any previous asymmetric method, b-ketoesters bearing hexynyl and heptynyl groups at the 
a-position could be cyclized to give the exo-methylenecyclohexene and exo-
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bearing a butynyl group at that position could be cyclized to yield the cyclobutane, although 
the yield and ee were somewhat diminished. 
Scheme 1.9.2.4. Iron-Catalyzed Asymmetric Conia-Ene Reported by Shaw and White 
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Decarboxylative Allylic Alkylation of 
Cyclopentanones† 
 
2.1  INTRODUCTION 
The efficient construction of all-carbon quaternary centers remains a challenge for 
the modern synthetic chemist.1 The difficulty associated with forming all-carbon 
quaternary centers arises from the inherent steric congestion during the C–C bond forming 
event. Toward this end, our laboratory disclosed the first palladium-catalyzed 
enantioselective decarboxylative allylic alkylation for the construction of all-carbon 
quaternary centers of non-stabilized enolates.2 Over the past decade we have continued to 
explore the breadth of our reaction manifold,3 including the development of new ligands 
based on the original PHOX scaffold.4 Cyclic ketones generally represent the most 
explored class of substrates, from the initially reported cyclohexanones (Scheme 2.1.1A),2,5 
                                               
† This research was performed in collaboration with Robert A. Craig, II, Justin T. Mohr, Douglas C. Behenna, 
and Andrew M. Harned, all alumni of the Stoltz group.  Additionally, this research has been published and 
adapted with permission Craig, II, R. A.; Loskot, S. A.; Mohr, J. T.; Behenna, D. C.; Harned, A. M.; Stoltz, 
B. M. Org. Lett. 2015, 17, 5160–5163. R.A.C. and S.A.L. contributed equally.  
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cycloheptanones,2,3d,5b,c and cyclooctanones2,3d,5b to the highly strained cyclobutanones 
(Scheme 2.1.1B).6  
Scheme 2.1.1. Cyclic Ketone Substrates in Transition Metal-Catalyzed 
Enantioselective Decarboxylative Allylic Alkylation 
 
Interestingly, cyclopentanones have typically performed worse than the 
corresponding 6-membered substrates, often furnishing the a-quaternary ketone products 
in comparatively reduced yields and ee.3d Only a few examples with limited substrate scope 
exist for the formation of a-quaternary cyclopentanones by transition metal-catalyzed 
enantioselective allylic alkylation.7 Yet cyclopentanes containing enantioenriched 
quaternary centers characterize a number of biologically pertinent and chemically 
fascinating natural products, including polycyclic terpenoids8 1799 and 710 as well as 
Pd0 or PdII (cat.)
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alkaloids 324,11 325,11 and 32612 (Figure 2.1.1). As part of our continued efforts to extend 
the utility of our reaction methodology, we revisited the problematic cyclopentanone 
substrate class, striving to develop the first general method for the construction of a-
quaternary center cyclopentanones and 5-membered cyclic ketone substrates by transition 
metal-catalyzed enantioselective decarboxylative allylic alkylation (Scheme 2.1.1C). 
Figure 2.1.1. Natural Products Characterized by Cyclopentane Rings Containing 
Chiral All-Carbon Quaternary Centers 
 
2.2  INITIAL REACTION OPTIMIZATION 
 Initial reaction development employed p-Me-benzyl-substituted b-ketoester 327, 
using catalytic Pd2(dba)3 at 20 °C in toluene in the presence of a chiral PHOX ligand, 
affording enantioenriched a-quaternary cyclopentanone 328 (Table 2.2.1).13,14 Using the 
classic (S)-t-BuPHOX ligand ((S)-158), cyclopentanone (S)-340 was provided in 87% ee 
(entry 1). Switching to the electron-deficient (S)-(p-CF3)3-t-BuPHOX ((S)-168) furnished 
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alternative to 168, (R)-(p-CF3)3-i-PrPHOXMe2 ((R)-329) provided cyclic ketone (R)-340 in 
a decreased 83% ee (entry 3).4a Similarly to (R)-329, geminally disubstituted valine-
derived (S)-(p-CF3)2-i-PrPHOXPh2 ((S)-330) afforded ketone (S)-340 with nearly 
equivalent ee (82%, entry 4). Switching to ester-substituted b-ketoester 331, we confirmed 
(S)-(p-CF3)3-t-BuPHOX ((S)-168) was indeed the optimal ligand for the desired 
enantioselective decarboxylative allylic alkylation, providing enantioenriched a-
quaternary cyclopentanone (S)-332 in 91% ee (entry 6). The remaining PHOX ligands (S)-
158, (R)-329, and (S)-330 furnished the desired product (332) in reduced ee’s, ranging 
between 80% and 82% (entries 5, 7, and 8, respectively).    
Table 2.2.1. PHOX Ligand Screen 
 
a Conditions: b-Ketoester 331 (0.19 mmol),  Pd2(dba)3 (2.75 
mol %), (S)-168 (6.00 mol %), toluene (5.8 mL). b Measured 
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Having identified the optimal ligand for the enantioselective decarboxylative allylic 
alkylation, we next examined the solvent effect using b-ketoester 331 (Table 2.2.2). 
Employing identical reaction conditions from our ligand screen, using toluene as the 
solvent, we isolated a-quaternary center cyclopentanone (S)-332 in 91% ee, achieving 
complete consumption of starting material 331 in 8.0 h (entry 1). Switching to the less polar 
solvent mixture 2:1 hexanes:toluene, which has previously provided increased ee’s for 
other a-quaternary cyclic ketones constructed through palladium-catalyzed 
enantioselective decarboxylative allylic alkylation,15 did not affect the reaction time, but 
furnished ketone (S)-332 in a diminished 88% ee (entry 2). Changing to ethereal solvents 
(entries 3 and 4) drastically decreased the reaction time, facilitating the full consumption 
of b-ketoester 331 in 1.0 h. While the use of MTBE (entry 3) afforded cyclopentanone (S)-
332 in nearly identical ee to the mixed nonpolar solvent system (entry 2), switching to THF 
(entry 4) proved deleterious. Ultimately, the use of Pd2(dba)3 (2.75 mol %) with (S)-(p-
CF3)3-t-BuPHOX ((S)-168, 6.00 mol %) in toluene (0.033 M in b-ketoester 331) at 20 °C 
proved optimal.  
Chapter 2 – Palladium-Catalyzed Enantioselective Decarboxylative Allylic  




Table 2.2.2. Solvent Effect on Enantiomeric Excess of Cyclopentanone Product (S)-
332a 
 
a Conditions: b-ketoester 331 (0.19 mmol), Pd2(dba)3 
(2.75 mol %), (S)-168 (6.00 mol %), toluene (5.8 mL). 
b Measured by analytical chiral SFC. 
 
2.3  EXPLORATION OF REACTION SCOPE 
 Subsequently, we explored the substrate scope of the enantioselective allylic 
alkylation of cyclopentanones. We found that our reaction manifold was tolerant of a 
variety of substitution at the a-position of the cyclopentanone (Scheme 2.3.1).16 Alkyl-
substituted a-quaternary cyclopentanones (S)-333, (S)-334, and (S)-335 were each 
produced over reaction times greater than 30 hours with ee’s ranging from 86% to 88%, 
providing the more sterically congested cyclopentanone (S)-335 over a slightly longer 
reaction time.13 Along with ester-substituted cyclopentanone (S)-332, nitrile (S)-336 and 
phthalimide (S)-337 were both produced quite rapidly at 20 °C in excellent yield with good 
ee (2.5 h, 97% yield, 87% ee and 3 h, 93% yield, 88% ee, respectively). We found that we 
could increase the ee of these two products significantly by lowering the temperature 
without any deleterious effect on the yield, providing cyclopentanones (S)-336 and (S)-337 
in an improved 90% ee and 93% ee, respectively, at 0 °C over 23 h. This result represents 
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CO2Et CO2Et
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system, employing THF as the solvent with (S)-158 as the ligand, which provided (S)-337 
in only 67% yield with 48% ee.3d Comparatively, benzyl-substituted cyclopentanones 
proved to have a correlation between the electronics of the aryl substituent and the overall 
reaction time. Electron rich p-OMe-benzyl cyclopentanone (S)-338 was furnished in only 
8 h, while the electron neutral benzyl and p-Me-benzyl products ((S)-339 and (S)-340) 
were each produced over a slightly extended reaction time (13 h). Interestingly, the reaction 
producing electron poor p-CF3-benzyl-substitued (S)-341 failed to proceed to full 
conversion over 96 h, affording the product in a reduced 56% overall yield (83% yield 
based on recovered b-ketoester). Interestingly, despite the variable reaction times, the ee 
of the benzyl-substituted cyclopentanone products was largely consistent (88%–89% ee), 
with a slight boost for the electron-rich p-OMe-benzyl product ((S)-338) to 92% ee. 
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Scheme 2.3.1. Substrate Scope of Cyclopentanone Substitution in Enantioselective 
Allylic Alkylation 
 
Unless otherwise noted, all reported yields are isolated yields. 
Enantiomeric excess (ee) was determined by either analytical chiral SFC 
or HPLC. a Conditions: b-ketoester 327 (0.19 mmol), Pd2(dba)3 (2.75 mol 
%), (S)-168 (6.00 mol %), toluene (5.8 mL). b Cyclopentanone product 
was volatile, resulting in a reduced isolated yield compared to other 
substrates. c Reaction performed at 0 C. d Isolated yield was 56%. 
 
Additionally, we found that indanones were competent substrates within our 
reaction manifold (Scheme 2.3.2).3d,5a,d,7g Methyl-substituted indanone product (S)-344 
was furnished over a greatly shortened 4.5 h compared to the methyl-substituted 
cyclopentanone product ((S)-333, see Scheme 2.3.1). Additionally, bicycle (S)-344 was 
provided in 94% yield with 84% ee. Comparatively, the fluorinated analog (S)-345 was 
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Scheme.  2.3.2 Enantioselective Allylic Alkylation of Indanone Substrates 
 
Having investigated the tolerance of our reaction manifold to a variety of 
substitution on the cyclopentanone ring, we next evaluated the potential to use 2-substituted 
allyl fragments in the enantioselective allylic alkylation of cyclopentanones (Scheme 
2.3.3). Methyl- and ethyl-substituted cyclopentanone products (S)-346 and (S)-347 
containing a 2-phenylallyl fragment were both produced in excellent yield and with 90% 
and 94% ee, respectively. Comparatively, cyclopentanones (S)-348 and (S)-349, each 
containing a 2-chloroallyl fragment, were produced with similar ee’s in slightly reduced 
yield. Interestingly, each of the alkyl-substituted cyclopentanone products possessing a 2-
substituted allyl fragment were produced over a shorter reaction time than the same 
substrates containing an unsubstituted allyl fragment (see Scheme 2.3.1). 
Scheme 2.3.3. Enantioselective Allylic Alkylation of Cyclopentanone Substrates with 
2-Substituted Allyl Fragmentsa 
 
a All reported yields are isolated yields. Enantiomeric excess (ee) was 
determined by analytical chiral SFC. Conditions: b-ketoester 321 
(0.19 mmol), Pd2(dba)3 (2.75 mol %), (S)-168 (6.00 mol %), toluene 
(5.8 mL). 
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(S)-(p-CF3)3-t-BuPHOX ((S)-168, 6.00 mol %)
toluene (0.033 M), 20 °C
(S)-344, R1 = Me, 4.5 h, 94% yield, 84% ee















Pd2(dba)3 (2.75 mol %)
(S)-(p-CF3)3-t-BuPHOX ((S)-168, 6.00 mol %)










20 h, 98% yield
94% ee
28.5 h, 72% yield
90% ee
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2.4  ADAPTING THE LOW CATALYST LOADING ALLYLIC ALKYLATION 
 Lastly, we examined the potential to apply our recently disclosed palladium(II) low 
catalyst loading protocol for enantioselective decarboxylative allylic alkylation to this new 
substrate class.17 We discovered that on small scale, ester-substituted cyclopentanone (S)-
332 was provided in an identical 91% ee and an improved 98% yield at 20 °C using only 
0.15 mol % palladium catalyst (Scheme 2.4.1) compared to our palladium(0)-mediated 
reaction conditions, which employ 5.50 mol % palladium (vide supra). Increasing the scale 
of the reaction slightly (0.22 mmol) as well as the temperature (28 °C) and catalyst loading 
(0.30 mol % Pd) furnished (S)-332 over a reduced 18 h in 96% yield with 89% ee. Using 
these reaction conditions and increasing the scale 17 times (3.73 mmol) provided (S)-332 
with identical 89% ee, although in a slightly diminished 82% yield. 
Scheme 2.4.1. Low Catalyst Loading Palladium(II)-Catalyzed Enantioselective Allylic 
Alkylation 
 
All reported yields are isolated yields. Enantiomeric excess (ee) was 
determined by analytical chiral SFC. a Pd(OAc)2 (0.15 mol %), (S)-
168 (1.50 mol %) used. 
 
2.5  CONCLUSION 
 In conclusion, we have disclosed the first general method for the construction of a-
quaternary-containing cyclopentanones by enantioselective palladium-catalyzed 
decarboxylative allylic alkylation. The reaction manifold proved optimal when electron-
deficient (S)-(p-CF3)3-t-BuPHOX ((S)-168) was employed, providing a variety of 
Pd(OAc)2 (0.30 mol %)






CO2Et CO2Et0.19 mmol 17, 20 °C, 28 h, 98% yield, 91% eea
0.22 mmol 17, 28 °C, 18 h, 96% yield, 89% ee 
3.73 mmol 17, 28 °C, 15 h, 82% yield, 89% ee
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substituted cyclopentanone products in up to near-quantitative yield and with up to 94% 
ee. Additionally, the enantioselective allylic alkylation was found to be tolerant of allyl 
fragments substituted at the 2-position. Employment of low-catalyst loading, 
palladium(II)-mediated reaction conditions was successfully accomplished, facilitating the 
synthesis of a-quaternary cyclopentanones on increased scale in a cost-effective manner. 
Currently, our lab is pursuing the further development of this technology through substrate 
scope extension and application in natural product synthesis. 
2.6  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
2.6.1  MATERIALS AND METHODS 
 Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried or oven-dried glassware under an argon or nitrogen atmosphere using dry, 
deoxygenated solvents (distilled or passed over a column of activated alumina).18 
Commercially obtained reagents were used as received with the exception of Pd(OAc)2, 
Pd2(dba)3, tetrakis(triphenylphosphine)palladium(0), and TBAT, which were stored in a 
nitrogen-filled glovebox. (S)-t-BuPHOX,4c (S)-(CF3)3-t-BuPHOX,4b (R)-(CF3)3-i-
PrPHOXMe2,4a,19 (S)-(CF3)2-i-PrPHOXPh2,20 allyl 2-oxocyclopentanecarboxylate,21 2-
phenylallyl alcohol,22 2-(p-methylbenzyl)-cyclopentanone,23 and 2,2-dimethyl-5-oxo-
cyclopenanecarboxylic acid methyl ester24 were prepared by known methods. Reactions 
requiring external heat were modulated to the specified temperatures using an IKAmag 
temperature controller.  Reaction progress was monitored by TLC, which was performed 
using E. Merck silica gel 60 F254 precoated glass plated (0.25 mm) and visualized by UV 
fluorescence quenching, potassium permanganate, or p-anisaldehyde staining. Silicycle 
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SiliaFlash® P60 Academic Silica gel (particle size 40-63 nm) was used for column 
chromatography. 1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 MHz 
and 126 MHz, respectively), Varian Mercury 300 spectrometer (300 MHz and 75 MHz, 
respectively), and a Bruker AV III HD spectrometer equipped with a Prodigy liquid 
nitrogen temperature cryoprobe (400 MHz and 101 MHz, respectively) and are reported in 
terms of chemical shift relative to CHCl3 (d 7.26 and d 77.16, respectively). 19F NMR 
spectra were recorded on a Varian Inova 500 spectrometer (470 MHz) and are reported in 
terms of absolute chemical shift according to IUPAC standard recommendations from 
CFCl3.25  Data for 1H NMR are reported as follows: chemical shift (d ppm) (multiplicity, 
coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sept = septet, m = multiplet, and br s = broad 
singlet. Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer 
using thin films deposited on NaCl plates and are reported in frequency of absorption (cm–
1). Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm path-length cell and are reported as: [a]DT 
(concentration in g/100 mL, solvent). Analytical SFC was performed with a Mettler SFC 
supercritical CO2 analytical chromatography system utilizing Chiralpak (AD-H) or 
Chiracel (OD-H, OJ-H or OB-H) columns (4.6 mm x 25 cm) obtained from Daicel 
Chemical Industries, Ltd. Analytical chiral HPLC was performed with an Agilent 1100 
Series HPLC utilizing chiralcel OD-H or OJ (4.6 mm x 25 cm) obtained from Daicel 
Chemical Industries, Ltd., with visualization at 254 and 210 nm.  High resolution mass 
spectra were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H 
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High Resolution Mass Spectrometer in fast atom bombardment (FAB+) ionization mode 
or a Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray 
ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or mixed 
(ESI/APCI) ionization mode. Julabo Presto LH45 was used to control reaction 
temperatures inside the nitrogen-filled glovebox. 
2.6.2  EXPERIMENTAL PROCEDURES 
 
2-Chlorodiallyl adipate (351): Esterification using alcohol S1 was adapted from the 
literature.3d Adipic acid (800 mg, 5.47 mmol, 1.00 equiv), 2-chloroallyl alcohol (350, 1.30 
mL, 16.4 mmol, 3.00 equiv), and p-TsOH  (3.0 mg, 0.03 mmol, 0.03 equiv) were added to 
a flask and diluted in benzene (8.00 mL, 0.68 M). The flask was then fitted with a Dean-
Stark trap filled with additional benzene. The reaction flask was heated to reflux with 
stirring for 16 h, at which time the starting material had been completely consumed 
(determined by TLC analysis, 9:1 Pentane:Et2O). The reaction solution was cooled to 23 
°C, washed with saturated aqueous NaHCO3 (10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude oil was purified by column chromatography (SiO2, 10% 
Et2O in pentane) to afford ester 351 (1.62 g, >99% yield) as a pale yellow oil; Rf = 0.21 
(9:1 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 5.49–5.38 (m, 4H), 4.68–4.63 (m, 4H), 
2.46–2.37 (m, 4H), 1.78–1.65 (m, 4H); 13C NMR (101 MHz, CDCl3) d 172.5 (C), 136.1 
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1740, 1637, 1419, 1374, 1134, 1077, 899, 720, 640 cm-1; HRMS (FAB+) m/z calc’d for 
C12H16Cl2O4 [M+H]+: 295.0504, found: 295.0516. 
 
2-Phenyldiallyl adipate (353): Esterification of 352 was adapted from the literature.3d A 
flask charged with alcohol 352 (5.10 g, 38.0 mmol, 1.90 equiv), adipic acid (2.93 g 20.0 
mmol, 1.00 equiv), and 4-(dimethylamino)-pyridine (DMAP, 1.88 g, 15.4 mmol, 0.77 
equiv), was evacuated and filled with argon (3 x 5 minutes). Dichloromethane (77 mL, 
0.26 M) was added and the solution was cooled to 0 °C (ice/H2O bath) with stirring. 
Diisopropylcarbodiimide (DIC, 6.20 mL, 39.6 mmol, 1.98 equiv) was added dropwise and 
the reaction mixture was allowed to stir for 5 minutes. The cooling bath was then removed 
and the solution was allowed to warm to ambient temperature (ca. 23 °C). After 11 h, the 
consumption of starting material was complete (as determined by TLC analysis, 12:1 
hexanes:EtOAc) and the reaction was filtered through filter paper and then diluted with 
dichloromethane (200 mL). The solution was washed with 0.1 M aqueous HCl (200 mL), 
saturated aqueous NaHCO3 (100 mL), and brine (100 mL). The combined organics were 
dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by 
column chromatography (SiO2, 7.7% EtOAc in hexanes) to provided diallyladipate 353 
(7.06 g, 93% yield) as a pale orange oil; Rf = 0.15 (12:1 hexanes:EtOAc); 1H NMR (400 
MHz, CDCl3) d 7.45–7.37 (m, 4H), 7.41–7.24 (m, 6H), 5.54 (d, J = 0.9 Hz, 2H), 5.35 (q, J 
= 1.2 Hz, 2H), 4.98 (d, J = 1.2 Hz, 4H), 2.36–2.23 (m, 4H), 1.61–1.56 (m, 4H); 13C NMR 
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115.3 (CH2), 65.6 (CH2), 33.9 (CH2), 24.3 (CH2); IR (thin film, NaCl) 2943, 1734, 1631, 
1496, 1444, 1387, 1165. 1076, 1026, 910, 709, 778 cm-1; HRMS (FAB+) m/z calc’d for 
C24H26O4 [M+H]+: 379.1904, found: 379.1908. 
 
2-Chloroallyl 2-oxocyclopentanecarboxylate (354):  Dieckmann condensation was 
adapted from the literature.21 A flask was charged with NaH (60% dispersion in mineral 
oil, 140 mg, 3.5 mmol, 1.04 equiv) and subsequently evacuated and re-filled with argon (3 
x 5 minutes). THF (17 mL, 0.20 M) was added followed by 2-chlorodiallyl adipate (351, 
1.00 g, 3.40 mmol, 1.00 equiv).  The reaction was then placed into a preheated 40 °C oil 
bath. After 16 h, the consumption of starting material was complete (as determined by TLC 
analysis, 9:1 hexanes:EtOAc) and the reaction was removed from the heating bath and 
allowed to cool to ambient temperature (ca. 23 °C). After cooling, the reaction was 
quenched with 1.0 M aqueous HCl (20 mL). The resultant solution was extracted with 
EtOAc (3 x 30 mL). The combined organics were washed with brine (90 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, 10% EtOAc in hexanes) to furnish b-ketoester 354 (502 mg, 73% 
yield) as a clear colorless oil; Rf = 0.27 (9:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) 
d 5.56 (q, J = 1.4 Hz, 1H), 5.44 (dd, J = 1.9, 0.9 Hz, 1H), 4.74 (qt, J = 13.9, 1.0 Hz, 2H), 
3.35–3.17 (m, 1H), 2.45–2.27 (m, 4H), 2.19 (ddq, J = 13.2, 7.8, 5.3 Hz, 1H), 2.01–1.82 (m, 
1H); 13C NMR (101 MHz, CDCl3) d 211.9 (C), 168.6 (C), 135.3 (C), 115.1 (CH2), 66.5 
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1730, 1656, 1639, 1405, 1333, 1295, 1248, 1179, 1108, 1003, 961, 901, 833 cm-1; HRMS 
(FAB+) m/z calc’d for C9H12O3Cl [M+H]+: 203.0475, found: 203.0470. 
 
2-Phenylallyl 2-oxocyclopentanecarboxylate (355):  Dieckmann condensation was 
adapted from the literature.3d A flask was charged with NaH (60% dispersion in mineral 
oil, 216 mg, 9.02 mmol, 1.10 equiv) and subsequently evacuated and re-filled with argon 
(3 x 5 minutes). Toluene (31.0 mL, 0.26 M) was added followed by 2-phenyldiallyl adipate 
(353, 3.10 g, 8.20 mmol, 1.00 equiv).  The reaction was then placed in a preheated 100 °C 
oil bath. After 16 h, the consumption of starting material was complete (as determined by 
TLC analysis, 8:2 hexanes:EtOAc) and the reaction was removed from the heating bath 
and allowed to cool to ambient temperature (ca. 23 °C). After cooling, the reaction was 
quenched with 1 M HCl (12.5 mL) and saturated aqueous NH4Cl (25 mL). The resultant 
solution was extracted with Et2O (3 x 30 mL). The combined organics were washed with 
a 50:50 mixture of H2O and brine (90 mL), dried over Na2SO4, filtered, and concentrated 
in vacuo. The crude solution was purified by column chromatography (SiO2, 20% EtOAc 
in hexanes) to afford b-ketoester 355 (1.54 g, 77% yield) as a faint pink oil; Rf = 0.42 (8:2 
hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) d 7.45–7.40 (m, 2H), 7.39–7.28 (m, 3H), 
5.56 (d, J = 0.9 Hz, 1H), 5.40 (q, J = 1.2 Hz, 1H), 5.12–4.96 (m, 2H), 3.28–3.06 (m, 1H), 
2.38–2.18 (m, 4H), 2.15–1.98 (m, 1H), 1.93–1.76 (m, 1H); 13C NMR (101 MHz, CDCl3) 
d 212.2 (C), 169.2 (C), 142.2 (C), 138.0 (C), 128.6 (CH), 128.2 (CH), 126.2 (CH), 115.5 
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3467, 3083, 3056, 2962, 1725, 1574, 1496, 1450, 1400, 1341, 1294, 1249, 1180, 1106, 
1025, 959, 914, 833, 778, 708 cm-1; HRMS (APCI/ESI) m/z calc’d for C15H17O3 [M+H]+: 
245.1182, found: 245.1173. 
 
Allyl 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (357):  Acylation of 356 was adapted 
from the literature.3d A flask was charged with NaH (60% dispersion in mineral oil, 500 
mg, 20.8 mmol, 2.50 equiv) and subsequently evacuated and re-filled with argon (3 x 5 
minutes). THF (10.8 mL, 1.92 M) was added and the resultant solution was cooled to 0 °C 
(ice/H2O bath). A solution of 1-indanone (356, 1.10 g, 8.30 mmol, 1.00 equiv) in THF (2.6 
mL, 3.20 M) was added dropwise. The solution was allowed to warm to room temperature 
(ca. 23 °C). After 15 minutes, diallyl carbonate (1.79 mL, 12.5 mmol, 1.50 equiv) was 
added dropwise. After 16 h, the consumption of starting material was complete (as 
determined by TLC analysis, 12:1 hexanes:EtOAc) and the solution was quenched with 
saturated aqueous NH4Cl and extracted with EtOAc (3 x 20 mL). The combined organics 
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was 
purified by column chromatography (SiO2, 7.7% EtOAc in hexanes) to provided b-
ketoester 357 (1.62 g, 91% yield) as a purple oil; Rf = 0.25 (12:1 hexanes:EtOAc). b-
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Allyl 2,2-dimethyl-5-oxocyclopentane-1-carboxylate (359): A solution of 358 (400 mg, 
2.35 mmol, 1.00 equiv) in toluene (1.96 mL, 1.20 M) was added zinc powder (31 mg, 0.47 
mmol, 0.20 equiv) and allyl alcohol (799 µL, 11.8 mmol, 5.00 equiv). The reaction mixture 
was allowed to stir at reflux. After 24 h the consumption of starting material was complete 
(as determined by TLC analysis, 9:1 hexanes:EtOAc). The crude solution was directly 
purified by column chromatography (SiO2, 10% Et2O in hexanes) to furnish 
cyclopentanone 359 (309 mg, 67% yield) as a clear colorless oil; Rf = 0.24 (9:1 
hexanes:Et2O); 1H NMR (400 MHz, CDCl3) d 5.91 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.34 
(dq, J = 17.2, 1.5 Hz, 1H), 5.25 (dq, J = 10.4, 1.2 Hz, 1H), 4.62 (ddt, J = 5.9, 3.0, 1.4 Hz, 
2H), 2.97–2.91 (m, 1H), 2.55–2.31 (m, 2H), 2.01 (ddd, J = 12.8, 9.1, 5.7 Hz, 1H), 1.82–
1.65 (m, 1H), 1.22 (s, 3H), 1.10 (s, 3H); 13C NMR (101 MHz, CDCl3) d 213.0 (C), 168.6 
(C), 131.8 (CH), 118.9 (CH2), 65.8 (CH), 65.7 (CH2), 41.0 (C), 36.8 (CH2), 36.1 (CH2), 
29.1 (CH3), 24.1 (CH3); IR (thin film, NaCl) 2959, 2872, 1757, 1761, 1734, 1729, 1647, 
1610, 1616, 1458, 1390, 1370, 1363, 1319, 1234, 1219, 1190, 1159, 1112, 1032, 991, 934, 
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2-(p-methylbenzyl)-1-triethylsiloxy-1-cyclopentene (361): To a solution of 
cyclopentanone 360 (300 mg, 1.59 mmol, 1.00 equiv) and sodium iodide (310 mg, 2.00 
mmol, 1.30 equiv) in acetonitrile (2.65 mL, 0.60 M) had Et3N (357 µL, 2.54 mmol, 1.60 
equiv) added dropwise. After 5 minutes of stirring, TESCl (347 µL, 2.07 mmol, 1.30 equiv) 
was added dropwise. After 6 hours of stirring, consumption of starting was complete (as 
determined by TLC analysis, 19:1 hexanes:Et2O). Crude solution was extracted with 
pentane (4 x 5 mL), the combined organic layers were washed with brine, dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography (SiO2, 0.5% Et3N, 1% Et2O in hexanes) to provide silyl enol ether 361 
(164 mg, 34%) as a pale yellow oil; Rf = 0.62 (19:1 hexanes:Et2O); 1H NMR (400 MHz, 
C6D6) d 7.21 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 7.7 Hz, 2H), 3.52 (s, 2H), 2.30 (dddd, J = 
8.6, 7.3, 3.4, 1.7 Hz, 2H), 2.19 (dddd, J = 9.5, 7.2, 3.0, 1.3 Hz, 2H), 2.13 (s, 3H), 1.72 – 
1.61 (m, 2H), 1.01 (t, J = 7.9 Hz, 9H), 0.65 (q, J = 7.8 Hz, 6H); 13C NMR (101 MHz, C6D6) 
d 147.6 (C), 138.2 (C), 135.1 (C), 129.3 (CH), 129.0 (CH), 115.8 (C), 34.2 (CH2), 33.0 
(CH2), 31.2 (CH2), 21.1 (CH3), 20.1 (CH2), 7.1 (CH3), 5.9 (CH2); IR (thin film, NaCl) 3044, 
2954, 2876, 2845, 1895, 1681, 1512, 1458, 1412, 1378, 1341, 1306, 1240, 1107, 1045, 
1016, 974, 888, 859, 746, 680 cm–1; HRMS (FAB+) m/z calc'd for C19H30OSi [M]+: 
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General Procedure A: a-Quaternary b-Ketoester Cyclopentanone Synthesis 
 
The alkylation b-ketoester 362 was adapted from the literature.3d b-ketoester 262 (500 mg, 
2.97 mmol, 1.00 equiv) was added to a suspension of anhydrous K2CO3 (822 mg, 5.95 
mmol, 2.00 equiv) in acetone (3.00 mL, 1.00 M). To the reaction mixture was added 
iodomethane (0.370 mL, 5.95 mmol, 2.00 equiv). The resultant solution was placed in a 
preheated 50 °C oil bath. After 14 h, the consumption of starting material was complete (as 
determined by TLC analysis, 9:1 Pentane:Et2O) and the reaction was removed from the 
heating bath and allowed to cool to ambient temperature (ca. 23 °C). After cooling, the 
solution was filtered with grade 4 filter paper and concentrated in vacuo. The crude product 
was purified by column chromatography (SiO2, 10% Et2O in pentane) to furnish b-
ketoester 363 (477 mg, 88% yield) as a clear colorless oil; Rf = 0.23 (9:1 Pentane:Et2O); 
1H NMR (400 MHz, CDCl3) d 5.88 (ddt, J = 17.3, 10.5, 5.6 Hz, 1H), 5.29 (dq, J = 17.2, 
1.6 Hz, 1H), 5.23 (dq, J = 10.5, 1.3 Hz, 1H), 4.60 (dq, J = 5.6, 1.4 Hz, 2H), 2.61–2.38 (m, 
2H), 2.39–2.26 (m, 1H), 2.14–1.98 (m, 1H), 2.02–1.80 (m, 2H), 1.33 (s, 3H); 13C NMR 
(101 MHz, CDCl3) d 215.8 (C), 172.0 (C), 131.7 (CH), 118.3 (CH2), 65.8 (CH2), 56.0 (C), 
37.7 (CH2), 36.2 (CH2), 19.6 (CH3), 19.5 (CH2). IR (thin film, NaCl) 3462, 3086, 2973, 
2886, 1752, 1731, 1648, 1457, 1406, 1375, 1316, 1273, 1153, 1064, 976, 939, 842, 814, 








K2CO3, acetone, 50 °C
88% yield
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2-Phenylallyl 1-methyl)-2-oxocyclopentanecarboxylate (364):  Prepared by using 
general procedure A above from 2-phenylallyl 2-oxocyclopentanecarboxylate (355, 1.64 
mmol), using iodomethane as the electrophile, and purified by column chromatography 
(SiO2, 10% Et2O in pentane) to afford b-ketoester 364 (292 mg, 69% yield) as a clear 
colorless oil; Rf = 0.25 (9:1 Pentane:Et2O);  1H NMR (400 MHz, CDCl3) d 7.43–7.28 (m, 
5H), 5.52 (q, J = 0.8 Hz, 1H), 5.33 (q, J = 1.3 Hz, 1H), 5.06 (ddd, J = 13.4, 1.5, 0.7 Hz, 
1H), 4.96 (ddd, J = 13.3, 1.3, 0.7 Hz, 1H), 2.46–2.34 (m, 1H), 2.31–2.18 (m, 2H), 1.94–
1.74 (m, 3H), 1.29 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 215.8 (C), 172.1 (C), 142.5 
(C), 138.0 (C), 128.6 (CH), 128.2 (CH), 126.2 (CH), 115.4 (CH2), 66.6 (CH2), 56.1 (C), 
37.7 (CH2), 36.3 (CH2), 19.61 (CH3), 19.59 (CH2); IR (thin film, NaCl) 3467, 2972, 1750, 
1729, 1496, 1457, 1405, 1374, 1316, 1262, 1230, 1150, 1063, 1027, 973, 911, 840, 778, 
709 cm-1; HRMS (FAB+) m/z calc’d for C16H19O3 [M+H]+: 259.1334, found: 259.1347. 
 
2-Phenylallyl 1-ethyl)-2-oxocyclopentanecarboxylate (365): Prepared by using general 
procedure A above from 2-phenylallyl 2-oxocyclopentanecarboxylate (355, 1.63 mmol), 
using iodoethane as the electrophile, and purified by column chromatography (SiO2, 10% 
Et2O in pentane) to provide b-ketoester 365 (288 mg, 65% yield) as a clear colorless oil; 
Rf = 0.29 (9:1 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 7.42–7.28 (m, 5H), 5.52 (d, J 
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= 13.4, 1.3, 0.6 Hz, 1H), 2.50–2.32 (m, 1H), 2.32–2.11 (m, 2H), 1.94 (dq, J = 14.1, 7.5 Hz, 
1H), 1.89–1.78 (m, 3H), 1.62 (dq, J = 14.0, 7.4 Hz, 1H), 0.83 (t, J = 7.5 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) d 215.0 (C), 170.9 (C), 142.6 (C), 138.1 (C), 128.6 (CH), 128.2 (CH), 
126.2 (CH), 115.5 (CH2), 66.5 (CH2), 61.0 (C), 38.2 (CH2), 32.3 (CH2), 26.9 (CH2), 19.6 
(CH2), 9.3(CH3); IR (thin film, NaCl) 3460, 2968, 2881, 1749, 1725, 1635, 1496, 1457, 
1405, 1318, 1294, 1223, 1142, 1078, 1027, 977, 915, 824, 779, 709 cm-1; HRMS (FAB+) 
m/z calc’d for C17H21O3 [M+H]+: 273.1491, found: 273.1480. 
 
2-Chloroallyl 1-ethyl)-2-oxocyclopentanecarboxylate (366): Prepared by using general 
procedure A above from 2-chloroallyl 2-oxocyclopentanecarboxylate (354, 0.99 mmol), 
using iodoethane as the electrophile, and purified by column chromatography (SiO2, 5% 
Et2O in pentane) to furnish b-ketoester 366 (228 mg, 80% yield) as a clear colorless oil; Rf 
= 0.3 (8:2 Pentane:Et2O); 1H NMR d 5.46 (q, J = 1.4 Hz, 1H), 5.39 (dd, J = 1.8, 0.8 Hz, 
1H), 4.75–4.59 (m, 2H), 2.60–2.49 (m, 1H), 2.49–2.38 (m, 1H), 2.34–2.21 (m, 1H), 2.14–
1.90 (m, 4H), 1.67 (dq, J = 13.9, 7.4 Hz, 1H), 0.92 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) d 214.7 (C), 170.4 (C), 135.5 (C), 115.3 (CH2), 66.5 (CH2), 61.0 (C), 38.3 (CH2), 
32.3 (CH2), 26.9 (CH2), 19.7 (CH2), 9.3 (CH3); IR (thin film, NaCl) 3466, 3115, 2970, 
2882, 1755, 1732, 1639, 1458, 1405, 1382, 1319, 1294, 1222, 1132, 1082, 1030, 904, 820, 
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2-Chloroallyl 1-(3-ethoxy-3-oxopropyl)-2-oxocyclopentanecarboxylate (367): 
Prepared by using general procedure A above from 2-chloroallyl 2-
oxocyclopentanecarboxylate (354, 0.99 mmol), using ethyl acrylate as the electrophile, and 
purified by column chromatography (SiO2, 20% Et2O in pentane) to afford b-ketoester 367 
(132 mg, 44% yield) as a clear colorless oil; Rf = 0.1 (8:2 Pentane:Et2O); 1H NMR d 5.46 
(dt, J = 2.2, 1.2 Hz, 1H), 5.43–5.39 (m, 1H), 4.75–4.61 (m, 2H), 4.12 (q, J = 7.1 Hz, 2H), 
2.58–2.47 (m, 2H), 2.47–2.39 (m, 1H), 2.39–2.19 (m, 3H), 2.13–1.88 (m, 4H), 1.24 (t, J = 
7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 214.1 (C), 173.0 (C), 170.3 (C), 135.4 (C), 
115.7 (CH2), 66.7 (CH2), 60.7 (CH2), 59.4 (C), 38.1 (CH2), 33.8 (CH2), 29.9 (CH2), 28.5 
(CH2), 19.8 (CH2), 14.3 (CH3); IR (thin film, NaCl) 3459, 2978, 1730, 1638, 1448, 1377, 
1180, 1109, 1023, 905, 642 cm-1; HRMS (FAB+) m/z calc’d for C14H20O5Cl [M+H]+: 
303.0999, found: 303.0986. 
 
Allyl 1-(3-ethoxy-3-oxopropyl)-2-oxocyclopentanecarboxylate (331): Prepared by 
using general procedure A above from allyl 2-cyclopentanonecarboxylate (362, 8.97 
mmol), using ethyl acrylate as the electrophile, and purified by column chromatography 
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colorless oil; Rf = 0.20 (8:2 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 5.83 (ddt, J = 
17.2, 10.4, 5.6 Hz, 1H), 5.33–5.11 (m, 2H), 4.55 (dt, J = 5.6, 1.4 Hz, 2H), 4.06 (q, J = 7.2 
Hz, 2H), 2.54–2.38 (m, 2H), 2.36 (ddd, J = 8.7, 6.3, 1.1 Hz, 1H), 2.32–2.12 (m, 3H), 2.08–
1.77 (m, 4H), 1.19 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 214.2 (C), 172.9 
(C), 170.7 (C), 131.5 (CH), 118.6 (CH2), 65.9 (CH2), 60.6 (CH2), 59.3 (C), 37.9 (CH2), 
33.7 (CH2), 29.8 (CH2), 28.4 (CH2), 19.6 (CH2), 14.2 (CH3); IR (thin film, NaCl) 3453, 
3086, 2979, 1731, 1648, 1451, 1377, 1182, 1113, 1025, 985, 939, 852 cm-1; HMRS (APCI) 
m/z calc’d for C14H21O5 [M+H]+:  269.1384, found: 269.1389. 
 
Allyl 1-ethyl-2-oxocyclopentanecarboxylate (368): Prepared by using general procedure 
A above from allyl 2-cyclopentanonecarboxylate (362, 9.17 mmol), using iodoethane as 
the electrophile, and purified by column chromatography (SiO2, 10% Et2O in hexanes) to 
afford b-ketoester 368 (1.53 g, 85% yield) as a clear colorless oil; Rf = 0.23 (9:1 
hexanes:Et2O); characterization data match known literature values.3d 
 
Allyl 1-isopropyl-2-oxocyclopentanecarboxylate (369): Prepared by using general 
procedure A above from allyl 2-cyclopentanonecarboxylate (362, 8.99 mmol), using 2-
iodopropane as the electrophile, and purified by column chromatography (SiO2, 10% to 
30% Et2O in hexanes) to provide b-ketoester 369 (1.55 g, 82% yield) as a clear colorless 
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Allyl 1-(cyanomethyl)-2-oxocyclopentanecarboxylate (370): Prepared by using general 
procedure A above from allyl 2-cyclopentanonecarboxylate (362, 2.66 mmol), using 
acrylonitrile as the electrophile, and purified by column chromatography (SiO2, 50% Et2O 
in pentane) to afford b-ketoester 370 (589 mg, 30% yield) as a clear colorless oil; Rf = 0.20 
(8:2 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 5.96–5.76 (m, 1H), 5.37–5.20 (m, 2H), 
4.67–4.54 (m, 2H), 2.67–2.41 (m, 4H), 2.41–2.26 (m, 1H), 2.26–2.15 (m, 1H), 2.14–1.88 
(m, 4H); 13C NMR (101 MHz, CDCl3) d 213.7 (C), 170.1 (C), 131.2 (CH), 119.4 (C), 119.3 
(CH2), 66.4 (CH2), 58.7 (C), 37.9 (CH2), 34.1 (CH2), 29.5 (CH2), 19.8 (CH2), 13.2 (CH2); 
IR (thin film, NaCl) 2962, 2247, 1748, 1726, 1648, 1451, 1362, 1261, 1232, 1164, 1115, 
938, 824 cm-1; HMRS (ESI+) m/z calc’d for C12H16O3N [M+H]+:  222.1125, found: 
222.1127. 
 
Allyl 1-((1,3-dioxoisoindolin-2-yl)methyl)-2-oxocyclopentanecarboxylate (371):  
Prepared by using general procedure A above from allyl 2-cyclopentanonecarboxylate 
(362, 8.83 mmol), using (N-chloromethyl)phthalimide as the electrophile, and purified by 
column chromatography (SiO2, 20% to 30% EtOAc in hexanes) to furnish b-ketoester 371 
(1.56 g, 54% yield) as a white amorphous solid; Rf = 0.27 (6:3 hexanes:EtOAc); 
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Allyl 1-(4-methoxybenzyl)-2-oxocyclopentanecarboxylate (372):  Prepared by using 
general procedure A above from allyl 2-cyclopentanonecarboxylate (362, 8.88 mmol), 
using 4-methoxybenzyl chloride as the electrophile, and purified by column 
chromatography (SiO2, 9% EtOAc in hexanes) to provide b-ketoester 372 (2.56 g, 95% 
yield) as a clear colorless oil; Rf = 0.17 (11:1 hexanes:EtOAc); characterization data match 
known literature values.3d 
 
Allyl 1-benzyl-2-oxocyclopentanecarboxylate (373): Prepared by using general 
procedure A above from allyl 2-cyclopentanonecarboxylate (362, 8.86 mmol). using 
benzyl bromide as the electrophile, and purified by column chromatography (SiO2, 10% 
Et2O in pentane) to furnish b-ketoester 373 (824 mg, 36% yield) as a clear colorless oil; Rf 
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Allyl 1-(4-methylbenzyl)-2-oxocyclopentanecarboxylate (374):  Prepared by using 
general procedure A above from allyl 2-cyclopentanonecarboxylate (362, 8.79 mmol), 
using 4-methylbenzyl bromide as the electrophile, and purified by column chromatography 
(SiO2, 10% Et2O in pentane) to afford b-ketoester 374 (2.13 g, 89% yield) as a clear 
colorless oil; Rf = 0.20 (9:1 Pentane:Et2O); characterization data match known literature 
values.3d 
 
Allyl 2-oxo-1-(4-(trifluoromethyl)benzyl)cyclopentanecarboxylate (375):  Prepared by 
using general procedure A above from allyl 2-cyclopentanonecarboxylate (362, 9.10 
mmol), using 4-trifluoromethylbenzyl bromide as the electrophile, and purified by column 
chromatography (SiO2, 10% Et2O in pentane) to furnish b-ketoester 375 (1.93 g, 65% 
yield) as an amorphous solid; Rf = 0.20 (9:1 Pentane:Et2O); characterization data match 
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Allyl 2-methyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (376):  Prepared by using 
general procedure A above from allyl 1-oxo-2,3-dihydro-1H-indene-2-carboxylate (357, 
1.84 mmol), using iodomethane as the electrophile, and purified by column 
chromatography (SiO2, 7.7% EtOAc in hexanes) to provide b-ketoester 376 (361 mg, 85% 
yield) as a pale yellow oil; Rf = 0.23 (12:1 hexanes:EtOAc); characterization data match 
known literature values.26 
 
Allyl 2-fluoro-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (377): TiCl4 (18 µL, 167 
µmol, 0.09 equiv) was added to a solution of indanone 357 (400 mg, 1.85 mmol, 1.00 
equiv) in acetonitrile (18.5 mL, 0.10 M). After 10 minutes, Selectfluor® (786 mg, 2.22 
mmol, 1.20 equiv) was added. After 3 h, the starting material had been completely 
consumed (determined by TLC analysis, 8:2 Pentane:Et2O) The solution was partitioned 
between H2O (100 mL) and Et2O (25 mL), extracted with Et2O (3 x 30 mL). The combined 
organics were dried over MgSO4, filtered, and concentrated in vacuo. Crude product was 
filtered through a silica plug (Et2O) to provide b-ketoester 377 (421 mg, 97% yield) as an 
amorphous orange solid; Rf = 0.23 (8:2 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 7.84 
(dt, J = 7.7, 1.0 Hz, 1H), 7.70 (td, J = 7.5, 1.3 Hz, 1H), 7.59–7.39 (m, 2H), 5.84 (ddt, J = 
17.2, 10.5, 5.7 Hz, 1H), 5.35–5.16 (m, 2H), 4.70 (dq, J = 5.7, 1.3 Hz, 2H), 3.92–3.72 (m, 
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NMR (101 MHz, CDCl3) d 195.2 (d, J = 18.2 Hz, C), 167.1 (d, J = 28.0 Hz, C), 150.9 (d, 
J = 3.7 Hz, C), 136.9 (CH), 133.4 (C), 130.8 (CH), 128.8 (CH), 126.7 (d, J = 1.5 Hz, CH), 
125.8 (CH), 119.4 (CH2), 94.7 (d, J = 201.8 Hz, C), 66.8 (CH2), 38.4 (d, J = 23.7 Hz, CH2); 
IR (thin film, NaCl) 3585, 3435, 3078, 2943, 1761, 1720, 1603, 1465, 1423, 1363, 1272, 
1181, 1155, 1067, 994, 917, 806, 751, 721, 692 cm-1; HRMS (ESI+) m/z calc’d for 
C13H12FO3 [M+H]+: 235.0765, found: 235.0768. 
 
Allyl 2,2-dimethyl-1-(4-methylbenzyl)-5-oxocyclopentane-1-carboxylate (378): 
Prepared by using general procedure A above from allyl 2,2-dimethyl-5-oxocyclopentane-
1-carboxylate (359, 1.48 mmol) and using 4-methylbenzyl chloride as the electrophile. 
Purified by column chromatography (SiO2, 10% Et2O in hexanes) to furnish b-ketoester 
378 (61 mg, 14% yield) as a clear colorless oil; Rf = 0.12 (9:1 hexanes:Et2O); 1H NMR d 
7.29 (d, J = 8.1 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 5.99 (ddt, J = 17.2, 10.6, 5.4 Hz, 1H), 
5.35 (dq, J = 17.2, 1.7 Hz, 1H), 5.19 (dq, J = 10.5, 1.5 Hz, 1H), 5.08 (s, 2H), 4.68 (dt, J = 
5.4, 1.6 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 2.37 (s, 3H), 1.69 (t, J = 7.4 Hz, 2H), 1.24 (s, 
6H); 13C NMR (101 MHz, CDCl3) d 167.7 (C), 165.0 (C), 137.8 (CH), 133.9 (CH), 133.0 
(CH), 129.3, 127.0, 117.3 (CH2), 113.4 (C), 71.5 (CH2), 64.1 (CH2), 43.0 (C), 37.2 (CH2), 
29.1 (CH2), 27.9 (CH3), 21.3 (CH3); IR (thin film, NaCl) 2948, 1685, 1617, 16517, 1457, 
1370, 1356, 1283, 1224, 1170, 1087, 1047, 1020, 994, 929, 801, 788 cm–1; HRMS (FAB+) 
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Allyl 3,3-dimethyl-1-(4-methylbenzyl)-2-oxocyclopentane-1-carboxylate (379): The 
alkylation of 374 was adapted from the literature.27 A flask was charged with sodium 
hydride (60% dispersion in mineral oil, 61.7 mg, 1.54 mmol, 3.00 equiv) and subsequently 
evacuated and re-filled with argon (3 x 5 minutes). DME (6 mL, 0.63 M) was added 
followed by methyliodide (0.16 mL, 2.57 mmol, 5.00 equiv) and b-ketoester 374 (140 mg, 
0.514 mmol, 1 equiv). The heterogeneous solution was heated to 55 °C with stirring. After 
2 hours, the consumption of starting was complete (as determined by TLC analysis, 9:1 
Pentane:Et2O). The solution was poured into water, and extracted with Et2O (3 x 5 mL), 
dried over MgSO4, filtered, and concentrated in vacuo. The crude solution was purified by 
flash chromatography (SiO2, 5% Et2O in hexanes) to afford b-ketoester 379 (80 mg, 52% 
yield) as a clear colorless oil; Rf = 0.60 (9:1 Pentane:Et2O); 1H NMR d 7.05 (d, J = 7.9 Hz, 
2H), 7.01 (d, J = 8.1 Hz, 2H), 5.89 (ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 5.32 (dq, J = 17.2, 1.5 
Hz, 1H), 5.24 (dq, J = 10.4, 1.3 Hz, 1H), 4.62 (ddt, J = 5.6, 2.7, 1.4 Hz, 2H), 3.14 (s, 2H), 
2.38–2.31 (m, 1H), 2.30 (s, 3H), 1.97 (ddd, J = 13.6, 8.5, 7.2 Hz, 1H), 1.78 (ddd, J = 12.8, 
8.4, 7.2 Hz, 1H), 1.41 (ddd, J = 12.7, 7.2, 5.4 Hz, 1H), 1.08 (s, 3H), 0.70 (s, 3H); 13C NMR 
(101 MHz, CDCl3) d 218.5 (C), 171.3 (C), 136.6 (C), 133.5 (C), 131.7 (CH), 130.6 (CH), 
129.1 (CH), 118.8 (CH2), 66.2 (CH2), 62.4 (C), 46.2 (C), 39.1 (CH2), 35.5 (CH2), 28.1 
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1515, 1457, 1380, 1361, 1315, 1252, 1197, 1183, 1130, 1061, 993, 977, 931, 888, 817, 775 
cm–1; HRMS (FAB+) m/z calc'd for C19H25O3 [M+H]+: 301.1798, found 301.1808. 
General Procedure B: Pd-Catalyzed Enantioselective Allylic Alkylation 
 
In a nitrogen-filled glovebox, separate stock solutions of Pd2(dba)3 (2.50 mg/mL), (S)-
(CF3)3-t-Bu-PHOX ((S)-168, 10.0 mg/mL), and b-ketoester 365 (100. mg/mL) in toluene 
were prepared. Pd2(dba)3 (1.92 mL, 4.8 mg, 5.20 µmol, 0.0275 equiv) and (S)-(CF3)3-t-Bu-
PHOX ((S)-168, 0.67 mL, 6.7 mg, 11.4 µmol, 0.06 equiv) were added to a 20 mL 
scintillation vial and placed in a pre-chilled 20 °C stirrer. After 20 minutes, the solution 
was diluted with toluene (2.69 mL, 20 °C) followed by b-ketoester 365 (0.517 mL, 51.7 
mg, 0.19 mmol, 1.00 equiv) in one portion (total volume 5.8 mL, 0.033 M). After 20 h, the 
consumption of starting material was complete (as determined by TLC analysis, 19:1 
Pentane:Et2O). The crude solution was directly purified by column chromatography (SiO2, 
100% pentane then 5% Et2O in pentane) to furnish cyclopentanone (S)-347 (43 mg, 98% 
yield) as a clear colorless oil; Rf = 0.20 (19:1 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) 
d 7.37–7.26 (m, 5H), 5.26 (d, J = 1.7 Hz, 1H), 5.07 (dt, J = 1.8, 0.9 Hz, 1H), 2.77 (dd, J = 
13.8, 1.1 Hz, 1H), 2.62 (d, J = 13.8 Hz, 1H), 2.17–2.04 (m, 1H), 1.99–1.84 (m, 1H), 1.82–
1.66 (m, 3H), 1.66–1.60 (m, 1H), 1.51–1.31 (m, 2H), 0.79 (t, J = 7.5 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) d 223.2 (C), 146.1 (C), 142.3 (C), 128.3 (CH), 127.6 (CH), 126.8 (CH), 
117.4 (CH2), 52.8 (C), 40.0 (CH2), 38.4 (CH2), 31.9 (CH2), 28.8 (CH2), 18.8 (CH2), 8.8 










Pd2(dba)3 (2.75 mol %)
(S)-(p-CF3)3-t-BuPHOX ((S)-168, 6.00 mol %)
toluene (0.033 M), 20 °C
98% yield
94% ee
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1380, 1306, 1268, 1160, 1083, 1028, 902, 778, 700 cm–1; HRMS (APCI/ESI) m/z calc'd 
for C16H21O [M+H]+: 229.1587, found 229.1589; [a]D 25 –40.78 (c 0.510, CHCl3, 94% ee). 
 
2-(2-Phenyl)allyl-2-methylcyclopentanone ((S)-346): Prepared by using general 
procedure B from b-ketoester 364 (0.19 mmol), reaction time = 27.5 h. Purified by column 
chromatography (SiO2, 5% Et2O in pentane) to provide cyclopentanone (S)-346 (39 mg, 
95% yield) as a clear colorless oil; Rf = 0.11 (19:1 Pentane:Et2O); 1H NMR (400 MHz, 
CDCl3) d 7.37–7.26 (m, 5H), 5.27 (d, J = 1.7 Hz, 1H), 5.08 (dt, J = 1.8, 1.0 Hz, 1H), 2.74 
(dd, J = 13.7, 1.1 Hz, 1H), 2.62 (d, J = 13.8 Hz, 1H), 2.29–2.14 (m, 1H), 2.04–1.90 (m, 
1H), 1.88–1.65 (m, 3H), 1.51–1.37 (m, 1H), 0.91 (s, 3H); 13C NMR (101 MHz, CDCl3) d 
223.3 (C), 146.1 (C), 142.5 (C), 128.4 (CH), 127.6 (CH), 126.8 (CH), 117.3 (CH2), 49.0 
(C), 41.8 (CH2), 37.6 (CH2), 35.4 (CH2), 22.6 (CH3), 18.8 (CH2); IR (thin film, NaCl) 3078, 
2960, 1734, 1623, 1491, 1457, 1405, 1160, 1061, 900, 778, 701 cm–1; HRMS (APCI/ESI) 
m/z calc'd for C15H19O [M+H]+: 215.21436, found 215.21430; [a]D 25 –99.32 (c 0.445, 
CHCl3, 90% ee). 
 
2-(2-Chloro)allyl-2-ethylcyclopentanone ((S)-348): Prepared by using general procedure 
B from b-ketoester 366 (0.19 mmol), reaction time = 28.5 h. Purified by column 
chromatography (SiO2, 10% Et2O in pentane) to furnish cyclopentanone (S)-348 (26 mg, 
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CDCl3) d 5.24 (t, J = 0.9 Hz, 1H), 5.15 (t, J = 1.1 Hz, 1H), 2.61 (dd, J = 14.4, 1.1 Hz, 1H), 
2.49 (d, J = 14.4 Hz, 1H), 2.34–2.21 (m, 2H), 2.16–2.00 (m, 1H), 1.98–1.79 (m, 3H), 1.48 
(qd, J = 7.4, 3.1 Hz, 2H), 0.84 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 222.1 
(C), 139.5 (C), 116.3 (CH2), 51.8 (C), 44.1 (CH2), 38.2 (CH2), 32.1 (CH2), 28.6 (CH2), 18.9 
(CH2), 8.6 (CH3); IR (thin film, NaCl) 2965, 1734, 1629, 1458, 1405, 1382, 1260, 1158, 
1115, 1085, 886 cm–1. HRMS (FAB+) m/z calc'd for C10H16ClO [M+H]+: 187.0890, found 
187.0897; [a]D 25 –38.57 (c 0.165, CHCl3, 90% ee). 
 
2-(2-Chloro)allyl-2-(3-ethoxy-3oxopropyl)cyclopentanone ((S)-349): Prepared by using 
general procedure B from b-ketoester 367 (0.19 mmol), reaction time = 21 h. Purified by 
column chromatography (SiO2, 20% Et2O in pentane) to afford cyclopentanone (S)-349 
(42 mg, 85% yield) as a clear colorless oil Rf = 0.32 (8:2 Pentane:Et2O); 1H NMR (400 
MHz, CDCl3) d 5.33–5.23 (m, 1H), 5.18 (t, J = 1.2 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 2.59 
(dd, J = 14.4, 1.1 Hz, 1H), 2.51 (d, J = 14.4 Hz, 1H), 2.40–2.21 (m, 4H), 2.19–2.05 (m, 
1H), 2.03–1.72 (m, 5H), 1.24 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 221.1 
(C), 173.3 (C), 138.9 (C), 116.7 (CH2), 60.7 (CH2), 50.7 (C), 43.9 (CH2), 37.8 (CH2), 33.5 
(CH2), 30.1 (CH2), 29.1 (CH2), 18.8 (CH2), 14.3 (CH3); IR (thin film, NaCl) 2962, 1734, 
1629, 1375, 1304, 1267, 1191, 1025, 888 cm–1; HRMS (ESI) m/z calc'd for C13H20ClO3 
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2-Allyl-2-(3-ethoxy-3-oxopropyl)cyclopentanone ((S)-332): Prepared by using general 
procedure B above from b-ketoester 331 (0.19 mmol), reaction time = 8 h. Purified by 
column chromatography (SiO2, 20% Et2O in pentane) to provide cyclopentanone (S)-332 
(40 mg, 93% yield) as a clear colorless oil; Rf = 0.30 (8:2 Pentane:Et2O); 1H NMR (400 
MHz, CDCl3) d 5.66 (ddt, J = 16.4, 10.6, 7.4 Hz, 1H), 5.11–5.01 (m, 2H), 4.09 (q, J = 7.1 
Hz, 2H), 2.39–2.10 (m, 6H), 1.95–1.67 (m, 4H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CDCl3) d 221.9 (C), 173.5 (C), 133.4 (CH), 118.7 (CH2), 60.6 (CH2), 50.9 (C), 39.1 
(CH2), 38.3 (CH2), 33.3 (CH2), 29.7 (CH2), 29.2 (CH2), 18.7 (CH2), 14.3 (CH3); IR (thin 
film, NaCl) 3076, 2961, 1734, 1639, 1445, 1406, 1376, 1303, 1252, 1190, 1096, 1028, 919 
cm–1; HRMS (FAB+) m/z calc'd for C13H21O3 [M+H]+: 225.1491, found 225.1498; [a]D 25 
–18.69 (c 1.950, CHCl3, 91% ee). 
 
2-Allyl-2-methylcyclopentanone ((S)-333): Prepared by using general procedure B from 
b-ketoester 363 (0.38 mmol), reaction time = 31 h. Purified by column chromatography 
(SiO2, 5% Et2O in pentane) to furnish cyclopentanone (S)-333 (43 mg, 81% yield) as a 
clear colorless oil; Rf = 0.24 (19:1 Pentane:Et2O); [a]D 25 –72.21 (c 0.245, CHCl3, 86% ee); 
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2-Allyl-2-ethylcyclopentanone ((S)-334): Prepared by using general procedure B from b-
ketoester 368 (0.38 mmol), reaction time = 31 h. Purified by column chromatography 
(SiO2, 7% Et2O in pentane) to afford cyclopentanone (S)-334 (69 mg, 79% yield) as a clear 
colorless oil; Rf = 0.44 (10:1 hexanes:EtOAc); [a]D 25 –20.22 (c 0.340, Et2O, 88% ee); 
characterization data match known literature values.3d 
 
2-Allyl-2-isopropylcyclopentanone ((S)-335): Prepared by using general procedure B 
from b-ketoester 369 (0.38 mmol), reaction time = 36 h. Purified by column 
chromatography (SiO2, 5% Et2O in pentane) to provide cyclopentanone (S)-335 (39 mg, 
62% yield) as a clear colorless oil; Rf = 0.44 (10:1 hexanes:EtOAc); [a]D 25 +33.57 (c 0.315, 
CHCl3, 87% ee); characterization data match known literature values.3d 
 
2-Allyl-2-(cyanomethyl)cyclopentanone ((S)-336): Prepared by using general procedure 
B from b-ketoester 370 (0.19 mmol), except catalyst pre-stir ran for 40 minutes (20 minutes 
at 30 °C followed by another 20 minutes at 0 °C) and the reaction was run at 0 °C, reaction 
time = 23 h. Purified by column chromatography (SiO2, 40% Et2O in pentane) to afford 
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hexanes:Et2O); 1H NMR (400 MHz, CDCl3) d 5.68 (ddt, J = 16.9, 10.2, 7.4 Hz, 1H), 5.26–
5.07 (m, 2H), 2.52–2.21 (m, 4H), 2.18 (dt, J = 7.4, 1.2 Hz, 2H), 2.10–1.79 (m, 6H); 13C 
NMR (101 MHz, CDCl3) d 221.0 (C), 132.4 (CH), 119.7 (C), 119.5 (CH2), 50.6 (C), 38.4 
(CH2), 38.0 (CH2), 33.2 (CH2), 30.2 (CH2), 18.6 (CH2), 12.3 (CH2); IR (thin film, NaCl) 
2961, 2246, 1731, 1444, 1159, 921 cm–1; HRMS (EI+) m/z calc'd for C11H15NO [M]+: 
177.1154, found 177.1171; [a]D 25 –13.41 (c 0.450, CHCl3, 90% ee). 
 
2-Allyl-((1,3-dioxoisoindolin-2-yl)methyl)cyclopentanone ((S)-337): Prepared by using 
general procedure B from b-ketoester 371 (0.19 mmol), except catalyst pre-stir ran for 40 
minutes (20 minutes at 30 °C followed by another 20 minutes at 0 °C) and the reaction was 
run at 0 °C, reaction time = 23 h. Purified by column chromatography (SiO2, 20% Et2O in 
pentane) to afford cyclopentanone (S)-337 (48 mg, 93% yield) as a white amorphous solid; 
Rf = 0.50 (1:1 Pentane:Et2O); [a]D 25 –25.16 (c 0.305, CHCl3, 92% ee); characterization 
data match known literature values.3d 
 
2-Allyl-2-(4-methoxybenzyl)cyclopentanone ((S)-338): Prepared by using general 
procedure B from b-ketoester 372 (0.19 mmol), reaction time = 8 h. Purified by column 
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>99% yield) as a clear colorless oil; Rf = 0.25 (9:1 Pentane:Et2O); [a]D 25 +6.40 (c 0.275, 
CHCl3, 92% ee); characterization data match known literature values.3d 
 
2-Allyl-2-benzylcyclopentanone ((S)-339): Prepared by using general procedure B from 
b-ketoester 373 (0.19 mmol), reaction time = 13 h. Purified by column chromatography 
(SiO2, 7% Et2O in pentane) to furnish cyclopentanone (S)-339 (39 mg, 95% yield) as a 
clear colorless oil; Rf = 0.41 (9:1 Pentane:Et2O); 1H NMR (400 MHz, CDCl3) d 7.32–7.15 
(m, 3H), 7.16–7.08 (m, 2H), 5.75 (dddd, J = 17.0, 10.2, 7.8, 6.9 Hz, 1H), 5.18–5.05 (m, 
2H), 2.94 (d, J = 13.3 Hz, 1H), 2.62 (d, J = 13.3 Hz, 1H), 2.31 (ddt, J = 13.8, 7.0, 1.3 Hz, 
1H), 2.24–2.11 (m, 2H), 2.07–1.93 (m, 1H), 1.97–1.81 (m, 2H), 1.75 (ddq, J = 12.8, 8.7, 
7.0 Hz, 1H), 1.56–1.41 (m, 1H); 13C NMR (101 MHz, CDCl3) d 223.0 (C), 137.9 (C), 133.8 
(CH), 130.4 (CH), 128.3 (CH), 126.5 (CH), 118.8 (CH2), 53.3 (C), 41.8 (CH2), 41.0 (CH2), 
39.0 (CH2), 31.1 (CH2), 18.8 (CH2); IR (thin film, NaCl) 3027, 2960, 1733, 1639, 1495, 
1453, 1404, 1156, 997, 920, 757 cm–1; HRMS (FAB+) m/z calc'd for C15H19O [M+H]+: 
215.1436, found 215.1433; [a]D 25 +6.88 (c 1.950, CHCl3, 88% ee). 
O
(S)-339
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2-Allyl-2-(4-methylbenzyl)cyclopentanone ((S)-340): Prepared by using general 
procedure B from b-ketoester 374 (0.19 mmol), reaction time = 13 h. Purified by column 
chromatography (SiO2, 5% Et2O in pentane) to afford cyclopentanone (S)-340 (50 mg, 
93% yield) as a clear colorless oil; Rf = 0.39 (9:1 Pentane:Et2O); [a]D 25 +12.78 (c 0.835, 
CHCl3, 89% ee); characterization data match known literature values.3d 
 
2-Allyl-2-(4-(trifluoromethyl)benzyl)cyclopentanone ((S)-341): Prepared by using 
general procedure B from b-ketoester 375 (0.19 mmol), reaction time = 96 h. Purified by 
column chromatography (SiO2, 7% Et2O in pentane) to furnish cyclopentanone (S)-341 (30 
mg, 54% yield (83% yield based on recovered starting material 375) as a clear colorless 
oil; Rf = 0.59 (6:3 Pentane:Et2O); [a]D 25 +10.22 (c 0.540, CHCl3, 88% ee); characterization 
data match known literature values.3d 
 
2-Allyl-2-methyl-2,3-dihydro-1H-inden-1-one ((S)-344): Prepared by using general 
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chromatography (SiO2, 10% Et2O in pentane) to afford cyclopentanone (S)-344 (33 mg, 
93% yield) as a clear colorless oil; Rf = 0.36 (9:1 hexanes:EtOAc); [a]D 25 –59.24 (c 0.595, 
CHCl3, 84% ee); characterization data match known literature values.3d 
 
2-Allyl-2-Fluoro-2,3-dihydro-1H-inden-1-one ((S)-345): Prepared by using general 
procedure B above from b-ketoester 377 (0.19 mmol), reaction time = 13 h. Purified by 
column chromatography (SiO2, 5% Et2O in pentane) to provide cyclopentanone (S)-345 
(36 mg, >99% yield) as a clear colorless oil; Rf = 0.19 (19:1 Pentane:Et2O); [a]D 25 –75.79 
(c 0.585, CHCl3, 87% ee); characterization data match known literature values.7g 
 
(S)-2-allyl-5,5-dimethyl-2-(4-methylbenzyl)cyclopentan-1-one ((S)-380): Prepared by 
using general procedure B from b-ketoester 379 (0.19 mmol), reaction time = 48 h. Purified 
by column chromatography (SiO2, 3% Et2O in hexanes) to afford cyclopentanone (S)-380 
(32 mg, 66% yield) as a clear colorless oil Rf = 0.24 (19:1 hexanes:Et2O); 1H NMR (400 
MHz, CDCl3) d 7.07–7.03 (m, 2H), 6.97 (d, J = 8.0 Hz, 2H), 5.73 (dddd, J = 17.0, 10.1, 
7.8, 7.0 Hz, 1H), 5.14–5.01 (m, 2H), 2.87 (d, J = 13.3 Hz, 1H), 2.55 (d, J = 13.3 Hz, 1H), 
2.30 (s, 3H), 2.26 (ddt, J = 13.7, 7.0, 1.3 Hz, 1H), 2.17 – 2.10 (m, 1H), 1.89–1.72 (m, 2H), 
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3H); 13C NMR (101 MHz, CDCl3) d 136.1 (C), 134.8 (C), 134.1 (CH), 130.6 (CH), 128.9 
(CH), 118.7 (CH2), 54.5 (C), 45.6 (C), 41.7 (CH2), 41.6 (CH2), 35.0 (CH2), 27.4 (CH2), 
24.7 (CH3), 23.9 (CH3), 21.2 (CH3); IR (thin film, NaCl) 2958, 2867, 1731, 1513, 1459, 
1379, 1061, 997, 916, 812, 752 cm–1; HRMS (ESI) m/z calc'd for C18H25O [M+H]+: 
257.1900, found 275.1901;  [a]D 25 +13.67 (c 0.58, CHCl3, 73% ee). 
General Procedure C: Phenyl Ester Derivative Synthesis 
 
Ketone (S)-333 (34 mg, 0.25 mmol, 1.00 equiv) was diluted in H2O (2.34 mL, 0.11 M), 
acetonitrile (1.50 mL, 0.160 M), and EtOAc (1.50 mL, 0.16 M). Sodium periodate (NaIO4, 
342 mg, 1.60 mmol, 6.40 equiv) and ruthenium(III) trichloride (RuCl3, 4.7 µL, 0.1 M 
solution in H2O, 0.019 equiv) were added in single portions. The reaction was allowed to 
stir at ambient temperature (ca. 23 °C) for 4 h, at which time consumption of starting 
material was complete (as determined by TLC analysis, 19:1 Pentane:Et2O). Crude reaction 
mixture was filtered through a celite plug and extracted with a saturated solution of 
NaHCO3. The aqueous solution was acidified to pH 1 with 1 M HCl. Acidified aqueous 
solution was extracted with dichloromethane, dried over Na2SO4, filtered, and concentrated 
in vacuo. Crude solution was carried on with no further purification. 
A flask charged with carboxylic acid (S)-381 (0.25 mmol, 1.00 equiv), phenol (14 mg, 0.27 
mmol, 1.10 equiv), and 4-(dimethylamino)-pyridine (DMAP, 14 mg, 0.11 mol, 0.45 equiv) 
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M) was added and the solution was cooled to 0 °C (ice/H2O bath). Diisopropylcarbodiimide 
(DIC, 42.0 µL, 0.27 mmol, 1.10 equiv) was added dropwise and allowed to stir for 5 
minutes. The cooling bath was then removed and the solution was allowed to warm to 
ambient temperature (ca. 23 °C). After 11 h, the consumption of starting material was 
complete (as determined by TLC analysis, 9:1 hexanes:EtOAc) and the reaction was 
filtered through filter paper and then diluted with dichloromethane (200 mL). The solution 
was washed with 0.1 M aqueous HCl (200 mL), 1 M aqueous NaOH,  saturated aqueous 
NaHCO3 (100 mL), and brine (100 mL). The combined organics were dried over MgSO4, 
filtered, and concentrated in vacuo. The crude residue was purified by column 
chromatography (SiO2, 10% hexanes in EtOAc) to provide ester (S)-382 (33 mg, 57% yield 
over 2 steps) as a clear colorless oil; Rf = 0.24 (9:1 hexanes:EtOAc); 1H NMR (400 MHz, 
CDCl3) d 7.42–7.31 (m, 2H), 7.22 (ddt, J = 7.9, 6.9, 1.2 Hz, 1H), 7.09–6.99 (m, 2H), 2.92 
(d, J = 16.6 Hz, 1H), 2.72 (d, J = 16.6 Hz, 1H), 2.45–2.30 (m, 2H), 2.27–2.13 (m, 1H), 
2.09–1.94 (m, 1H), 1.97–1.81 (m, 2H), 1.13 (s, 3H); 13C NMR (101 MHz, CDCl3) d 221.7 
(C), 170.2 (C), 150.5 (C), 129.6 (CH), 126.1 (CH), 121.6 (CH), 46.5 (C), 41.6 (CH2), 37.3 
(CH2), 35.1 (CH2), 22.8 (CH3), 18.9 (CH2); IR (thin film, NaCl) 3459, 3066, 2964, 2873, 
1756, 1738, 1592, 1493, 1456, 1404, 1375, 1350, 1317, 1266, 1242, 1193, 1162, 1127, 
1070, 1023, 1006, 969, 925, 896, 817, 800, 772, 749, 772, 722, 698, 687 cm–1; HRMS 
(FAB+) m/z calc'd for C14H17O3 [M+H]+: 233.1178, found 233.1176; [a]D 25 –45.05 (c 
0.280, CHCl3, 86% ee). 
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(1-Ethyl-2-oxo-cyclopentyl)-acetic acid phenyl ester ((S)-383): Prepared by using 
general procedure C from cyclopentanone (S)-334 (0.25 mmol). Purified by column 
chromatography (SiO2, 10% EtOAc in hexanes) to furnish ester (S)-383 (46 mg, 75% yield 
over 2 steps) as an amorphous solid; Rf = 0.28 (9:1 hexanes:EtOAc); 1H NMR (400 MHz, 
CDCl3) d 7.39–7.33 (m, 2H), 7.21 (tt, J = 7.1, 1.1 Hz, 1H), 7.07–7.02 (m, 2H), 2.90 (d, J 
= 16.7 Hz, 1H), 2.73 (d, J = 16.7 Hz, 1H), 2.48– 2.27 (m, 2H), 2.14 (ddd, J = 13.1, 10.3, 
7.8 Hz, 1H), 2.06–1.94 (m, 2H), 1.95–1.80 (m, 1H), 1.53 (p, J = 7.4 Hz, 2H), 0.93 (t, J = 
7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) d 221.8 (C), 170.5 (C), 150.5 (C), 129.6 (CH), 
126.0 (CH), 121.6 (CH), 50.0 (C), 39.5 (CH2), 37.6 (CH2), 32.4 (CH2), 28.6 (CH2), 18.8 
(CH2), 8.6 (CH3); IR (thin film, NaCl) 3455, 3066, 2965, 2881, 1733, 1592, 1492, 1456, 
1404, 1383, 1349, 1262, 1238, 1190, 1161, 1125, 1024, 1006, 951, 926, 895, 810, 768, 
721, 688 cm–1; HRMS (APCI/ESI) m/z calc'd for C15H19O3 [M+H]+: 247.1329, found 
247.1327; [a]D 25 +2.45 (c 0.445, CHCl3, 88% ee). 
 
(1-(1-Methylethyl)-2-oxo-cyclopentyl)-acetic acid phenyl ester ((S)-384): Prepared by 
using general procedure C from cyclopentanone (S)-335 (0.20 mmol). Purified by column 
chromatography (SiO2, 10% EtOAc in hexanes) to afford ester (S)-384 (27 mg, 52% yield 
over 2 steps) as an amorphous white solid; Rf = 0.36 (9:1 hexanes:EtOAc); 1H NMR (400 
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2.94 (d, J = 16.6 Hz, 1H), 2.73 (d, J = 16.6 Hz, 1H), 2.56–2.42 (m, 1H), 2.33–2.20 (m, 1H), 
2.20–1.80 (m, 5H), 0.95 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) d 223.1 (C), 170.8 (C), 150.5 (C), 129.6 (CH), 126.0 (CH), 121.6 (CH), 52.9 (C), 
39.8 (CH2), 38.5 (CH2), 33.4 (CH), 29.7 (CH2), 18.9 (CH2), 18.4 (CH3), 17.6 (CH3); IR 
(thin film, NaCl) 2963, 1757, 1734, 1592, 1492, 1404, 1389, 1372, 1350, 1271, 1237, 1193, 
1162, 1127, 1069, 1023, 932, 898, 818, 764, 719, 687 cm–1; HRMS (FAB+) m/z calc'd for 
C16H21O3 [M+H]+: 261.1491, found 261.1495; [a]D 25 –45.05 (c 0.280, CHCl3, 88% ee). 
Low-Catalyst Loading, Pd(II)-Catalyzed Enantioselective Allylic Alkylation 
 
In a nitrogen-filled glovebox, stock solutions of Pd(OAc)2 (1.00 mg/mL), (S)-(CF3)3-t-Bu-
PHOX ((S)-168, 10.0 mg/mL), and b-ketoester 331 (100. mg/mL) in toluene were 
prepared. Pd(OAc)2 (64.0 µL, 0.064 mg, 0.285 µmol, 0.0015 equiv) and (S)-(CF3)3-t-Bu-
PHOX (0.17 mL, 1.69 mg, 2.85 µmol, 0.015 equiv) were added to a 20 mL scintillation 
vial and placed in a pre-chilled 20 °C stirrer. After 40 minutes, the solution was diluted 
with toluene (1.16 mL, 20 °C) followed by b-ketoester 331 (0.51 mL, 51.0 mg, 0.19 mmol, 
1.00 equiv) in one portion (total volume 1.9 mL, 0.10 M). After 28 h, the consumption of 
starting material was complete (as determined by TLC analysis, 19:1 Pentane:Et2O). The 
crude solution was directly purified by column chromatography (SiO2, 100% pentane then 
20% Et2O in pentane) to furnish (S)-332 (42 mg, 98% yield) as a clear colorless oil; Rf = 
0.30 (8:2 Pentane:Et2O); characterization data match those that are reported above. 
Pd(OAc)2 (0.15 mol %)
(S)-(p-CF3)3-t-BuPHOX ((S)-168, 1.50 mol %)
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Large Scale Low-Catalyst Loading, Pd(II)-Catalyzed Enantioselective Allylic 
Alkylation 
 
In a nitrogen filled glovebox, Pd(OAc)2 (2.49 mg, 11.1 µmol, 0.003 equiv) and (S)-(CF3)3-
t-Bu-PHOX 168 (65.7 mg, 0.111 µmol, 0.03 equiv) were added to a flask and diluted with 
toluene (37.3 mL, 0.10M). The solution stirred in the ambient glovebox atmosphere (ca. 
30 °C) for 40 minutes. b-ketoester 331 (1.00 g, 3.73 mmol, 1.00 equiv) was then added in 
one portion. After 15 h, the consumption of starting material was complete (as determined 
by TLC analysis, 19:1 Pentane:Et2O). The crude solution was directly purified by column 
chromatography (SiO2, 100% pentane then 20% Et2O in pentane) to furnish (S)-332 (682 
mg, 82% yield, 89% ee) as a clear colorless oil; Rf = 0.30 (8:2 Pentane:Et2O); 
characterization data match those that are reported above. 
Fluoride Triggered, Pd(0)-Catalyzed Enantioselective Allylic Alkylation 
 
In a nitrogen-filled glovebox, separate stock solutions of Pd2(dba)3 (2.50 mg/mL), (S)-
(CF3)3-t-Bu-PHOX ((S)-168, 10.0 mg/mL), and silyl enol ether 361 (100. mg/mL) in 
toluene were prepared. Pd2(dba)3 (1.92 mL, 4.8 mg, 5.20 µmol, 0.0275 equiv), (S)-(CF3)3-
t-Bu-PHOX ((S)-168, 0.67 mL, 6.7 mg, 11.4 µmol, 0.06 equiv), and TBAT (103 mg, 0.19 
Pd(OAc)2 (0.30 mol %)
(S)-(p-CF3)3-t-BuPHOX ((S)-168, 3.00 mol %)






Pd2(dba)3 (2.75 mol %)
(S)-(p-CF3)3-t-BuPHOX ((S)-168, 6.00 mol %)
TBAT (1 equiv)
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mmol, 1.00 equiv) were added to a 20 mL scintillation vial and placed in a pre-chilled 20 
°C well with stirring. After 20 minutes, the solution was diluted with toluene (2.69 mL, 20 
°C) followed by the addition of diallyl carbonate (28.7 µL, 0.20 mmol, 1.05 equiv) and 
silyl enol ether 361 (0.574 mL, 57.4 mg, 0.19 mmol, 1.00 equiv) in one portion (total 
volume 5.8 mL, 0.033 M). After 48 h, the consumption of starting material appeared stalled 
(as determined by TLC analysis, 19:1 Pentane:Et2O). The crude solution was directly 
purified by column chromatography (SiO2, 100% hexanes then 5% Et2O in hexanes) to 
furnish cyclopentanone (S)-340 (17 mg, 40% yield, 75% ee) as a clear colorless oil; 
characterization data match those that are reported above. 
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 Figure A1.2. Infrared spectrum (Thin Film, NaCl) of compound 331. 
 
 Figure A1.3. 13C NMR (101 MHz, CDCl3) of compound 331. 
 























































































































 Figure A1.5. Infrared spectrum (Thin Film, NaCl) of compound 332. 
 
 Figure A1.6. 13C NMR (101 MHz, CDCl3) of compound 332. 
 






















































































































 Figure A1.8. Infrared spectrum (Thin Film, NaCl) of compound 336. 
 
 Figure A1.9. 13C NMR (101 MHz, CDCl3) of compound 336. 
 





















































































































 Figure A1. 11. Infrared spectrum (Thin Film, NaCl) of compound 339. 
 
 Figure A1. 12. 13C NMR (101 MHz, CDCl3) of compound 339. 
 























































































































 Figure A1. 14. Infrared spectrum (Thin Film, NaCl) of compound 346. 
 
 Figure A1.15. 13C NMR (101 MHz, CDCl3) of compound 346. 
 





























































































































 Figure A1.17. Infrared spectrum (Thin Film, NaCl) of compound 347. 
 
 Figure A1.18. 13C NMR (101 MHz, CDCl3) of compound 347. 
 






















































































































 Figure A1.20. Infrared spectrum (Thin Film, NaCl) of compound 348. 
 
 Figure A1.21. 13C NMR (101 MHz, CDCl3) of compound 348. 
 


























































































































 Figure A1.23. Infrared spectrum (Thin Film, NaCl) of compound 349. 
 
 Figure A1.24. 13C NMR (101 MHz, CDCl3) of compound 349. 
 

























































































































 Figure A1.26. Infrared spectrum (Thin Film, NaCl) of compound 351. 
 
 Figure A1.27. 13C NMR (101 MHz, CDCl3) of compound 351. 
 


























































































































 Figure A1.29. Infrared spectrum (Thin Film, NaCl) of compound 353. 
 
 Figure A1.30. 13C NMR (101 MHz, CDCl3) of compound 353. 
 
























































































































 Figure A1.32. Infrared spectrum (Thin Film, NaCl) of compound 354. 
 
 Figure A1.33. 13C NMR (101 MHz, CDCl3) of compound 354. 
 
























































































































 Figure A1.35. Infrared spectrum (Thin Film, NaCl) of compound 355. 
 
 Figure A1.36. 13C NMR (101 MHz, CDCl3) of compound 355. 
 






















































































































 Figure A1.38. Infrared spectrum (Thin Film, NaCl) of compound 359. 
 
 Figure A1.39. 13C NMR (101 MHz, CDCl3) of compound 359. 
 






















































































































 Figure A1.41. Infrared spectrum (Thin Film, NaCl) of compound 361. 
 
 Figure A1.42. 13C NMR (101 MHz, C6D6) of compound 361. 
 


























































































































 Figure A1. 44. Infrared spectrum (Thin Film, NaCl) of compound 363. 
 
 Figure A1. 45. 13C NMR (101 MHz, CDCl3) of compound 363. 
 























































































































 Figure A1.47. Infrared spectrum (Thin Film, NaCl) of compound 364. 
 
 Figure A1.48. 13C NMR (101 MHz, CDCl3) of compound 364. 
 























































































































 Figure A1.50. Infrared spectrum (Thin Film, NaCl) of compound 365. 
 
 Figure A1.51. 13C NMR (101 MHz, CDCl3) of compound 365. 
 























































































































 Figure A1.53. Infrared spectrum (Thin Film, NaCl) of compound 366. 
 
 Figure A1.54. 13C NMR (101 MHz, CDCl3) of compound 366. 
 



























































































































 Figure A1.56. Infrared spectrum (Thin Film, NaCl) of compound 367. 
 
 Figure A1.57. 13C NMR (101 MHz, CDCl3) of compound 367. 
 























































































































 Figure A1.59. Infrared spectrum (Thin Film, NaCl) of compound 370. 
 
 Figure A1.60. 13C NMR (101 MHz, CDCl3) of compound 370. 
 























































































































 Figure A1.62. Infrared spectrum (Thin Film, NaCl) of compound 377. 
 
 Figure A1.63. 13C NMR (101 MHz, CDCl3) of compound 377. 
 












































































































































































































 Figure A1.66. Infrared spectrum (Thin Film, NaCl) of compound 378. 
 
 Figure A1.67. 13C NMR (101 MHz, CDCl3) of compound 378. 
 

























































































































 Figure A1.69. Infrared spectrum (Thin Film, NaCl) of compound 379. 
 
 Figure A1.70. 13C NMR (101 MHz, CDCl3) of compound 379. 
 




















































































































 Figure A1.72. Infrared spectrum (Thin Film, NaCl) of compound 380. 
 
 Figure A1.73. 13C NMR (101 MHz, CDCl3) of compound 380. 
 



























































































































 Figure A1.75. Infrared spectrum (Thin Film, NaCl) of compound 382. 
 
 Figure A1.76. 13C NMR (101 MHz, CDCl3) of compound 382. 
 




























































































































 Figure A1.78. Infrared spectrum (Thin Film, NaCl) of compound 383. 
 
 Figure A1.79. 13C NMR (101 MHz, CDCl3) of compound 383. 
 




























































































































 Figure A1.81. Infrared spectrum (Thin Film, NaCl) of compound 384. 
 
 Figure A1.82. 13C NMR (101 MHz, CDCl3) of compound 384. 
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Enantioselective Total Synthesis of Nigelladine A 
Via Late-Stage C–H Oxidation Enabled by an 
Engineered P450 Enzyme† 
 
3.1  INTRODUCTION 
 The field of organic synthetic chemistry has benefited greatly from the many recent 
advances in selective C–H functionalization.1  Indeed, chemical oxidations of C–H bonds 
are some of the most important transformations in synthetic chemistry because they allow 
for direct access to oxidized intermediates, without the need for synthetic handles or 
functional group interconversions.  Despite recent advances, there remain significant 
limitations regarding the regioselectivity of non-directed C–H oxidation reactions.  We 
envisioned that the recently isolated norditerpenoid alkaloids nigelladines A–C (385–387) 
and pyrroloquinoline alkaloid nigellaquinomine (388) (Figure 3.1.1)2 would present a 
challenging test bed to evaluate the viability of late-stage C–H oxidation methods. 
                                               
† This research was performed in collaboration with David K. Romney, an postdoctoral scholar of the Arnold 
group.  Additionally, this research has been published and adapted with permission Loskot, S. A.; Romney, 
D. K.; Arnold, F. A.; Stoltz, B. M. J. Am. Chem. Soc. 2017, 139, 10196–10199. 
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Figure 3.1.1. Structures of Nigelladines A–C and Nigellaquinomine 
 
With respect to nigelladine A, we believed that late-stage installation of the C7 
ketone would offer significant flexibility in how we chose to construct the highly 
conjugated core of alkaloid 385.  However, despite the abundance of chemical allylic 
oxidation conditions, there are relatively few examples of selective oxidation at a 2° carbon 
(e.g., C7) in the presence of a non-bridging 3° carbon (e.g., C10),3 since oxidation generally 
occurs at the position where hydrogen abstraction is most favorable.4  On the other hand, 
enzymes are well known to catalyze oxidation reactions with regioselectivity that defies 
conventional trends of chemical reactivity.  Despite this, enzymatic methods are often 
overlooked in total synthesis efforts due to a typically narrow substrate scope deriving from 
their exceptional specificity.  Fortunately, recent progress in the field of directed evolution 
has greatly increased the viability of biocatalysis in total synthesis by increasing the 
reactivity and selectivity of enzymes for non-native transformations.5,6  Biocatalytic C–H 
oxidations with engineered enzymes thus present an alternative approach that can 
circumvent the limitations of traditional chemical oxidations.  Nonetheless, even though 
there have been examples of the use of engineered enzymes for the functionalization of 
complex molecules,7 their application in total syntheses is still very limited. Herein we 
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selective late-stage allylic oxidation of unsaturated imine 389 via an engineered P450 
enzyme. 
3.2  RETROSYNTHETIC ANALYSIS 
Retrosynthetically, we surmised that selective late-stage allylic oxidation of 389 at 
C7 would be essential to the synthesis of enone 385 (Scheme 3.2.1).  Imine 389 could be 
generated by the cross-coupling of vinyl boronic ester 390 and bromide dienone 391.  Vinyl 
bromide 391 was envisioned to arise via annulation of enone 392, with the quaternary 
stereocenter constructed by an asymmetric allylic alkylation reaction from b-ketoester 
393.8  With this retrosynthetic analysis, we recognized that the strategically planned C–H 
oxidation would be particularly challenging due to issues of site selectivity.  Imine 389 
contains three different allylic carbon centers that could be susceptible to oxidation, a 1°, 
2°, and 3°, in addition to a relatively acidic α–carbon adjacent to the imine.  Together, the 
natural product combined with our strategic analysis unveiled a challenging problem for 
selective C–H functionalization that would need to be addressed in a successful synthesis. 
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Scheme 3.2.1. Retrosynthetic Analysis of Nigelladine A 
 
3.3  SYNTHESIS OF CROSS-COUPLING FRAGMENTS 
 In the forward direction, known enone 394 can be synthesized in excellent yield 
through a Stork-Danheiser transposition from 1,3-cyclohexanedione.9,10  Unfortunately, 
attempts to directly acylate the a-carbon of 394 resulted in low yields due to competing 
self-aldol additions.  To avoid these issues, we chose to increase the reactivity and steric 
environment of the enolate by synthesizing the 1,1-dimethyl hydrazone 395.11  Hydrazone 
395 was readily acylated then hydrolyzed, and the resulting b-ketoester 396 was 
subsequently methylated, providing our desired asymmetric allylic alkylation substrate 
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Scheme 3.3.1. Synthesis of Asymmetric Allylic Alkylation Precursor 
 
With b-ketoester 393 in hand, we evaluated a variety of reaction parameters for the 
key quaternary stereocenter-forming asymmetric allylic alkylation and determined that the 
use of (CF3)3-t-Bu-PHOX (168)12 in 2:1 hexanes–toluene with Pd2(dba)3 was optimal, 
generating desired enone 392 in 96% yield and 87% ee.  Standard Tsuji–Wacker oxidation 
of enone 392 using PdCl2 and CuCl under an atmosphere of oxygen generated the desired 
ketone,13 which subsequently underwent an aldol condensation to provide dienone 397 in 
good yield (76% yield over 2 steps).14  Enone 397 was then selectively mono-brominated 
to form vinyl bromide 391, the desired electrophilic cross-coupling fragment, in 83% yield 
on gram scale (Scheme 3.3.2).15 











1. LDA, THF, –78 °C


















1. PdCl2 (20 mol %)
CuCl (2 equiv)
DMF:H2O (9:1), 23 °C
2. KOH, xylenes 110 °C









Pd2(dba)3 (2.75 mol %)
(R)-CF3-t-BuPHOX (6.0 mol %)
(2:1) hexanes:toluene, 40 °C
96% yield, 87% ee
O
392
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The nucleophilic cross-coupling fragment, Vinyl boronic ester 390, was readily 
prepared in three steps from commercially available ethyl isobutyrate (398 ,scheme 3.3.3). 
Propargylation of ethyl isobutyrate followed by concomitant saponification yielded known 
acid 399. Curtius rearrangement of acid 399 followed by a Markovnikov hydroboration of 
the resultant alkyne 400 generated the desired nucleophilic cross-coupling fragment 390 in 
three steps. 
Scheme 3.3.3. Synthesis of the Nucleophilic Cross-Coupling Fragment 
 
3.4  CROSS-COUPLING AND ELABORATION TO THE CARBOCYCLIC 
CORE 
 The cross coupling of 390 and 391 was next evaluated for optimal reaction 
conditions.  Ultimately, we found that Buchwald’s 2nd generation precatalyst with XPhos 
(XPhos Pd G2)16 allowed for the union of 390 and 391 in 88% yield using only a slight 
excess (1.1 equiv) of 390 (Scheme 3.4.1).  Furthermore, triene 401 provided crystals 
suitable for X-ray diffraction and allowed us to ascertain absolute stereochemistry.17 
399
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Scheme 3.4.1. Cross-Coupling of Dienone 391 and Vinyl Boronic Ester 390 
 
With triene 401 in hand, we turned our attention to the synthesis of the heterocyclic 
portion of the alkaloid and the final stages of the synthesis.  Toward that end, triene 401 
was treated with trifluoroacetic acid (TFA) in CH2Cl2 to deprotect the amine, which 
spontaneously cyclized to form the requisite imine upon quenching with aqueous sodium 
bicarbonate (Scheme 3.4.2).  Fortuitously, upon removal of the aqueous layer, treatment 
with silica gel promoted isomerization of the exocyclic olefin into the ring, which, after 
purification, afforded the TFA salt of 389 in 75% yield (25% over 10 steps from enone 
394).18 
XPhos Pd G2 (3 mol %)
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Scheme 3.4.2. Synthesis of the Tricyclic Core of Nigelladine A 
 
3.5  CHEMICAL OXIDATION OF DESOXY-NIGELLADINE A 
 With only an allylic oxidation separating tricycle 389 from nigelladine A (385), we 
initiated a broad exploration of oxidation methods for installing an oxidation handle at the 
desired C7 position.  Unfortunately, the required site-selective C–H oxidation of 389 or the 
intermediate enone 397 proved intractable for traditional synthetic methods (Table 3.5.1).  
While numerous conditions were probed on both substrates,19,20 only a limited few effected 
oxidation at the desired position.  These reactions also exhibited poor selectivity, 
generating an inseparable mixture of mono-oxidation products, along with over-oxidized 
byproducts that constituted the majority of the product mixture.  We thus turned our 
attention to enzymes as a potential means to achieve the desired oxidation. 
75% yield
TFA, DCM, 23 °C;
then NaHCO3 (aq); then SiO2
389•TFA
NH
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Table 3.5.1. Attempted Chemical Oxidationsa 
 
a See section 3.8 for reaction conditions and description of the product 
distribution. b Approximated by separating the products on UHPLC-MS and 
comparing ion count of the various oxidation products. c Remaining percent 
balance were unidentified side products. d Numbers given in parenthesis 
indicate isolated yields of the oxidized product. e Protection of 389 as an N-
acyl enamide results in oxidation at C-14. f Shortened reaction time used to 
observe inherent regioselectivity without over oxidation. g Oxidation at C-5 
occurred. 
 
3.6  ENZYMATIC OXIDATION OF DESOXY-NIGELLADINE A 
 The cytochrome P450 enzyme from Bacillus megaterium (P450BM3) is a workhorse 
of protein engineering studies because it is soluble and self-contained, exhibits one of the 
fastest reaction rates of any P450-catalyzed hydroxylation (17,000 min–1 for arachidonic 
acid),5a and possesses good stability (t1/2 = 68 min at 50 °C).21  Since the substrate scope of 
the wild-type protein is mostly limited to long-chain fatty acids, many engineering efforts 
have focused on expanding the substrate scope of P450BM3 to accept larger and more 
complex substrates.  To this end, various approaches have been applied to develop 
biocatalysts derived from P450BM3 that perform regioselective C–H oxygenation of 
complex molecules for which the wild-type enzyme exhibits minimal activity.6c,22 
ConditionsSubstrate HPLC Yield of Oxygenation Products (%)
b,c,d
SeO2, DCM, 40 °C
Pd/C (10 wt%), TBHP, 0 °C
SeO2, DCM, 40 °C
Pd/C (10 wt%), TBHP, 0 °Cf
Cr(V) (1 equiv), MnO2
 CF3C6H5, 15-crown-5, 80 °C
Rh2(esp)2, T-HYDRO, 23 °C






















R' = H, OH, or t-BuOO
R'' =H, OH, t-BuOO, or O
R''' =H, OH, t-BuOO, or O
C1 C7 C10 Polyoxygenation
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However, these approaches involved extensive screening endeavors, often requiring high-
throughput screening and limiting them to substrates that were readily available.   
For biocatalysis to be a viable strategy for the late-stage of a total synthesis, it is 
desirable to identify a synthetically useful catalyst with minimal screening. Thus, we 
elected to screen a focused library of variants that had been previously engineered to accept 
large substrates,22 but had otherwise never encountered substrate 389.  To compare the 
catalysts, we chose to allow the reactions to proceed to only low conversion and compare 
the ratio of desired to undesired oxidation products (Table 3.6.1).  Encouragingly, wild-
type P450BM3 exhibited some selectivity for C7, although oxidation of the isopropyl C–H 
bond was favored 1.2:1 (Table 3.6.1, entry 1).  We then probed a small selection of 
engineered variants that all derive from the same parent (12 mutations from P450BM3).  
These enzymes were previously evolved for regioselective oxidation of methoxymethyl-
protected glycosides, but are distinct in that different combinations of active-site residues 
have been mutated to alanine.  The variant 2A1, in which leucine residues 75, 181, and 437 
are mutated to alanine, exhibited a worse selectivity compared to wild-type, favoring the 
isopropyl oxidation product, as well as an unidentified oxidation product (Table 3.6.1, 
entry 2).  The two other variants, however, exhibited a reversal in selectivity, favoring 
oxidation at the desired position in excess of 2:1 (Table 3.6.1, entries 3–4).  The best variant 
proved to be 8C7, which is identical to 2A1, but lacks the L437A mutation.  This variant 
favors oxidation at the desired position in a 2.8:1 ratio (Table 3.6.1, entry 4). 
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Table 3.6.1. Screening of Focused Library for Allylic Oxidation 
 
a See section 3.8 for full list of mutations. b 
Approximated by separating the products 
on UHPLC-MS and comparing ion count 
of C-7 oxidation product to all other mono-
oxygenation products (m/z = 286). See 
section 3.8 for more details. 
 
Since enzyme active sites are well known to bind substrate enantiomers differently, 
we wished to test if the stereochemistry of 389 would affect the activity or selectivity of 
8C7.  Using the Pd-catalyzed alkylation, we obtained both enantiomers of 389, which were 
then enriched to enantiopurity by chiral preparative HPLC.  Each enantiomer was then 
subjected to oxidation by catalyst 8C7.  Interestingly, at both short (15 min) and long (12 
h) reaction times, the enantiomers gave nearly identical results, although the R enantiomer 
exhibited a slightly higher initial rate by a factor of 1.3. 
Having achieved the desired regioselectivity, we then needed to improve the yield.  
Furthermore, we wished to supplant the stoichiometric use of NADPH, which is required 
if oxygen is used as the terminal oxidant.  Fortunately, we could use NADPH in catalytic 
amounts by regenerating it in situ with an alcohol dehydrogenase (ADH) and isopropanol 
as the terminal reductant.23  With these new conditions, we conducted the oxidation on a 
160 mg scale, followed by subjecting the crude product mixture to oxidation with Dess-
Martin periodinane, thus affording the natural product in 21% yield over both steps (43% 
yield based on recovered 389, Scheme 3.6.1).  The recovered starting material (389) was 
Entry Catalysta Active-SiteAla Substitutions
Desired/
Undesiredb
1 P450BM3 – 0.86
2 2A1 L75A, L181A, L437A 0.37
3 4H5 L75A, L177A, L181A 2.1
4 8C7 L75A, L181A 2.8
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competent in the same two-step procedure with no loss in efficiency (26% yield).24  Under 
these conditions, we observed up to 1700 turnovers to the C7 mono-oxygenation product. 
Scheme. 3.6.1. Completion of the Synthesis of Nigelladine A 
 
3.7  CONCLUSION 
In summary, we have completed the first total synthesis of nigelladine A in an 
expedient 12 steps and 5% overall yield (11% yield based on recovered 389).  The 
asymmetric allylic alkylation allowed for the construction of the quaternary center in high 
yield and enantioselectivity.  Expedient identification of engineered enzymes allowed for 
a site-selective 2° allylic oxidation without the need for extensive generational screening 
or reaction optimization. These results demonstrate that enzymatic transformations are 
capable of defying standard chemical limitations and should be included in the repertoire 
of reactions that are traditionally considered for the late stages of total syntheses.  
3.8  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
3.8.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried or oven-dried glassware under an argon or nitrogen atmosphere using dry, 
deoxygenated solvents (distilled or passed over a column of activated alumina).25 
Commercially obtained reagents were used as received with the exception of anhydrous 
cerium trichloride (CeCl3)10 dipalladium tris(dibenzylideneacetone) (Pd2(dba)3), palladium 
21% yield over 2 steps
43% yield






P450 8C7 (0.02 to 0.04 mol %)
NADP (10 mol %), i-PrOH, ADH
2.5% DMSO in KPi buffer (pH 8) 
23 °C , 12h
1.
DMP, CH2Cl2, 0 °C, 4h2.
OTFA
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(II) chloride (PdCl2), anhydrous copper (I) chloride (CuCl), bis(pinacolato)diboron 
(B2Pin2), anhydrous lithium chloride (LiCl), and anhydrous potassium acetate (KOAc), 
which were stored in a nitrogen-filled glovebox. Triethylamine (Et3N) and 
Diisopropylethylamine (i-Pr2NH) were distilled over potassium hydride prior to use, while 
allyl chloroformate was freshly distilled prior to use. N-bromosuccinimide was 
recrystallized prior to use.26 (S)-(CF3)3-t-BuPHOX,12 (R)-(CF3)3-t-BuPHOX,12 and Dess–
Martin periodinane27 were prepared by known methods. Reactions requiring external heat 
were modulated to the specified temperatures using an IKAmag temperature controller. 
Reaction progress was monitored by thin-layer chromatography (TLC), which was 
performed using E. Merck silica gel 60 F254 precoated glass plated (0.25 mm) and 
visualized by UV fluorescence quenching, potassium permanganate, p-anisaldehyde, or 
iodine staining. Silicycle SiliaFlash® P60 Academic Silica gel (particle size 40-63 nm) was 
used for column chromatography. 1H and 13C NMR spectra were recorded on a Varian 
Inova 500 (500 MHz and 126 MHz, respectively), Varian Mercury 300 spectrometer (300 
MHz and 75 MHz, respectively), Varian 600 MHz Spectrometer (600 MHz), and a Bruker 
AV III HD spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe 
(400 MHz and 101 MHz, respectively) and are reported in terms of chemical shift relative 
to CHCl3 (d 7.26 and d 77.16, respectively) and CH3OH (d 3.31 and d 39.00 respectively). 
Data for 1H NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling 
constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = doublet, 
t = triplet, q = quartet, p = pentet, sext = sextet, sept = septet, m = multiplet, and br s = 
broad singlet. Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 
spectrometer using thin films deposited on NaCl plates and are reported in frequency of 
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absorption (cm–1). Optical rotations were measured with a Jasco P-2000 polarimeter 
operating on the sodium D-line (589 nm), using a 100-mm path-length cell and are reported 
as: [a]DT (concentration in g/100 mL, solvent). Analytical SFC was performed with a 
Mettler SFC supercritical CO2 analytical chromatography system utilizing CHIRALCEL 
OB-H and CHIRALPAK IC columns (4.6 mm x 25 cm) obtained from Daicel Chemical 
Industries, Ltd. with visualization at 254, 230, and 210 nm. High resolution mass spectra 
were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H High 
Resolution Mass Spectrometer in fast atom bombardment (FAB+) ionization mode or a 
Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray 
ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or mixed 
(ESI/APCI) ionization mode. 
3.8.2  PROTOCOLS FOR PROTEIN EXPRESSION AND LYSIS 
The genes for wild-type P450BM3 and the variants were previously cloned into the 
pCWori vector, which was used to transform Escherichia coli DH5a.21 In addition to the 
mutations listed in Table 3.6.1, all variants had the following mutations: V78A F87V 
P142S T175I A184V S226R H236Q E252G A290V L353V I366V E442K. 
For protein expression, a culture (typically 5 mL) of lysogeny broth with 100 µg/mL 
of ampicillin (LBamp) was inoculated with a glycerol stock of E. coli DH5a containing the 
desired plasmid. This culture was shaken at 37 °C and 230 rpm. After 12 hours, the culture 
was used to inoculate an expression culture (1:100 v/v) of Terrific Broth containing 100 
µg/mL of ampicillin (TBamp) plus 0.1% by volume of trace metal mix (aqueous solution of 
50 mM FeCl3, 20 mM CaCl2, 10 mM MnSO4, 10 mM ZnSO4, 2 mM CoSO4, 2 mM CuCl2, 
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2 mM NiCl2, 2 mM Na2MoO4, 2 mM H3BO3). The expression culture was shaken at 37 °C 
and 230 rpm. After ~3 hours, the OD600 was 0.6–0.8, whereupon the culture was chilled in 
ice for 30 minutes, then induced with the addition of aminolevulinic acid (1 mM final 
concentration) and isopropyl b-d-thiogalactopyranoside (0.5 mM final concentration). The 
culture was then shaken at 230 rpm and 20 °C. After 16–20 hours, the culture was subjected 
to centrifugation at 5,000×g and 4 °C for 10 minutes. The supernatant was discarded, and 
then the cell pellet was stored at –30 °C until further use. 
For lysis, the cell pellet was thawed, and then suspended in 4 mL/mg of potassium 
phosphate buffer (100 mM, pH 8) that contained 1 mg/mL of hen egg white lysozyme and 
0.1 mg/mL of bovine pancreas DNase I. The suspension was shaken at 37 °C and 230 rpm 
(19 mm radius). After 1 hour, the culture was cooled on ice, then subjected to centrifugation 
at 15,000×g and 4 °C for 10 min. The supernatant was used directly in the biocatalytic 
transformation. To determine protein concentration, 900 µL of fivefold-diluted lysate was 
treated with a spatula tip of dithionite, then exposed to an atmosphere of carbon monoxide 
(CO) for 30 minutes. The absorbance of the CO-bound lysate at 450 nm minus the 
absorbance at 490 nm was converted to protein concentration using the extinction 
coefficient ε = 91 mM–1cm–1. 
3.8.3  EXPERIMENTAL PROCEDURES 
 
3-isobutoxycyclohex-2-en-1-one (403):28 1,3-cyclohexadione (402, 22.4 g, 200 mmol, 1.0 
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0.005 equiv) were added to a flask and diluted in benzene (123 mL, 1.6 M). The flask was 
then fitted with a Dean–Stark trap filled with additional benzene. The reaction flask was 
heated to reflux with stirring for 8 h, at which time the starting material had been 
completely consumed (determined by TLC analysis, 8:1 hexanes:EtOAc). The reaction 
mixture was cooled to ambient temperature (ca. 23 °C) and Et3N (0.7 mL, 5 mmol, 0.025 
equiv) was added. The crude reaction mixture was then concentrated in vacuo and distilled 
by short path distillation (Pressure 1.0 torr, neck temperature 118 °C, bath temperature 150 
°C) to provide vinylogous ester 403 (32.6 g, 97% yield) as a clear colorless oil; Rf = 0.5 
(8:1 hexanes:EtOAc); 1H NMR (300 MHz, CDCl3) δ 5.34 (s, 1H), 3.59 (d, J = 6.5 Hz, 2H), 
2.41 (t, J = 6.3 Hz, 2H), 2.34 (dd, J = 7.2, 6.0 Hz, 2H), 2.10–1.91 (m, 3H), 0.97 (dd, J = 
6.7, 0.7 Hz, 6H). All other characterization matches literature values.29 
 
3-isopropylcyclohex-2-en-1-one (394): In a nitrogen-filled glovebox, CeCl3 (49g, 200 
mmol, 1.5 equiv) was added to a round bottom flask with a magnetic stir bar. The flask 
was sealed with a rubber septum and removed from the glovebox. The flask was heated at 
140 °C under vacuum (ca. 1 Torr) with stirring for 8 h. CeCl3 was allowed to cool to 
ambient temperature (23 °C) and the flask was refilled with Ar. The CeCl3 was then cooled 
to 0 °C (H2O:ice bath) and diluted with THF (444 mL, 0.3 M) with vigorous stirred for 3 
h. The reaction flask was then cooled to –78 °C (dry ice:acetone bath) whereupon ester 403 
(22.4 g, 133 mmol, 1 equiv) was added. After 1h at –78 °C, i-PrMgCl (2.0 M in THF, 100 
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the starting material had been completely consumed (determined by TLC, 8:1 
hexanes:Et2O). The reaction was then quenched with 1 M HCl (300 mL) and allowed to 
warm to ambient temperature. The product was extracted from the biphasic mixture with 
Et2O (3 × 200 mL), and then the combined organic layers were washed with brine, dried 
over MgSO4, and concentrated in vacuo. The crude product can be purified by either flash 
chromatography (SiO2, 4:1 hexanes:Et2O) or by Kugelrohr distillation (pressure 1.0 Torr, 
115 °C) to provide enone 394 (16.8 g, 91% yield) as a pale yellow oil, which solidifies to 
a white solid upon cooling to –20 °C; Rf = 0.29 (4:1 hexanes:Et2O); 1H NMR (500 MHz, 
C6D6) δ 5.95 (q, J = 1.4 Hz, 1H), 2.17–2.10 (m, 2H), 1.88 (pd, J = 6.8, 1.0 Hz, 1H), 1.66–
1.60 (m, 2H), 1.47–1.38 (m, 2H), 0.74 (d, J = 6.9 Hz, 6H). All other characterization 
matches literature values.30 
 
2-(3-isopropylcyclohex-2-en-1-ylidene)-1,1-dimethylhydrazine (395): Hydrazone 
condensation was adapted from the literature.31 Enone 394 (8.2g, 59.0 mmol, 1 equiv), 
N,N-dimethylhydrazine (9 mL, 118 mmol, 2 equiv), TFA (0.1 mL), and benzene (120 mL, 
0.4 M) were added to a round-bottom flask. The flask was fitted with a Dean-Stark trap 
filled with additional benzene. The reaction flask was heated to reflux with stirring for 8 h, 
at which time the starting material had been completely consumed (determined by TLC 
analysis, 1:1 hexanes:EtOAc). The crude reaction mixture was then cooled to ambient 
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chromatography (SiO2, 1:1 hexanes:EtOAc) or short path distillation (pressure 1 Torr, neck 
temperature 130 °C, bath temperature 160 °C) to generate hydrazone 395 (9.7 g, 91% yield, 
1.7:1 E:Z ratio) as a yellow oil; Rf = 0.5 (E); 0.26 (Z) (1:1 hexanes:EtOAc); 1H NMR (400 
MHz, CDCl3) (E) δ 6.00 (q, J = 1.4 Hz, 1H), 2.59 (dd, J = 7.5, 5.8 Hz, 2H), 2.52 (s, 6H), 
2.33 (sept, J = 6.9 Hz, 1H), 2.20–2.16 (m, 2H), 1.79 (dtd, J = 7.5, 6.4, 5.6 Hz, 2H), 1.08 
(d, J = 6.9 Hz, 6H), (Z) δ 6.54 (q, J = 1.5 Hz, 1H), 2.49 (s, 6H), 2.43–2.33 (m, 3H), 2.21–
2.17 (m, 2H), 1.85–1.78 (m, 2H), 1.08 (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) 
(E) δ 164.9, 157.3, 121.1, 47.4, 35.6, 27.7, 26.2, 22.5, 21.0, (Z) δ 162.5, 160.2, 113.6, 47.9, 
36.0, 31.9, 27.7, 22.9, 21.1; IR thin film, NaCl) 2960, 2857, 2816, 2771, 1634, 1589, 1466, 
1436, 1383, 1362, 1327, 1304, 1267, 1251, 1222, 1200, 1154, 1142, 1089, 1022, 980, 969, 
890, 790 cm-1; HRMS (ES/APCI) m/z calc’d C11H21N2 [M+H]+: 181.1699, found: 
181.1705. 
 
Allyl 4-isopropyl-2-oxocyclohex-3-ene-1-carboxylate (396): A flame-dried round 
bottom flask was charged with diisopropylamine (i-Pr2NH, 9.58 mL, 68.4 mmol, 1.5 equiv) 
in THF (61 mL, 1.1 M) and cooled to 0 °C. A solution of n-BuLi in hexanes (2.3 M, 29.7 
mL, 68.4 mmol, 1.5 equiv) was added dropwise and the resulting solution was allowed to 
stir for 0.5 h at 0 °C. Hydrazone 395 (8.22 g, 45.6 mmol, 1 equiv) was added dropwise to 
the LDA solution, which was then stirred for 1 h at 0 °C. The reaction mixture was 




1. LDA, THF, –78 °C
2. 1 M HCl, THF, 50 °C
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1.5 equiv) in THF (320 mL, 0.2 M) at –78 °C. The solution was stirred for 1 h, at which 
time the starting material had been completely consumed (determined by TLC analysis, 
4:1 hexanes:EtOAc). The solution was quenched at –78 °C with aqueous NH4Cl (200 mL) 
and allowed to warm to ambient temperature. The product was extracted from the biphasic 
solution with Et2O (3 × 150 mL), and the combined organic layers were washed with brine, 
dried over MgSO4 and concentrated in vacuo. The crude compound was diluted with THF 
(230 mL, 0.2 M) and 1 M HCl (91.2 mL, 91.2 mmol, 2.0 equiv) and heated to 50 °C for 12 
h, at which time the starting material had been completely consumed (determined by TLC 
analysis, 4:1 pentane:Et2O). The product was extracted with Et2O (3 × 100 mL) and the 
combined organic layers were washed with brine, dried over MgSO4, and concentrated in 
vacuo. The crude product was purified by flash chromatography (SiO2, 9:1 
hexanes:EtOAc) to yield b-Ketoester 396 (7.96 g, 79% yield) as a pale yellow oil; Rf = 0.2 
(4:1 pentane:Et2O); 1H NMR (500 MHz, CDCl3) δ 5.98–5.85 (m, 2H), 5.32 (dd, J = 17.2, 
1.6 Hz, 1H), 5.22 (dd, J = 10.5, 1.3 Hz, 1H), 4.71–4.58 (m, 2H), 3.42–3.32 (m, 1H), 2.50–
2.29 (m, 4H), 2.24–2.17 (m, 1H), 1.09 (dd, J = 6.8, 0.9 Hz, 6H); 13C NMR (126 MHz, 
CDCl3) δ 194.3, 172.2, 170.1, 131.9, 123.0, 118.5, 65.8, 53.2, 35.8, 26.3, 26.0, 20.8, 20.6; 
IR thin film, NaCl) 2965, 2940, 2875, 1741, 1650, 1624, 1457, 1425, 1375, 1364, 1307, 
1275, 1216, 1166, 1151, 1050, 1027, 989, 884, 767 cm-1; HRMS (ES/APCI) m/z calc’d 
C13H19O3 [M+H]+: 223.1329, found: 223.1329. 
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Allyl 4-isopropyl-1-methyl-2-oxocyclohex-3-ene-1-carboxylate (393): NaH (60% 
dispersion, 3.3 g, 81.9 mmol, 1.4 equiv) was added to DMF (31.5 mL, 2.6 M) at 0 °C. The 
solution was then charged with b-Ketoester 396 (13 g, 58.4 mmol, 1.0 equiv) in a solution 
of DMF (25 mL, 2.3 M) and allowed to stir for 1 h at 0 °C. MeI (12.7 mL, 204.4 mmol, 
3.5 equiv) was added, followed by additional DMF (20 mL). The reaction was allowed to 
stir for 1.5 h, at which time the starting material had been completely consumed 
(determined by TLC analysis, 9:1 hexanes:EtOAc). The reaction was then quenched with 
water and the product was extracted with Et2O (40 mL × 3). The combined organic layers 
were washed with brine (3 × 50 mL), dried over Na2SO4, filtered, and concentrated in 
vacuo. The crude product was purified by flash chromatography (SiO2, 9:1 
hexanes:EtOAc) to generate b-Ketoester 393 (12.7 g, 92% yield) as a pale yellow oil; Rf = 
0.30 (9:1 hexanes:EtOAc); 1H NMR (500 MHz, CDCl3) δ 5.92 (dt, J = 2.1, 1.1 Hz, 1H), 
5.86 (ddt, J = 17.2, 10.5, 5.5 Hz, 1H), 5.28 (dq, J = 17.2, 1.6 Hz, 1H), 5.20 (dq, J = 10.5, 
1.3 Hz, 1H), 4.64 (ddt, J = 13.4, 5.6, 1.5 Hz, 1H), 4.56 (ddt, J = 13.4, 5.5, 1.5 Hz, 1H), 
2.53–2.37 (m, 3H), 2.33–2.26 (m, 1H), 1.87 (ddd, J = 13.0, 8.4, 5.0 Hz, 1H), 1.39 (s, 3H), 
1.09 (d, J = 6.9 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 197.4, 172.7, 170.7, 131.9, 122.8, 
118.3, 65.7, 52.9, 35.7, 33.6, 25.3, 20.9, 20.7, 20.5; IR thin film, NaCl) 2965, 2935, 2875, 
1731, 16678, 1626, 1456, 1425, 1375, 1302, 1248, 1217, 1170, 1105, 987, 26, 882, 771, 
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(R)-6-allyl-3-isopropyl-6-methylcyclohex-2-en-1-one (392): In a nitrogen filled 
glovebox, Pd2(dba)3 (725 mg, 0.79 mmol, 0.024 equiv) and (R)-(CF3)3-t-Bu-PHOX (1.3 g, 
2.2 mmol, 0.065 equiv) were added to a flask. The flask was sealed and removed from the 
glovebox. The catalyst and ligand were then diluted with a 2:1 hexanes:toluene (1 L, 
0.033M) and allowed to stir for 40 minutes at 40 °C. b-Ketoester 393 (8.0 g, 33.9 mmol, 
1.0 equiv) was then added in one portion. After 62 h, the consumption of starting material 
was complete (as determined by TLC analysis, 9:1 hexanes:EtOAc). The crude solution 
was directly purified by column chromatography (SiO2, 100% hexanes then 12:1 
hexanes:Et2O) to furnish enone 392 (6.25 g, 96% yield, 87% ee) as a pale yellow oil; Rf = 
0.46 (9:1 hexanes:EtOAc); 1H NMR (500 MHz, CDCl3) δ 5.79 (q, J = 1.4 Hz, 1H), 5.73 
(ddt, J = 16.8, 10.3, 7.4 Hz, 1H), 5.09–5.01 (m, 2H), 2.43–2.35 (m, 1H), 2.35–2.29 (m, 
3H), 2.16 (ddt, J = 13.7, 7.7, 1.2 Hz, 1H), 1.90 (ddd, J = 13.6, 6.9, 5.6 Hz, 1H), 1.71 (ddd, 
J = 13.6, 6.6, 5.4 Hz, 1H), 1.09 (d, J = 6.8 Hz, 6H), 1.05 (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 204.3, 169.8, 134.4, 122.4, 118.0, 43.7, 41.3, 35.6, 33.4, 24.8, 21.9, 20.9, 20.9; 
IR thin film, NaCl) 2964, 2929, 2873, 1663, 1627, 461, 1428, 1373, 1323, 1274, 1213, 
1126, 1107, 999, 912, 881, 613 cm-1; HRMS (ES/APCI) m/z calc’d C13H21O [M+H]+: 
193.1587, found: 193.1582; (R): [a]D25 +3.15° (c 1.215, CDCl3, 87% ee); (S): [a]D25 –
1.34° (c 0.675, CDCl3, 87% ee); SFC (OB-H (4 x 25 cm), 1% i-PrOH) (R) retention time: 
1.93 min, (S) retention time: 2.30 min. 
Pd2(dba)3 (2.4 mol %)
(R)-(CF3)3-t-Bu-Phox (6.5 mol %)
2:1 hexanes:toluene, 40 °C
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(R)-5-isopropyl-7a-methyl-1,6,7,7a-tetrahydro-2H-inden-2-one (397): A flask 
containing enone 392 (1.0 g, 5.2 mmol, 1.0 equiv) in 9:1 DMF:H2O (52 mL, 0.1 M) was 
charged with PdCl2 (0.18 g, 1 mmol, 0.2 equiv) and CuCl2 (1.0 g, 10.4 mmol, 2.0 equiv). 
The reaction was evacuated/backfilled (vacuum/O2) and allowed to stir for 14 h, at which 
time the consumption of starting material was complete (as determined by TLC analysis, 
8:2 hexanes:EtOAc). The reaction was then diluted with H2O and brine and the product 
was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with 
brine (3 × 100 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
product was purified by flash chromatography (SiO2, 9:1 hexanes:EtOAc to 8:2 
hexanes:EtOAc) to generate ketone 404 (1.02 g, 7:1 ketone:aldehyde) as a pale yellow oil 
which was carried on to the next reaction without further purification. 
Enone 404 (1.0 g, 4.8 mmol, 1.0 equiv) was dissolved in xylenes (53 mL) in a flask 
fitted with a Dean–Stark trap and a reflux condenser. Freshly powdered KOH (300 mg, 5.3 
mmol, 1.1 equiv) was added in one portion. The reaction was allowed to stir for 14 h at 
110 °C, at which time the consumption of starting material was complete (as determined 
by TLC analysis, 4:1 hexanes:EtOAc). The crude solution was directly purified by flash 
chromatography (SiO2, 100% hexanes then 9:1 hexanes:EtOAc) to furnish enone 397 (674 
mg, 76% yield over 2 steps) as a yellow oil; Rf = 0.24 (4:1 hexanes:EtOAc); 1H NMR (400 
MHz, CDCl3) δ 6.36 (d, J = 2.4 Hz, 1H), 5.69 (s, 1H), 2.46–2.28 (m, 4H), 2.20 (d, J = 17.4 
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Hz, 1H), 1.92 (ddd, J = 12.9, 5.3, 1.7 Hz, 1H), 1.71–1.62 (m, 1H), 1.15 (s, 3H), 1.11 (dd, 
J = 6.9, 0.9 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 208.1, 179.2, 159.3, 122.7, 116.4, 
51.7, 40.4, 35.9, 34.2, 25.8, 25.6, 21.5, 21.1; IR thin film, NaCl) 2962, 2927, 2872, 1698, 
1622, 1581, 1464, 1414, 1375, 1329, 1288, 1266, 1247, 1179, 1143, 898 882 cm-1; HRMS 
(ES/APCI) m/z calc’d C13H19O [M+H]+: 191.1430, found: 191.1440; (R): [a]D25 –435.36° 
(c 0.93, CDCl3, 87% ee); (S): [a]D25 +302.67° (c 0.59, CDCl3, 87% ee). 
 
(R)-3-bromo-5-isopropyl-7a-methyl-1,6,7,7a-tetrahydro-2H-inden-2-one (391): A 
flask covered in aluminum foil with enone 397 (100 mg, 0.53 mmol, 1.0 equiv) diluted 
with MeCN (16 mL, 0.03 M) and cooled to 0 °C. NBS (104 mg, 0.58 mmol, 1.1 equiv) 
dissolved in MeCN (1.6 mL, 0.3 M) was added dropwise to the reaction over 4 h via syringe 
pump. After complete addition of NBS, the reaction was allowed to stir for 1 h at 0 °C, at 
which time complete consumption of starting material was observed (determined by TLC 
analysis, 4:1hexanes:EtOAc). The reaction was concentrated in vacuo and purified directly 
by flash chromatography (9:1 hexanes:EtOAc) to yield vinyl bromide 391 (118 mg, 83% 
yield) as a yellow oil; Rf = 0.36 (4:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) δ 6.43 
(dq, J = 2.5, 0.9 Hz, 1H), 2.53–2.23 (m, 5H), 1.92 (ddd, J = 13.1, 5.1, 2.0 Hz, 1H), 1.64 
(ddd, J = 13.0, 11.1, 6.1 Hz, 1H), 1.17 (s, 3H), 1.15 (d, J = 6.9 Hz, 6H); 13C NMR (101 
MHz, CDCl3) δ 199.8, 173.6, 162.2, 115.4, 114.8, 49.6, 40.7, 36.2, 34.2, 26.2, 25.7, 21.5, 
21.1; IR thin film, NaCl) 2963, 2928, 2872, 1712, 1614, 1579, 1458, 1421, 1374, 1314, 
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269.0536, found: 269.0547; (R): [a]D25 –311.57° (c 0.875, CDCl3, 87% ee); (S): [a]D25 
+329.26° (c 1.245, CDCl3, 87% ee). 
 
2,2-dimethylpent-4-ynoic acid (399): Acid 399 was formed using known literature 
procedures32 as a pale orange amorphous solid; 1H NMR (400 MHz, CDCl3) δ 11.52 (bs, 
1H), 2.47 (d, J = 2.7 Hz, 2H), 2.04 (t, J = 2.7 Hz, 1H), 1.32 (s, 6H). All other 
characterization data match known literature values.32 
 
tert-butyl (2-methylpent-4-yn-2-yl)carbamate (400): A flask containing alkyne 399 (3.5 
g, 28 mmol, 1.0 equiv) in anhydrous t-BuOH (100 mL, 0.28 M) was charged with Et3N 
(5.9 mL, 42 mmol, 1.5 equiv) and diphenyl phosphoryl azide (DPPA, 6.7 mL, 30.8 mmol, 
1.1 equiv). The reaction was heated to reflux and allowed to stir for 24 h. The reaction was 
then concentrated in vacuo, dissolved in EtOAc (100 mL), and washed sequentially with 
5% citric acid and saturated NaHCO3. The organic layer was then dried over Na2SO4, 
filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography (SiO2, 5% EtOAc in hexanes) to generate alkyne 400 (3.3 g, 59% yield) 
as a white amorphous solid; Rf = 0.35 (12:1 hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) 
δ 4.59 (bs, 1H), 2.59 (d, J = 2.7 Hz, 2H), 2.00 (t, J = 2.7 Hz, 1H), 1.43 (s, 9H), 1.35 (s, 




1. LDA, Propargyl bromide
THF, –78 °C
2. 4 N KOH, EtOH, 23 °C
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film, NaCl) 3361, 3310, 2977, 2932, 1718, 1501, 1457, 1390, 1367, 1290, 1247, 1170, 




yl)carbamate (390): Hydroboration of 400 was adapted from a known procedure.33 In a 
nitrogen-filled glovebox, CuCl (420 mg, 4.3 mmol, 1.2 equiv) and LiCl (175 mg, 4.3 mmol, 
1.2 equiv) were distributed evenly between seven 1-dram vials (60 mg and 25 mg per vial 
respectively). DMF (0.85 mL, 0.6 M) was added to each vial and the resulting suspensions 
were stirred vigorously for 1 h. Each vial was then charged sequentially with KOAc (60 
mg, 0.61 mmol, 1.2 equiv), B2Pin2 (154 mg, 0.61 mmol, 1.2 equiv), and alkyne 400 (100 
mg, 0.51 mmol, 1.0 equiv) dissolved in DMF (0.2 mL). The reactions were heated to 50 
°C and stirred for 24 h. The vials were combined and diluted with saturated aqueous 
solution of NH4Cl (40 mL) and EtOAc (50 mL). The product was extracted from the 
biphasic solution with EtOAc (3 × 50 mL) and the combined organic layers were washed 
with brine (3 × 100 mL), dried over MgSO4, filtered, and concentrated in vacuo. The crude 
solution was purified by flash chromatography (SiO2, 5% Et2O in hexanes) to generate 
vinyl boronic ester 390 (610 mg, 53% yield) as a white amorphous solid; Rf = 0.33 (12:1 
hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.98 (d, J = 3.6 Hz, 1H), 5.65 (d, J = 3.6 
Hz, 1H), 5.40 (bs, 1H), 2.33 (d, J = 1.0 Hz, 2H), 1.41 (s, 9H), 1.28 (s, 18H); 13C NMR (101 
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NaCl) 3396, 2976, 2930, 1719, 1517, 1447, 1365, 1305, 1269, 1252, 1165, 1142, 1064, 




methylpent-4-en-2-yl)carbamate (401): A flask was charged with vinyl bromide 391 
(300 mg, 1.11 mmol, 1.0 equiv), vinyl boronic acid 390 (387 mg, 1.22 mmol, 1.1 equiv), 
0.5 M K3PO4 in degassed H2O (4.4 mL, 0.25 M), and THF (2.2 mL, 0.5 M). Buchwald’s 
2nd generation precatalyst XPhos (26 mg, 0.03 mmol, 0.03 equiv) was added to the reaction 
with an overpressure of Ar. The reaction was allowed to stir for 16 h at 60 °C, at which 
time complete consumption of starting material was observed (determined by TLC 
analysis, 9:1 hexanes:EtOAc). The product was extracted with Et2O (3 x 10 mL) and the 
combined organic layers were washed with brine, dried with MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash chromatography (SiO2 9:1 
hexanes:EtOAc) to furnish enone 401 (377 mg, 88% yield) as a white crystalline solid; Rf 
= 0.17 (9:1 hexanes:EtOAc); mp: 97.7 – 98.5 °C; 1H NMR (400 MHz, CDCl3) δ 6.49 (d, J 
= 2.5 Hz, 1H), 5.24 (d, J = 2.3 Hz, 1H), 5.00 (d, J = 2.4 Hz, 1H), 4.49 (s, 1H), 2.79 (d, J = 
13.6 Hz, 1H), 2.66 (d, J = 13.5 Hz, 1H), 2.49–2.24 (m, 4H), 2.20 (d, J = 17.4 Hz, 1H), 1.93 
(ddd, J = 12.9, 5.4, 1.6 Hz, 1H), 1.62 (dt, J = 12.5, 6.2 Hz, 1H), 1.41 (s, 9H), 1.22 (s, 3H), 
1.20 (s, 3H), 1.13 (s, 3H), 1.13 (d, J = 0.9 Hz, 3H), 1.11 (d, J = 0.9 Hz, 3H); 13C NMR (101 
391
OBr
 G2 Pd XPhos (3 mol %)
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MHz, CDCl3) δ 206.2, 171.3, 159.1, 137.9, 135.2, 121.0, 115.5, 78.5, 52.7, 51.4, 45.7, 38.4, 
36.0, 34.1, 28.5, 27.5, 25.5, 25.1, 21.6, 21.0; IR thin film, NaCl)  cm-1; HRMS (ES/APCI) 
m/z calc’d C24H38NO3 [M+H]+: 388.2846, found: 388.2864; (R): [α]D25 –256.26° (c 0.45, 
CDCl3, 87% ee); (S): [α]D25 +265.13° (c 0.27, CDCl3, 87% ee); SFC (IC, 30% IPA) (R) 
retention time: 6.385, (S) retention time: 5.691. The ee of 401 can be increased to 99% 
through preparative HPLC (IC, 20 x 250 µm, 30% IPA in hexanes, (R) retention time: 18.2 
min, (S) retention time: 16.6 min); (R): [a]D25 –297.74° (c 0.51, CHCl3, 99% ee); (S): 
[a]D25 +294.25° (c 0.44, CHCl3, 99% ee). 
 
(R)-6-isopropyl-2,2,4,8a-tetramethyl-7,8,8a,9-tetrahydro-2H-indeno[2,1-b]pyridine 
(389): TFA (0.34 mL, 0.4 M) was added to enone 401 (53 mg, 0.14 mmol) in CH2Cl2 (1.4 
mL, 0.1 M) at 0 °C. The reaction was allowed to warm to ambient temperature and stirred 
for an additional 1 h, at which time complete consumption of starting material was 
observed (determined by TLC analysis (4:1 hexanes:EtOAc). The reaction was quenched 
with saturated aqueous NaHCO3 until the solution was neutralized and allowed to stir for 
1 h, at which time complete cyclization occurred (determined through LC-MS analysis, 
m/z = 270.1 [M+H]+). The product was extracted from the biphasic mixture with CH2Cl2 
(3 × 30 mL), dried over Na2SO4, and filtered. SiO2 was added and the suspension was 
stirred for 1 h. The solution was concentrated and purified by flash chromatography (SiO2, 
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can be deprotonated by washing a 10% aqueous solution of potassium carbonate to afford 
389 (28 mg, 75% yield) as a viscous yellow oil; Rf = 0.25 (8% methanol in EtOAc); 1H 
NMR (400 MHz, CDCl3) δ 6.56 (d, J = 2.4 Hz, 1H), 5.56 (d, J = 1.5 Hz, 1H), 2.51 – 2.27 
(m, 4H), 2.24 – 2.15 (m, 1H), 2.02 (d, J = 1.5 Hz, 3H), 1.88 (ddd, J = 12.7, 5.6, 1.7 Hz, 
1H), 1.59 (td, J = 12.3, 5.8 Hz, 1H), 1.24 (d, J = 4.1 Hz, 6H), 1.08 (d, J = 6.8 Hz, 6H), 1.06 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.1, 152.2, 150.5, 135.6, 125.0, 119.3, 115.1, 
58.4, 45.9, 39.3, 34.9, 33.6, 30.3, 30.1, 27.4, 24.1, 24.0, 20.6, 20.2, 20.1; IR thin film, 
NaCl) 2962, 2922, 2177, 1660, 1615, 1456, 1407, 1374, 1286, 1261, 1154, 1048, 873, 842, 
811, 732 cm-1; HRMS (ES/APCI) m/z calc’d C19H28N [M+H]+: 270.2216, found: 
270.2228; (R): [a]D25 –223.18 (c 0.3, CHCl3, 87% ee); (S): [a]D25 +250.16° (c 0.28, 
CDCl3, 87% ee); (R): [a]D25 –340.60° (c 0.6, CHCl3, 99% ee); (S): [a]D25 +391.68° (c 1.39, 
CHCl3, 99% ee). 
 
Nigelladine A (385): Lysate containing the enzyme “8C7” was prepared from a 500-mL 
TBamp expression culture as described above. The concentration of 8C7 was determined to 
be 8.5 µM.  
A 1-L Erlenmeyer flask was charged with 5•trifluoroacetate (160 mg, 417 µmol), 











21% yield over 2 steps
43% yield based on recovered 389
P450 8C7, NADP (10 mol %)
i-PrOH (100 equiv), ADH
2.5% DMSO in KPi buffer (pH 8) 
23 °C , 12h
OTFA
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of DMSO and 400 mL of potassium phosphate buffer (100 mM, pH 8). Next, isopropanol 
(3.2 mL) and lysate (21 mL) were added. Finally, alcohol dehydrogenase (recombinant 
from E. coli, 49641 Sigma) was added. The reaction was shaken at ambient temperature 
and 100 rpm (19 mm radius). After 12 hours, the reaction volume was reduced in vacuo to 
~100 mL, then the products were extracted with ethyl acetate (250 mL plus 2×100 mL). 
An emulsion formed on the third extraction, so the mixture was subjected to centrifugation 
(5,000×g, 20 °C, 2 minutes) in order to separate the layers. The combined organic extracts 
were dried over sodium sulfate, filtered, and then concentrated in vacuo. The crude reaction 
was subjected to column chromatography (SiO2, 0–15% methanol in ethyl acetate) yielding 
free imine 389 (57 mg, 0.21 mmol, 51% recovery) and an inseparable mixture of 
diastereomers and constitutional isomers of oxidation products, which were carried on to 
the next reaction without further purification.  
Crude alcohol 405 (55.4 mg, 0.19 mmol, 1.0 equiv) was dissolved in wet CH2Cl2 
(4 mL, 0.05M). DMP (98.7 mg, 0.23 mmol, 1.2 equiv) was added in one portion and 
allowed to stir at ambient temperature. After 3 hours, the reaction was quenched with 
saturated aqueous Na2S2O3 and the product was extracted with CH2Cl2 (3 × 15 mL). The 
organic layers were combined and washed with a saturated aqueous solution of K2CO3 
dried over Na2SO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, 0–16% methanol in ethyl acetate) to generate nigelladine A (385) 
(25 mg, 21% yield) as an orange oil; Rf = 0.54 (8% methanol in ethyl acetate); 1H NMR 
(400 MHz, C6D6) δ 7.22 (d, J = 1.0 Hz, 1H), 5.63 (q, J = 1.4 Hz, 1H), 3.16 (pd, J = 6.8, 1.1 
Hz, 1H), 2.47 (d, J = 15.4 Hz, 1H), 2.42 (d, J = 16.9 Hz, 1H), 2.27 (d, J = 16.9 Hz, 1H), 
2.09 (dd, J = 15.4, 0.9 Hz, 1H), 1.77 (d, J = 1.4 Hz, 3H), 1.40 (s, 3H), 1.35 (s, 3H), 1.06 
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(d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H), 0.93 (s, 3H); 13C NMR (101 MHz, C6D6) δ 
196.1, 170.2, 147.2, 147.0, 141.9, 130.6, 126.0, 125.1, 61.2, 51.7, 46.5, 43.6, 31.1, 30.8, 
27.5, 26.8, 22.1, 21.7, 21.0; IR thin film, NaCl) 2962, 2926, 2872, 1670, 1618, 1458, 1375, 
1303, 1230, 1147, 1045, 920, 840 cm-1; HRMS (ES/APCI) m/z calc’d C19H26NO [M+H]+: 
284.2009, found: 284.2021; (R): [a]D25 –200.3 (c 0.10, MeOH). 
3.8.4  ENZYMATIC SCREENS AND ENANTIOMER SCREEN 
Initial screen of enzymes:  
Lysates containing the desired enzymes were prepared from 5-mL expression cultures 
according to the procedure described above.  
A 2-mL vial was charged with 5•trifluoroacetate as a solution in DMSO (5 µL, 280 
mM). Potassium phosphate buffer (100 mM, pH 8, 35 µL) was added, followed by lysate 
(80 µL). The reactions were initiated by the addition of NADPH (80 µL, 50 mM aqueous 
solution) and shaken at ambient temperature and 450 rpm (Labnet Orbit P4 shaker). After 
1 hour, the reactions were diluted with 1:1 CH3CN/H2O (800 µL), and subjected to 
centrifugation at 20,000×g and 4 °C (10 minutes). The supernatant was analyzed by LCMS 
(ESI, positive mode) with a C-18 column (1.8 µm, 2.1 × 50 mm). The compounds were 
eluted with water (0.1% acetic acid by volume) and acetonitrile at a gradient of 5% to 95% 
acetonitrile over 4 minutes. Selectivity was approximated by extracting m/z = 286 from the 
total ion count, and comparing the integration of the desired product (1.6 min) to the 
isopropyl oxidation product (1.3 min) and an additional product (1.8 min).  
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Comparison of enantiomers:  
Lysates containing the desired enzymes were prepared from 5-mL expression cultures 
according to the procedure described above. Reactions were conducted in duplicate. 
A 2-mL vial was charged with 5•trifluoroacetate as a solution in DMSO (10 µL, 
200 mM). Potassium phosphate buffer (100 mM, pH 8, 290 µL) was added, followed by 
lysate (20 µL). Finally, the reactions were initiated by the addition of NADPH (80 µL, 50 
mM aqueous solution) and shaken at ambient temperature and 500 rpm (Labnet Orbit P4 
shaker). After 15 minutes, the reactions were diluted fivefold with 1:1 CH3CN/H2O, and 
subjected to centrifugation at 20,000×g and 4 °C (10 minutes). The supernatant was 
analyzed by LCMS using the method described above. Selectivity was approximated by 
extracting m/z from 269.5 to 286.5, so as to include residual starting material and all mono-
oxygenation products. The desired product peak partially overlapped with a trace oxidation 
byproduct formed during preparation of the starting material, therefore the % integration 
of the peak at 1.4 minutes was subtracted by the % integration of the corresponding peak 
in the unreacted starting material. This gave % integrations of the desired product of 
2.763% and 3.144% for the S enantiomer, and 3.828% and 4.069% for the R enantiomer. 
The krel was approximated as the ratio of the average % integration for each enantiomer. 
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3.8.5  CHEMICAL OXIDATION TABLES 
Table 3.8.5.1. Oxidations of Imine 389 
 
a Approximated by separating the products on UHPLC-MS and comparing ion counts of the various oxidation 
products. b Remaining percent balance remaining were unidentified side products. c Numbers given in 
parenthesis indicate isolated yields of the oxidized product. d Protection of 389 as an N-acyl enamide results 













R' = H, OH, or t-BuOO
R'' =H, OH, t-BuOO, or O
R''' =H, OH, t-BuOO, or O
ConditionsEntry
HPLC Yield of Oxygenation Products (%)a,b,c
SeO2, DCM, 40 °C
Pd/C (10 wt%), TBHP, 0 °C
1
3
Cr(V) (5 equiv), MnO2, CF3C6H5, 
15-crown-5, 80 °C4
Rh2(esp)2, T-HYDRO, 23 °C6
C1 C7 C10 PolyoxygenationSM






















































Cr(V) (1 equiv), MnO2, CF3C6H5, 
15-crown-5, 80 °C5 ––312––35
e–355 ––
SeO2 (anhydrous),




8C7 P450 oxidation8 –––1––11–32–47 ––
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Table 3.8.5.2. Oxidations of Enone 397 
 
a Approximated by separating the products on UHPLC-MS and comparing ion count of the various oxidation 
products. b Remaining percent balance were unidentified side products. c Numbers given in parentheses 
indicate isolated yields of the oxidized product. d Shortened reaction time used to observe inherent 
regioselectivity without over oxidation. e Site-selectivity determined by analogy from Table 3.8.5.1 entry 3. 











R' = H, OH, or t-BuOO
R'' =H, OH, t-BuOO, or O
R''' =H, OH, t-BuOO, or O
ConditionsEntry
HPLC Yield of Oxygenation Products (%)a,b,c
SeO2, DCM, 40 °C1
Pd/C (10 wt%), TBHP, 0 °Cd2
Rh2(esp)2, T-HYDRO, 23 °C3
C1 C7 C10 PolyoxygenationSM



































Cr(V) (5 equiv), MnO2, CF3C6H5, 
15-crown-5, 80 °C4










 trityl peroxide,0 °C CH2Cl2
13
PIFA, TBHP, Cs2CO3,
O2, 4 Å mol sieves,
EtOAc, –78 to – 15 °C
6
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3.8.6  COMPARISON OF NATURAL AND SYNTHETIC NIGELLADINE A 
Table 3.8.6.1.Comparison of Synthetic and Natural Nigelladine A34 
Synthetic mono-deuterated, DCl salt of 
Nigelladine A (385) 
Isolated Nigelladine A2a 
1H NMR (400 MHz, methanol-d4) 1H NMR (600 MHz, methanol-d4) 
7.64 (br, 1H) 7.64 (br, 1H) 
5.97 (q, J = 1.5 Hz, 1H) 5.97 (q, J = 1.2 Hz, 1H) 
3.05 (pd, J = 6.8, 1.1 Hz, 1H) 3.05 (pd, J = 6.9, 0.8 Hz, 1H) 
2.99 (s, 1H) 3.01 (s, 1H) 
2.84 (s, 2H) 2.84 (s, 2H) 
2.25 (d, J = 1.5 Hz, 3H) 2.25 (d, J = 1.2 Hz, 3H) 
1.55 (s, 3H) 1.55 (s, 3H) 
1.53 (s, 3H) 1.54 (s, 3H) 
1.17 (d, J = 6.8 Hz, 3H) 1.17 (d, J = 6.9 Hz, 3H) 
1.14 (d, J = 6.9 Hz, 3H) 1.14 (d, J = 7.2 Hz, 3H) 




















 Optical Rotation  Optical Rotation 
[a]D26 = –200.3 (c 0.10, MeOH) [a]D20 = –53 (c 0.10, MeOH) 
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1. LDA, THF, –78 °C
















1. PdCl2 (20 mol %)
CuCl (2 equiv)
DMF:H2O (9:1), 23 °C
2. KOH, xylenes 110 °C








Pd2(dba)3 (2.75 mol %)
(R)-CF3-t-BuPHOX (6.0 mol %)
(2:1) hexanes:toluene, 40 °C
96% yield, 87% ee
O
392
390, XPhos Pd G2 (3 mol %)











21% yield over 2 steps
43% yield




P450 8C7 (0.02 to 0.04 mol %)
NADP (10 mol %), i-PrOH, ADH
2.5% DMSO in KPi buffer (pH 8) 
23 °C , 12h
1.











Spectra Relevant to Chapter 3: 
Enantioselective Total Synthesis of Nigelladine A 
Via Late-Stage C–H Oxidation Enabled by an 
Engineered P450 Enzyme 
  
























































































































 Figure A3.2. Infrared spectrum (Thin Film, NaCl) of compound 395. 
 
 Figure A3.3. 13C NMR (101 MHz, CDCl3) of compound 395. 
 



















































































































 Figure A3.5. Infrared spectrum (Thin Film, NaCl) of compound 396. 
 
 Figure A3.6. 13C NMR (126 MHz, CDCl3) of compound 396. 
 




















































































































 Figure A3.8. Infrared spectrum (Thin Film, NaCl) of compound 393. 
 
 Figure A3.9. 13C NMR (126 MHz, CDCl3) of compound 393. 
 


















































































































 Figure A3.11. Infrared spectrum (Thin Film, NaCl) of compound 392. 
 
 Figure A3.12. 13C NMR (126 MHz, CDCl3) of compound 392. 
 



















































































































 Figure A3.14. Infrared spectrum (Thin Film, NaCl) of compound 397. 
 
 Figure A3.15. 13C NMR (101 MHz, CDCl3) of compound 397. 
 




















































































































 Figure A3.17. Infrared spectrum (Thin Film, NaCl) of compound 391. 
 
 Figure A3.18. 13C NMR (101 MHz, CDCl3) of compound 391. 
 





















































































































 Figure A3.20. Infrared spectrum (Thin Film, NaCl) of compound 400. 
 
 Figure A3.21. 13C NMR (101 MHz, CDCl3) of compound 400. 
 
























































































































 Figure A3.23. Infrared spectrum (Thin Film, NaCl) of compound 390. 
 
 Figure A3.24. 13C NMR (101 MHz, CDCl3) of compound 390. 
 






















































































































 Figure A3.26. Infrared spectrum (Thin Film, NaCl) of compound 401. 
 
 Figure A3.27. 13C NMR (101 MHz, CDCl3) of compound 401. 
 



















































































































 Figure A3.29. Infrared spectrum (Thin Film, NaCl) of compound 389. 
 
 Figure A3.30. 13C NMR (101 MHz, CDCl3) of compound 389. 
 




















































































































 Figure A3.32. Infrared spectrum (Thin Film, NaCl) of compound 385. 
 
 Figure A3.33. 13C NMR (101 MHz, CDCl3) of compound 385. 
 



















































































































 Figure A3.35. 13C NMR (101 MHz, C6D6) of compound 385. 
 



























































































































 Figure A3.37. 13C NMR (101 MHz, CD3OD) of compound 385•DCl. 
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A4.1   X-RAY CRYSTAL STRUCTURE ANALYSIS OF TRIENE 401 
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Table A4.1.8. Hydrogen Bond Distances and Angle 









Table A4.1.1.  Experimental Details for X-Ray Structure Determination of 
Triene 401 
 Low-temperature diffraction data (f-and w-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to a APEX II CCD detector with graphite 
monochromated Mo Ka radiation (l = 0.71073 Å) for the structure of triene 401. The 
structure was solved by direct methods using SHELXS1 and refined against F2 on all data 
by full-matrix least squares with SHELXL-20142 using established refinement techniques.3 
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were included 
into the model at geometrically calculated positions and refined using a riding model. The 
isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms they are linked to (1.5 times for methyl groups).  
  




Table A4.1.2. Crystal Data and Structure Refinement for Triene 401 
Empirical formula  C24 H37 N O3 
Formula weight  387.54 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 9.6892(11) Å a = 89.402(8)° 
 b = 10.0478(9) Å b = 77.360(8)° 
 c = 11.9882(11) Å g = 89.745(8)° 
Volume 1138.76(19) Å3 
Z 2 
Density (calculated) 1.130 Mg/m3 
Absorption coefficient 0.574 mm-1 
F(000) 424 
Crystal size 0.31 x 0.15 x 0.15 mm3 
Theta range for data collection 3.779 to 79.188°. 
Index ranges -12<=h<=12, -12<=k<=12, -15<=l<=15 
Reflections collected 44144 
Independent reflections 9136 [R(int) = 0.0587] 
Completeness to theta = 67.000° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9470 and 0.8656 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9136 / 3 / 521 
Goodness-of-fit on F2 1.062 
Final R indices [I>2sigma(I)] R1 = 0.0497, wR2 = 0.1066 
R indices (all data) R1 = 0.0568, wR2 = 0.1114 
Absolute structure parameter 0.08(8) 
Extinction coefficient n/a 








Table A4.1.3. Atomic Coordinates (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2x 103) for Triene 401. U(eq) is Defined as One Third of the Trace of 
the Orthogonalized Uij Tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 6427(3) 5529(2) 4290(2) 25(1) 
O(2) 1594(2) 3334(2) 8236(2) 24(1) 
O(3) 2950(3) 2423(2) 9381(2) 24(1) 
N(1) 3663(3) 4279(3) 8426(2) 19(1) 
C(1) 8553(4) 3624(3) 5846(3) 22(1) 
C(2) 9499(4) 2396(4) 5692(3) 27(1) 
C(3) 9318(4) 1614(3) 6823(3) 26(1) 
C(4) 7794(4) 1450(3) 7447(3) 23(1) 
C(5) 6748(4) 2160(3) 7164(3) 21(1) 
C(6) 7031(4) 3176(3) 6278(3) 19(1) 
C(7) 6109(3) 3839(3) 5775(3) 19(1) 
C(8) 6912(4) 4726(3) 4874(3) 21(1) 
C(9) 8471(4) 4390(3) 4741(3) 25(1) 
C(10) 8980(4) 4589(4) 6705(3) 28(1) 
C(11) 7516(4) 404(3) 8396(3) 28(1) 
C(12) 6811(5) 994(4) 9543(3) 40(1) 
C(13) 6667(5) -743(4) 8076(4) 45(1) 
C(14) 4548(3) 3702(3) 6030(2) 18(1) 
C(15) 3982(4) 2511(3) 5934(3) 24(1) 
C(16) 3632(3) 4898(3) 6411(3) 18(1) 
C(17) 3666(3) 5403(3) 7625(3) 19(1) 
C(18) 5001(4) 6206(3) 7619(3) 22(1) 
C(19) 2376(4) 6285(3) 8055(3) 24(1) 
C(20) 2632(3) 3355(3) 8639(3) 19(1) 
C(21) 1988(4) 1295(3) 9736(3) 26(1) 
C(22) 1986(4) 410(3) 8715(3) 31(1) 
C(23) 2671(5) 576(4) 10590(3) 37(1) 




Table A4.1.3 Cont’d 
C(24) 514(5) 1766(4) 10308(4) 47(1) 
O(1B) 6314(3) 4207(2) -587(2) 25(1) 
O(2B) 1567(2) 6339(2) 3346(2) 23(1) 
O(3B) 3051(2) 7332(2) 4333(2) 21(1) 
N(1B) 3720(3) 5462(3) 3414(2) 20(1) 
C(1B) 8278(3) 6485(3) 780(3) 21(1) 
C(2B) 8972(4) 6488(4) 1797(3) 27(1) 
C(3B) 8775(4) 7833(4) 2410(3) 30(1) 
C(4B) 7286(4) 8363(3) 2592(3) 23(1) 
C(5B) 6354(4) 7851(3) 2047(3) 21(1) 
C(6B) 6729(3) 6804(3) 1209(3) 19(1) 
C(7B) 5858(3) 6011(3) 769(3) 19(1) 
C(8B) 6728(4) 5017(3) 34(3) 22(1) 
C(9B) 8233(4) 5137(4) 190(3) 27(1) 
C(10B) 8957(4) 7542(4) -132(3) 29(1) 
C(11B) 6859(4) 9458(3) 3462(3) 26(1) 
C(12B) 7716(4) 10730(4) 3123(4) 38(1) 
C(13B) 6903(5) 8998(5) 4671(3) 39(1) 
C(14B) 4297(3) 6029(3) 1009(3) 19(1) 
C(15B) 3619(4) 7141(3) 826(3) 24(1) 
C(16B) 3495(3) 4785(3) 1467(3) 21(1) 
C(17B) 3681(4) 4317(3) 2662(3) 21(1) 
C(18B) 5065(4) 3555(3) 2590(3) 24(1) 
C(19B) 2448(4) 3397(3) 3194(3) 27(1) 
C(20B) 2677(3) 6368(3) 3662(3) 19(1) 
C(21B) 2079(4) 8434(3) 4721(3) 22(1) 
C(22B) 2867(4) 9229(3) 5458(3) 28(1) 
C(23B) 1886(4) 9273(4) 3704(3) 33(1) 
C(24B) 690(4) 7918(4) 5439(3) 29(1) 
___________________________________________________________________________ 
  




Table A4.1.4. Bond Lengths [Å] and angles [°] for Triene 401 
_____________________________________________________  
O(1)-C(8)  1.221(4) 
O(2)-C(20)  1.208(4) 
O(3)-C(20)  1.365(4) 
O(3)-C(21)  1.470(4) 
N(1)-H(1)  0.8800 
N(1)-C(17)  1.475(4) 
N(1)-C(20)  1.348(4) 
C(1)-C(2)  1.522(5) 
C(1)-C(6)  1.520(5) 
C(1)-C(9)  1.542(4) 
C(1)-C(10)  1.543(5) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(2)-C(3)  1.537(5) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(3)-C(4)  1.510(5) 
C(4)-C(5)  1.337(5) 
C(4)-C(11)  1.522(4) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.450(4) 
C(6)-C(7)  1.351(4) 
C(7)-C(8)  1.478(4) 
C(7)-C(14)  1.484(4) 
C(8)-C(9)  1.520(5) 




Table A4.1.4. cont’d 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-H(10A)  0.9800 
C(10)-H(10B)  0.9800 
C(10)-H(10C)  0.9800 
C(11)-H(11)  1.0000 
C(11)-C(12)  1.520(6) 
C(11)-C(13)  1.520(5) 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(12)-H(12C)  0.9800 
C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
C(13)-H(13C)  0.9800 
C(14)-C(15)  1.335(4) 
C(14)-C(16)  1.505(4) 
C(15)-H(15A)  0.9500 
C(15)-H(15B)  0.9500 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(16)-C(17)  1.554(4) 
C(17)-C(18)  1.526(4) 
C(17)-C(19)  1.526(5) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 




Table A4.1.4. cont’d 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(21)-C(22)  1.520(5) 
C(21)-C(23)  1.512(5) 
C(21)-C(24)  1.519(6) 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
C(24)-H(24A)  0.9800 
C(24)-H(24B)  0.9800 
C(24)-H(24C)  0.9800 
O(1B)-C(8B)  1.234(4) 
O(2B)-C(20B)  1.217(4) 
O(3B)-C(20B)  1.365(4) 
O(3B)-C(21B)  1.463(4) 
N(1B)-H(1B)  0.8800 
N(1B)-C(17B)  1.474(4) 
N(1B)-C(20B)  1.343(4) 
C(1B)-C(2B)  1.516(5) 
C(1B)-C(6B)  1.510(5) 
C(1B)-C(9B)  1.539(5) 
C(1B)-C(10B)  1.557(4) 




Table A4.1.4. cont’d 
C(2B)-H(2BA)  0.9900 
C(2B)-H(2BB)  0.9900 
C(2B)-C(3B)  1.536(5) 
C(3B)-H(3BA)  0.9900 
C(3B)-H(3BB)  0.9900 
C(3B)-C(4B)  1.507(5) 
C(4B)-C(5B)  1.333(5) 
C(4B)-C(11B)  1.516(5) 
C(5B)-H(5B)  0.9500 
C(5B)-C(6B)  1.451(4) 
C(6B)-C(7B)  1.355(4) 
C(7B)-C(8B)  1.473(5) 
C(7B)-C(14B)  1.477(4) 
C(8B)-C(9B)  1.515(5) 
C(9B)-H(9BA)  0.9900 
C(9B)-H(9BB)  0.9900 
C(10B)-H(10D)  0.9800 
C(10B)-H(10E)  0.9800 
C(10B)-H(10F)  0.9800 
C(11B)-H(11B)  1.0000 
C(11B)-C(12B)  1.529(5) 
C(11B)-C(13B)  1.526(5) 
C(12B)-H(12D)  0.9800 
C(12B)-H(12E)  0.9800 
C(12B)-H(12F)  0.9800 
C(13B)-H(13D)  0.9800 




Table A4.1.4. cont’d 
C(13B)-H(13E)  0.9800 
C(13B)-H(13F)  0.9800 
C(14B)-C(15B)  1.334(5) 
C(14B)-C(16B)  1.509(4) 
C(15B)-H(15C)  0.9500 
C(15B)-H(15D)  0.9500 
C(16B)-H(16C)  0.9900 
C(16B)-H(16D)  0.9900 
C(16B)-C(17B)  1.551(4) 
C(17B)-C(18B)  1.528(5) 
C(17B)-C(19B)  1.534(4) 
C(18B)-H(18D)  0.9800 
C(18B)-H(18E)  0.9800 
C(18B)-H(18F)  0.9800 
C(19B)-H(19D)  0.9800 
C(19B)-H(19E)  0.9800 
C(19B)-H(19F)  0.9800 
C(21B)-C(22B)  1.523(4) 
C(21B)-C(23B)  1.520(5) 
C(21B)-C(24B)  1.520(5) 
C(22B)-H(22D)  0.9800 
C(22B)-H(22E)  0.9800 
C(22B)-H(22F)  0.9800 
C(23B)-H(23D)  0.9800 
C(23B)-H(23E)  0.9800 
C(23B)-H(23F)  0.9800 




Table A4.1.4. cont’d 
C(24B)-H(24D)  0.9800 
C(24B)-H(24E)  0.9800 
C(24B)-H(24F)  0.9800 
 
C(20)-O(3)-C(21)  119.5(3) 
C(17)-N(1)-H(1) 118.6 
C(20)-N(1)-H(1) 118.6 



































































































































































































































































































Symmetry transformations used to generate equivalent atoms:  
  




Table A4.1.5. Anisotropic Displacement Parameters (Å2x103) for Triene 401. The 
Anisotropic Displacement Factor Exponent Takes the Form: -2p2[h2a*2U11 + … + 
2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 24(1)  28(1) 23(1)  8(1) -7(1)  -1(1) 
O(2) 21(1)  26(1) 26(1)  6(1) -8(1)  -4(1) 
O(3) 32(1)  18(1) 23(1)  6(1) -12(1)  -4(1) 
N(1) 21(1)  19(1) 17(1)  2(1) -6(1)  -1(1) 
C(1) 22(2)  22(2) 24(2)  3(1) -6(1)  -1(1) 
C(2) 23(2)  29(2) 27(2)  0(1) -4(1)  2(2) 
C(3) 26(2)  25(2) 31(2)  -1(1) -10(2)  5(1) 
C(4) 27(2)  20(2) 23(2)  -1(1) -7(1)  1(1) 
C(5) 23(2)  21(2) 19(2)  2(1) -4(1)  -1(1) 
C(6) 22(2)  16(1) 17(1)  -3(1) -2(1)  1(1) 
C(7) 24(2)  14(1) 17(1)  0(1) -1(1)  -1(1) 
C(8) 23(2)  21(2) 20(2)  -1(1) -5(1)  -3(1) 
C(9) 20(2)  28(2) 27(2)  6(1) -6(1)  -5(1) 
C(10) 28(2)  27(2) 32(2)  1(2) -10(2)  -3(2) 
C(11) 34(2)  21(2) 31(2)  8(1) -11(2)  0(2) 
C(12) 50(3)  38(2) 30(2)  11(2) -7(2)  4(2) 
C(13) 55(3)  31(2) 54(3)  16(2) -27(2)  -14(2) 
C(14) 20(2)  20(1) 14(1)  2(1) -2(1)  -1(1) 
C(15) 23(2)  24(2) 25(2)  0(1) -4(1)  -2(1) 
C(16) 18(2)  18(1) 19(1)  3(1) -4(1)  0(1) 
C(17) 21(2)  17(1) 18(1)  2(1) -4(1)  0(1) 
C(18) 26(2)  20(2) 20(2)  0(1) -5(1)  -2(1) 
C(19) 26(2)  22(2) 24(2)  0(1) -3(1)  4(1) 
C(20) 21(2)  17(1) 17(1)  0(1) -2(1)  2(1) 
C(21) 33(2)  17(2) 26(2)  6(1) -1(2)  -2(1) 
C(22) 33(2)  21(2) 42(2)  0(2) -13(2)  -5(2) 
C(23) 57(3)  20(2) 34(2)  9(2) -12(2)  -1(2) 




Table A4.1.5. cont’d 
C(24) 43(3)  35(2) 50(3)  18(2) 16(2)  8(2) 
O(1B) 27(1)  24(1) 24(1)  -6(1) -6(1)  4(1) 
O(2B) 20(1)  27(1) 24(1)  -6(1) -7(1)  2(1) 
O(3B) 22(1)  20(1) 23(1)  -6(1) -8(1)  4(1) 
N(1B) 21(1)  21(1) 19(1)  -5(1) -5(1)  2(1) 
C(1B) 19(2)  23(2) 19(2)  1(1) -1(1)  0(1) 
C(2B) 22(2)  31(2) 28(2)  0(1) -7(1)  2(2) 
C(3B) 26(2)  36(2) 32(2)  -6(2) -12(2)  0(2) 
C(4B) 25(2)  22(2) 22(2)  1(1) -5(1)  -1(1) 
C(5B) 21(2)  20(2) 20(2)  1(1) -1(1)  -1(1) 
C(6B) 21(2)  19(2) 16(1)  3(1) -2(1)  -2(1) 
C(7B) 23(2)  19(1) 16(1)  2(1) -3(1)  1(1) 
C(8B) 26(2)  19(2) 19(2)  2(1) -4(1)  2(1) 
C(9B) 24(2)  27(2) 31(2)  -7(1) -6(1)  6(2) 
C(10B) 26(2)  28(2) 31(2)  6(2) 2(2)  2(2) 
C(11B) 27(2)  25(2) 27(2)  -5(1) -8(1)  -1(2) 
C(12B) 34(2)  33(2) 45(2)  -10(2) -3(2)  -2(2) 
C(13B) 45(3)  45(2) 30(2)  -7(2) -10(2)  11(2) 
C(14B) 21(2)  20(2) 15(1)  -3(1) -4(1)  -1(1) 
C(15B) 25(2)  23(2) 25(2)  2(1) -6(1)  0(1) 
C(16B) 20(2)  23(2) 19(2)  -5(1) -3(1)  -1(1) 
C(17B) 24(2)  20(2) 18(2)  -4(1) -3(1)  0(1) 
C(18B) 31(2)  19(2) 21(2)  1(1) -4(1)  4(1) 
C(19B) 29(2)  23(2) 25(2)  1(1) 1(1)  -5(2) 
C(20B) 20(2)  20(2) 16(1)  -2(1) -2(1)  0(1) 
C(21B) 25(2)  16(1) 26(2)  -2(1) -5(1)  -1(1) 
C(22B) 27(2)  22(2) 32(2)  -9(1) -2(2)  -4(1) 
C(23B) 34(2)  23(2) 43(2)  6(2) -13(2)  2(2) 
C(24B) 26(2)  28(2) 31(2)  -9(2) 0(2)  -4(2) 
______________________________________________________________________________  
  




Table A4.1.6. Hydrogen Coordinates (x104) and Isotropic Displacement Parameters 
(Å2x103) for Triene 401. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 4366 4207 8780 22 
H(2A) 10499 2670 5430 32 
H(2B) 9253 1819 5100 32 
H(3A) 9749 721 6664 32 
H(3B) 9838 2079 7328 32 
H(5) 5799 1993 7553 25 
H(9A) 9048 5210 4663 30 
H(9B) 8810 3830 4061 30 
H(10A) 8415 5405 6742 43 
H(10B) 9985 4809 6455 43 
H(10C) 8810 4167 7463 43 
H(11) 8453 39 8472 34 
H(12A) 7392 1723 9724 60 
H(12B) 6712 304 10138 60 
H(12C) 5873 1337 9504 60 
H(13A) 5734 -419 8004 67 
H(13B) 6551 -1434 8672 67 
H(13C) 7167 -1115 7346 67 
H(15A) 4578 1765 5703 29 
H(15B) 2983 2410 6095 29 
H(16A) 2643 4676 6392 22 
H(16B) 3935 5632 5855 22 
H(18A) 4964 6554 8386 33 
H(18B) 5063 6949 7074 33 
H(18C) 5833 5631 7394 33 
H(19A) 1512 5767 8092 36 
H(19B) 2392 7042 7531 36 
H(19C) 2396 6611 8819 36 




Table A4.1.6. cont’d 
H(22A) 1610 910 8140 47 
H(22B) 1391 -370 8965 47 
H(22C) 2954 120 8383 47 
H(23A) 3615 266 10207 55 
H(23B) 2089 -189 10912 55 
H(23C) 2753 1185 11206 55 
H(24A) 576 2379 10925 71 
H(24B) -67 998 10624 71 
H(24C) 83 2225 9743 71 
H(1B) 4464 5557 3715 24 
H(2BA) 9994 6299 1534 32 
H(2BB) 8554 5774 2340 32 
H(3BA) 9033 7732 3161 36 
H(3BB) 9429 8489 1953 36 
H(5B) 5412 8182 2213 25 
H(9BA) 8914 5122 -557 33 
H(9BB) 8462 4400 674 33 
H(10D) 8543 7468 -805 44 
H(10E) 9979 7390 -355 44 
H(10F) 8774 8435 190 44 
H(11B) 5851 9685 3469 31 
H(12D) 8713 10555 3115 57 
H(12E) 7359 11429 3676 57 
H(12F) 7623 11020 2359 57 
H(13D) 6310 8206 4871 59 
H(13E) 6548 9711 5211 59 
H(13F) 7880 8782 4707 59 
H(15C) 4140 7918 543 29 
H(15D) 2615 7157 980 29 
H(16C) 3803 4057 918 25 
H(16D) 2476 4943 1507 25 
H(18D) 5865 4149 2300 36 
H(18E) 5101 2802 2071 36 




Table A4.1.6. cont’d 
H(18F) 5116 3225 3352 36 
H(19D) 2575 3069 3938 40 
H(19E) 2426 2642 2688 40 
H(19F) 1556 3892 3296 40 
H(22D) 3045 8663 6083 41 
H(22E) 2293 9998 5777 41 
H(22F) 3769 9539 4990 41 
H(23D) 2813 9553 3259 49 
H(23E) 1315 10060 3976 49 
H(23F) 1405 8746 3220 49 
H(24D) 188 7418 4952 44 
H(24E) 105 8670 5780 44 
H(24F) 881 7332 6046 44 
________________________________________________________________________________   
  






























































































































Symmetry transformations used to generate equivalent atoms:  
  




Table A4.1.8. Hydrogen Bonds for Triene 401 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1)...O(1B)#1 0.88 2.18 3.054(4) 170.5 
 N(1B)-H(1B)...O(1) 0.88 2.16 3.032(4) 171.0 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Progress Toward the Total Synthesis 
of Scabrolide A† 
 
4.1  INTRODUCTION 
 Throughout history, natural products have played an integral role in the 
development of new medicines.1 These products have been used to treat a number of 
different ailments including cancer, pain, and infectious bacteria.2 Despite the numerous 
medical advances attributed to natural products, there remains a need for new and more 
effective therapies for the treatment of diseases. The norcembranoid class of natural 
products is a vast family of highly oxygenated diterpenoids, some of which display 
biological activity including antileukemic and anti-inflammatory activity of IL-6.3 While 
the polycyclic norcembranoids have been known since 1975,4 there has only been one 
reported de novo synthesis of any norcembranoid diterpenoid, Pavidolide B, by Yang and 
coworkers.5 The lack of completed total syntheses of this family of natural products is a 
testament to the inherent synthetic challenges that are associated with their highly 
congested structures. Some examples of the polycyclic norcembranoids are scabrolide A 
(407), scabrolide B (408), yonarolide (409), sinolochmodin C (410), and ineleganolide 
                                               
† This research was performed in collaboration with Dr. Beau Pritchett, Chris Reimann, and Nick Hafeman 
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(411) (Figure 4.1.1). All except ineleganolide consist of a [5,5,6,7]-tetracyclic core 
containing a high degree of oxygenation and 4–7 stereocenters. We are drawn to the unique 
scaffold of these norcembranoid diterpenoids and sought to design a convergent synthesis 
of late-stage intermediate 412 which would allow for divergent access to a number of the 
norcembranoid diterpenoids including 407, 408, 409, and 410. 
Figure 4.1.1. Select Examples of Polycyclic Furanobutenolide-Derived 
Norcembranoid Diterpenes 
 
4.2  RETROSYNTHETIC ANALYSIS; TRANSANNULAR DIELS–ALDER 
 From a retrosynthetic perspective, we believed that construction of scabrolide A 
(407), can be achieved through the oxidation and olefin isomerization of 1,6-hexadiene 412 
(Scheme 4.2.1). The central cyclohexadiene ring in 412 may be generated from an 
intramolecular Diels–Alder reaction of macrocycle 413 in order to form the core carbon 
skeleton. Ring-closing metathesis (RCM) of tetraene 414 would allow access to requisite 
macrocycle 413. Finally, tetraene 414 can be convergently synthesized from the coupling 





























scabrolide A (407) scabrolide B (408) yonarolide (409)
sinolochmodin C (410) ineliganolide (411)
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Scheme 4.2.1. Retrosynthetic Analysis of Scabrolide A via Transannular Diels–Alder 
 
4.3  SYNTHESIS OF CONVERGENT COUPLING FRAGMENTS 
 In 2005, Theodorakis and coworkers reported the synthesis of isocarvone (421) 
from carvone (417) .6 Starting from (+)-carvone (417), they were able to perform a 
nucleophilic epoxidation with hydrogen peroxide to generate epoxy ketone 418 (Scheme 
4.3.1). Epoxide 418 is then hydrolyzed followed by oxidative cleavage with NaIO4 to 
afford acid 419 in a modest yield. Amidation of acid 419 with methoxy methylamine 
generates Weinreb amide 420 can be progressed to isocarvone in 5 further steps. 
















































    THF:H2O, 65°C
2. NaIO4, SiO2
    DCM:H2O 0 °C
(MeO)NHMe•HCl
Et3N, EDC•HCl
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 By utilizing Theodorakis’ key Weinreb amide intermediate (420), we can 
expediently synthesize alkyne ent•416 with the isopropenyl stereocenter set (Scheme 
4.3.2). Treatment of aldehyde 420 with the Ohira–Bestmann reagent furnishes alkyne 422,7 
which upon addition of allyl magnesium bromide affords our desired ketone ent•416 in a 
71% yield over 2 steps. Unfortunately, protection of the ketone moiety is necessary to 
couple ent•416 with diol 415, in order to avoid competing enolate formation and 
subsequent olefin isomerization during the carboxylation. Gratifyingly, treatment of ketone 
ent•416 with ethylene glycol and anhydrous oxalic acid in triethylorthoformate and 
acetonitrile affords 1,3-dioxolane 423 in 83% yield and without any observable olefin 
isomerization.8 
Scheme. 4.3.2. Synthesis of Alkyne 423 from Carvone 
  
Fortunately in 2017, our lab reported the utility of the key cyclopentene diol 
ent•415 in a convergent synthesis of ineleganoloids.9 The first generation enantioselective 
synthesis of diol ent•415 starts from dimethyl ketal 424 and TRIS•HCl (425) through a 6 
step sequence (28% yield) to generate silyl enol ether 426 (Scheme 4.3.3). Silyl enol ether 
426 then undergoes an asymmetric allylic alkylation, setting the tertiary stereocenter of 
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by an aldol condensation to afford enone 428. Ketone 428 is then subjected to a 1,2 
reduction, benzoyl protection, and acetonide cleavage to provide triol 429, in an excellent 
yield over three steps. DMP oxidation of the primary alcohol, followed by Wittig 
olefination and benzoyl deprotection affords the desired diol ent•415 in a 15 step sequence 
and 18% overall yield. 
Scheme 4.3.3. 1st Generation Synthesis of Cyclopentene Diol ent•415 
 
4.4  FRAGMENT COUPLING AND RING CLOSING METATHESIS 
 Having successfully synthesized both fragments ent•415 and 423, we turned our 
attention to investigating the coupling of these two compounds to form macrocycle 430. 
Carboxylation of alkyne 423 was performed followed by Yamaguchi esterification with 
























    acetone, 0 °C
2. (n-Bu)3P, Et3N






1. DIBAL, THF, –78 to 0 °C
2. Bz2O, DMAP, Et3N
    CH2Cl2, 0 °C
3. fumaric acid, HC(OMe)3
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Scheme 4.4.1. Convergent Coupling of RCM Precursor 430 
 
 We anticipated that the RCM of tetraene 430 would be challenging due to the 
presence of 3 terminal olefins, a diene, and an ynoate moiety. We Subjected tetraene 430 
to a variety of RCM catalysts (e.g. Grubbs I, Grubbs II, Hoveyda-Grubbs II, and Stewart–
Grubbs), solvent, and temperatures, but  unfortunately no desired RCM was observed (i.e. 
431, Scheme 4.4.2). Instead, cyclohexenone 432 is observed as the sole product. We 
suspect this selectivity problem arises from the fact that the catalyst preferentially inserts 
into the most accessible olefin, as is common with Ru-based catalysts.11 Although both the 
diene and allyl moieties possess mono-substituted olefins, the vinyl diene is electronically 
deactivated through conjugation. Therefore, the allyl group is the preferred initial site of 
metathesis in order to form Ru carbenoid 433. Carbenoid 433 then undergoes olefin 
metathesis with the undesired isopropenyl fragment to form cyclohexene 432. Due to these 
factors, we presumed that controlling the site selectivity for the initial insertion of the Ru 
catalyst will be crucial to the success to the RCM. Relay ring-closing metathesis (RRCM) 
offers an appealing solution to this challenge. Initially disclosed by Hoye and coworkers,12 
RRCM has been shown to overcome inherent selectivity bias as well as to allow 
traditionally inert olefins such as dienes to react smoothly under standard RCM conditions. 
Unfortunately, any attempt to direct Rh insertion into the diene moiety preferentially failed, 
and we observed either no reaction or the removal of the relay handle. 
423
OO
1. n-BuLi, CO2, THF, –78 °C
2. 2,4,5 trichlorobenzoyl chloride 
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Scheme 4.4.2. Ring-Closing Metathesis of Ester 430 
 
 Even though we have yet to successfully perform the desired RCM to generate 
macrocycle 431, obtaining these late-stage intermediates allowed us to test whether an 
intramolecular Diels–Alder reaction would be able to generate the central cyclohexane ring 
of the norcembranoid diterpenes. Indeed, heating ester 430 at 130 °C in xylenes furnished 
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Scheme 4.4.3. Intramolecular Diels–Alder of Ester 430 
 
4.5  RETROSYNTHETIC ANALYSIS; OXIDATIVE ENOLATE COUPLING 
 The potential challenges associated with the late stage RCM have incentivized the 
formulation an alternative retrosynthetic analysis. Thus, scabrolide A (407), can arise from 
the olefin isomerization of 435, which itself may be generated from an intramolecular 
oxidative enolate coupling of 436 (Scheme 4.5.1). Tricycle 436 may arise from the 
oxidation of the intramolecular Diels–Alder reaction of diene 437, which will be formed 
from the convergent esterification of the previous diol fragment 415 and methyl ketone 
438. 
Scheme 4.5.1. 2nd Generation Retrosynthetic Analysis of Scabrolide A 
 
 At this time we also were interested in developing a second generation synthesis of 
diol 415. The first generation route hinged upon the previously developed asymmetric 
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15 steps and afforded an 18% overall yield of the desired product (Scheme 4.5.2). We  
believed that by taking advantage of readily available chiral terpenes, we would be able to 
not only decrease the number of synthetic steps and increase the yield, but also obtain the 
diol product enantiopure. 
Scheme 4.5.2. Development of Modified Synthesis of Diol 415 
 
4.6  SECOND GENERATION SYNTHESIS OF THE CYCLOPENTENE DIOL 
FRAGMENT 
 In 2016, Maimone and coworkers disclosed the enantioselective synthesis of 
ophiobolin N, and showed that commercially available (–)-linalool can afford 
cyclopentenone 440 in a two-step sequence.13 Linalool (339) first undergoes an RCM with 
Hoveyda–Grubbs II and TBS protection of the tertiary alcohol followed by a RuCl3-
catalyzed allylic oxidation generates the desired enone 440 (Scheme 4.6.1). We believed 
enone 440 would allow rapid access to our desired diol 415. a-Bromonation generates a-
bromo enone 441, allowing for tandem phase-transfer mediated sodium cyanide conjugate 
addition and halide elimination to afford vinylogous ketonitrile 442.14 Unfortunately we 
observed low yields and diastereoselectivity upon double reduction of the nitrile and ketone 
moieties in 442. Instead using a Luche reduction at low temperatures performs a 
diastereoselective reduction of the enone to the syn-diol, which can subsequently be TES-










1st generation 2nd generation
415
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Scheme 4.6.1. Terpene-Derived Synthesis Toward Diol 415 
  
 After initial reduction and protection of enone 442, a reduction of nitrile 443 with 
DIBAL, affords enal 444 in excellent yield (Scheme 4.6.2). Enal 444 then undergoes a 
Wittig olefination to yield bis-protected diol 445. Due to the judicious choice of protecting 
groups, we next selectively deprotected the secondary alcohol in the presence of the tertiary 
to afford diene 446. Treating diol 445 with harsh deprotection conditions such as an excess 
of TBAF in refluxing THF, we can obtain the same cyclopentene diol 415 fragment as the 
first generation route. This second generation synthesis not only decreased the number of 
steps required from 15 to 9 but also increased the overall yield to 30%. 
Scheme 4.6.2. Synthesis of Cyclopentene Diol 415 
 
HO
1. HG-II (0.1 mol %), neat
    then, NaH, THF, TBSCl
2. RuCl3, t-BuOOH, Mg(OAc)2
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4.7  ALKYNE SYNTHESIS AND FRAGMENT COUPLING 
 Alkyne ent•422 was synthesized in 5 steps from (–)-carvone following previously 
described methods (Scheme 4.7.1). The Weinreb amide moiety was then monomethylated 
with methyl magnesiumbromide to afford ketone 447, which then undergoes a palladium-
catalyzed oxidative carbonylation using one atmosphere of a 1:1 mixture of CO:O2 in a 
methanol:DMF solution, affording methyl ester 448.15 Saponification of ester 448 followed 
by Steglich esterification with DIC yields the Diels–Alder precursor 449. 
Scheme 4.7.1. Synthesis of Methyl Ketone Diels–Alder Precursor 
 
4.8  INTRAMOLECULAR DIELS–ALDER REACTION AND LATE-STAGE 
FUNCTIONALIZATION 
 Similar to tetraene 430, heating triene 449 to 140 °C in rigorously degassed xylenes 
produces the desired Diels–Alder products as a single diastereomer (450) in excellent yield 
(75%, Scheme 4.8.1). Having synthesized 3 of the 4 rings of the carbocyclic core of 
scabrolide A, we intended to deprotect the tertiary alcohol of 450 in order to set the stage 
for a directed oxidation of the 1,4-cyclohexadiene moiety. Unfortunately, after subjecting 









THF, –78 to 0 °C
79% yield
Pd(OAc)2 (30 mol %)
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1. LiOH, 1:1 THF:H2O
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451 and 452 as a mixture of diastereomers. Tricycle 450 and analogous compounds appear 
to be extremely sensitive to base, treatment with milder bases such as triethylamine at 0 °C 
still result in quantitative aldol reaction. Any attempt to functionalize, protect, or anneal 
the final ring onto tricycle 450 again resulted in the deleterious aldol product. 
Scheme 4.8.1. Unexpected Aldol Condensation of Tricycle 450 
 
 In order to avoid the problematic aldol reaction, double deprotection of the 
cyclopentene diol fragment is required prior to the requisite coupling and Diels–Alder 
reaction. Ester 437 successfully undergoes the Diels–Alder reaction at 140 °C in xylenes 
to afford tricycle 453 (Scheme 4.8.2). The free alcohol is now able to participate in a 
directed epoxidation utilizing vanadyl acetylacetonate to generate the syn-epoxy alcohol 
454 in an excellent 91% yield. Epoxide 454 can be selectively reduced to the 1,3 diol 
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investigated possible oxidation conditions to obtain oxidative enolate coupling precursor 
436. Unfortunately we have yet to determine optimal conditions to effect the desired 
transformation. Basic oxidation conditions such as the Swern oxidation17 again resulted in 
an undesired aldol product. Neutral oxidations, such as the Ley oxidation18 and Stahl 
oxidation,19 afforded recovered starting material due to the large steric encumbrance posed 
by the caged tricyclic core. Moreover, acidic oxidation primarily resulted in 
decomposition. Ultimately we were unable to obtain sufficient quantities of enone 436 to 
investigate the oxidative enolate coupling, necessitating the development of a new 
retrosynthetic analysis. 
Scheme 4.8.2. Selective Oxidation of Deprotected Tricycle 437 
 
4.9  THIRD GENERATION RETROSYNTHETIC ANALYSIS; RING 
EXPANSION 
 Learning from our previous synthetic routes, direct construction of the 7-membered 
ring would likely require the avoidance of ketone functionalities on the carvone fragment 
in order to prevent the problematic aldol reaction. Retrosynthetically, we believed that 
using the inherit energy in a strained small membered ring would facilitate the synthesis of 









































Chapter 4 – Progress Toward the Total Synthesis of Scabrolide A 
 
330 
cyclobutanol 456, which itself can be formed through a photocatalytic [2+2] cycloaddition 
of enone 457 (Scheme 4.9.1). Tricycle 457 again can be synthesized through the redox 
manipulation of the Diels–Alder adduct of ester 458. Finally, ester 458 can be convergently 
synthesized from diol 415 and diyne 459. 
Scheme 4.9.1. 3rd Generation Retrosynthetic Analysis Utilizing Energy of a Strained 
Cyclobutane Ring 
 
4.10  SYNTHESIS OF [2+2] PRECURSOR 
 In order to provide more facile access to late stage material, a model system was 
constructed. Employing 1,6-heptadiyne as the starting material instead of carvone, we 
could rapidly access ester 460 in a single known step instead of 6 steps (Scheme 4.10.1).21 
Ester 460 then undergoes saponification and Steglich esterification with diol 415 to afford 
the Diels–Alder precursor 458 efficiently and in excellent yield. 
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 Cyclization of ester 458 was again performed in xylenes at 140 °C to furnish the 
desired tricycle 461 (Scheme 4.10.2). By utilizing the double deprotected diol 415 instead 
of 446, we can perform a directed epoxidation utilizing vanadyl acetylacetonate and TBHP 
to afford the syn-epoxy alcohol 462. Epoxide 462 can be selectively opened using in situ-
generated titanocene(III) chloride to form the syn-1,3 diol 463, which upon treatment with 
DMP is oxidized to afford enone 464, a moiety that strongly absorbs UV light at 350 nm. 
Scheme 4.10.2. Diels–Alder and Oxidation of Model System 458 
 
4.11  [2+2] PHOTOCYCLOADDITION AND RING EXPANSION 
 The successful installation of the enone moiety of tricycle 464 allowed us to 
perform the Markovnikov hydrosilylation using RuCp*(MeCN)3PF6 and 
dimethylphenylsilane (Scheme 4.11.1).22 While other hydrosilanes are competent in the 
hydrosilylation reaction,23 the presence of an aryl group was paramount to the success of 
the subsequent Tamao–Fleming oxidation. [2+2] cyclization of enone 457, affords a 2:1 
mixture of diastereomers 465 and 466 in quantitative yield. The structures of 465 and 466 
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Scheme 4.11.1. [2+2] Cyclization of Enone 457 
 
 Oxidation of 466 using conditions developed by Fleming, using Hg(OAc)2 in 
peracetic acid generated the desired cyclobutanol 456 in moderate yield (30%, Scheme 
4.11.2).24 Interestingly only diastereomer 466 reacted under these oxidation conditions, 
while 465 required harsher conditions.25 Finally, having synthesized cyclobutanol 456, we 
focused our attention on the strain-release-driven ring expansion. Multiple attempts to form 
the hypoiodite of 456 in-situ followed by homolytic cleavage by thermal or photochemical 
means, resulted in either no reaction or decomposition.26 Fortunately in 2016, Xhang and 
coworkers reported the AgOTf-catalyzed b-scission of cyclic alcohols to the corresponding 
chloroketone.27 Subjecting cyclobutanol 456 to these reaction conditions (Scheme 4.11.2), 
we hoped to obtain the tetracyclic core of scabrolide A 467, but unfortunately these 
conditions also failed to afford the expected product. Fortunately, concentration of this 









CH2Cl2, 0 to 23 °C





























X-ray Crystal Structure of 466X-ray Crystal Structure of 465
Chapter 4 – Progress Toward the Total Synthesis of Scabrolide A 
 
333 
crystal structure. From this data we determined that the product of this reaction was actually 
furan 468. Similar to expected tetracycle 467, furan 468 possesses the key seven membered 
ring, thus completing the carbocyclic skeleton of scabrolide A. 
Scheme 4.11.2. Ring Expansion of Cyclobutanol 466 
 
4.12  FUTURE DIRECTIONS 
 Having achieved the successful synthesis of the carbocyclic skeleton of scabrolide 
A through the use of the ring expansion of a four-membered ring on model system 458, we 
can now focus on the late-stage functionalization to complete the total synthesis. Currently 
we envision furan 468 to undergo a retro-oxa-Michael reaction to afford cycloheptenone 
followed by selective enolization, Segusa–Ito oxidation, and diastereoselective conjugate 
addition of isopropenyl organometallic to complete the synthesis of scabrolide A (Scheme 
4.12.1). If derivatization of model system 458 fails it may be possible to synthesize the 
carvone fragment with the isopropenyl fragment already installed. Early introduction of 
the isopropenyl stereocenter removes the need for late-stage functionalize of tetracycle 468 
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Scheme. 4.12.1. Future Directions Toward the Completion of Scabrolide A 
 
4.13  CONCLUSION 
 We have reported significant progress toward the total synthesis of scabrolide A. A 
key ring expansion of a strained small ring allowed for the synthesis of the [5,5,6,7] 
tetracyclic core in an expedient 16 steps (longest linear) from known enone 440 and in an 
overall yield of 1.1 %. Current endeavors include early introduction of the isopropenyl 
fragment by adapting the carvone route yet again. Moreover we are also investigating the 
oxidation of furan 468 to allow for a diastereoselective conjugate addition of isopropenyl 
organometallic reagent, thus completing the synthesis of scabrolide A. 
4.14  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
4.14.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried or oven-dried glassware under an argon or nitrogen atmosphere using dry, 
deoxygenated solvents (distilled or passed over a column of activated alumina).28 
Commercially obtained reagents were used as received with the exception of 
[RuCp*(MeCN)3]PF6 and Ph3PMeBr which were stored in a nitrogen-filled glovebox. 
Triethylamine (Et3N) was distilled over potassium hydride prior to use. Dess–Martin 
periodinane29 were prepared by known methods. Reactions requiring external heat were 
modulated to the specified temperatures using an IKAmag temperature controller. Reaction 
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E. Merck silica gel 60 F254 precoated glass plated (0.25 mm) and visualized by UV 
fluorescence quenching, potassium permanganate, p-anisaldehyde, or iodine staining. 
Silicycle SiliaFlash® P60 Academic Silica gel (particle size 40-63 nm) was used for column 
chromatography. 1H and 13C NMR spectra were recorded on a Varian Inova 500 (500 MHz 
and 126 MHz, respectively), Varian Mercury 300 spectrometer (300 MHz and 75 MHz, 
respectively), Varian 600 MHz Spectrometer (600 MHz), and a Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz 
and 101 MHz, respectively) and are reported in terms of chemical shift relative to CHCl3 
(d 7.26 and d 77.16, respectively) and C6H6 (d 7.16 and d 128.4 respectively). Data for 1H 
NMR are reported as follows: chemical shift (d ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, p = pentet, sext = sextet, sept = septet, m = multiplet, and br s = broad singlet. 
Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and are reported in frequency of absorption (cm–1). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the sodium 
D-line (589 nm), using a 100-mm path-length cell and are reported as: [a]DT (concentration 
in g/100 mL, solvent). High resolution mass spectra were obtained from the Caltech Mass 
Spectral Facility using a JEOL JMS-600H High Resolution Mass Spectrometer in fast atom 
bombardment (FAB+) ionization mode or a Agilent 6200 Series TOF with an Agilent 
G1978A Multimode source in electrospray ionization (ESI+), atmospheric pressure 
chemical ionization (APCI+), or mixed (ESI/APCI) ionization mode. 
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4.14.2  EXPERIMENTAL PROCEDURES 
 
(S)-N-methoxy-N-methyl-3-(prop-1-en-2-yl)hex-5-ynamide (422): In a round-bottom 
flask, known aldehyde 420 (6.27 g, 31.5 mmol, 1.0 equiv) and K2CO3 (8.7 g, 62.9 mmol, 
2.0 equiv) was diluted with dry methanol (52.5 mL, 0.6 M) and cooled to 0 °C (ice/water 
bath). Neat Ohira–Bestmann reagent (7.25 g, 37.8 mmol, 1.2 equiv) was added dropwise 
via syringe and the resultant solution was allowed to stir for 12 h and warm to ambient 
temperature (23 °C). Upon complete consumption of starting material (determined by TLC 
analysis, 9:1 CH2Cl2:EtOAc), the reaction was diluted with Et2O and washed with a 
saturated solution of NaHCO3. The organic layer was dried over Na2SO4, filtered, and 
concentrated in vacuo. The crude product was purified by flash chromatography (SiO2, 9:1 
CH2Cl2:EtOAc) to generate alkyne 422 (5.0 g, 82% yield) as a pale yellow oil; Rf = 0.71 
(9:1 CH2Cl2:EtOAc); 1H NMR (500 MHz, CDCl3) d 4.85 (p, J = 1.5 Hz, 1H), 4.82 (dp, J 
= 1.7, 0.9 Hz, 1H), 3.70 (s, 3H), 3.17 (s, 3H), 2.92–2.82 (m, 1H), 2.76–2.60 (m, 2H), 2.38 
(ddd, J = 6.4, 3.5, 2.7 Hz, 2H), 1.99 (t, J = 2.7 Hz, 1H), 1.77 (dd, J = 1.6, 0.8 Hz, 3H); 13C 
NMR (126 MHz, CDCl3) d 173.0, 146.2, 111.6, 82.4, 69.9, 61.3, 40.8, 34.8, 32.2, 23.0, 
20.7; IR (thin film, NaCl) 3293, 3250, 3076, 2967, 2938, 2820, 2116, 1661, 1430, 1384, 
1334, 1175, 1175, 1108, 1002, 936, 894 cm-1; HRMS (ES/APCI) m/z calc’d C11H18O2N 
























(S)-6-(prop-1-en-2-yl)non-1-en-8-yn-4-one ent•416: In a flame dried round bottom flask, 
amide 422 (50 mg, 0.26 mmol, 1.0 equiv) was dissolved in THF (0.8 mL, 0.3 M) and cooled 
to –78 °C. Allyl magnesium bromide (0.52 mL, 0.52 mmol, 1.0 M, 2.0 equiv) was added 
dropwise to the reaction solution. The reaction was allowed to stir for 15 min at –78 °C 
and then warmed to 0 °C and stirred for 16 h. Upon complete consumption of starting 
material (determined by TLC analysis, 9:1 hexanes:Et2O), the reaction was quenched with 
a saturated solution of NH4Cl and the product was extracted from the biphasic mixture with 
Et2O (3 x 10 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography (SiO2, 9:1 hexanes:Et2O) to generate alkyne ent•416 (39 mg, 87% yield) 
as a pale yellow oil; 1H NMR (500 MHz, CDCl3) d 5.91 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 
5.18 (dq, J = 10.2, 1.3 Hz, 1H), 5.14 (dq, J = 17.1, 1.5 Hz, 1H), 4.82 (p, J = 1.5 Hz, 1H), 
4.78 (dt, J = 1.5, 0.8 Hz, 1H), 3.18 (dt, J = 6.9, 1.4 Hz, 2H), 2.86–2.77 (m, 1H), 2.74 (dd, 
J = 16.7, 6.6 Hz, 1H), 2.62 (dd, J = 16.7, 7.4 Hz, 1H), 2.32 (ddd, J = 14.5, 6.5, 2.7 Hz, 2H), 
1.99 (t, J = 2.7 Hz, 1H), 1.73 (dd, J = 1.5, 0.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) d 
207.3, 145.9, 130.52, 119.1, 111.8, 82.2, 70.3, 48.2, 45.1, 40.2, 23.0, 20.7; IR (thin film, 
NaCl) 3297, 3078, 2969, 2917, 2117, 1715, 1646, 1430, 1376, 993, 920, 895 cm-1; HRMS 
(ESI) m/z calc’d C12H16O [M•]+: 176.1201, found: 176.1191. [a]D25 – 24.90 (c 3.7, CDCl3). 
O
ent•416











(S)-2-allyl-2-(2-(prop-1-en-2-yl)pent-4-yn-1-yl)-1,3-dioxolane (423): Dried oxalic acid 
(109 mg, 1.2 mmol, 8.5 equiv) was dissolved in a solution of ethylene glycol (0.27 mL, 
4.69 mmol, 33 equiv), triethyl orthoformate (0.14 mL, 0.85 mmol, 6 equiv), and MeCN 
(1.95 mL, 0.073 M). After complete dissolution of the oxalic acid, ketone ent•416 (25 mg, 
0.14 mmol, 1 equiv) was added. The reaction was sealed and allowed to stir at ambient 
temperature (23 °C) for 36 h. Upon complete consumption of starting material (as 
determined by TLC analysis, 4:1 hexanes: Et2O), the reaction was diluted with H2O and 
the product was extracted with Et2O (3 x 5 mL). The combined organic layers were washed 
with brine, dried with MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography (SiO2, 4:1 hexanes:Et2O) to afford dioxolane 423 (26 
mg, 83% yield) as a pale yellow oil (Rf = 0.68, 4:1 hexanes:EtOAc); 1H NMR (400 MHz, 
CDCl3) d = 5.81 (ddt, J = 16.9, 10.5, 7.2 Hz, 1H), 5.12 (ddt, J = 8.2, 2.2, 1.3 Hz, 1H), 5.08 
(t, J = 1.3 Hz, 1H), 4.79 (q, J = 1.3 Hz, 2H), 3.94 (q, J = 1.3 Hz, 4H), 2.52 (dq, J = 8.2, 6.3 
Hz, 1H), 2.43–2.34 (m, 3H), 2.26 (ddd, J = 16.7, 8.1, 2.7 Hz, 1H), 1.97 (t, J = 2.6 Hz, 1H), 
1.83 (d, J = 6.5 Hz, 2H), 1.70 (t, J = 1.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) d = 147.5, 
133.3, 118.4, 111.4, 110.8, 83.3, 69.4, 65.0, 65.0, 42.5, 41.3, 39.2, 24.1, 19.2; IR (thin film, 
NaCl) 3302, 3075, 2949, 2888, 2117, 1643, 1433, 1374, 1311, 1124, 1100, 996, 918, 890, 
862, 837, 635 cm-1; HRMS (FAB+) m/z calc’d C14H21O2 [M+H]+: 221.1536, found: 
















yl)methyl)-6-methylhept-6-en-2-ynoate (430): Dioxolane 423 (95 mg, 0.43 mmol, 1 
equiv) was dissolved in THF (4.3 mL, 0.1 M) and cooled –78 °C. The solution was allowed 
to stir for 5 min followed by the addition powdered dry ice (0.56 g, 1.3 g/mmol of 423). 
After 10 min, the reaction was quenched with a saturated solution of NH4Cl and was 
allowed to warm to ambient temperature (23°C). The solution was acidified with a 5% 
solution of citric acid (5 mL) and the product was extracted with EtOAc (5 x 15 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude product 469 (103 mg, 93%) was used crude in the following reaction. 
To a solution of acid 469 (58 mg, 0.22 mmol, 1.1 equiv) in THF (2 mL, 0.1 M), 
Et3N (92 µL, 0.66 mmol, 3.3 equiv) and 2,4,6-trichlorobenzoyl chloride (34 µL, 0.22 
mmol, 1.1 equiv) was added. The reaction was allowed to stir for 1 h followed by the 
addition of a THF solution (2 mL, 0.1 M) of diol 415 (28 mg, 0.2 M, 1 equiv) and DMAP 
(24 mg, 0.2 mmol, 1 equiv). The reaction was allowed to stir at ambient temperature (23 
°C) until complete. Upon complete consumption of diol 415 (as determined by TLC 
analysis, 4:1 hexanes:EtOAc) the reaction was directly purified by column 
chromatography (SiO2, 100% hexanes then 1:1 hexanes:EtOAc) to afford ester 430 (43 
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11.3 Hz, 1H), 5.87–5.73 (m, 3H), 5.53 (ddd, J = 7.1, 4.5, 2.3 Hz, 1H), 5.32 (dd, J = 11.3, 
1.6 Hz, 1H), 5.16–5.10 (m, 1H), 5.08 (t, J = 1.3 Hz, 1H), 4.80 (d, J = 1.2 Hz, 2H), 3.94 (s, 
4H), 2.65–2.53 (m, 3H), 2.45–2.39 (m, 1H), 2.36 (dq, J = 6.1, 1.2 Hz, 2H), 2.08–2.01 (m, 
1H), 1.92 (s, 1H), 1.85 (dd, J = 14.7, 6.1 Hz, 1H), 1.77 (dd, J = 14.7, 6.2 Hz, 1H), 1.69 (t, 
J = 1.2 Hz, 3H), 1.43 (s, 3H); 13C NMR (101 MHz, CDCl3) d 153.6, 151.7, 146.6, 133.2, 
129.0, 126.2, 119.5, 118.6, 112.1, 110.7, 88.9, 81.0, 77.0, 74.2, 65.1, 65.0, 49.0, 42.5, 40.6, 
39.4, 26.7, 24.2, 19.4; IR (thin film, NaCl) 3369lm2956, 2918, 2847, 2232, 1705, 1633, 
1460, 1418, 1372, 1258, 1063, 801 cm-1; HRMS (FAB+) m/z calc’d C23H31O5 [M+H]+: 
387.2171, found: 387.2158; [a]25D = + 26.7 (c = 0.045, CHCl3). 
 
 (1R,4S)-4-hydroxy-4-methyl-3-vinylcyclopent-2-en-1-yl 3-((S)-8-methyl-1,4-
dioxaspiro[4.5]dec-8-en-7-yl)propiolate (432): To a stirred, Ar sparged solution of ester 
430 (6 mg, 0.016 mmol, 1.0 equiv) in toluene (1 mL, 0.016 M) had Grubbs II (2.6 mg, 3.1 
µmol, 0.2 equiv) added in one portion. The reaction was allowed to stir for 2 h followed 
by direct purification of column chromatography (SiO2, 100% hexanes to 4:1 
hexanes:EtOAc) to afford ester 432 (1.7 mg, 31 %) as a pale yellow oil (Rf = 0.17); 1H 
NMR (400 MHz, CDCl3) d 6.26 (ddt, J = 17.8, 11.3, 0.7 Hz, 1H), 5.76 (d, J = 2.4 Hz, 1H), 
5.75–5.68 (m, 1H), 5.52–5.45 (m, 1H), 5.35 (ddt, J = 4.6, 3.2, 1.5 Hz, 1H), 5.27 (dd, J = 
11.3, 1.6 Hz, 1H), 3.94–3.87 (m, 4H), 2.58 (dd, J = 14.3, 7.3 Hz, 1H), 2.50 (d, J = 1.9 Hz, 
3H), 2.26–2.11 (m, 2H), 2.00 (dd, J = 14.2, 4.4 Hz, 1H), 1.90–1.76 (m, 2H), 1.64 (q, J = 
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121.8, 119.6, 108.0, 88.5, 81.1, 77.1, 74.4, 64.7, 64.5, 49.0, 38.1, 36.2, 36.1, 26.8, 22.6, 
21.1; IR (thin film, NaCl) 3447, 2926, 2233, 1734, 1701, 1559, 1540, 1420, 1372, 1248, 
1122, 1072, 988, 948, 874, 810, 753, 731; HRMS (ESI) m/z calc’d C21H27O5 [M+H]+: 
358.1853, found: 358.1833; [a]D23 + 125.4 (c 0.75, CHCl3). 
 
(2a1R,6S,7aR)-3-((S)-2-((2-allyl-1,3-dioxolan-2-yl)methyl)-3-methylbut-3-en-1-yl)-6-
hydroxy-6-methyl-4,6,7,7a-tetrahydroindeno[1,7-bc]furan-2(2a1H)-one (434): Ester 
430 (5.3 mg, 13.7 µmol, 1 equiv) was dissolved xylenes (0.5 mL), sparged with Ar, sealed, 
and heated to 130 °C for 1 h. Upon complete consumption of starting material (as 
determined by TLC analysis, 1:1 hexanes: EtOAc), the reaction was loaded directly flash 
column (SiO2, 100% hexanes to 1:1 hexanes:EtOAc) to afford tricycle 434 (2.1 mg, 40% 
yield) as an amorphous solid; 1H NMR (400 MHz, CDCl3) d 5.91–5.72 (m, 2H), 5.16–5.03 
(m, 2H), 4.96 (ddd, J = 9.1, 8.0, 7.0 Hz, 1H), 4.64 (dq, J = 2.9, 1.5 Hz, 1H), 4.57 (dd, J = 
2.3, 1.0 Hz, 1H), 4.01–3.86 (m, 4H), 3.30 (t, J = 9.7 Hz, 1H), 3.10–2.90 (m, 2H), 2.75–
2.59 (m, 3H), 2.50 (ddd, J = 12.7, 7.0, 0.9 Hz, 1H), 2.39 (dq, J = 7.2, 1.5 Hz, 2H), 1.90 (dd, 
J = 14.8, 7.9 Hz, 1H), 1.72–1.64 (m, 4H), 1.64–1.60 (m, 1H), 1.40 (d, J = 1.0 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) d 168.3, 156.7, 152.0, 148.6, 133.5, 124.9, 118.4, 116.6, 111.3, 
110.9, 80.0, 75.2, 65.1, 65.0, 49.8, 45.7, 42.5, 41.9, 39.4, 36.8, 35.3, 26.6, 18.3; IR (thin 
film, NaCl) 3458, 2924, 1749, 1642, 1432, 1210, 1093, 1044, 823 cm-1; HRMS (FAB+) 





















(R)-2-bromo-4-((tert-butyldimethylsilyl)oxy)-4-methylcyclopent-2-en-1-one (441): In 
a flame dried round-bottom flask, Enone 440 (2.76g, 12.2 mmol, 1.0 equiv) dissolved in 
CH2Cl2 (122 mL, 0.1 M) was cooled to 0 °C (ice: water bath). Br2 (0.687 mL, 13.4 mmol, 
1.1 equiv) was added dropwise over 10 min and the resultant solution stirred for 30 min. 
Upon complete consumption of starting material (as determined by TLC analysis, 9:1 
hexanes:EtOAc), Et3N (2.5 mL, 18.3 mmol, 1.5 equiv) was added and allowed to stir for 1 
h at ambient temperature (23 °C). The reaction was diluted with a saturated solution of 
Na2S2O3 and the product was extracted with EtOAc (3 x 100 mL). The combined organic 
layers were washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The 
crude product was purified by column chromatography (SiO2, 9:1 hexanes:EtOAc) to 
afford enone 441 (3.3 g, 90% yield) as a colorless oil (Rf = 0.45); 1H NMR (400 MHz, 
CDCl3) d = 7.51 (s, 1H), 2.64 (d, J = 3.6 Hz, 2H), 1.51 (s, 3H), 0.85 (d, J = 0.5 Hz, 9H), 
0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 198.9, 165.0, 125.4, 50.4, 29.2, 
25.7, 18.0, -2.3, -2.4; IR (thin film, NaCl) 2956, 2930, 2888, 2858, 1733, 1593, 1472, 1463, 
1374, 1292, 1254, 1205, 1106, 1081, 1018, 922, 837, 776 cm-1; HRMS (ESI) m/z calc’d 









CH2Cl2, 0 to 23 °C
90% yield





(442): In a round-bottom flask, NaCN (2.3 g, 47 mmol, 2.2 equiv) and TBAI (1.1 g, 3.6 
mmol, 0.17 equiv) is dissolved in H2O (66 mL, 0.32 M). Upon complete dissolution, a 
solution of enone 441 (6.5 g, 21.3 mmol, 1 equiv) in CH2Cl2 (107 mL, 0.2 M) was added 
and the biphasic mixture was stirred vigorously for 16 h. Upon completion of starting 
material (as determined by TLC analysis, 9:1 hexanes:EtOAc), the reaction was allowed 
to stand until complete separation of the biphasic mixture occured. The organic layer was 
separated and the aqueous layer was extracted with EtOAc (5 x 100 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in 
vacuo. The crude product was purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford enone 442 (3.8 g, 72% yield) as a pale yellow oil (Rf = 0.43); 1H 
NMR (400 MHz, CDCl3) d = 6.56 (s, 1H), 2.65 (d, J = 3.7 Hz, 2H), 1.64 (s, 3H), 0.88 (s, 
9H), 0.17 (s, 3H), 0.13 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 203.0, 149.6, 139.6, 
113.3, 78.8, 51.1, 28.1, 25.6, 18.1, -2.4, -2.7; IR (thin film, NaCl) 3449, 3087, 2957, 2932, 
2888, 2859, 2231, 2736, 1606, 1473, 1378, 1290, 1254, 1217, 1170, 1093, 1006, 838, 778, 
673 cm-1; HRMS (FAB+) m/z calc’d C13H22O2NSi [M+H]+: 252.1420, found: 252.1416; 
















carbonitrile (470): In a round bottom flask, enone 442 (9.4 g, 37.3 mmol, 1 equiv) was 
dissolved in methanol (373 mL, 0.1 M). The solution was stirred for 5 min followed by the 
addition of CeCl3•7H2O (13.2 g, 41 mmol, 1.1 equiv). Once the reaction is homogeneous, 
the solution is cooled to – 78 °C and allowed to stir for 1 h. NaBH4 (1.4 g, 37.3 mmol, 1 
equiv) was added slowly in portions to the reaction and was allowed to stir until completion 
(as determined by TLC analysis 4:1 hexanes:EtOAc). Upon complete consumption of 
starting material, the reaction was quenched with a saturated solution of NH4Cl (300 mL) 
and the biphasic mixture was allowed to warm to room temperature. The biphasic mixture 
was extracted with 2:1 Et2O:hexanes (3 x 300 mL) and the combined organic layers were 
dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was assumed to 
have quantitative conversion and was used directly into the next reaction without further 
purification. Alcohol 470 could be purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford pure alcohol 470 as a white amorphous powder; Rf = 0.74 (4:1 
hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) d = 6.40 (d, J = 2.1 Hz, 1H), 4.60 (dddd, J 
= 8.1, 7.1, 5.2, 2.2 Hz, 1H), 2.34 (dd, J = 13.3, 6.9 Hz, 1H), 1.80 (dd, J = 13.2, 5.2 Hz, 1H), 
1.65 (d, J = 8.2 Hz, 1H), 1.29 (d, J = 0.6 Hz, 3H), 0.72 (s, 9H), 0.00 (s, 3H), -0.01 (s, 3H); 
13C NMR (101 MHz, CDCl3) d 146.6, 127.2, 114.7, 83.0, 74.2, 50.8, 27.8, 25.7, 18.0, -2.2, 
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1082, 1031, 868, 838, 777, 668 cm-1; HRMS (ESI) m/z calc’d C13H27N2O2Si [M+NH4]+: 
271.1836; found: 271.1842; [a]D23 – 53.0 (c 0.28, CHCl3). 
(3S,5R)-5-((tert-butyldimethylsilyl)oxy)-5-methyl-3-((triethylsilyl)oxy)cyclopent-1-
ene-1-carbonitrile (443): Crude alcohol 470 (37.3 mmol, 1 equiv) was dissolved in 
CH2Cl2 (266 mL, 0.14 M). Once the solution is homogeneous Imidazole (7.6 g, 111.9 
mmol, 3 equiv) and TESCl (7.1 mL, 55.9 mL, 1.5 equiv) was added. The reaction was 
allowed to stir until completion at 23 °C. Upon complete consumption of starting material 
(as determined by TLC analysis, 9:1 hexanes:EtOAc), the reaction was quenched with H2O 
(200 mL) and the biphasic mixture was extracted with Et2O (3 x 400 mL). The combined 
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated in 
vacuo. The resultant crude product was the purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford nitrile 443 (12.5 g, 91% yield, 11:1 dr) as a pale yellow oil (Rf  
= 0.5); 1H NMR (400 MHz, CDCl3) d = 6.41 (d, J = 2.0 Hz, 1H), 4.72 (ddd, J = 7.0, 6.2, 
2.0 Hz, 1H), 2.49 (dd, J = 12.8, 7.0 Hz, 1H), 1.98 (ddd, J = 12.8, 6.3, 0.8 Hz, 1H), 1.40 (d, 
J = 0.8 Hz, 3H), 0.96 (t, J = 7.9 Hz, 9H), 0.89 (s, 9H), 0.61 (q, J = 7.8 Hz, 6H), 0.14 (s, 
3H), 0.13 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 147.3, 126.1, 114.9, 82.4, 73.8, 51.5, 
28.7, 25.8, 18.1, 6.8, 4.8, -2.2, -2.6; IR (thin film, NaCl) 2957, 2879, 2858, 2224, 1463, 
1414, 1360, 1308, 1254, 1198, 1177, 1132, 1099, 1047, 1006, 893, 869, 837, 809, 777 cm-
1; HRMS (ESI) m/z calc’d C19H38NO2Si2 [M+H]+: 268.2436; found: 368.2449; [a]D23 – 
52.0 (c 0.40, CHCl3). 





ene-1-carbaldehyde (444): Nitrile 443 (250 mg, 0.68 mmol, 1 equiv) was added to CH2Cl2 
(6.8 mL, 0.1M) and cooled to –78 °C. DIBAL (1.36 mL, 1 M in DCM, 2 equiv) was added 
dropwise and allowed to stir for 1 h at –78 °C. Upon complete consumption of starting 
material (as determined by TLC analysis, 19:1 hexanes:Et2O) the reaction was quenched 
with EtOAc (0.5 mL), diluted with Et2O and warmed to room temperature. A 50% solution 
of Rochelle’s salt (10 mL) was added and the biphasic mixture was allowed to stir for 0.5 
h. If the biphasic mixture does not separate completely, another portion of Rochelle’s salt 
is add and stirred for another 0.5 h. The biphasic mixture is separated and the aqueous layer 
is extracted with Et2O (3 x 10 mL). The combined organic layers are dried over MgSO4, 
filtered, and concentrated in vacuo. The resultant crude product was the purified by column 
chromatography (SiO2, 19:1 hexanes:Et2O) to afford enal 444 (252 mg, 91% yield, 17:1 
dr) as a pale yellow oil (Rf  = 0.46); 1H NMR (400 MHz, CDCl3) d = 9.77 (s, 1H), 6.53 (d, 
J = 1.8 Hz, 1H), 4.70 (td, J = 6.9, 1.9 Hz, 1H), 2.49 (dd, J = 12.7, 7.1 Hz, 1H), 2.08 (dd, J 
= 12.6, 6.6 Hz, 1H), 1.45 (s, 3H), 0.97 (t, J = 7.9 Hz, 9H), 0.84 (d, J = 0.9 Hz, 9H), 0.63 
(q, J = 7.9 Hz, 6H), 0.11 (s, 3H), 0.07 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 189.7, 
149.8, 147.8, 80.6, 72.9, 53.9, 28.6, 25.8, 18.1, 6.9, 4.9, -2.2, -2.4; IR (thin film, NaCl) 
2956, 2936, 2879, 2857, 2805, 2708, 1698, 1627, 1472, 1462, 1414, 1359, 1253, 1203, 
1172, 1103, 1058, 975, 897, 837, 806, 775, 746, 671; HRMS (FAB+) m/z calc’d 


















yl)oxy)silane (445): To a round-bottom flask in an N2-filled glovebox were charged 
Ph3PMeBr (1.7 g, 4.86 mmol, 3.00 equiv) and KOt-Bu (490 mg, 4.37 mmol, 2.70 equiv) 
as solids followed by THF (162 mL, 0.01 M). The bright yellow reaction mixture was then 
sealed with a rubber septum, removed from the glovebox, and placed under an argon 
atmosphere with stirring. After 2 h, a solution of aldehyde 444 in THF (3.00 mL) was added 
dropwise, causing the reaction mixture to become dark orange-brown. After the 
consumption of starting material was complete (as determined by TLC analysis, 19:1 
hexanes:EtOAc). The reaction was poured onto a mixture of H2O (90 mL) and Et2O (30 
mL). The organics were separated and the aqueous layer was extracted with Et2O (3 x 30 
mL). The combined organic layers were washed with brine (30 mL), dried over MgSO4, 
filtered, and concentrated in vacuo. The crude dark brown residue was purified by column 
chromatography (SiO2, 19:1 hexanes:Et2O) to afford diene 445 (567 mg, 95% yield) as a 
colorless oil (Rf = 0.80); 1H NMR (400 MHz, CDCl3) d = 6.24 (dd, J = 17.3, 11.2 Hz, 1H), 
5.68 (dd, J = 18.2, 2.0 Hz, 1H), 5.62 (d, J = 1.9 Hz, 1H), 5.18 (ddt, J = 11.3, 2.2, 0.6 Hz, 
1H), 4.60 (dddd, J = 6.7, 6.0, 2.0, 0.9 Hz, 1H), 2.43 (dd, J = 12.2, 6.8 Hz, 1H), 2.00 (ddd, 
J = 12.1, 6.6, 0.9 Hz, 1H), 1.34 (d, J = 0.9 Hz, 3H), 0.97 (t, J = 7.9 Hz, 9H), 0.86 (s, 9H), 
0.61 (q, J = 7.9 Hz, 6H), 0.11 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 149.4, 
130.0, 129.9, 117.4, 82.1, 73.2, 53.5, 29.0, 26.0, 18.2, 7.0, 5.0, -2.0, -2.5; IR (thin film, 
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1018, 1004, 855, 836, 774, 744 cm-1; HRMS (FAB+) m/z calc’d C20H44NO2Si [M+NH4]+: 
386.2905, found: 386.2889; [a]D23 – 3.87 (c 0.35, CHCl3). 
 
(1S,4R)-4-((tert-butyldimethylsilyl)oxy)-4-methyl-3-vinylcyclopent-2-en-1-ol (446): A 
solution of Diene 445 (195 mg, 0.53 mmol, 1 equiv) in THF (7.6 mL, 0.07 M) had a THF 
solution of TBAF (0.58 mL, 0.58 mmol, 1 M, 1.1 equiv). The reaction was allowed to stir 
for 15 min at which time total consumption of starting material occur (as determined by 
TLC analysis, 3:1 hexanes:Et2O). The reaction was diluted with water (10 mL) and the 
aqueous layer was extracted with Et2O (3 x 10 mL). The combined organic layers were 
washed with brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified by column chromatography (SiO2, 3:1 hexanes:Et2O) to afford diene 
446 (117 mg, 87%) as a viscous colorless oil which solidifies at –20 °C (Rf = 0.2); 1H NMR 
(400 MHz, CDCl3) d = 6.32–6.22 (m, 1H), 5.75–5.67 (m, 2H), 5.25–5.19 (m, 1H), 4.64–
4.55 (m, 1H), 2.53 (dd, J = 12.7, 6.9 Hz, 1H), 1.93 (ddd, J = 12.7, 6.0, 0.8 Hz, 1H), 1.59 
(s, 1H), 1.36 (d, J = 0.9 Hz, 3H), 0.86 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H); 13C NMR (101 
MHz, CDCl3) d = 150.6, 129.8, 129.1, 118.1, 82.5, 73.5, 53.2, 28.7, 25.9, 18.2, -2.0, -2.4; 
IR (thin film, NaCl) 3324, 2957, 2929, 2886, 2857, 1590, 1472, 1462, 1370, 1254, 1204, 
1170, 1134, 1042, 1017, 835, 774, 679; HRMS (FAB+) m/z calc’d C14H30NO2Si 














(1R,3S)-1-methyl-5-vinylcyclopent-4-ene-1,3-diol (415): A solution of Diene 445 (270 
mg, 0.57 mmol, 1 equiv) in THF (8.1 mL, 0.07 M) had a THF solution of TBAF (1.25 mL, 
1.25 mmol, 1 M, 2.2 equiv). The reaction was allowed to stir for 2 h at 65 °C at which time 
another solution of TBAF (0.25 mL, 0.25 mmol, 0.5 equiv) was added. Upon total 
consumption of starting material (as determined by TLC analysis, 3:1 hexanes:Et2O), the 
reaction was diluted with water (10 mL) and the aqueous layer was extracted with Et2O (5 
x 25 mL). The combined organic layers were washed with brine, dried over MgSO4, 
filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, 1:3 hexanes:EtOAc) to afford diene 415 (64 mg, 81%) as a white 
amorphous solid; 1H NMR (300 MHz, CDCl3) d 6.30 (dd, J = 17.8, 11.3, 1H), 5.82 (d, J = 
2.1, 1H), 5.73 (dd, J = 17.9, 1.7, 1H), 5.26 (dd, J = 11.2, 1.7, 1H), 4.65 (dd, J = 11.5, 5.1, 
1H), 2.54 (dd, J = 13.6, 6.8, 1H), 1.85 (dd, J = 13.6, 4.8, 2H), 1.68 (d, J = 6.6, 1H), 1.40 (s, 
3H). All other characterization data matched known values.9 
 
(S)-4-(prop-1-en-2-yl)hept-6-yn-2-one (447): Amide ent•422 (2.0 g, 10.2 mmol, 1 equiv) 
in THF (51 mL, 0.2 M) was cooled to –78 °C. A solution of MeMgBr in Et2O(7.1 mL, 21.5 
mmol, 3 M, 2.1 equiv) was added dropwise. The reaction was allowed to stir for 12 h, 


















THF, –78 to 0 °C
79% yield
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starting material (as determined by TLC analysis, 4:1 hexanes:Et2O), the reaction was 
quenched with a saturated solution of NH4Cl (50 mL), and diluted with Et2O (25 mL). The 
organics were separated and the aqueous layer was extracted with Et2O (3 x 40 mL) and 
the combined organic layers were washed with brine, dried over MgSO4, filtered, and 
concentrated in vacuo. The crude product was purified by column chromatography (SiO2, 
4:1 hexanes, Et2O) to afford ketone 447 (1.2 g, 79%) as a pale yellow oil (Rf = 0.6); 1H 
NMR (400 MHz, CDCl3) d = 4.83 (p, J = 1.5 Hz, 1H), 4.78 (dt, J = 1.6, 0.8 Hz, 1H), 2.81 
(p, J = 6.7 Hz, 1H), 2.73 (dd, J = 16.5, 6.6 Hz, 1H), 2.59 (dd, J = 16.5, 7.5 Hz, 1H), 2.36 
(ddd, J = 16.9, 6.3, 2.7 Hz, 1H), 2.29 (ddd, J = 16.9, 6.6, 2.7 Hz, 1H), 2.15 (s, 3H), 1.99 (t, 
J = 2.6 Hz, 1H), 1.73 (dd, J = 1.5, 0.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) d = 207.6, 
145.9, 111.9, 82.2, 70.2, 46.5, 40.5, 30.5, 23.1, 20.6; IR (thin film, NaCl) 3294, 3078, 2970, 
2918, 2117, 1715, 1648, 1433, 1360, 1233, 1160, 1059, 997, 896, 641; HRMS (ESI) m/z 
calc’d C10H15O [M+H]+: 151.1197, found: 151.1115; [a]D23 + 22.2 (c 0.59, CHCl3). 
 
methyl (S)-7-oxo-5-(prop-1-en-2-yl)oct-2-ynoate (448): Palladium acetate (112 mg, 0.5 
mmol, 0.3 equiv) and triphenylphosphine (260 mg, 1.0 mmol, 0.6 equiv) were mixed in 
dimethylformamide (17 mL, 0.1 M) in a round-bottomed flask under N2 and allowed to stir 
for 5 min. Methanol (1.7 mL, 41.5 mmol, 25 equiv) and ketone 447 (250 mg, 1.66 mmol, 
1 equiv) were added, followed by attachment of 2 rubber balloons, one filled with oxygen 
and the other CO, to the flask. The reaction was sparged with both CO andO2 balloons for 
O
447
Pd(OAc)2 (30 mol %)
Ph3P (60 mol %)
DMF:MeOH
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5 min and allowed to stir at ambient temperature (23 °C) for 16 h. Upon complete 
consumption of starting material (as determined by TLC, 4:1 hexanes:EtOAc), the mixture 
was diluted with Et2O and a saturated solution of LiCl and the aqueous layer was extracted 
with Et2O. The combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. The crude product was purified by column chromatography (SiO2, 4:1 
hexanes:EtOAc) to afford ester 448 (249 mg, 86%) as a colorless oil (Rf = 0.25); 1H NMR 
(400 MHz, CDCl3) d =4.86 (t, J = 1.4 Hz, 1H), 4.81 (q, J = 0.9 Hz, 1H), 3.75 (s, 3H), 2.85 
(p, J = 6.7 Hz, 1H), 2.66 (dd, J = 9.4, 7.1 Hz, 2H), 2.48 (dd, J = 6.5, 4.9 Hz, 2H), 2.16 (s, 
3H), 1.73 (dd, J = 1.4, 0.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) d =207.0, 154.2, 145.2, 
112.5, 87.3, 74.6, 52.8, 46.3, 39.7, 30.6, 23.1, 20.7; IR (thin film, NaCl) 2923, 2236, 1714, 
1647, 1434, 1361, 1259, 1158, 1074, 942, 901, 752, 679 cm-1, HRMS (FAB+) m/z calc’d 
C12H17O3 [M+H]+: 209.1172; found 209.1164; [a]D23 + 46.5 (c 0.18, CHCl3). 
 
(1S,4R)-4-((tert-butyldimethylsilyl)oxy)-4-methyl-3-vinylcyclopent-2-en-1-yl (R)-7-
oxo-5-(prop-1-en-2-yl)oct-2-ynoate (471): Ester 448 (1.5 g, 5.7 mmol, 1 equiv) in a 
solution of THF (28 mL, 0.2M), was added to a solution of LiOH (205 mg, 8.6 mmol, 1.5 
equiv) in H2O (28 mL, 0.2M). The reaction was stirred vigorously for 4 h when complete 
consumption of starting material was observed (as determined by TLC analysis 4:1 
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was subsequently acidified to a pH of 1 with 1 N HCl. The acidic aqueous layer was then 
extracted with EtOAc (5 x 30 mL) and the combined organic layers were washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude acid 471 (1.3 g, 
81%) was used without further purification or characterization. 
Diol 446 (10 mg, 0.039 mmol, 1 equiv), acid 471 (15 mg, 0.079 mmol 2 equiv), 
and DMAP (16 mg, 0.039 mmol, 1 equiv) were added to a solution of CH2Cl2 (0.4 mL, 0.1 
M) and cooled to 0 °C. DIC (12 µL, 0.079 mmol, 2 equiv) was added dropwise and the 
reaction was allowed to stir for 2 h. Upon complete consumption of starting material (as 
determined by TLC analysis, 4:1 hexanes:EtOAc), the reaction was diluted with H2O (5 
mL) and extracted with Et2O (3 x 5 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, 4:1 hexanes:EtOAc) to afford ester 449 (12 mg, 70%) as a pale 
yellow oil (Rf = 0.4); 1H NMR (400 MHz, CDCl3) d = 6.27 (ddd, J = 17.8, 11.2, 0.8 Hz, 
1H), 5.75–5.69 (m, 2H), 5.53 (dddd, J = 7.3, 5.9, 2.3, 0.8 Hz, 1H), 5.27 (dd, J = 11.3, 1.9 
Hz, 1H), 4.86–4.83 (m, 1H), 4.83–4.77 (m, 1H), 2.93–2.81 (m, 1H), 2.67 (dd, J = 13.2, 7.1 
Hz, 2H), 2.63–2.56 (m, 1H), 2.48 (dd, J = 7.5, 6.4 Hz, 2H), 2.16 (s, 3H), 2.10 (ddd, J = 
13.1, 5.9, 0.8 Hz, 1H), 1.73 (dd, J = 1.5, 0.8 Hz, 3H), 1.38 (d, J = 0.8 Hz, 3H), 0.86 (s, 9H), 
0.12 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 207.1, 153.7, 152.7, 145.2, 
129.3, 123.9, 119.0, 112.4, 87.2, 82.3, 74.9, 48.9, 46.3, 39.7, 30.5, 29.2, 25.9, 23.2, 20.7, 
18.2, -2.2, -2.6; IR (thin film, NaCl) 2956, 2929, 2856, 2234, 1711, 1649, 1472, 1439, 
1359, 1250, 1169, 1069, 1022, 837, 774, 752 cm-1; HRMS (FAB+) m/z calc’d C25H39O4Si 
[M+H]+: 431.2612; found 431.2629; [a]D23 –71.1 (c 0.59, CHCl3). 





yl)pentyl)-4,6,7,7a-tetrahydroindeno[1,7-bc]furan-2(2a1H)-one (450): Ester 449 (65 
mg, 0.15 mmol) was transferred to a Schlenk bomb with xylenes (15 mL, 0.01 M). The 
Schlenk was the rigorously degassed by standard freeze-pump-thaw technique and upon 
reaching ambient temperature (23 °C) the flask was sealed and heat to 140 °C. The reaction 
was allowed to stir at this temperature of 2 h at which time complete consumption of 
starting material was observed (as determined by TLC analysis, 4:1 hexanes:EtOAc). The 
reaction was allowed to cool to room temperature and was directly purified by column 
chromatography (SiO2, 100% hexanes then 4:1 hexanes:EtOAc) to furnish tricycle 450 (53 
mg, 82%) as a white amorphous solid (Rf = 0.35); 1H NMR (400 MHz, CDCl3) d = δ 5.78 
(ddd, J = 6.4, 2.9, 1.9 Hz, 1H), 4.93 (ddd, J = 9.0, 8.1, 7.0 Hz, 1H), 4.68 (p, J = 1.5 Hz, 
1H), 4.63 (dt, J = 1.8, 0.8 Hz, 1H), 3.19 (t, J = 9.6 Hz, 1H), 3.13–3.04 (m, 1H), 2.93 (p, J 
= 7.1 Hz, 1H), 2.84 (dddd, J = 10.7, 7.1, 2.4, 1.3 Hz, 1H), 2.75 (ddd, J = 12.7, 7.7, 1.2 Hz, 
1H), 2.66 (ddt, J = 18.1, 10.1, 1.6 Hz, 1H), 2.59 (d, J = 1.4 Hz, 1H), 2.57 (d, J = 1.5 Hz, 
1H), 2.42–2.34 (m, 1H), 2.12 (s, 3H), 1.70–1.63 (m, 4H), 1.36 (d, J = 1.0 Hz, 3H), 0.86 (s, 
9H), 0.10 (s, 3H), 0.03 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 208.0, 168.7, 156.7, 151.8, 
146.4, 125.4, 116.5, 112.3, 81.2, 76.2, 48.8, 47.3, 44.8, 40.9, 35.7, 34.8, 30.8, 28.1, 25.8, 
19.5, 18.1, -2.1, -2.3; IR (thin film, NaCl) 2957, 2929, 2857, 1753, 1714, 1645, 1442, 1359, 
1327, 1291, 1257, 1209, 1177, 1028, 856, 836, 774, 680 cm-1; HRMS (FAB+) m/z calc’d 



















9-one (451) and (2R,2a1S,6R,8S,8aS,10aS)-2-((tert-butyldimethylsilyl)oxy)-8-
hydroxy-2,8-dimethyl-6-(prop-1-en-2-yl)-1,2,2a1,5,6,7,8,10a-octahydro-9H-
benzo[6,7]indeno[1,7-bc]furan-9-one (452): Tricycle XXX (3 mg, 7.2 µmol, 1 equiv) in 
THF (0.2 mL) had DBU (1.7 µL, 7.2 µmol, 1 equiv). After 5 min, the reaction was 
concentrated and directly purified by column chromatography (SiO2, 4:1 hexanes:EtOAc) 
to afford tetracycle 451 and 452 (1:1.8 dr, 3 mg, >99%) as an amorphous film (Rf = 0.48 
452 and 0.34 451) 
452: 1H NMR (400 MHz, CDCl3) d = 5.99 (dd, J = 5.7, 2.5 Hz, 1H), 5.83 (ddd, J = 
5.8, 2.8, 1.1 Hz, 1H), 4.89 – 4.68 (m, 3H), 3.76–3.69 (m, 1H), 2.88–2.76 (m, 1H), 2.47 (dd, 
J = 13.7, 7.4 Hz, 1H), 2.39–2.27 (m, 2H), 2.27–2.04 (m, 1H), 1.86 (dd, J = 13.7, 3.9 Hz, 
1H), 1.78 (dd, J = 1.5, 0.8 Hz, 3H), 1.71 (dt, J = 13.0, 2.6 Hz, 1H), 1.40 (d, J = 1.0 Hz, 
3H), 1.25 (s, 3H), 0.89 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) d 
= 176.6, 148.1, 142.2, 131.1, 123.2, 112.7, 110.2, 80.0, 79.7, 74.4, 56.7, 49.0, 42.0, 40.7, 
40.0, 35.7, 29.9, 28.5, 25.9, 24.9, 20.6, 18.2, 14.3, -2.0, -2.2; IR (thin film, NaCl) 3523, 
2925, 2856, 2759, 1461, 1372, 1292, 1257, 1153, 1065, 964, 833, 771, 732, 705, 655 cm-
1; HRMS (FAB+) m/z calc’d C25H42O4SiN [M+NH4]+ 448.2878, found: 448.2889; [a]D23 
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451: 1H NMR (400 MHz, CDCl3) d = 5.86 (dd, J = 5.7, 2.6 Hz, 1H), 5.82 (ddd, J = 
5.8, 2.7, 1.0 Hz, 1H), 4.89 (td, J = 7.2, 3.2 Hz, 1H), 4.80 (dq, J = 1.8, 0.9 Hz, 1H), 4.78 (q, 
J = 1.5 Hz, 1H), 3.47 (d, J = 7.4 Hz, 1H), 2.86–2.73 (m, 1H), 2.48–2.36 (m, 2H), 2.31 (ddd, 
J = 15.0, 4.4, 1.9 Hz, 1H), 2.20 (tt, J = 12.8, 3.8 Hz, 1H), 1.94 (dd, J = 14.0, 3.1 Hz, 1H), 
1.78 (s, 3H), 1.66 (ddd, J = 12.0, 3.4, 1.9 Hz, 1H), 1.39 (d, J = 1.1 Hz, 3H), 1.29 (d, J = 0.8 
Hz, 3H), 0.88 (d, J = 1.1 Hz, 9H), 0.12 (s, 3H), 0.08 (s, 3H); 13C NMR (101 MHz, CDCl3) 
d = 177.3, 148.1, 142.1, 132.2, 121.3, 113.4, 110.1, 80.1, 80.0, 76.2, 57.8, 48.7, 42.7, 42.3, 
41.3, 35.5, 29.2, 26.7, 25.9, 20.5, 18.2, -2.0, -2.3; IR (thin film, NaCl) 3462, 2956, 2928, 
2856, 1739, 1643, 1450, 1375, 1293,1257, 1163, 1132, 1018, 837, 809, 773 cm-1; HRMS 




yl)oct-2-ynoate (437): Diol 415 (18 mg, 0.13 mmol, 1 equiv), acid 471 (56 mg, 0.28 mmol 
2.2 equiv), and DMAP (17 mg, 0.17 mmol, 1.1 equiv) were added to a solution of CH2Cl2 
(1.4 mL, 0.09 M) and cooled to 0 °C. DIC (44 µL, 0.28 mmol, 2.2 equiv) was added 
dropwise and the reaction was allowed to stir for 1 h. Upon complete consumption of 
starting material (as determined by TLC analysis, 1:1 hexanes:EtOAc), the reaction was 












Chapter 4 – Progress Toward the Total Synthesis of Scabrolide A 
 
356 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by column chromatography (SiO2, 1:1 hexanes:EtOAc) to afford ester 437 (30 mg, 
73%) as a colorless oil (Rf = 0.27); 1H NMR (400 MHz, CDCl3) d = 6.32 (ddt, J = 17.8, 
11.3, 0.8 Hz, 1H), 5.85–5.75 (m, 2H), 5.54 (ddd, J = 7.1, 4.7, 2.5 Hz, 1H), 5.33 (dd, J = 
11.3, 1.6 Hz, 1H), 4.90–4.82 (m, 1H), 4.80 (q, J = 0.9 Hz, 1H), 2.86 (p, J = 6.6 Hz, 1H), 
2.74–2.59 (m, 3H), 2.55–2.41 (m, 2H), 2.16 (s, 3H), 2.06 (dd, J = 14.3, 4.4 Hz, 1H), 1.73 
(dd, J = 1.4, 0.8 Hz, 3H), 1.44 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 207.1, 153.5, 
151.9, 145.2, 129.0, 126.1, 119.6, 112.5, 87.5, 81.1, 77.4, 74.8, 48.9, 46.4, 39.7, 30.6, 26.8, 
23.2, 20.7; IR (thin film, NaCl) 3462, 2969, 2926, 2233, 1704, 1422, 1249, 1163, 1071, 
944, 751; HRMS (ESI) m/z calc’d C19H26O5 [M+H2O]+: 334.1775, found: 334.1785; [a]D23 
–65.9 (c 0.18, CHCl3). 
 
(2a1S,6R,7aS)-6-hydroxy-6-methyl-3-((R)-4-oxo-2-(prop-1-en-2-yl)pentyl)-4,6,7,7a-
tetrahydroindeno[1,7-bc]furan-2(2a1H)-one (453): Ester 437 (100 mg, 0.32 mmol) was 
transferred to a Schlenk bomb with xylenes (32 mL, 0.01 M). The Schlenk was the 
rigorously degassed by standard freeze-pump-thaw technique and upon reaching ambient 
temperature (23 °C) the flask was sealed and heat to 140 °C. The reaction was allowed to 
stir at this temperature of 2 h at which time complete consumption of starting material was 
observed (as determined by TLC analysis, 1:1 hexanes:EtOAc). The reaction was allowed 
to cool to room temperature and was directly purified by column chromatography (SiO2, 
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amorphous solid (Rf = 0.27); 1H NMR (400 MHz, CDCl3) d = δ 5.84 (dt, J = 6.4, 2.3 Hz, 
1H), 5.02–4.91 (m, 1H), 4.75–4.69 (m, 1H), 4.67 (d, J = 1.9 Hz, 1H), 3.26 (t, J = 9.6 Hz, 
1H), 3.12–2.98 (m, 2H), 2.97–2.87 (m, 1H), 2.74 (ddt, J = 18.2, 10.1, 1.6 Hz, 1H), 2.59 
(dd, J = 6.7, 4.1 Hz, 2H), 2.57–2.44 (m, 2H), 2.11 (s, 3H), 1.69 (d, J = 1.3 Hz, 3H), 1.64 
(dd, J = 12.8, 8.0 Hz, 1H), 1.40 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 207.9, 168.4, 
156.5, 151.6, 146.9, 125.2, 116.6, 112.0, 80.0, 75.4, 49.7, 47.2, 45.6, 41.1, 36.2, 35.4, 30.7, 
26.7, 19.6; IR (thin film, NaCl) 3440, 2968, 1746, 1713, 1644, 1442, 1418, 1359, 1289, 
1213, 1117, 1042, 1021, 995, 973, 913, 810, 732; HRMS (ESI) m/z calc’d C19H25O4 
[M+H]+: 317.1747, found: 317.1733; [a]D23 –99.1 (c 0.375, CHCl3). 
 
(1aR,1a1S,2R,3aS,7aS)-2-hydroxy-2-methyl-6-((R)-4-oxo-2-(prop-1-en-2-yl)pentyl)-
1a1,2,3,3a,7,7a-hexahydro-5H-oxireno[2',3':3a,4]indeno[1,7-bc]furan-5-one (454): To 
a pale yellow stirred solution of diene 453 (80 mg, 0.25 mmol, 1.0 equiv) in a round-bottom 
flask in benzene (8.4 mL, 0.044M) and CH2Cl2 (0.2 mL, 1 M) was added VO(acac)2 (6.7 
mg, 0.025 mmol, 0.1 equiv). After 15 minutes, to this dark green solution was added t-
butyl hydroperoxide (TBHP, 76 µL, 0.38 mmol, 1.5 equiv) as a 5 M solution in decane 
dropwise causing the reaction to immediately become deep ruby red. After 1 hour, the 
reaction had lost all red color and became pale yellow, and complete consumption of 
starting material was observed (as determined by TLC analysis, 1:1 hexanes:EtOAc). The 
crude reaction was directly purified by column chromatography (SiO2, 100% hexanes then 
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(Rf = 0.11); 1H NMR (400 MHz, C6D6) d 4.83 (q, J = 0.9 Hz, 1H), 4.75 (t, J = 1.6 Hz, 1H), 
4.08 (ddd, J = 8.5, 7.4, 6.3 Hz, 1H), 3.38–3.31 (m, 1H), 3.05 (d, J = 3.4 Hz, 1H), 2.90 (dq, 
J = 9.3, 6.3 Hz, 1H), 2.41 (dd, J = 17.0, 6.8 Hz, 3H), 2.29–2.20 (m, 3H), 2.11 (ddd, J = 
12.7, 5.4, 1.9 Hz, 1H), 2.05 (dd, J = 13.5, 7.5 Hz, 1H), 1.86 (dd, J = 16.7, 2.4 Hz, 1H), 
1.82–1.74 (m, 1H), 1.70 (s, 3H), 1.63 (t, J = 1.2 Hz, 3H), 0.99 (s, 3H); 13C NMR (101 MHz, 
C6D6) d = 206.0, 168.9, 149.6, 147.7, 120.8, 111.5, 76.3, 73.3, 69.5, 51.6, 50.2, 47.0, 44.5, 
41.0, 37.6, 36.0, 30.2, 22.4, 20.0; IR (thin film, NaCl) 3469, 2933, 1746, 1711, m1645, 
1360, 1294, 1200, 1114, 1029, 967, 792 cm,-1; HRMS (ESI) m/z calc’d C19H25O5 [M+H]+: 




Preparation of a 0.50 M Stock Solution: of Titanocene Monochloride (Cp2TiCl): Into 
a thoroughly flame-dried Schlenk tube under an overpressure of argon was charged with 
zinc(0) dust (647 mg, 9.90 mmol, 3.00 equiv) and titanocene dichloride (Cp2TiCl2, 822 
mg, 3.30 mmol, 1.00 equiv). The flask was then evacuated and back filled with argon (3 x 
5 minute cycles). To the reaction vessel was then added THF (6.6 mL). After 1.5 h, the 
bright red reaction mixture had become dark green and stirring was halted. After 30 
minutes, the supernatant was used as a 0.50 M stock solution of Cp2TiCl.  
A stirred solution of epoxide 454 (15 mg, 0.045 mmol, 1.0 equiv) in THF (1.5 mL, 
0.03 M). The homogeneous reaction mixture was then cooled to –78 °C followed by the 
TiCp*2Cl2, Zn°
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addition of H2O (62 µL, 3.46 mmol, 76.9 equiv). After stirring for 5 minutes, Cp2TiCl (0.87 
mmol, 0.50 M in THF, 19.2  equiv) was added dropwise. After 2 h, was allowed to warm 
to ambient temperature (23 °C). After an additional 12 h, the complete consumption of 
starting material was observed (as determined by TLC 3:1 EtOAc:hexanes). The reaction 
was quenched by the addition of saturated NaH2PO4 (1.0 mL) and brine (1.0 mL), sparged 
with compressed air for 5 minutes, and allowed to stir for an additional 15 minutes. The 
reaction mixture was then filtered through a Celite® plug, washing with H2O and EtOAc. 
The biphasic mixture was separated and the aqueous layer was extracted with EtOAc (3 X 
3 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo. The crude product was purified by column chromatography (SiO2, 3:1 
EtOAc:hexanes), furnishing diol 455 (14 mg, 92% yield) as a white amorphous solid (Rf = 
0.22); 1H NMR (400 MHz, CDCl3) d = 4.90 (ddd, J = 8.2, 6.6, 4.1 Hz, 1H), 4.80 (dt, J = 
1.7, 0.8 Hz, 1H), 4.76 (p, J = 1.5 Hz, 1H), 4.69 (dt, J = 7.8, 3.2 Hz, 1H), 3.35–3.25 (m, 
1H), 3.05 (ddd, J = 9.9, 8.0, 2.0 Hz, 1H), 2.94 (dq, J = 9.2, 6.5 Hz, 1H), 2.67–2.49 (m, 3H), 
2.41–2.29 (m, 2H), 2.14–1.98 (m, 6H), 1.75 (dd, J = 1.5, 0.8 Hz, 3H), 1.43 (s, 3H); 13C 
NMR (101 MHz, CDCl3) d = 208.3, 169.7, 151.7, 147.8, 124.9, 111.5, 81.7, 79.2, 68.5, 
49.6, 48.5, 47.2, 44.4, 41.3, 40.6, 37.7, 30.8, 28.8, 20.1; IR (thin film, NaCl) 3384, 2966, 
1738, 1666, 1420, 1359, 1304, 1222, 1200, 1145, 1105, 1040, 1020, 910, 733 cm-1; HRMS 
(ESI) m/z calc’d C19H27O5 [M+H]+: 335.1853, found: 335.1844; [a]D23 –15.4 (c 0.205, 
CHCl3). 





bc]furan-2(2a1H)-one (461): Ester 460 was saponified under the same conditions 
reported above for ester 448. A stirred solution of Diol 415 (250 mg, 1.8 mmol, 1 equiv), 
octa-2,7-diynoic acid (435 mg, 3.2 mmol, 1.8 equiv), and DMAP (21.8 mg, 0.18 mmol, 
0.1 equiv) in CH2Cl2 (18 mL, 0.1 M) and THF (10 mL, 0.18 M) was cooled to 0 °C. DIC 
(0.50 mL, 3.2 mmol, 1.8 equiv) was added dropwise via syringe and the resultant solution 
was allowed to stir for 2 h. Upon complete consumption of starting material (as 
determined by TLC analysis, 4:1 hexanes:EtOAc), the reaction was diluted with H2O (20 
mL) and extracted with Et2O (3 x 20 mL). The combined organic layers were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by column 
chromatography (SiO2, 4:1 hexanes:EtOAc) to afford a mixture of triphenylphosphine 
oxide and ester 458 which is used directly in the next reaction. Ester 458 can be further 
purified by another column of the same eluent to obtain pure ester 458 (Rf = 0.22); 1H 
NMR (400 MHz, CDCl3) d = 6.32 (ddt, J = 17.8, 11.3, 0.8 Hz, 1H), 5.82 (dd, J = 2.3, 0.8 
Hz, 1H), 5.81–5.75 (m, 1H), 5.55 (dddd, J = 7.4, 4.4, 2.3, 0.7 Hz, 1H), 5.33 (dd, J = 11.3, 
1.5 Hz, 1H), 2.64 (dd, J = 14.3, 7.3 Hz, 1H), 2.48 (t, J = 7.1 Hz, 2H), 2.32 (td, J = 6.9, 2.7 
Hz, 2H), 2.06 (dd, J = 14.3, 4.4 Hz, 1H), 1.98 (t, J = 2.6 Hz, 1H), 1.80 (p, J = 7.0 Hz, 
2H), 1.44 (s, 3H); 13C NMR (101 MHz, CDCl3) d =. 153.5, 151.9, 128.9, 126.0, 119.6, 








2. DIC, DMAP, 415
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2972, 2236, 1703, 1432, 1252, 1073, 990, 950, 872, 752, 641 cm-1; HRMS (ESI) m/z 
calc’d C16H22NO3 [M+NH4]+: 276.1595, found: 276.1581l; [a]D23 –155.1 (c 0.57, 
CHCl3). 
Crude ester 458 (460 mg, 1.78 mmol) was transferred to a Schlenk bomb with 
xylenes (178 mL, 0.01 M). The Schlenk was the rigorously degassed by standard freeze-
pump-thaw technique and upon reaching ambient temperature (23 °C) the flask was sealed 
and heat to 140 °C. The reaction was allowed to stir at this temperature of 2 h at which 
time complete consumption of starting material was observed (as determined by TLC 
analysis, 1:1 hexanes:EtOAc). The reaction was allowed to cool to room temperature and 
was directly purified by column chromatography (SiO2, 100% hexanes then 1:1 
hexanes:EtOAc) to furnish tricycle 461 (560 mg, 84% over 3 steps) as a pale yellow solid 
(Rf = 0.25); 1H NMR (400 MHz, CDCl3) d = 5.85 (ddd, J = 6.3, 2.9, 1.9 Hz, 1H), 4.97 (ddd, 
J = 9.0, 7.9, 7.1 Hz, 1H), 3.30 (ttd, J = 9.2, 1.9, 1.0 Hz, 1H), 3.11–2.96 (m, 2H), 2.75 (ddt, 
J = 18.4, 10.1, 1.5 Hz, 1H), 2.62–2.54 (m, 1H), 2.51 (ddd, J = 12.8, 7.1, 0.8 Hz, 1H), 2.22 
(tt, J = 7.1, 2.5 Hz, 2H), 1.98 (t, J = 2.6 Hz, 1H), 1.78 (td, J = 6.6, 5.5, 3.3 Hz, 1H), 1.76–
1.63 (m, 3H), 1.41 (d, J = 1.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) d =. 168.2, 157.1, 
152.1, 124.4, 116.4, 84.0, 80.0, 75.4, 69.1, 49.7, 45.5, 35.2, 31.0, 27.2, 26.8, 18.4; IR (thin 
film, NaCl) 3425, 3288, 2971, 1738, 1643, 1439, 1326, 1288, 1256, 1218, 1194, 1117, 
1041, 996, 967, 817, 742, 638 cm-1; HRMS (ESI) m/z calc’d C16H19O3 [M+H]+: 259.1329, 
found: 259.1323; [a]D23 –120.3 (c 0.635, CHCl3). 





hexahydro-5H-oxireno[2',3':3a,4]indeno[1,7-bc]furan-5-one (462): To a pale yellow 
stirred solution of diene 461 (376 mg, 1.5 mmol, 1.0 equiv) in a round-bottom flask in 
benzene (49 mL, 0.03M) was added VO(acac)2 (29 mg, 0.11 mmol, 0.075 equiv). After 15 
minutes, to this dark green solution was added t-butyl hydroperoxide (TBHP, 0.58 mL, 2.9 
mmol, 2.0 equiv) as a 5 M solution in decane dropwise causing the reaction to immediately 
become deep ruby red. After 2 hours, the reaction had lost all red color and become pale 
yellow and complete consumption of starting material was observed (as determined by 
TLC analysis, 3:7 hexanes:EtOAc). The crude reaction was directly purified by column 
chromatography (SiO2, 100% hexanes then 3:7 hexanes:EtOAc) to furnish epoxide 462 
(307 mg, 77%) as a white amorphous solid (Rf = 0.3); 1H NMR (400 MHz, CDCl3) d = 
4.83 (ddd, J = 8.5, 7.4, 6.3 Hz, 1H), 3.81 (dd, J = 3.3, 0.8 Hz, 1H), 3.28 (d, J = 8.1 Hz, 1H), 
2.88 (dd, J = 16.7, 3.4 Hz, 1H), 2.84–2.68 (m, 2H), 2.59 (ddd, J = 13.6, 7.4, 0.6 Hz, 1H), 
2.55–2.45 (m, 2H), 2.35–2.12 (m, 2H), 2.08–1.99 (m, 1H), 1.98 (t, J = 2.6 Hz, 1H), 1.81–
1.62 (m, 2H), 1.44 (d, J = 1.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) d = 169.1, 150.9, 
119.9, 84.1, 76.6, 73.6, 70.0, 69.0, 51.8, 50.1, 44.8, 35.7, 31.6, 26.9, 22.7, 18.3; IR (thin 
film, NaCl) 3529, 3270, 2976, 2938, 2116, 1742, 1649, 1454, 1422, 1391, 1348, 1324, 
1296, 1268, 1195, 1113, 1093, 1030, 964, 923, 899, 795, 756, 733, 678 cm-1; HRMS (ESI) 



















hexahydroindeno[1,7-bc]furan-2(2a1H)-one (463): A stirred solution of epoxide 462 
(278 mg, 1.01 mmol, 1.0 equiv) in THF (34 mL, 0.03 M). The homogeneous reaction 
mixture was then cooled to –78 °C followed by the addition of H2O (0.9 mL, 50.0 mmol, 
50 equiv). After stirring for 5 minutes, Cp2TiCl (11.1 mmol, 0.50 M in THF, 11  equiv) 
was added dropwise. After 2 h, was allowed to slowly warm to ambient temperature (23 
°C). After an additional 12 h, the complete consumption of starting material was observed 
(as determined by TLC 3:1 EtOAc:hexanes). The reaction was quenched by the addition 
of saturated NaH2PO4 (20 mL) and brine (10 mL), sparged with compressed air for 5 
minutes, and allowed to stir for an additional 15 minutes. The reaction mixture was then 
filtered through a Celite® plug, washing with H2O and EtOAc. The biphasic mixture was 
separated and the aqueous layer was extracted with EtOAc (3 X 50 mL). The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified by column chromatography (SiO2, 3:1 EtOAc:hexanes), furnishing 
diol 463 (270 mg, 96% yield) as a viscous colorless oil (Rf = 0.3); 1H NMR (400 MHz, 
CDCl3) d = 4.91 (ddd, J = 8.1, 6.7, 3.1 Hz, 1H), 4.69 (ddd, J = 8.1, 3.5, 2.8 Hz, 1H), 3.43 
(s, 2H), 3.08 (ddd, J = 9.7, 7.9, 2.0 Hz, 1H), 2.98–2.88 (m, 1H), 2.70 (dtd, J = 12.6, 7.4, 
1.8 Hz, 1H), 2.58 (dd, J = 14.9, 2.8 Hz, 1H), 2.39 (dd, J = 9.4, 8.0 Hz, 1H), 2.23 (qd, J = 
7.2, 2.6 Hz, 2H), 2.13 (dd, J = 14.4, 3.1 Hz, 1H), 2.10–2.03 (m, 1H), 1.99 (dd, J = 14.3, 
6.6 Hz, 1H), 1.95 (t, J = 2.6 Hz, 1H), 1.72 (p, J = 7.4 Hz, 2H), 1.44 (s, 3H); 13C NMR (101 
TiCp2Cl2, Zn°
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MHz, CDCl3) d = 169.9, 152.5, 124.3, 84.4, 82.0, 79.5, 68.8, 68.3, 49.8, 48.6, 44.6, 41.4, 
31.9, 28.6, 26.5, 18.5; IR (thin film) 3302, 2966, 2930, 2251, 1738, 1731, 1668, 1454, 
1427, 1358, 1336, 1305, 1278, 1248, 1222, 1198, 1144, 1119, 1104, 1069, 1045, 1018, 
989, 926, 912, 874, 853, 768, 737, 650; HRMS (ESI) m/z calc’d C16H21O4 [M+H]+: 
277.1434, found: 277.1430; [a]D23 –16.0 (c 0.72, CHCl3). 
 
(2aS,2a1S,5aS,6R,7aS)-6-hydroxy-6-methyl-3-(pent-4-yn-1-yl)-2a,2a1,5a,6,7,7a-
hexahydroindeno[1,7-bc]furan-2,5-dione (464): Diol 463 (270 mg, 0.98 mmol, 1.0 
equiv) in CH2Cl2 (27 mL, 0.036 M) was added NaHCO3 (330 mg, 3.9 mmol, 4 equiv) and 
DMP (538 mg, 1.3 mmol, 1.3 equiv) at ambient temperature (23 °C) with stirring. The 
reaction vessel was then sealed and stirred for 3 h. Each subsequent hour, more DMP was 
added (1 equiv) until complete consumption of starting material (as determined by TLC 
analysis, 1:3 hexanes:EtOAc). The reaction was then quenched by the addition of saturated 
NaS2O3 (30 mL) and saturated NaHCO3 (20 mL). After stirring for 10 minutes, the reaction 
mixture was extracted with CH2Cl2 (3 x 30 mL). The combined organics were then dried 
over MgSO4, filtered, and concentrated in vacuo. The crude product was then purified by 
column chromatography (SiO2, 1:3 hexanes:EtOAc) to afford enone 464 (117 mg, 47%) as 
a colorless viscous oil (Rf = 0.6); 1H NMR (400 MHz, CDCl3) d = 6.07 (q, J = 1.5 Hz, 1H), 
5.12 (dd, J = 7.1, 5.4 Hz, 1H), 3.63 (dddd, J = 10.9, 10.2, 7.1, 0.6 Hz, 1H), 3.51–3.45 (m, 
1H), 2.90–2.78 (m, 1H), 2.78–2.66 (m, 1H), 2.53 (d, J = 10.2 Hz, 1H), 2.33 (d, J = 15.0 
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5.5 Hz, 1H), 1.87–1.74 (m, 2H), 1.51 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 196.0, 
173.5, 157.6, 127.5, 83.6, 82.8, 82.5, 69.4, 55.2, 47.4, 42.5, 42.2, 34.7, 26.4, 25.6, 18.2; IR 
(thin film, NaCl) 3442, 3282, 2966, 1757, 1649, 1375, 1289, 1255, 1214, 1179, 1104, 1033, 
1017, 993, 938; HRMS (ESI) m/z calc’d C16H19O4 [M+H]+: 275.1278, found: 275.1269; 
[a]D23 –195 (c 0.32, CHCl3). 
 
(2aS,2a1S,5aS,6R,7aS)-3-(4-(dimethyl(phenyl)silyl)pent-4-en-1-yl)-6-hydroxy-6-
methyl-2a,2a1,5a,6,7,7a-hexahydroindeno[1,7-bc]furan-2,5-dione (457): Alkyne 464 
(28 mg, 0.1 mmol, 1 equiv) and dimethylphenylsilane (18 µL, 0.12 mmol, 1.2 equiv) was 
dissolved in CH2Cl2 (0.5 mL, 0.2 M) and sparged with Ar for 5 min. A stock solution of 
[RuCp*(MeCN)3]PF6 (0.5 mg, 1mg/mL, 0.01 equiv) prepared in the gloved box and was 
added to the reaction. The reaction was allowed to stir for 15 min, at which time complete 
consumption of starting material was observed (as determined by TLC analysis, 1:3 
hexanes:EtOAc). The solution was then concentrated and directly purified by column 
chromatography (SiO2, 1:3 hexanes:EtOAc) to afford vinyl silane 457 (19 mg, 64%) as a 
colorless amorphous solid (Rf = 0.55); 1H NMR (400 MHz, CDCl3) d = 7.60–7.48 (m, 2H), 
7.44–7.30 (m, 3H), 5.94 (q, J = 1.4 Hz, 1H), 5.70 (dt, J = 2.9, 1.5 Hz, 1H), 5.46 (dt, J = 
2.7, 1.0 Hz, 1H), 5.07 (dd, J = 7.2, 5.4 Hz, 1H), 3.48 (dddd, J = 10.9, 10.2, 7.1, 0.6 Hz, 
1H), 3.16 (dd, J = 11.1, 1.5 Hz, 1H), 2.66–2.50 (m, 2H), 2.48 (d, J = 10.2 Hz, 1H), 2.30 (d, 
J = 15.0 Hz, 1H), 2.24–2.08 (m, 2H), 1.89 (dd, J = 15.0, 5.5 Hz, 1H), 1.67–1.51 (m, 2H), 









CH2Cl2, 0 to 23 °C
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138.4, 134.1, 129.1, 128.0, 127.3, 126.7, 82.7, 82.4, 55.2, 47.4, 42.2, 41.9, 35.7, 35.4, 26.5, 
26.1, -2.8, -2.9; IR (thin film, NaCl) 3450, 2958, 1759, 1650, 1378, 1290, 1248, 1173, 
1107, 992, 818 cm-1; HRMS (ESI) m/z calc’d C23H31O4Si [M+H]+: 411.1986, found: 




dione (465) and (2aS,2a1S,4R,4aS,5aR,6aR,9aR,9bS)-6a-(dimethyl(phenyl)silyl)-4-
hydroxy-4-methyldodecahydrocyclopenta[2',3']cyclobuta[1',2':5,6]indeno[1,7-
bc]furan-1,5-dione (466): Enone 457 (19 mg, 0.0465 mmol, 1 equiv) in a 20 mL vial was 
dissolved in benzene (4.65 mL, 0.01 M) and was sparged with Ar for 10 min. The reaction 
vessel was sealed and irradiated with UVB light. After 2 hours complete consumption of 
starting material was observed (as determined by TLC analysis, 1:1 hexanes:EtOAc) and 
was directly purified by column chromatography (SiO2, 100% hexanes then 1:1 
hexanes:EtOAc) to afford a 2:1 mixture of pentacycle 465 and 466 (19 mg, >99%) as a 
colorless amorphous solid which crystalizes in benzene (Rf = 0.85, 465, and 0.65, 366). 
465: 1H NMR (400 MHz, CDCl3) d = 7.66–7.53 (m, 2H), 7.45–7.37 (m, 3H), 4.59 (ddd, J 
= 6.6, 5.6, 2.0 Hz, 1H), 3.02 (s, 1H), 2.92 (ddd, J = 11.1, 9.8, 6.7 Hz, 1H), 2.74–2.66 (m, 
2H), 2.41–2.33 (m, 2H), 2.31–2.21 (m, 1H), 2.17 (s, 1H), 2.13 (dd, J = 14.6, 2.0 Hz, 1H), 
2.03–1.82 (m, 4H), 1.81–1.72 (m, 1H), 1.66–1.59 (m, 1H), 1.18 (s, 3H), 0.41 (s, 3H), 0.30 
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80.9, 55.4, 53.3, 48.4, 45.8, 44.5, 43.4, 39.7, 39.0, 38.7, 29.0, 28.6, 24.5, -2.9, -3.9; IR (thin 
film, NaCl) 3416, 2957, 1759, 1673, 1359, 1107, 731 cm-1; HRMS (ESI) m/z calc’d 
C23H31O4Si [M+H]+: 411.1986, found: 411.1976; [a]D23 –17.7 (c 0.3, CHCl3). 
466: 1H NMR (400 MHz, CDCl3) d = 7.57–7.47 (m, 2H), 7.37–7.28 (m, 3H), 4.91 (dd, J = 
6.1, 4.5 Hz, 1H), 3.60–3.52 (m, 1H), 3.52–3.48 (m, 1H), 2.94 (dd, J = 9.0, 0.7 Hz, 1H), 
2.56 (d, J = 10.6 Hz, 1H), 2.36 (d, J = 15.2 Hz, 1H), 2.21–2.14 (m, 2H), 2.08–2.00 (m, 1H), 
1.96–1.88 (m, 2H), 1.88–1.76 (m, 1H), 1.73–1.59 (m, 2H), 1.45 (s, 3H), 1.32 (dd, J = 11.9, 
6.6 Hz, 1H), 0.55 (s, 3H), 0.52 (s, 3H); 13C NMR (101 MHz, CDCl3) d =205.7, 174.8, 
141.4, 134.2, 128.5, 127.6, 82.1, 81.4, 60.6, 60.1, 51.3, 50.1, 48.6, 47.7, 43.9, 39.9, 37.1, 
27.6, 27.1, 24.5, -2.1, -4.7; IR (thin film, NaCl) 3393, 2949, 1769, 1687, 1373, 1242, 1209, 
1147, 1104, 1089, 826, 783, 733; HRMS (ESI) m/z calc’d C23H31O4Si [M+H]+: 411.1986, 




dione (456): To a solution of lactone 466 (25 mg, 0.061 mmol) in 35% AcOOH-AcOH 
(3.05 mL, 0.02 M) at 23 °C was added Hg(OAc)2 (92 mg, 0.29 mmol, 4.8 equiv), and the 
clear solution was stirred for 1 h at which time complete consumption of starting material 
was observed (as determined by TLC analysis, 1:3 hexanes:EtOAc). The reaction mixture 
was diluted with Et2O (5 mL), washed sequentially with 10% aq Na2S2O3 (7 mL), H2O (7 
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and concentrated in vacuo. The crude product was purified by column chromatography 
(SiO2, 1:3 hexanes:EtOAc) to afford diol 456 (6 mg, 30%) as a white amorphous powder 
(Rf = 0.20) 1H NMR (400 MHz, CDCl3) d = 6.16 (s, 1H), 5.13 (dd, J = 5.9, 4.6 Hz, 1H), 
3.90 (t, J = 9.5 Hz, 1H), 3.57–3.43 (m, 1H), 3.21 (dd, J = 9.0, 0.8 Hz, 1H), 2.58 (d, J = 10.6 
Hz, 1H), 2.47–2.34 (m, 2H), 2.07–1.94 (m, 2H), 1.94–1.87 (m, 1H), 1.87–1.78 (m, 1H), 
1.78–1.68 (m, 3H), 1.48 (s, 3H), 1.25 (d, J = 2.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) d 
=205.5, 179.1, 88.5, 86.1, 81.5, 60.8, 55.4, 52.3, 49.4, 47.7, 47.1, 38.1, 36.4, 34.5, 27.8, 
23.1; IR (thin film, NaCl) 3421, 2972, 2923, 1741, 1686, 1448, 1400, 1377, 1305, 1276, 
1211, 1161, 1112, 1088, 1069, 1010, 921, 850, 813, 777, 733, 719; HRMS (ESI) m/z calc’d 
C16H21O5 [M+H]+: 293.1384, found: 293.1372; [a]D23 –40.4 (c 0.13, CHCl3). 
 
(2aS,2a1S,4R,4aS,5aR,7R,10aR,10bS)-7-chloro-4-hydroxy-4-methyldodecahydro-
7,10a-epoxycyclohepta[5,6]indeno[1,7-bc]furan-1,5-dione (468): Diol 456 (10 mg, 
0.034 mmol, 1 equiv), AgOTf (1.2 mg, 0.012 mmol, 0.4 equiv), and 1,10-phenanthroline 
(4.8 mg, 0.024 mmol, 0.8 equiv) were placed in a round-bottom flask and dissolved in 
MeCN (1 mL, 0.034 M) followed by the addition of t-BuOCl (7.8 µL, 0.068 mmol, 2 
equiv). The reaction mixture was stirred at ambient temperature (23 °C) for 6 h. The 
reaction was the quenched with saturated solution of Na2S2O3 and extracted with EtOAc (3 
x 5 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, 
and concentrated in vacuo. The crude product was purified by column chromatography 
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which can be crystalized in CHCl3 (Rf = 0.26); 1H NMR (400 MHz, CDCl3) d = 5.02 (dd, 
J = 5.9, 4.5 Hz, 1H), 3.79–3.66 (m, 1H), 3.42 (dddd, J = 10.3, 9.5, 5.9, 0.6 Hz, 1H), 3.34 
(dd, J = 9.5, 0.7 Hz, 1H), 2.88 (ddd, J = 13.8, 7.4, 0.9 Hz, 1H), 2.71 (d, J = 10.4 Hz, 1H), 
2.42 (d, J = 15.4 Hz, 1H), 2.35 (ddd, J = 13.8, 11.6, 1.1 Hz, 1H), 2.29–2.09 (m, 1H), 2.07–
1.96 (m, 2H), 1.75–1.64 (m, 3H), 1.49 (s, 3H), 1.46–1.34 (m, 1H); 13C NMR (101 MHz, 
CDCl3) d =202.8, 172.0, 101.8, 85.2, 82.7, 82.3, 60.6, 56.4, 48.6, 47.5, 45.9, 40.1, 36.3, 
33.1, 27.6, 18.9; IR (thin film, NaCl) 3472, 2921, 1766, 1713, 1359, 1243, 1214, 1171, 
1126, 1093, 1000, 953, 905, 845, 759, 731; HRMS (ESI) m/z calc’d C16H20O5Cl [M+H]+: 
327.0994, found: 327.0980; [a]D23 –43.3 (c 0.13, CHCl3). 
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    THF:H2O, 65°C
2. NaIO4, SiO2
    DCM:H2O 0 °C
(MeO)NHMe•HCl
Et3N, EDC•HCl
CH2Cl2, 0 °C to 23 °C






















1. n-BuLi, CO2, THF, –78 °C
2. 2,4,5 trichlorobenzoyl chloride 
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1. HG II (0.1 mol %), neat
    then, NaH, THF, TBSCl
2. RuCl2, t-BuOOH, Mg(OAc)2





















    MeOH, –78 °C
2. TESCl, imidazole
    CH2Cl2, 23 °C
CN



























a) TBAF (2.7 equiv), THF, 65 °C
b) TBAF (1.1 equiv), THF, 23 °C
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Scheme A5.3 Synthetic Summary for Undesired Aldol Products 451 and 452 
 












THF, –78 to 0 °C
79% yield
Pd(OAc)2 (30 mol %)
Ph3P (60 mol %)
DMF:MeOH





1. LiOH, 1:1 THF:H2O
2. 446, DIC, DMAP
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2. 415, DIC, DMAP
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 Figure A6.2. 13C NMR (126 MHz, CDCl3) of compound 422. 
 




















































































































 Figure A6.4. 13C NMR (126 MHz, CDCl3) of compound ent•416. 
 


















































































































 Figure A6.6. Infrared spectrum (Thin Film, NaCl) of compound 423. 
 
 Figure A6.7. 13C NMR (101 MHz, CDCl3) of compound 423. 
 






















































































































 Figure A6.9. 13C NMR (101 MHz, CDCl3) of compound 430. 
 






















































































































 Figure A6.11. Infrared spectrum (Thin Film, NaCl) of compound 432. 
 
 Figure A6.12. 13C NMR (101 MHz, CDCl3) of compound 432. 
 
























































































































 Figure A6.14. Infrared spectrum (Thin Film, NaCl) of compound 434. 
 
 Figure A6.15. 13C NMR (101 MHz, CDCl3) of compound 434. 
 






















































































































 Figure A6.17. Infrared spectrum (Thin Film, NaCl) of compound 441. 
 
 Figure A6.18. 13C NMR (101 MHz, CDCl3) of compound 441. 
 






















































































































 Figure A6.20. Infrared spectrum (Thin Film, NaCl) of compound 442. 
 
 Figure A6.21. 13C NMR (101 MHz, CDCl3) of compound 442. 
 























































































































 Figure A6.23. Infrared spectrum (Thin Film, NaCl) of compound 470. 
 
 Figure A6.24. 13C NMR (101 MHz, CDCl3) of compound 470. 
 
























































































































 Figure A6.26. Infrared spectrum (Thin Film, NaCl) of compound 443. 
 
 Figure A6.27. 13C NMR (101 MHz, CDCl3) of compound 443. 
 




























































































































 Figure A6.29. Infrared spectrum (Thin Film, NaCl) of compound 444. 
 
 Figure A6.30. 13C NMR (101 MHz, CDCl3) of compound 444. 
 























































































































 Figure A6.32. Infrared spectrum (Thin Film, NaCl) of compound 445. 
 
 Figure A6.33. 13C NMR (101 MHz, CDCl3) of compound 445. 
 






















































































































 Figure A6.35. Infrared spectrum (Thin Film, NaCl) of compound 446. 
 
 Figure A6.36. 13C NMR (101 MHz, CDCl3) of compound 446. 
 



















































































































 Figure A6.38. Infrared spectrum (Thin Film, NaCl) of compound 447. 
 
 Figure A6.39. 13C NMR (101 MHz, CDCl3) of compound 447. 
 






















































































































 Figure A6.41. Infrared spectrum (Thin Film, NaCl) of compound 448. 
 
 Figure A6.42. 13C NMR (101 MHz, CDCl3) of compound 448. 
 























































































































 Figure A6.44. Infrared spectrum (Thin Film, NaCl) of compound 449. 
 
 Figure A6.45. 13C NMR (101 MHz, CDCl3) of compound 449. 
 
























































































































 Figure A6.47. Infrared spectrum (Thin Film, NaCl) of compound 450. 
 
 Figure A6.48. 13C NMR (101 MHz, CDCl3) of compound 450. 
 
























































































































 Figure A6.50. Infrared spectrum (Thin Film, NaCl) of compound 451. 
 
 Figure A6.51. 13C NMR (101 MHz, CDCl3) of compound 451. 
 
























































































































 Figure A6.53. Infrared spectrum (Thin Film, NaCl) of compound 452. 
 
 Figure A6.54. 13C NMR (101 MHz, CDCl3) of compound 452. 
 






















































































































 Figure A6.56. Infrared spectrum (Thin Film, NaCl) of compound 437. 
 
 Figure A6.57. 13C NMR (101 MHz, CDCl3) of compound 437. 
 























































































































 Figure A6.59. Infrared spectrum (Thin Film, NaCl) of compound 453. 
 
 Figure A6.60. 13C NMR (101 MHz, CDCl3) of compound 453. 
 























































































































 Figure A6.62. Infrared spectrum (Thin Film, NaCl) of compound 454. 
 
 Figure A6.63. 13C NMR (101 MHz, C6D6) of compound 454. 
 


























































































































 Figure A6.65. Infrared spectrum (Thin Film, NaCl) of compound 455. 
 
 Figure A6.66. 13C NMR (101 MHz, CDCl3) of compound 455. 
 























































































































 Figure A6.68. Infrared spectrum (Thin Film, NaCl) of compound 458. 
 
 Figure A6.69. 13C NMR (101 MHz, CDCl3) of compound 458. 
 























































































































 Figure A6.71. Infrared spectrum (Thin Film, NaCl) of compound 461. 
 
 Figure A6.72. 13C NMR (101 MHz, CDCl3) of compound 461. 
 
























































































































 Figure A6.74. Infrared spectrum (Thin Film, NaCl) of compound 462. 
 
 Figure A6.75. 13C NMR (101 MHz, CDCl3) of compound 462. 
 

























































































































 Figure A6.77. Infrared spectrum (Thin Film, NaCl) of compound 463. 
 
 Figure A6.78. 13C NMR (101 MHz, CDCl3) of compound 463. 
 
























































































































 Figure A6.80. Infrared spectrum (Thin Film, NaCl) of compound 464. 
 
 Figure A6.81. 13C NMR (101 MHz, CDCl3) of compound 464. 
 






























































































































 Figure A6.83. Infrared spectrum (Thin Film, NaCl) of compound 457. 
 
 Figure A6.84. 13C NMR (101 MHz, CDCl3) of compound 457. 
 































































































































 Figure A6.86. Infrared spectrum (Thin Film, NaCl) of compound 465. 
 
 Figure A6.87. 13C NMR (101 MHz, CDCl3) of compound 465. 
 































































































































 Figure A6.89. Infrared spectrum (Thin Film, NaCl) of compound 466. 
 
 Figure A6.90. 13C NMR (101 MHz, CDCl3) of compound 466. 
 





























































































































 Figure A6.92. Infrared spectrum (Thin Film, NaCl) of compound 456. 
 
 Figure A6.93. 13C NMR (101 MHz, CDCl3) of compound 456. 
 





























































































































 Figure A6.95. Infrared spectrum (Thin Film, NaCl) of compound 468. 
 
 Figure A6.96. 13C NMR (101 MHz, CDCl3) of compound 468. 
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Table A7.1.1. Experimental Details for X-Ray Structure Determination of Tetracycle 
452 
Low-temperature diffraction data (f-and w-scans) were collected a Bruker AXS D8 
VENTURE KAPPA diffractometer coupled to a PHOTON II CPAD detector with Cu Ka 
radiation (l = 1.54178 Å) from an IµS micro-source for the structure of compound 
V18139. The structure was solved by direct methods using SHELXS1 and refined against 
F2 on all data by full-matrix least squares with SHELXL-20162 using established 
refinement techniques.3 All non-hydrogen atoms were refined anisotropically. All 
hydrogen atoms were included into the model at geometrically calculated positions and 
refined using a riding model. The isotropic displacement parameters of all hydrogen 
atoms were fixed to 1.2 times the U value of the atoms they are linked to (1.5 times for 
methyl groups).  
Compound 452 crystallizes in the orthorhombic space group P212121 with one 
molecule in the asymmetric unit. The coordinates for the hydrogen atom bound to O4 
were located in the difference Fourier synthesis and refined semi-freely with the help of a 












Table A7.1.2. Crystal Data and Structure Refinement for Tetracycle 452 
Empirical formula  C25 H38 O4 Si 
Formula weight  430.64 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.3347(3) Å a= 90°. 
 b = 12.3768(5) Å b= 90°. 
 c = 30.9537(13) Å g = 90°. 
Volume 2426.87(18) Å3 
Z 4 
Density (calculated) 1.179 Mg/m3 
Absorption coefficient 1.064 mm-1 
F(000) 936 
Crystal size 0.300 x 0.150 x 0.100 mm3 
Theta range for data collection 2.855 to 74.566°. 
Index ranges -7<=h<=7, -15<=k<=14, -38<=l<=38 
Reflections collected 25153 
Independent reflections 4954 [R(int) = 0.0480] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6036 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4954 / 1 / 282 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0315, wR2 = 0.0776 
R indices (all data) R1 = 0.0341, wR2 = 0.0795 
Absolute structure parameter 0.001(10) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.271 and -0.190 e.Å-3 
 




Table A.7.1.3. Atomic Coordinates (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2x 103) for Tetracycle 452. U(eq) is Defined as One Third of the 
Orthogonalized Uij Tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
C(1) 2853(3) 1349(2) 3662(1) 17(1) 
C(15) 4285(4) 511(2) 3878(1) 27(1) 
O(2) 2611(2) 1129(1) 3218(1) 19(1) 
Si(1) 1788(1) 60(1) 2947(1) 16(1) 
C(20) 4027(3) -872(2) 2822(1) 24(1) 
C(21) -250(4) -722(2) 3251(1) 27(1) 
C(22) 679(3) 665(2) 2435(1) 22(1) 
C(23) -1264(4) 1358(2) 2539(1) 34(1) 
C(24) 2358(4) 1396(2) 2225(1) 27(1) 
C(25) 61(4) -241(2) 2120(1) 31(1) 
C(2) 716(3) 1448(2) 3904(1) 23(1) 
C(3) 1072(3) 2289(2) 4263(1) 21(1) 
O(1) -488(2) 3141(1) 4231(1) 24(1) 
C(4) 390(3) 4128(2) 4204(1) 18(1) 
O(3) -697(2) 4922(1) 4186(1) 26(1) 
C(5) 2811(3) 4065(2) 4224(1) 14(1) 
C(6) 3546(3) 4471(2) 4685(1) 15(1) 
O(4) 5671(2) 4121(1) 4755(1) 17(1) 
C(16) 2269(3) 3954(2) 5047(1) 18(1) 
C(7) 3408(3) 5707(1) 4721(1) 16(1) 
C(8) 4719(3) 6285(2) 4379(1) 16(1) 
C(17) 4820(3) 7503(2) 4426(1) 18(1) 
C(18) 3432(4) 8079(2) 4649(1) 24(1) 
C(19) 6667(4) 8017(2) 4198(1) 24(1) 
C(9) 3849(3) 5956(2) 3933(1) 20(1) 
C(10) 3843(3) 4750(2) 3871(1) 16(1) 
C(11) 4656(3) 4292(2) 3517(1) 20(1) 




Table A.7.1.3. Cont’d 
C(12) 4409(3) 3144(2) 3418(1) 18(1) 
C(13) 3699(3) 2478(2) 3720(1) 15(1) 
C(14) 3205(3) 2845(1) 4173(1) 15(1) 
________________________________________________________________________________   




Table A7.1.4. Bond Lengths [Å] and angles [°] for Tetracycle 452 
_____________________________________________________  
C(1)-O(2)  1.412(2) 
C(1)-C(13)  1.507(3) 
C(1)-C(15)  1.530(3) 
C(1)-C(2)  1.551(3) 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
O(2)-Si(1)  1.6507(14) 
Si(1)-C(21)  1.868(2) 
Si(1)-C(20)  1.869(2) 
Si(1)-C(22)  1.887(2) 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
C(22)-C(23)  1.534(3) 
C(22)-C(25)  1.537(3) 
C(22)-C(24)  1.540(3) 
C(23)-H(23A)  0.9800 
C(23)-H(23B)  0.9800 
C(23)-H(23C)  0.9800 
C(24)-H(24A)  0.9800 
C(24)-H(24B)  0.9800 
C(24)-H(24C)  0.9800 
C(25)-H(25A)  0.9800 
C(25)-H(25B)  0.9800 
C(25)-H(25C)  0.9800 
C(2)-C(3)  1.541(3) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 




Table A.7.1.4. Cont’d 
C(3)-O(1)  1.448(3) 
C(3)-C(14)  1.542(3) 
C(3)-H(3)  1.0000 
O(1)-C(4)  1.345(3) 
C(4)-O(3)  1.201(3) 
C(4)-C(5)  1.537(2) 
C(5)-C(10)  1.529(2) 
C(5)-C(14)  1.538(2) 
C(5)-C(6)  1.585(2) 
C(6)-O(4)  1.430(2) 
C(6)-C(16)  1.522(3) 
C(6)-C(7)  1.535(2) 
O(4)-H(4O)  0.84(2) 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(7)-C(8)  1.524(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(17)  1.515(3) 
C(8)-C(9)  1.540(3) 
C(8)-H(8)  1.0000 
C(17)-C(18)  1.326(3) 
C(17)-C(19)  1.506(3) 
C(18)-H(18A)  0.9500 
C(18)-H(18B)  0.9500 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(9)-C(10)  1.505(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.336(3) 
C(11)-C(12)  1.462(3) 




Table A.7.1.4. Cont’d 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.325(3) 
C(12)-H(12)  0.9500 
C(13)-C(14)  1.505(2) 

































































































































































Symmetry transformations used to generate equivalent atoms:  
  
  




Table A7.1.5. Anisotropic Displacement Parameters (Å2x103) for Tetracycle 452. The 
Anisotropic Displacement Factor Exponent Takes the Form: -2p2[h2a*2U11 + … + 
2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
C(1) 20(1)  18(1) 13(1)  -1(1) 0(1)  -3(1) 
C(15) 38(1)  19(1) 24(1)  -3(1) -8(1)  4(1) 
O(2) 25(1)  18(1) 14(1)  -2(1) 0(1)  -4(1) 
Si(1) 16(1)  15(1) 17(1)  -2(1) 0(1)  -1(1) 
C(20) 20(1)  19(1) 34(1)  -5(1) -2(1)  3(1) 
C(21) 28(1)  25(1) 28(1)  -2(1) 4(1)  -10(1) 
C(22) 24(1)  21(1) 21(1)  -2(1) -5(1)  0(1) 
C(23) 28(1)  29(1) 47(1)  0(1) -10(1)  7(1) 
C(24) 35(1)  26(1) 20(1)  -1(1) 0(1)  -2(1) 
C(25) 38(1)  31(1) 25(1)  -5(1) -11(1)  -6(1) 
C(2) 25(1)  23(1) 22(1)  -4(1) 6(1)  -9(1) 
C(3) 22(1)  23(1) 18(1)  -1(1) 5(1)  -6(1) 
O(1) 16(1)  28(1) 27(1)  -7(1) 5(1)  -5(1) 
C(4) 13(1)  26(1) 15(1)  -5(1) -1(1)  1(1) 
O(3) 16(1)  31(1) 32(1)  -6(1) -4(1)  6(1) 
C(5) 13(1)  17(1) 12(1)  -1(1) 0(1)  1(1) 
C(6) 15(1)  19(1) 13(1)  -1(1) 1(1)  1(1) 
O(4) 14(1)  21(1) 15(1)  1(1) -2(1)  2(1) 
C(16) 20(1)  21(1) 13(1)  1(1) 3(1)  -1(1) 
C(7) 16(1)  18(1) 13(1)  -2(1) 0(1)  2(1) 
C(8) 16(1)  16(1) 16(1)  -1(1) 0(1)  2(1) 
C(17) 21(1)  18(1) 16(1)  1(1) -4(1)  0(1) 
C(18) 28(1)  17(1) 28(1)  -1(1) 1(1)  2(1) 
C(19) 27(1)  18(1) 28(1)  0(1) 3(1)  -3(1) 
C(9) 27(1)  18(1) 15(1)  2(1) 0(1)  0(1) 
C(10) 16(1)  18(1) 13(1)  2(1) -2(1)  -1(1) 
C(11) 25(1)  20(1) 16(1)  1(1) 5(1)  -5(1) 




Table A.7.1.5. Cont’d 
C(12) 19(1)  22(1) 15(1)  -4(1) 5(1)  -2(1) 
C(13) 13(1)  17(1) 16(1)  -3(1) -1(1)  2(1) 
C(14) 15(1)  16(1) 13(1)  1(1) 1(1)  0(1) 
______________________________________________________________________________   




Table A7.1.6. Hydrogen Coordinates (x104) and Isotropic Displacement Parameters 
(Å2x103) for Tetracycle 452. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(15A) 3655 -209 3848 41 
H(15B) 4443 685 4185 41 
H(15C) 5674 519 3738 41 
H(20A) 5104 -483 2656 37 
H(20B) 3507 -1485 2653 37 
H(20C) 4646 -1136 3092 37 
H(21A) 372 -1007 3517 41 
H(21B) -752 -1323 3072 41 
H(21C) -1437 -247 3322 41 
H(23A) -1856 1647 2270 52 
H(23B) -850 1957 2728 52 
H(23C) -2326 914 2685 52 
H(24A) 1858 1638 1942 40 
H(24B) 3675 990 2190 40 
H(24C) 2611 2026 2410 40 
H(25A) -1010 -704 2254 47 
H(25B) 1310 -674 2050 47 
H(25C) -513 76 1855 47 
H(2A) -408 1691 3704 28 
H(2B) 300 743 4029 28 
H(3) 1053 1945 4555 25 
H(4O) 6480(40) 4290(20) 4552(8) 20 
H(16A) 2464 3169 5040 27 
H(16B) 771 4125 5008 27 
H(16C) 2751 4236 5326 27 
H(7A) 1914 5930 4691 19 
H(7B) 3899 5931 5011 19 
H(8) 6195 6004 4400 19 




Table A.7.1.6. Cont’d 
H(18A) 3586 8841 4669 29 
H(18B) 2284 7730 4788 29 
H(19A) 6682 8794 4258 36 
H(19B) 6537 7900 3886 36 
H(19C) 7982 7690 4302 36 
H(9A) 2391 6233 3902 24 
H(9B) 4723 6293 3705 24 
H(11) 5428 4732 3322 24 
H(12) 4756 2877 3140 22 
H(14) 4310 2591 4380 18 
________________________________________________________________________________   




































































































Symmetry transformations used to generate equivalent atoms:  
  
  




Table A7.1.8. Hydrogen Bonds for Tetracycle 452 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(3)-H(3)...O(4)#1 1.00 2.52 3.514(2) 171.9 
 O(4)-H(4O)...O(1)#2 0.84(2) 2.59(3) 3.167(2) 127(2) 
 O(4)-H(4O)...O(3)#2 0.84(2) 2.25(2) 3.062(2) 162(3) 
 C(7)-H(7A)...O(3) 0.99 2.59 3.231(2) 122.0 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1/2,-y+1/2,-z+1    #2 x+1,y,z       
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Table A7.2.1. Experimental Details for X-Ray Structure Determination of Cyclobutane 
465 
Low-temperature diffraction data (f-and w-scans) were collected on a Bruker AXS 
KAPPA APEX II diffractometer coupled to an PHOTON 100 CMOS detector with 
graphite monochromated Mo Ka radiation (l = 0.71073 Å) for the structure of compound 
465. The structure was solved by direct methods using SHELXS and refined against F2 on 
all data by full-matrix least squares with SHELXL-2017 using established refinement 
techniques. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups).  
Compound 465 crystallizes in the monoclinic space group P21 with one molecule 















Table A7.2.2. Crystal Data and Structure Refinement for Cyclobutane 465 
Empirical formula  C24 H30 O4.16 Si 
Formula weight  413.21 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 7.267(3) Å a= 90°. 
 b = 9.667(3) Å b= 99.237(16)°. 
 c = 15.436(4) Å g = 90°. 
Volume 1070.3(7) Å3 
Z 2 
Density (calculated) 1.282 Mg/m3 
Absorption coefficient 0.138 mm-1 
F(000) 443 
Crystal size 0.300 x 0.100 x 0.050 mm3 
Theta range for data collection 2.495 to 30.501°. 
Index ranges -10<=h<=9, -13<=k<=13, -22<=l<=22 
Reflections collected 16781 
Independent reflections 5995 [R(int) = 0.0322] 
Completeness to theta = 25.242° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7466 and 0.6535 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5995 / 2 / 280 
Goodness-of-fit on F2 1.024 
Final R indices [I>2sigma(I)] R1 = 0.0392, wR2 = 0.0861 
R indices (all data) R1 = 0.0494, wR2 = 0.0897 
Absolute structure parameter 0.04(4) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.316 and -0.247 e.Å-3 
  




Table A.7.2.3. Atomic Coordinates (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2x 103) for Cyclobutane 465. U(eq) is Defined as One Third of the 
Trace of the Orthogonalized Uij Tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Si(1) 4386(1) 6279(1) 8522(1) 15(1) 
C(1) 3245(3) 4685(2) 7973(1) 12(1) 
C(2) 3535(3) 3370(2) 8547(1) 17(1) 
C(3) 2928(3) 2185(2) 7909(1) 16(1) 
C(4) 3789(3) 2600(2) 7113(1) 12(1) 
C(5) 3459(3) 4173(2) 7001(1) 10(1) 
C(6) 4859(3) 4923(2) 6488(1) 12(1) 
O(6B) 6250(11) 5648(9) 7055(5) 9(3) 
C(7) 6204(3) 3975(2) 6103(2) 17(1) 
O(1) 6138(2) 4182(2) 5238(1) 20(1) 
O(2) 7296(2) 3157(2) 6489(1) 24(1) 
C(8) 5001(3) 5372(2) 4925(1) 17(1) 
C(9) 3445(3) 4958(2) 4187(1) 18(1) 
C(10) 1752(3) 4665(2) 4626(1) 13(1) 
C(18) -89(3) 4728(2) 4002(1) 19(1) 
O(3) 1978(2) 3371(2) 5078(1) 15(1) 
C(11) 1954(3) 5803(2) 5343(1) 12(1) 
C(12) 4054(3) 5873(2) 5706(1) 13(1) 
C(13) 749(3) 5568(2) 6031(1) 12(1) 
O(4) -691(2) 6223(2) 6041(1) 17(1) 
C(14) 1345(3) 4496(2) 6715(1) 11(1) 
C(15) 1116(3) 4936(2) 7652(1) 14(1) 
C(16) 6926(3) 6088(3) 8901(2) 27(1) 
C(17) 3947(4) 7835(3) 7791(2) 26(1) 
C(21) 3208(3) 6548(2) 9508(1) 19(1) 
C(22) 1903(3) 7607(3) 9547(2) 25(1) 
C(23) 1014(4) 7768(3) 10273(2) 35(1) 




Table A.7.2.3. Cont’d 
C(24) 1401(4) 6871(3) 10974(2) 37(1) 
C(25) 2668(4) 5819(3) 10955(2) 30(1) 
C(26) 3574(3) 5662(3) 10235(1) 23(1) 
________________________________________________________________________________   




Table A7.2.4. Bond Lengths [Å] and angles [°] for Cyclobutane 465 
 _____________________________________________________  
Si(1)-C(16)  1.853(2) 
Si(1)-C(17)  1.877(3) 
Si(1)-C(21)  1.881(2) 
Si(1)-C(1)  1.886(2) 
C(1)-C(2)  1.545(3) 
C(1)-C(15)  1.566(3) 
C(1)-C(5)  1.611(3) 
C(2)-C(3)  1.529(3) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.520(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-C(5)  1.545(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-C(14)  1.561(3) 
C(5)-C(6)  1.564(3) 
C(6)-O(6B)  1.412(8) 
C(6)-C(7)  1.529(3) 
C(6)-C(12)  1.554(3) 
C(6)-H(6)  1.0000 
O(6B)-H(6OB)  0.8400 
C(7)-O(2)  1.207(3) 
C(7)-O(1)  1.343(3) 
O(1)-C(8)  1.452(3) 
C(8)-C(9)  1.525(3) 
C(8)-C(12)  1.558(3) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.524(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 




Table A7.2.4. Cont’d 
C(10)-O(3)  1.430(2) 
C(10)-C(18)  1.519(3) 
C(10)-C(11)  1.551(3) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
O(3)-H(3O)  0.81(2) 
C(11)-C(13)  1.499(3) 
C(11)-C(12)  1.541(3) 
C(11)-H(11)  1.0000 
C(12)-H(12)  1.0000 
C(13)-O(4)  1.225(2) 
C(13)-C(14)  1.492(3) 
C(14)-C(15)  1.542(3) 
C(14)-H(14)  1.0000 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(21)-C(26)  1.403(3) 
C(21)-C(22)  1.403(3) 
C(22)-C(23)  1.390(3) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.380(5) 
C(23)-H(23)  0.9500 
C(24)-C(25)  1.375(4) 
C(24)-H(24)  0.9500 
C(25)-C(26)  1.387(3) 
C(25)-H(25)  0.9500 
C(26)-H(26)  0.9500 


























































































































































Symmetry transformations used to generate equivalent atoms:  
   




Table A7.2.5. Anisotropic Displacement Parameters (Å2x103) for Cyclobutane 465. 
The Anisotropic Displacement Factor Exponent Takes the Form: -2p2[h2a*2U11 + … + 
2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Si(1) 15(1)  15(1) 14(1)  -4(1) 1(1)  1(1) 
C(1) 13(1)  14(1) 10(1)  -1(1) 1(1)  3(1) 
C(2) 20(1)  17(1) 13(1)  1(1) 3(1)  2(1) 
C(3) 18(1)  14(1) 16(1)  2(1) 5(1)  1(1) 
C(4) 14(1)  10(1) 14(1)  -1(1) 3(1)  1(1) 
C(5) 11(1)  10(1) 10(1)  -1(1) 1(1)  -1(1) 
C(6) 10(1)  10(1) 16(1)  -1(1) 1(1)  -3(1) 
O(6B) 4(4)  15(5) 9(4)  -3(3) 2(3)  -1(3) 
C(7) 11(1)  14(1) 28(1)  0(1) 7(1)  -5(1) 
O(1) 16(1)  22(1) 24(1)  -4(1) 8(1)  1(1) 
O(2) 12(1)  21(1) 42(1)  7(1) 8(1)  1(1) 
C(8) 17(1)  18(1) 18(1)  1(1) 8(1)  -3(1) 
C(9) 22(1)  19(1) 14(1)  -1(1) 6(1)  -2(1) 
C(10) 15(1)  11(1) 12(1)  1(1) 2(1)  1(1) 
C(18) 21(1)  21(1) 16(1)  0(1) -1(1)  1(1) 
O(3) 21(1)  10(1) 13(1)  -1(1) 1(1)  -1(1) 
C(11) 14(1)  9(1) 13(1)  1(1) 2(1)  0(1) 
C(12) 14(1)  11(1) 15(1)  -1(1) 5(1)  -2(1) 
C(13) 14(1)  8(1) 13(1)  -3(1) -1(1)  0(1) 
O(4) 14(1)  18(1) 18(1)  2(1) 3(1)  5(1) 
C(14) 10(1)  11(1) 11(1)  -1(1) 2(1)  0(1) 
C(15) 16(1)  15(1) 12(1)  0(1) 3(1)  2(1) 
C(16) 16(1)  35(2) 29(1)  -1(1) 2(1)  -2(1) 
C(17) 37(2)  18(1) 24(1)  -2(1) 3(1)  -1(1) 
C(21) 14(1)  23(1) 18(1)  -10(1) 2(1)  -2(1) 
C(22) 16(1)  29(1) 29(1)  -14(1) 0(1)  -1(1) 
C(23) 18(1)  41(2) 47(2)  -23(1) 11(1)  -4(1) 




Table A7.2.5. Cont’d 
C(24) 26(1)  51(2) 38(1)  -24(1) 21(1)  -12(1) 
C(25) 32(1)  38(2) 23(1)  -10(1) 11(1)  -13(1) 
C(26) 21(1)  29(1) 19(1)  -9(1) 5(1)  -4(1) 
______________________________________________________________________________   




Table A7.2.6. Hydrogen Coordinates (x104) and Isotropic Displacement Parameters 
(Å2x103) for Cyclobutane 465. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2A) 4860 3268 8816 20 
H(2B) 2760 3400 9019 20 
H(3A) 3424 1287 8151 19 
H(3B) 1553 2127 7765 19 
H(4A) 3185 2097 6584 15 
H(4B) 5140 2390 7209 15 
H(6) 5647 5529 6924 15 
H(6OB) 6985 6026 6759 90(90) 
H(8) 5785 6123 4729 20 
H(9A) 3177 5718 3754 21 
H(9B) 3801 4124 3881 21 
H(18A) -81 4048 3531 29 
H(18B) -260 5657 3747 29 
H(18C) -1113 4520 4324 29 
H(3O) 1630(40) 2740(20) 4749(16) 22 
H(11) 1581 6705 5049 15 
H(12) 4418 6853 5851 15 
H(14) 646 3617 6555 13 
H(15A) 297 4314 7928 17 
H(15B) 733 5913 7695 17 
H(16A) 7531 5787 8409 40 
H(16B) 7141 5397 9371 40 
H(16C) 7449 6978 9122 40 
H(17A) 4148 8677 8147 40 
H(17B) 2659 7815 7483 40 
H(17C) 4805 7824 7362 40 
H(22) 1622 8227 9066 30 
H(23) 140 8495 10287 42 




Table A7.2.6. Cont’d 
H(24) 792 6979 11471 44 
H(25) 2924 5197 11436 36 
H(26) 4461 4941 10235 27 
________________________________________________________________________________   





























































































































Symmetry transformations used to generate equivalent atoms:  
  
  




Table A7.2.8. Hydrogen Bonds for Cyclobutane 465 [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(9)-H(9A)...O(2)#1 0.99 2.40 3.280(3) 147.2 
 C(18)-H(18C)...O(1)#2 0.98 2.64 3.622(3) 175.1 
 O(3)-H(3O)...O(4)#3 0.81(2) 1.96(2) 2.766(2) 177(3) 
 C(14)-H(14)...O(2)#2 1.00 2.46 3.182(3) 128.6 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y+1/2,-z+1    #2 x-1,y,z    #3 -x,y-1/2,-z+1       
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Table A7.3.1.  Experimental Details for X-Ray Structure Determination of 
Cyclobutane 466 
Low-temperature diffraction data (f-and w-scans) were collected on a Bruker AXS 
D8 VENTURE KAPPA diffractometer coupled to a PHOTON II CPAD detector with Cu 
Ka radiation (l = 1.54178 Å) from an IµS micro-source for the structure of compound 
V19015. The structure was solved by direct methods using SHELXS1 and refined against 
F2 on all data by full-matrix least squares with SHELXL-20172 using established 
refinement techniques.3 All non-hydrogen atoms were refined anisotropically. Unless 
otherwise noted, all hydrogen atoms were included into the model at geometrically 
calculated positions and refined using a riding model. The isotropic displacement 
parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they are 
linked to (1.5 times for methyl groups).  
Compound 466 crystallizes in the monoclinic space group P21 with one molecule in 
the asymmetric unit. The coordinates for the hydrogen atom bound to O2 were located in 
the difference Fourier synthesis and refined semi-freely with the help of a restraint on the 
O-H distance (0.84(4) Å). The structure was refined as a twin [-1 0 0 0 -1 0 1 0 1]. 
  




Table A7.3.2. Crystal Data and Structure Refinement for Cyclobutane 466 
Empirical formula  C24 H30 O4 Si 
Formula weight  410.57 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 6.7649(5) Å a= 90°. 
 b = 10.9273(9) Å b= 103.394(5)°. 
 c = 14.4629(14) Å g = 90°. 
Volume 1040.05(15) Å3 
Z 2 
Density (calculated) 1.311 Mg/m3 
Absorption coefficient 1.224 mm-1 
F(000) 440 
Crystal size 0.200 x 0.150 x 0.050 mm3 
Theta range for data collection 3.141 to 74.630°. 
Index ranges -7<=h<=8, -13<=k<=13, -18<=l<=17 
Reflections collected 17179 
Independent reflections 4172 [R(int) = 0.0797] 
Completeness to theta = 67.679° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7504 and 0.5626 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4172 / 2 / 269 
Goodness-of-fit on F2 1.071 
Final R indices [I>2sigma(I)] R1 = 0.0880, wR2 = 0.2288 
R indices (all data) R1 = 0.0893, wR2 = 0.2312 
Absolute structure parameter 0.03(6) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.686 and -0.364 e.Å-3 
  




Table A.7.3.3. Atomic Coordinates (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2x 103) for Cyclobutane 466. U(eq) is Defined as One Third of the 
Trace of the Orthogonalized Uij Tensor. 
_______________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Si(1) 5500(3) 3644(2) 3733(2) 26(1) 
C(1) 5454(13) 4028(8) 5009(6) 28(2) 
C(2) 3622(15) 4276(9) 5275(7) 34(2) 
C(3) 3582(16) 4570(10) 6208(8) 38(2) 
C(4) 5409(17) 4598(10) 6909(8) 37(2) 
C(5) 7217(15) 4334(10) 6668(7) 35(2) 
C(6) 7249(16) 4064(9) 5719(7) 34(2) 
C(7) 3130(15) 2738(10) 3256(7) 34(2) 
C(8) 7879(13) 2754(9) 3754(8) 33(2) 
C(11) 5539(13) 5208(8) 3156(6) 26(2) 
C(12) 3363(14) 5841(9) 3012(7) 32(2) 
C(13) 2992(13) 5596(8) 1937(6) 26(2) 
C(14) 2128(13) 6460(8) 1150(6) 26(2) 
O(1) 1187(12) 7376(6) 1210(5) 34(2) 
C(15) 2743(13) 6116(8) 223(6) 27(2) 
C(16) 1075(14) 5330(8) -431(6) 28(2) 
C(26) -690(15) 6100(9) -971(7) 34(2) 
O(2) 321(10) 4436(6) 135(5) 31(1) 
C(17) 2279(15) 4700(8) -1074(6) 28(2) 
C(18) 4326(15) 4391(8) -447(6) 29(2) 
C(19) 4824(13) 5439(8) 283(6) 26(2) 
C(20) 5848(13) 4788(8) 1237(6) 27(2) 
C(21) 5101(13) 3456(8) 1047(6) 27(2) 
O(3) 4251(10) 3301(6) 116(5) 30(1) 
O(4) 5290(12) 2622(6) 1593(5) 34(2) 
C(22) 5312(13) 5490(8) 2053(6) 27(2) 
C(23) 6384(15) 6755(8) 2115(7) 30(2) 




Table A.7.3.3. Cont’d 
C(24) 8208(15) 6643(10) 2960(8) 39(2) 
C(25) 7315(15) 5980(9) 3715(7) 34(2) 
________________________________________________________________________________   




Table A7.3.4. Bond Lengths [Å] and angles [°] for Cyclobutane 466 
Si(1)-C(8)  1.874(9) 
Si(1)-C(7)  1.875(10) 
Si(1)-C(1)  1.900(9) 
Si(1)-C(11)  1.905(9) 
C(1)-C(6)  1.397(13) 
C(1)-C(2)  1.406(13) 
C(2)-C(3)  1.393(14) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.406(15) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.378(15) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.409(14) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(11)-C(25)  1.535(12) 
C(11)-C(12)  1.596(12) 
C(11)-C(22)  1.598(12) 
C(12)-C(13)  1.541(13) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-C(14)  1.489(12) 
C(13)-C(22)  1.544(12) 
C(13)-H(13)  1.0000 
C(14)-O(1)  1.201(12) 
C(14)-C(15)  1.541(12) 
C(15)-C(16)  1.552(12) 




Table A.7.3.4. Cont’d 
C(15)-C(19)  1.574(12) 
C(15)-H(15)  1.0000 
C(16)-O(2)  1.441(11) 
C(16)-C(26)  1.521(13) 
C(16)-C(17)  1.534(12) 
C(26)-H(26A)  0.9800 
C(26)-H(26B)  0.9800 
C(26)-H(26C)  0.9800 
O(2)-H(2A)  0.83(3) 
C(17)-C(18)  1.508(13) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(18)-O(3)  1.450(11) 
C(18)-C(19)  1.541(12) 
C(18)-H(18)  1.0000 
C(19)-C(20)  1.565(12) 
C(19)-H(19)  1.0000 
C(20)-C(22)  1.520(12) 
C(20)-C(21)  1.544(12) 
C(20)-H(20)  1.0000 
C(21)-O(4)  1.193(11) 
C(21)-O(3)  1.347(11) 
C(22)-C(23)  1.554(13) 
C(23)-C(24)  1.527(13) 
C(23)-H(23A)  0.9900 
C(23)-H(23B)  0.9900 
C(24)-C(25)  1.545(14) 
C(24)-H(24A)  0.9900 
C(24)-H(24B)  0.9900 
C(25)-H(25A)  0.9900 























































































































































Symmetry transformations used to generate equivalent atoms:  
  
  




Table A7.3.5. Anisotropic Displacement Parameters (Å2x103) for Cyclobutane 466. 
The Anisotropic Displacement Factor Exponent Takes the Form: -2p2[h2a*2U11 + … + 
2hka*b*U12]. 
 U11 U22  U33 U23 U13 U12 
Si(1) 19(1)  29(1) 32(1)  0(1) 7(1)  -1(1) 
C(1) 26(4)  33(4) 24(4)  2(3) 7(3)  0(3) 
C(2) 31(5)  36(5) 35(4)  3(4) 11(4)  -4(4) 
C(3) 26(4)  44(5) 44(5)  -1(4) 10(4)  -13(4) 
C(4) 42(6)  32(4) 39(5)  -4(4) 15(4)  -2(4) 
C(5) 27(4)  41(5) 34(5)  2(4) 4(4)  -8(4) 
C(6) 30(4)  34(5) 37(5)  2(3) 5(4)  -2(4) 
C(7) 27(4)  41(5) 37(5)  -3(4) 10(4)  -1(4) 
C(8) 20(4)  34(5) 47(5)  1(4) 11(4)  7(3) 
C(11) 21(4)  31(4) 30(4)  -2(3) 10(3)  4(3) 
C(12) 26(4)  32(4) 37(5)  3(4) 10(4)  7(4) 
C(13) 21(4)  29(4) 31(4)  -1(3) 11(3)  0(3) 
C(14) 15(3)  30(4) 34(4)  -1(3) 7(3)  -2(3) 
O(1) 32(3)  38(4) 36(3)  0(3) 12(3)  9(3) 
C(15) 22(4)  31(4) 28(4)  2(3) 7(3)  2(3) 
C(16) 24(4)  28(4) 31(4)  2(3) 7(3)  -3(4) 
C(26) 26(4)  35(5) 42(5)  -2(4) 9(4)  -1(4) 
O(2) 25(3)  34(3) 35(3)  1(2) 12(3)  0(3) 
C(17) 30(4)  24(4) 34(4)  -1(3) 12(3)  -1(3) 
C(18) 30(4)  26(4) 33(4)  -2(3) 13(3)  -2(4) 
C(19) 21(4)  29(4) 29(4)  0(3) 8(3)  2(3) 
C(20) 20(4)  22(4) 40(4)  -2(3) 10(3)  5(3) 
C(21) 22(4)  29(4) 31(4)  -1(3) 9(3)  6(3) 
O(3) 27(3)  29(3) 32(3)  -1(2) 7(2)  2(2) 
O(4) 35(4)  31(3) 37(3)  3(3) 9(3)  -1(3) 
C(22) 20(4)  28(4) 33(4)  3(3) 6(3)  5(3) 
C(23) 29(4)  28(4) 34(4)  0(3) 7(4)  0(4) 
C(24) 26(5)  41(5) 48(6)  2(4) 4(4)  -9(4) 
C(25) 32(4)  31(4) 35(4)  1(4) 3(4)  -6(4) 
______________________________________________________________________________   




Table A7.3.6. Hydrogen Coordinates (x104) and Isotropic Displacement Parameters 
(Å2x103) for Cyclobutane 466. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 2380 4242 4806 40 
H(3) 2330 4751 6369 45 
H(4) 5397 4799 7547 44 
H(5) 8449 4333 7144 42 
H(6) 8510 3903 5559 41 
H(7A) 1946 3280 3161 52 
H(7B) 3004 2092 3709 52 
H(7C) 3201 2367 2647 52 
H(8A) 8045 2119 4244 50 
H(8B) 9051 3307 3897 50 
H(8C) 7785 2371 3133 50 
H(12A) 2417 5398 3324 38 
H(12B) 3426 6721 3180 38 
H(13) 2354 4772 1789 31 
H(15) 2817 6900 -124 32 
H(26A) -1691 5569 -1381 51 
H(26B) -188 6704 -1362 51 
H(26C) -1329 6524 -518 51 
H(2A) -100(200) 3860(90) -230(80) 46 
H(17A) 1573 3948 -1357 34 
H(17B) 2433 5255 -1594 34 
H(18) 5385 4317 -825 35 
H(19) 5814 6014 96 31 
H(20) 7355 4806 1316 32 
H(23A) 6832 6932 1524 36 
H(23B) 5462 7416 2222 36 
H(24A) 8746 7459 3189 47 
H(24B) 9308 6156 2792 47 




Table A.7.3.6. Cont’d 
H(25A) 8353 5450 4119 40 
H(25B) 6829 6579 4125 40 
________________________________________________________________________________   








































































































Symmetry transformations used to generate equivalent atoms:  
  
  




Table A7.3.8. Hydrogen Bonds for Cyclobutane 466 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 C(13)-H(13)...O(2) 1.00 2.49 3.079(11) 116.9 
 C(15)-H(15)...O(3)#1 1.00 2.50 3.246(11) 130.8 
 O(2)-H(2A)...O(1)#2 0.83(3) 2.16(3) 2.996(10) 178(15) 
 C(17)-H(17A)...O(1)#2 0.99 2.58 3.430(11) 143.8 
 C(19)-H(19)...O(3)#1 1.00 2.52 3.267(11) 131.5 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y+1/2,-z    #2 -x,y-1/2,-z       
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Table A7.4.1.  Experimental Details for X-Ray Structure Determination of 
Cycloheptane 468 
Refinement details 
A crystal was mounted on a polyimide MiTeGen loop with STP Oil Treatment and 
placed under a nitrogen stream. Low temperature (100K) X-ray data were collected with 
a Bruker AXS D8 VENTURE KAPPA diffractometer running at 50 kV and 1mA (Cu Ka 
= 1.54178 Å; PHOTON II CPAD detector and Helios focusing multilayer mirror optics). 
All diffractometer manipulations, including data collection, integration, and scaling were 
carried out using the Bruker APEX3 software. An absorption correction was applied 
using SADABS. The space group was determined and the structure solved by intrinsic 
phasing using XT.  Refinement was full-matrix least squares on F2 using XL. All non-
hydrogen atoms (except the carbon of a disordered chloroform) were refined using 
anisotropic displacement parameters. Hydrogen atoms were placed in idealized positions 
and refined using a riding model. The isotropic displacement parameters of all hydrogen 
atoms were fixed at 1.2 times (1.5 times for methyl groups) the Ueq value of the bonded 
atom.  
Special refinement details 
Compound 468 crystallizes in the monoclinic space group C2 with two molecules, one 
water molecule, and 38% of a chloroform in the asymmetric unit. The structure was 








Table A7.4.2. Crystal Data and Structure Refinement for Cycloheptane 468 
Empirical formula  C16.19 H20.19 Cl1.59 O5.50 
Formula weight  359.09 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  C 1 2 1 
Unit cell dimensions a = 34.102(5) Å a= 90° 
 b = 14.485(2) Å b= 94.960(10)° 
 c = 6.6087(11) Å g = 90° 
Volume 3252.2(9) Å3 
Z 8 
Density (calculated) 1.467 g/cm3 
Absorption coefficient 3.208 mm-1 
F(000) 1507 
Crystal size 0.11 x 0.04 x 0.03 mm3 
Theta range for data collection 3.317 to 76.122°. 
Index ranges -41 £ h £ 40, -17 £ k £ 17, 0 £ l £ 8 
Reflections collected 6144 
Independent reflections 6144 [R(int) = ?] 
Completeness to theta = 67.679° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9904 and 0.7072 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6144 / 4 / 434 
Goodness-of-fit on F2 1.065 
Final R indices [I>2sigma(I)] R1 = 0.0840, wR2 = 0.2207 
R indices (all data) R1 = 0.0969, wR2 = 0.2291 
Absolute structure parameter [Flack] 0.163(12) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.708 and -0.538 e.Å-3 
  




Table A.7.4.3. Atomic Coordinates (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2x 103) for Cycloheptane 468. U(eq) is Defined as One Third of the 
Trace of the Orthogonalized Uij Tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
Cl(1) 6462(1) 349(2) 11229(4) 36(1) 
O(1) 6294(2) 1950(4) 12668(10) 25(1) 
O(2) 5281(2) 2980(5) 8327(10) 29(2) 
O(3) 6853(2) 3559(5) 11901(10) 28(1) 
O(4) 6508(2) 4844(4) 11323(10) 25(1) 
O(5) 6000(2) 4396(5) 7538(10) 27(1) 
C(1) 6013(2) 2698(6) 12313(13) 23(2) 
C(2) 5664(3) 2506(7) 13588(15) 31(2) 
C(3) 5480(3) 1561(8) 13098(18) 38(2) 
C(4) 5790(3) 823(7) 12868(19) 40(3) 
C(5) 6094(3) 1208(7) 11574(16) 30(2) 
C(6) 5924(3) 1617(7) 9532(16) 32(2) 
C(7) 5919(3) 2650(6) 10038(12) 21(2) 
C(8) 5562(3) 3240(7) 9446(13) 25(2) 
C(9) 5591(2) 4203(6) 10287(12) 21(2) 
C(10) 5876(3) 4396(6) 12246(13) 19(2) 
C(11) 6178(2) 3656(6) 12938(13) 20(2) 
C(12) 6543(3) 3974(7) 12019(13) 23(2) 
C(13) 6124(2) 5226(6) 11765(12) 20(2) 
C(14) 5911(3) 5671(6) 9851(14) 24(2) 
C(15) 5723(2) 4889(7) 8647(13) 23(2) 
C(16) 5371(3) 5187(8) 7186(16) 37(2) 
Cl(1B) 5600(1) 7225(2) 14099(5) 54(1) 
O(1B) 6287(2) 7010(5) 16090(11) 35(2) 
O(2B) 7121(2) 8559(5) 12394(11) 41(2) 
O(3B) 6650(2) 5146(5) 15897(10) 31(2) 
O(4B) 7290(2) 5266(6) 15553(12) 43(2) 




Table A.7.4.3. Cont’d  
O(5B) 7372(2) 6411(5) 11759(11) 33(2) 
C(1B) 6692(4) 7307(8) 16092(16) 42(3) 
C(2B) 6754(5) 8185(9) 17260(18) 64(4) 
C(3B) 6466(5) 8945(9) 16450(19) 65(4) 
C(4B) 6047(5) 8570(9) 15850(20) 63(4) 
C(5B) 6081(3) 7679(8) 14762(17) 42(3) 
C(6B) 6326(3) 7773(7) 12972(15) 33(2) 
C(7B) 6725(3) 7396(7) 13782(13) 30(2) 
C(8B) 7108(3) 7877(7) 13444(13) 32(2) 
C(9B) 7466(3) 7454(8) 14569(15) 40(3) 
C(10B) 7409(3) 6845(10) 16518(15) 46(3) 
C(11B) 6992(3) 6573(9) 16972(16) 42(3) 
C(12B) 6950(3) 5610(8) 16141(16) 36(2) 
C(13B) 7614(3) 5924(10) 16200(20) 55(4) 
C(14B) 7873(3) 6067(10) 14504(19) 51(3) 
C(15B) 7675(3) 6800(8) 13096(15) 35(2) 
C(16B) 7962(3) 7313(9) 11897(15) 44(3) 
O(6) 7478(2) 4630(5) 10479(12) 41(2) 
Cl(2) 5193(2) -332(5) 7527(14) 100(5) 
Cl(3) 4852(3) -647(9) 11220(19) 169(12) 
Cl(4) 5237(3) -2147(5) 9390(20) 147(9) 
C(17) 4947(2) -1158(6) 8908(16) 130(30) 
________________________________________________________________________________   




Table A7.4.4. Bond Lengths [Å] and angles [°] for Cycloheptane 468 
_____________________________________________________  
Cl(1)-C(5)  1.796(10) 
O(1)-C(1)  1.452(10) 
O(1)-C(5)  1.435(11) 
O(2)-C(8)  1.217(11) 
O(3)-C(12)  1.224(11) 
O(4)-C(12)  1.343(11) 
O(4)-C(13)  1.473(10) 
O(5)-H(5)  0.8400 
O(5)-C(15)  1.434(10) 
C(1)-C(2)  1.542(12) 
C(1)-C(7)  1.512(12) 
C(1)-C(11)  1.541(12) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(2)-C(3)  1.528(15) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(3)-C(4)  1.521(15) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(4)-C(5)  1.505(15) 
C(5)-C(6)  1.540(13) 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(6)-C(7)  1.533(13) 
C(7)-H(7)  1.0000 
C(7)-C(8)  1.511(13) 
C(8)-C(9)  1.501(13) 
C(9)-H(9)  1.0000 
C(9)-C(10)  1.576(12) 
C(9)-C(15)  1.564(12) 
C(10)-H(10)  1.0000 




Table A.7.4.4. Cont’d  
C(10)-C(11)  1.528(12) 
C(10)-C(13)  1.520(12) 
C(11)-H(11)  1.0000 
C(11)-C(12)  1.504(12) 
C(13)-H(13)  1.0000 
C(13)-C(14)  1.544(12) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(14)-C(15)  1.497(13) 
C(15)-C(16)  1.534(13) 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
Cl(1B)-C(5B)  1.788(13) 
O(1B)-C(1B)  1.447(13) 
O(1B)-C(5B)  1.448(13) 
O(2B)-C(8B)  1.210(12) 
O(3B)-C(12B)  1.223(12) 
O(4B)-C(12B)  1.350(14) 
O(4B)-C(13B)  1.495(14) 
O(5B)-H(5B)  0.8400 
O(5B)-C(15B)  1.416(12) 
C(1B)-C(2B)  1.494(16) 
C(1B)-C(7B)  1.546(13) 
C(1B)-C(11B)  1.553(18) 
C(2B)-H(2C)  0.9900 
C(2B)-H(2D)  0.9900 
C(2B)-C(3B)  1.54(2) 
C(3B)-H(3C)  0.9900 
C(3B)-H(3D)  0.9900 
C(3B)-C(4B)  1.55(2) 
C(4B)-H(4D)  0.9900 
C(4B)-H(4C)  0.9900 
C(4B)-C(5B)  1.487(18) 




Table A.7.4.4. Cont’d  
C(5B)-C(6B)  1.513(15) 
C(6B)-H(6C)  0.9900 
C(6B)-H(6D)  0.9900 
C(6B)-C(7B)  1.519(15) 
C(7B)-H(7B)  1.0000 
C(7B)-C(8B)  1.514(13) 
C(8B)-C(9B)  1.504(16) 
C(9B)-H(9B)  1.0000 
C(9B)-C(10B)  1.586(14) 
C(9B)-C(15B)  1.572(16) 
C(10B)-H(10B)  1.0000 
C(10B)-C(11B)  1.531(15) 
C(10B)-C(13B)  1.53(2) 
C(11B)-H(11B)  1.0000 
C(11B)-C(12B)  1.502(17) 
C(13B)-H(13B)  1.0000 
C(13B)-C(14B)  1.503(18) 
C(14B)-H(14C)  0.9900 
C(14B)-H(14D)  0.9900 
C(14B)-C(15B)  1.531(16) 
C(15B)-C(16B)  1.510(13) 
C(16B)-H(16D)  0.9800 
C(16B)-H(16E)  0.9800 
C(16B)-H(16F)  0.9800 
O(6)-H(6E)  0.8689 
O(6)-H(6F)  0.9962 
Cl(2)-Cl(3)#1  0.969(17) 
Cl(2)-C(17)  1.7602 
Cl(3)-Cl(4)#1  2.227(5) 
Cl(3)-C(17)  1.7534 
Cl(4)-C(17)  1.7546 
C(17)-H(17)  0.9198 
 
C(5)-O(1)-C(1) 101.4(6) 














































































































































































































































Table A.7.4.4. Cont’d 
Cl(4)-C(17)-H(17) 110.1 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+2       
  




Table A7.4.5. Anisotropic Displacement Parameters (Å2x103) for Cycloheptane 468. 
The Anisotropic Displacement Factor Exponent Takes the Form: -2p2[h2a*2U11 + … + 
2hka*b*U12]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
Cl(1) 36(1)  26(1) 42(1)  -7(1) -7(1)  4(1) 
O(1) 21(3)  22(3) 31(3)  -2(3) -3(3)  3(2) 
O(2) 21(3)  42(4) 22(3)  2(3) -10(2)  -9(3) 
O(3) 24(3)  28(3) 33(4)  -11(3) 1(3)  6(3) 
O(4) 24(3)  20(3) 32(3)  -2(3) 2(3)  3(3) 
O(5) 28(3)  32(4) 22(3)  -4(3) 10(3)  -6(3) 
C(1) 22(4)  22(4) 23(4)  2(4) 3(3)  1(4) 
C(2) 27(5)  30(5) 36(5)  11(4) 8(4)  3(4) 
C(3) 30(5)  38(6) 47(6)  20(5) 5(4)  4(4) 
C(4) 41(6)  24(5) 56(7)  10(5) -2(5)  -5(4) 
C(5) 25(5)  28(5) 36(5)  3(4) -9(4)  -1(4) 
C(6) 32(5)  26(5) 34(5)  -2(4) -16(4)  2(4) 
C(7) 27(4)  15(4) 19(4)  -5(3) -4(3)  -2(4) 
C(8) 24(5)  35(5) 17(4)  0(4) 1(3)  -2(4) 
C(9) 18(4)  31(5) 14(4)  2(4) 0(3)  1(4) 
C(10) 28(4)  14(4) 14(4)  1(3) -1(3)  4(3) 
C(11) 20(4)  24(4) 16(4)  -7(3) 2(3)  -1(3) 
C(12) 23(4)  28(5) 18(4)  -12(4) -4(3)  1(4) 
C(13) 21(4)  21(4) 18(4)  -8(3) 1(3)  0(3) 
C(14) 26(4)  21(4) 24(5)  0(4) -2(4)  1(3) 
C(15) 22(4)  32(5) 15(4)  1(4) 3(3)  -1(4) 
C(16) 37(5)  42(6) 30(5)  12(5) -6(4)  -1(5) 
Cl(1B) 45(2)  40(2) 77(2)  16(2) 14(1)  11(1) 
O(1B) 44(4)  32(4) 31(4)  9(3) 9(3)  -5(3) 
O(2B) 65(5)  26(4) 34(4)  -2(3) 13(4)  -15(3) 
O(3B) 27(3)  37(4) 27(3)  5(3) -3(3)  -5(3) 
O(4B) 20(3)  52(5) 55(5)  28(4) -6(3)  -6(3) 




Table A7.4.5. Cont’d 
O(5B) 35(4)  26(4) 37(4)  0(3) -9(3)  -1(3) 
C(1B) 58(7)  38(6) 29(5)  -10(5) 4(5)  -19(5) 
C(2B) 122(13)  46(7) 27(6)  -11(6) 20(7)  -34(8) 
C(3B) 129(14)  37(7) 32(6)  -17(5) 28(8)  -16(8) 
C(4B) 97(11)  37(7) 59(8)  7(6) 39(8)  10(7) 
C(5B) 50(6)  35(6) 42(6)  5(5) 8(5)  1(5) 
C(6B) 50(6)  19(5) 28(5)  2(4) 3(4)  -6(4) 
C(7B) 42(5)  32(6) 17(4)  -6(4) 7(4)  -12(4) 
C(8B) 50(6)  32(5) 12(4)  2(4) 2(4)  -15(5) 
C(9B) 50(6)  45(7) 23(5)  -2(5) -2(4)  -32(5) 
C(10B) 43(6)  75(9) 19(5)  4(5) -8(4)  -38(6) 
C(11B) 45(6)  59(8) 23(5)  2(5) 5(4)  -29(6) 
C(12B) 29(5)  47(7) 31(5)  14(4) -7(4)  -13(4) 
C(13B) 34(6)  79(10) 50(7)  32(7) -12(5)  -24(6) 
C(14B) 30(6)  75(9) 46(7)  27(6) -10(5)  -20(6) 
C(15B) 36(5)  43(6) 25(5)  13(4) -4(4)  -14(5) 
C(16B) 53(7)  59(8) 20(5)  5(5) 6(4)  -22(6) 
O(6) 39(4)  37(4) 49(5)  -11(4) 14(3)  -6(3) 
Cl(2) 78(8)  64(7) 162(16)  5(8) 34(9)  31(6) 
Cl(3) 74(10)  310(40) 120(15)  28(19) 16(10)  -12(15) 
Cl(4) 100(10)  200(20) 148(15)  93(14) 27(10)  74(12) 
______________________________________________________________________________   




Table A7.4.6. Hydrogen Coordinates (x104) and Isotropic Displacement Parameters 
(Å2x103) for Cycloheptane 468. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(5) 6187 4747 7314 40 
H(2A) 5756 2532 15049 37 
H(2B) 5462 2991 13313 37 
H(3A) 5316 1380 14197 46 
H(3B) 5307 1603 11821 46 
H(4A) 5916 646 14219 49 
H(4B) 5667 266 12218 49 
H(6A) 6096 1485 8433 38 
H(6B) 5656 1381 9136 38 
H(7) 6145 2937 9406 25 
H(9) 5321 4391 10601 25 
H(10) 5717 4553 13399 23 
H(11) 6226 3680 14452 24 
H(13) 6152 5671 12926 24 
H(14A) 5710 6117 10229 29 
H(14B) 6101 5999 9056 29 
H(16A) 5464 5588 6130 56 
H(16B) 5182 5525 7941 56 
H(16C) 5244 4640 6555 56 
H(5B) 7454 5921 11262 49 
H(2C) 7028 8401 17168 77 
H(2D) 6719 8068 18709 77 
H(3C) 6568 9239 15249 78 
H(3D) 6451 9426 17506 78 
H(4D) 5906 8475 17082 75 
H(4C) 5896 9019 14961 75 
H(6C) 6347 8427 12557 39 
H(6D) 6213 7408 11798 39 




Table A7.4.6. Cont’d 
H(7B) 6744 6755 13237 36 
H(9B) 7653 7965 14989 48 
H(10B) 7542 7158 17739 55 
H(11B) 6981 6547 18479 51 
H(13B) 7768 5712 17474 66 
H(14C) 7903 5483 13754 61 
H(14D) 8138 6279 15048 61 
H(16D) 8113 6870 11152 66 
H(16E) 8143 7671 12826 66 
H(16F) 7818 7732 10933 66 
H(6E) 7684 4303 10257 62 
H(6F) 7299 4281 11315 62 
H(17) 4712 -1315 8203 155 
________________________________________________________________________________   











































































































































































Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+2       
  




Table A7.4.8. Hydrogen Bonds for Cycloheptane 468 [Å and °]. 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(5)-H(5)...O(3B)#2 0.84 1.99 2.772(9) 154.9 
 O(5B)-H(5B)...O(6) 0.84 1.94 2.749(10) 160.2 
 O(6)-H(6E)...O(2B)#3 0.87 2.21 2.886(10) 134.6 
 O(6)-H(6F)...O(3) 1.00 1.91 2.858(9) 157.8 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+1,y,-z+2    #2 x,y,z-1    #3 -x+3/2,y-1/2,-z+2       





A7.5  NOTES AND REFERENCES 
1. Sheldrick, G. M. Acta Cryst. 1990, A46, 467-473. 
2. Sheldrick, G. M. Acta Cryst. 2015, C71, 3-8. 
3. Müller, P. Crystallography Reviews 2009, 15, 57-83. 
                                               







Alternative Strategy Toward the  
Total Synthesis of Scabrolide A 
 
A8.1  ALTERNATIVE APPROACH TO SCABROLIDE A 
 During the development of the ultimately successful ring expansion of a small-
membered ring for the synthesis of the cycloheptanone ring in the core of scabrolide A, we 
concurrently investigated numerous alternative routes (Scheme A8.1.1). 
Retrosynthetically, we envisioned access to scabrolide A 407 through an intramolecular 
transannular Diels–Alder reaction from intermediate 472. We believed intermediate 472 
could be formed through a Yamaguchi macrolactonization from masked 1,4-diketone 473. 
The key masked 1,4 diketone moiety of 473 is believed to be generated from an umpolung 
1,2 addition of allyl carbamate 475 and aldehyde 444. 




Scheme A8.1.1. Retrosynthetic Analysis of Scabrolide A 
 
A8.2  SYNTHESIS OF DIISOPROPYL CARBAMATE 
 Exploration of the proposed synthetic route began with the derivatization of key 
carvone derived Weinreb amide ent•422 (Scheme A8.2.1). Single addition of vinyl 
Grignard followed by subsequent Luche reduction of the resultant ketone, afforded allylic 
alcohol 476 in 51% yield over 2 steps as a 1:1 mixture of diastereomers. The mixture of 
diastereomers can then be TMS protected at the terminal alkyne followed by the 
carbamoylation of the allylic alcohol generating carbamate 475 in a 70% yield over 2 steps 
in a 1:1 mixture of diastereomers. Ultimately, silyl protection of the alkyne is required to 
avoid statistical mixtures of the desired carbamate and the undesired acetylated alkyne. 
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A8.3  UMPOLUNG ALDEHYDE ADDITION 
 Successful synthesis of allylic carbamate 475, allows for the investigation of the 
synthesis of the 1,4-diketone moiety of scabrolide A. Deprotonation of the allylic 
carbamate 475 with n-BuLi in the presence of TMEDA at low temperatures, generates a 
stabilized allylic carbanion, which are known to undergo selective 1,2 additions into 
aldehydes (Scheme A8.3.1).1 Addition of previously synthesized aldehyde 444 to the 
stabilized allylic anion followed by an oxidation with DMP affords our desired masked 
1,4-diketone 473 in 20% yield over 2 steps. While we were able to selective generate enol 
carbamate 473, albeit in low yield, we were unable to progress this intermediate toward 
macrocycle 472. Attempts to deprotect the alkyne and affect Yamaguchi esterification 
resulted in decomposition. Deprotection of the enol carbamate moiety similarly resulted in 
decomposition. Ultimately we were unable to advance this interesting intermediate any 
further in the synthesis. 
Scheme A8.3.1. Coupling of Carbamate 475 and Aldehyde 444 
 
A8.4  EXPERIMENTAL METHODS AND ANALYTICAL DATA 
A8.4.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
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deoxygenated solvents (distilled or passed over a column of activated alumina).2 
Commercially obtained reagents were used as received. Triethylamine (Et3N) and 
trimethylsilyl chloride (TMSCl) were distilled over potassium hydride prior to use. 
Reactions requiring external heat were modulated to the specified temperatures using an 
IKAmag temperature controller. Reaction progress was monitored by thin-layer 
chromatography (TLC), which was performed using E. Merck silica gel 60 F254 precoated 
glass plated (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, p-anisaldehyde, or iodine staining. Silicycle SiliaFlash® P60 Academic 
Silica gel (particle size 40-63 nm) was used for column chromatography. 1H and 13C NMR 
spectra were recorded on a Varian Inova 500 (500 MHz and 126 MHz, respectively), 
Varian Mercury 300 spectrometer (300 MHz and 75 MHz, respectively), Varian 600 MHz 
Spectrometer (600 MHz), and a Bruker AV III HD spectrometer equipped with a Prodigy 
liquid nitrogen temperature cryoprobe (400 MHz and 101 MHz, respectively) and are 
reported in terms of chemical shift relative to CHCl3 (d 7.26 and d 77.16, respectively) and 
C6H6 (d 7.16 and d 128.4 respectively). Data for 1H NMR are reported as follows: chemical 
shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported 
as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sext = sextet, sept = 
septet, m = multiplet, and br s = broad singlet. Infrared (IR) spectra were recorded on a 
Perkin Elmer Paragon 1000 spectrometer using thin films deposited on NaCl plates and are 
reported in frequency of absorption (cm–1). Optical rotations were measured with a Jasco 
P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100-mm path-length 
cell and are reported as: [a]DT (concentration in g/100 mL, solvent). High resolution mass 
spectra were obtained from the Caltech Mass Spectral Facility using a JEOL JMS-600H 




High Resolution Mass Spectrometer in fast atom bombardment (FAB+) ionization mode 
or a Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray 
ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or mixed 
(ESI/APCI) ionization mode. 
A8.4.2  EXPERIMENTAL PROCEDURES 
 
(5R)-5-(prop-1-en-2-yl)oct-1-en-7-yn-3-ol (476): In a flame dried round bottom flask, 
amide ent•422 (250 mg, 1.3 mmol, 1.0 equiv) was dissolved in THF (4.2 mL, 0.3 M) and 
cooled to –78 °C. Allyl magnesium bromide (2.6 mL, 2.6 mmol, 1.0 M, 2.0 equiv) was 
added dropwise to the reaction solution. The reaction was allowed to stir for 15 min at –78 
°C and then warmed to 0 °C and stirred for 16 h. Upon complete consumption of starting 
material (determined by TLC analysis, 9:1 hexanes:EtOAc), the reaction was quenched 
with a saturated solution of NH4Cl and the product was extracted from the biphasic mixture 
with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by flash 
chromatography (SiO2, 9:1 hexanes:EtOAc) to generate an intermediate enone (128 mg, 
62% yield) as a pale yellow oil which was used without further characterization. 
In a round bottom flask, crude enone (490 mg, 3 mmol, 1 equiv) was dissolved in 
methanol (30 mL, 0.1 M). The solution was stirred for 5 min followed by the addition of 
CeCl3•7H2O (1.1 g, 3.3 mmol, 1.1 equiv). Once the reaction is homogeneous, the solution 
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added slowly in portions to the reaction and was allowed to stir until completion (as 
determined by TLC analysis 4:1 hexanes:EtOAc). Upon complete consumption of starting 
material, the reaction was quenched with a saturated solution of NH4Cl (30 mL) and the 
biphasic mixture was allowed to warm to room temperature. The biphasic mixture was 
extracted with 2:1 Et2O:hexanes (3 x 30 mL) and the combined organic layers were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude product was assumed to have 
quantitative conversion and was used directly into the next reaction without further 
purification. Alcohol 476 could be purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) to afford pure alcohol 476 as a colorless oil; Rf = 0.44 (4:1 
hexanes:EtOAc); 1H NMR (400 MHz, CDCl3) d = 5.89 (ddd, J = 17.2, 10.4, 5.8 Hz, 1H), 
5.23 (dt, J = 17.2, 1.5 Hz, 1H), 5.10 (dt, J = 10.4, 1.4 Hz, 1H), 4.84 (ddt, J = 5.6, 2.0, 1.1 
Hz, 2H), 2.58 (dtd, J = 9.6, 7.1, 4.9 Hz, 1H), 2.31 (d, J = 1.4 Hz, 1H), 2.29 (s, 1H), 1.69 
(dd, J = 1.5, 0.8 Hz, 3H), 1.68–1.63 (m, 2H), 1.25 (s, 2H); 5.84 (ddd, J = 17.0, 10.4, 6.5 
Hz, 1H), 5.24 (dt, J = 17.2, 1.4 Hz, 1H), 5.13 (dt, J = 10.4, 1.3 Hz, 1H), 4.84–4.78 (m, 2H), 
4.19 – 4.11 (m, 2H), 2.45–2.34 (m, 1H), 2.32 (d, J = 2.3 Hz, 1H), 2.30 (d, J = 3.8 Hz, 1H), 
1.77–1.69 (m, 5H); 13C NMR (101 MHz, CDCl3) d =  146.7, 146.1, 141.3, 140.7, 115.5, 
114.4, 113.0, 112.6, 82.8, 82.8, 71.9, 70.9, 69.7, 69.6, 42.9, 42.5, 39.5, 39.4, 23.8, 23.5, 
19.1, 18.8; IR (thin film, NaCl) 3305, 3076, 2972, 2935, 2117, 1645, 1429, 1376, 1122, 
992, 924, 895, 633 cm-1; HRMS (ESI) m/z calc’d C11H17O [M+H]+: 165.1279, found: 
165.1299; [a]D23 +17.3 (c 0.125, CHCl3). 







To a stirred solution of alcohol 476 (58 mg, 0.35 mmol, 1.0 equiv) in THF (2.2 mL, 0.15 
M) at –78 °C has n-BuLi (0.35 mL, 0.812 mmol, 2.16 M, 2.3 equiv) added. The reaction 
was warmed to 0 °C, stirred for 10 min, and cooled back to –78 °C. TMSCl (89 µL, 0.71 
mmol, 2 equiv) was added and allowed to for 1 h. Upon complete consumption of starting 
material (as determined by TLC analysis, 4:1 hexanes:EtOAc), 1 N HCl (1.8 mL, 0.2 M) 
was added and allowed to stir for 20 min. The organic layer was separated and the aqueous 
layer was extracted with Et2O (3 X 5 mL). The combined organic layers were washed with 
brine, dried over MgSO4, filtered, and concentrated in vacuo. The crude product was 
purified by column chromatography (SiO2, 4:1 hexanes:EtOAc) and carried onto the next 
reaction without further purification. 
To a stirred solution of alcohol (68 mg, 0.29 mmol, 1 equiv) in toluene (2.9 mL, 
0.1 M) had NaH (23 mg, 0.58 mmol, 2 equiv), DMAP (3.5 mg, 0.03 mmol, 0.1 equiv), and 
diisopropyl carbamoyl chloride (118 mg, 0.72 mg, 2.5 equiv) added. The reaction was 
sealed and heated go 110 °C. Upon complete consumption of starting material (as 
determined by TLC analysis, 4:1 hexanes:EtOAc) , the reaction was cooled to 23 °C and 
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with Et2O (3 x 5 mL) and the combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. The crude product was purified by column chromatography 
(SiO2, 9:1 hexanes:EtOAc) to afford carbamate 475 (86 mg, 98%) as a viscous colorless 
oil (Rf = 057, 4:1 hexanes:EtOAc) 1H NMR (400 MHz, CDCl3) d = 5.79 (ddd, J = 17.3, 
10.4, 6.9 Hz, 1H), 5.26 (dt, J = 17.2, 1.4 Hz, 1H), 5.20–5.05 (m, 2H), 4.82–4.73 (m, 2H), 
4.20–3.64 (bd, 1H), 2.36–2.24 (m, 3H), 2.06 (s, 1H), 1.93–1.75 (m, 2H), 1.71 (dd, J = 1.5, 
0.8 Hz, 3H), 1.20 (dd, J = 7.0, 2.9 Hz, 12H), 0.13 (s, 9H); 6.00–5.65 (m, 1H), 5.33–5.07 
(m, 3H), 4.84 (q, J = 1.6 Hz, 1H), 4.76–4.73 (m, 1H), 4.06 (bs, 1H), 3.80 (bs, 1H), 2.45 
(dddd, J = 10.4, 8.0, 6.1, 4.1 Hz, 1H), 2.38–2.18 (m, 2H), 2.07–1.91 (m, 1H), 1.74–1.57 
(m, 4H), 1.32–1.16 (m, 12H), 0.13 (s, 9H); 13C NMR (101 MHz, CDCl3) d = 155.12, 
145.77, 137.20, 117.01, 112.61, 105.71, 86.41, 73.82, 69.76, 46.24, 42.50, 36.87, 25.19, 
21.26, 19.17, 0.22; 155.05, 145.52, 138.16, 137.12, 117.09, 115.45, 112.87, 112.83, 
105.84, 86.10, 73.00, 42.77, 37.30, 25.42, 19.31, 0.23; IR (thin film, NaCl) 3076, 2967, 
2175, 1742, 1693, 1646, 1435, 1368, 1285, 1249, 1157, 1133, 1048, 842, 760, 694 cm-1; 
HRMS (FAB+) m/z calc’d C21H37NO2SiNa [M+Na]+: 386.2486, found: 386.2470; [a]D23 
+5.6 (c 0.305, CHCl3). 
 
 







(trimethylsilyl)non-3-en-8-yn-4-yl diisopropylcarbamate (473): To a stirred solution of 
carbamate 475 (16 mg, 0.0275 mmol, 1 equiv) and TMEDA ( 6 µL, 0.04225 mmol, 1.3 
equiv) in Et2O (0.33 mL, 0.1 M) was cooled to –78 °C. n-BuLi (0.02 mL, 0.04 mmol, 2.16 
M, 1.3 equiv) was added and stirred for 2 h. Aldehyde 444 ( 27.4 mg, 0.98 mmol, 2.2 equiv) 
in a solution of Et2O (0.33 mL, 0.1 M) was added dropwise and allowed to stir for 2 h. 
Upon complete consumption of starting material (as determined by TLC, 9:1 
hexanes:EtOAc) the reaction was quenched with H2O (3 mL) and extracted with Et2O (3 x 
5 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo. The crude product was purified by column chromatography (SiO2, 9:1 
hexanes:EtOAc) and carried on to the next reaction. 
The crude alcohol product (8 mg, 0.011 mmol, 1 equiv) in wet CH2Cl2 (0.55 mL, 
0.02 M) had DMP (9 mg, 0.022 mmol, 2 equiv) added. The reaction was allowed to stir for 
2 h, at which time complete consumption of starting material was observed (by TLC 
analysis, 9:1 hexanes:EtOAc). The reaction was quenched with Na2S2O3, poured into a 
saturated solution of NaHCO3, and extracted with Et2O (3 x 5 mL). The combined organic 
layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was 
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20% over 2 steps) as a colorless oil (Rf = 0.46); 1H NMR (400 MHz, CDCl3) d = 6.33 (d, J 
= 1.8 Hz, 1H), 5.34 (t, J = 6.5 Hz, 1H), 4.79 (q, J = 1.6 Hz, 1H), 4.75 (d, J = 1.6 Hz, 1H), 
4.60 (td, J = 7.0, 1.8 Hz, 1H), 3.93 (s, 2H), 3.45 (dd, J = 18.7, 6.5 Hz, 1H), 3.26 (dd, J = 
18.8, 6.7 Hz, 1H), 2.55 – 2.26 (m, 6H), 2.03 – 1.96 (m, 1H), 1.69 (dd, J = 1.5, 0.9 Hz, 3H), 
1.52 – 1.43 (m, 3H), 1.26 (d, J = 6.7 Hz, 12H), 0.96 (t, J = 7.9 Hz, 9H), 0.82 (s, 9H), 0.67 
– 0.56 (m, 6H), 0.12 (s, 9H), 0.08 (s, 3H), 0.05 (s, 3H); 13C NMR (101 MHz, CDCl3) d = 
196.0, 152.5, 149.3, 148.5, 145.9, 141.9, 112.2, 110.3, 105.8, 86.2, 81.9, 72.6, 53.9, 46.6, 
43.4, 37.8, 37.2, 28.6, 25.9, 24.4, 21.7, 20.7, 19.9, 18.2, 6.9, 4.9, 0.3, 0.2, -2.3, -2.4; HRMS 
(FAB+) m/z calc’d C40H74NO5Si3 [M+H]+: 732.4875, found: 732.4869. 
A8.5  NOTES AND REFERENCES 
1. Hoppe, D. Synthesis, 2009 43–55.  
2. Pangborn, A. M.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Organometallics 1996, 15, 1518–1520. 
                                               








Spectra Relevant to Appendix 8: 
Alternative Strategy Toward the  
Total Synthesis of Scabrolide A 
  





















































































































 Figure A9.2. Infrared spectrum (Thin Film, NaCl) of compound 476. 
 
 Figure A9.3. 13C NMR (101 MHz, CDCl3) of compound 476. 
 




























































































































 Figure A9.5. Infrared spectrum (Thin Film, NaCl) of compound 475. 
 
 Figure A9.6. 13C NMR (101 MHz, CDCl3) of compound 475. 
 




































































































































 Figure A9.8. 13C NMR (101 MHz, CDCl3) of compound 473. 
 









for New Compounds 
 
A10.1  CONTENTS 
The following notebook cross-reference provides the file name for all original 
spectroscopic data obtained for new compounds presented within this thesis. The 
information is organized by chapter or appendix and sequentially by compound number. 
All 1H NMR, 13C NMR, as well as 19F NMR and any two-dimensional NMR data, if 
applicable, are electronically stored on the Caltech NMR laboratory server 
(mangia.caltech.edu, most typically under the usernames ‘sloskot’, ‘nhafeman’, ‘bpritche’,  
or ‘rcraig’) and on the Stoltz group server. Electronic copies of all IR spectra can also be 
found on the Stoltz group server. All laboratory notebooks are stored in the Stoltz group 
archive.  
A10.2  NOTEBOOK CROSS-REFERENCE TABLES 
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(Florence) SAL-II-125 SAL-II-125 
359 SAL-III-161 (Florence) 
SAL-III-161 
(Florence) SAL-III-161 SAL-III-161 
361 SAL-III-169 (Florence) 
SAL-III-169 












364 SAL-II-133 (Florence) 
SAL-II-133 
(Florence) SAL-II-133 SAL-II-133 
365 SAL-II-135 (Florence) 
SAL-II-135 
(Florence) SAL-II-135 SAL-II-135 
366 SAL-II-179 (Florence) 
SAL-II-179 
(Florence) SAL-II-179 SAL-II-179 
367 SAL-II-181 (Florence) 
SAL-II-181 












377 SAL-II-123 (Florence) 
SAL-II-123 
(Florence) SAL-II-123 SAL-II-123 
378 SAL-III-167 (Florence) 
SAL-III-167 
(Florence) SAL-III-167 SAL-III-167 












379 SAL-III-165 (Florence) 
SAL-III-165 
(Florence) SAL-III-165 SAL-III-165 
380 SAL-III-173 (Florence) 
SAL-III-173 
(Florence) SAL-III-173 SAL-III-173 
382 SAL-II-169 (Florence) 
SAL-II-169 
(Florence) SAL-II-169 SAL-II-169 
383 SAL-II-173 (Florence) 
SAL-II-173 
(Florence) SAL-II-173 SAL-II-173 
384 SAL-II-177 (Florence) 
SAL-II-177 
(Florence) SAL-II-177 SAL-II-177 
 















































































422 BPP-V-287 (Indy) 
BPP-V-287 
(Indy) BPP-V-287 NJH-II-221 
416 BPP-V-295 (Indy) 
BPP-V-295 
(Indy) BPP-V-295 SAL-VI-245 





430 BPP-VI-197 (Florence) 
BPP-VI-197 
(Florence) BPP-VI-197 SAL-VI-261 
432 SALVI-267 (Florence) 
SALVI-267 










437 SAL-IX-263 (Florence) 
SAL-IX-263 
(Florence) SAL-IX-263 SAL-IX-197 


















443 SAL-VIII-153 (Florence) 
SAL-VIII-153 
(Florence) SAL-VIII-153 SAL-IX-141 

























448 SAL-X-203 (Florence) 
SAL-X-203 
(Florence) SAL-X-203 NJH-II-093 









































453 SAL-IX-267 (Florence) 
SAL-IX-267 
(Florence) SAL-IX-267 SAL-IX-197 
454 SAL-IX-271-2 (Florence) 
SAL-IX-271-2 
(Florence) SAL-IX-271-2 SAL-IX-241 
455 SAL-IX-243 (Florence) 
SAL-IX-243 
(Florence) SAL-IX-243 SAL-IX-031 
456 SAL-X-201 (Florence) 
SAL-X-201 
(Florence) SAL-X-201 SAL-X-201 
457 SAL-X-197 (Florence) 
SAL-X-197 
(Florence) SAL-X-197 SAL-X-197 
458 SAL-X-183 (Florence) 
SAL-X-183 
(Florence) SAL-X-183 SAL-X-183 
461 SAL-X-185 (Florence) 
SAL-X-185 
(Florence) SAL-X-185 SAL-X-185 
462 SAL-X-189 (Florence) 
SAL-X-189 
(Florence) SAL-X-189 SAL-X-189 
463 SAL-X-193 (Florence) 
SAL-X-193 
(Florence) SAL-X-193 SAL-X-079 
464 SAL-X-195 (Florence) 
SAL-X-195 
(Florence) SAL-X-195 SAL-X-091 
465 SAL-X-199-1 (Florence) 
SAL-X-199-1 
(Florence) SAL-X-199-1 SAL-X-119 
466 SAL-X-199-2 (Florence) 
SAL-X-199-2 
(Florence) SAL-X-199-2 SAL-X-119 
468 SAL-X-163 (Florence) 
SAL-X-163 
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